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SUMMARY 
 The cellular metabolism is a highly dynamic process where mitochondria network is a 
prominent actor in regulation of both energy metabolism and apoptotic pathways. To 
preserve the integrity of a healthy mitochondrial population within the cell but also the 
integrity of the cell itself, mitochondrial networks come in varied shapes and ultrastructures to 
ensure the main energy supply, stored in the form of adenosine triphosphate (ATP), by 
oxidative reactions from nutritional sources. Therefore, alterations in both mitochondrial 
dynamics and metabolism are often related to each other as early and prominent events in 
the pathogenesis of several age-related disorders including Alzheimer’s disease (AD). 
Advances in the understanding of the mechanisms underlying the coordination between 
mitochondrial dynamics and the functional state of mitochondria in health are essential for 
the characterization of disease-related changes of mitochondria in the course of 
neurodegenerative disorders. 
 The purpose of this thesis was therefore to pinpoint the mechanistic processes that 
are involved in the regulation of mitochondrial bioenergetics and dynamics. To better 
understand (I) the tight equilibrium between mitochondrial morphology and function in 
physiological state and (II) its impact on abnormal mitochondrial, the thesis was divided in 
two main parts: 
I. The first aim of the thesis was to investigate the potential influence of (A) the circadian 
clock and (B) neurosteroids on the maintenance of mitochondrial homeostasis. 
(A) Since biological clocks are tightly connected to metabolic processes within the cell, 
we first determined whether mitochondrial dynamics and metabolism are coupled 
events that are coordinated by the circadian system. 
(B)  Considering compelling evidence that highlighted neuroprotective effects of steroids 
in the brain, we examined whether different neurosteroids are able to improve 
mitochondrial bioenergetics to prevent age-related mitochondrial alterations which 
eventually lead to neurodegeneration. 
II. In the second part (C), we determined whether amyloid-beta (Ab) impacts the integrity of 
the mitochondrial structure–function relationship since both mitochondrial dynamics and 
bioenergetics are hallmarks of Aβ-induced neuronal toxicity in AD. 
I. (A) The circadian clock is a hierarchical network of oscillators that coordinate a wide 
variety of daily biological functions, including metabolic functions, to the optimal time of day 
anticipating the periodical changes of the external environment for all living organisms. 
Mitochondria are dynamic organelles at the crossroad of the cellular metabolism that fuse 
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2 
and divide continuously to fulfill their role in the maintenance of the cellular bioenergetic 
homeostasis. While it is well known that metabolism is a complex biochemical network that is 
tightly intertwined with the circadian clock through reciprocal regulation from metabolites to 
transcription factors, the mechanistic connections between the biological clock and the 
mitochondrial network remain mostly elusive. We therefore addressed the questions whether 
and how the circadian clock intervenes in the coordination between mitochondrial dynamics 
and functions and whether the coupled mitochondrial network- metabolism may be able to 
influence the circadian clock. 
We demonstrated in vitro and in vivo that mitochondrial fission-fusion dynamics were 
strongly clock-controlled, as well as all other aspects of mitochondrial metabolic flux, 
including oxidative phosphorylation, generation of ATP and reactive oxygen species (ROS). 
The changes in cell cycle-based mitochondrial morphology required the circadian 
phosphorylation of the key protein, dynamin-related protein 1 (DRP1), the major protein 
involved in mitochondrial fission. Genetic or pharmacological abrogation of DRP1 activity 
abolished circadian mitochondrial network dynamics and mitochondrial respiratory activity, as 
well as eliminated circadian ATP production. The disruption of circadian mitochondrial 
dynamics furthermore feeds back to impair the core circadian clock. 
Overall, our findings are consistent with the existence of a crosstalk between the clock 
and the mitochondrial network that maintains bioenergetic homeostasis in response to 
circadian metabolic changes. 
I. (B) We aimed to investigate the potential role of different neurosteroids on mitochondrial 
bioenergetics and redox homeostasis in neuronal cells. In contrast to steroid hormones 
produced by endocrine glands, neurosteroids are synthetized within the nervous system itself 
and are defined as neuroactive molecules acting on the nervous system in an auto/paracrine 
manner. Neurosteroids exhibit several biological functions that are essential during brain 
development as well as in the adult brain. Moreover, progressive depletion in neurosteroid 
content might contribute to an age-related neuronal decline that eventually leads to the 
development of neurodegenerative disorders including AD. Although compelling evidence 
has shown that estradiol interacts with mitochondria to counteract oxidative stress occurring 
in age-related diseases such as AD, the potential role of other neurosteroids on mitochondria 
is rather poorly investigated and understood. 
To expand our knowledge on the mechanisms behind the neuroprotective action of 
neurosteroids, a selection of sex-hormone-related neurosteroids, including progesterone, 
estradiol, estrone, testosterone, 3a-androstanediol, dehydroepiandrosterone (DHEA) as well 
as allopregnolone, were tested on mitochondrial function. Using human SH-SY5Y 
neuroblastoma cells, we determined which of the neurosteroids exhibited the capacity to 
enhance mitochondrial metabolism by increasing ATP content along with an augmentation of 
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mitochondrial membrane potential and mitochondrial respiration. Interestingly, particular 
bioenergetic profiles were found for each neurosteroid, which might be due to an involvement 
of different receptors. When the respective steroid receptors were blocked with specific 
inhibitors, ATP contents were entirely depleted confirming a receptor-specific mode of action 
of neurosteroids. Concomitantly with the enhanced mitochondrial metabolism, treatment with 
neurosteroids induced an augmentation of ROS levels in parallel to an up-regulation of 
antioxidant defenses suggesting a direct or indirect role of neurosteroids on redox 
homeostasis in neuronal cells. 
Collectively, these novel findings demonstrate that neurosteroids are able to 
differentially improve mitochondrial function as well as to modulate redox homeostasis 
through distinct receptors. Because of the disparate effects of neurosteroids on mitochondrial 
metabolism, the underlying mechanisms have to be further elucidated in future studies, 
particularly the effect of neurosteroids on mitochondrial dynamics, as well as those in models 
of neurodegenerative diseases, such as AD. 
II. (C) The aim of the second part of this thesis was to investigate the impact of Ab on the 
balance between mitochondrial structure and function since abnormalities in mitochondrial 
dynamics and bioenergetics are hallmarks of Aβ-induced neuronal toxicity in AD. For that 
purpose, we examined mitochondrial architecture and bioenergetics in cell-cycle controlled 
human primary fibroblast cultures treated with Ab1-42 peptide compared to non-treated cells. 
We demonstrated that variations in mitochondrial respiration, ATP and ROS content 
coincided with the oscillations pattern of the mitochondrial network in physiological conditions 
in control cells confirming the existence of a direct link between the mitochondrial network 
and the metabolic state of mitochondria. Indeed, in between the switch from tubular to 
fragmented mitochondrial network, we observed an increase in ATP level which correlated 
with a higher oxygen consumption rate (OCR) in the basal respiration as well as in ATP 
turnover and maximal respiration. In contrast, Ab1-42 almost completely dampened the 
oscillations of mitochondrial dynamics followed by a decline of mitochondrial metabolism 
including reduced ATP level and OCR. Furthermore, Aβ-induced mitochondrial defects 
provoked a drastic augmentation in mitochondrial ROS level which might participate, along 
with an imbalance in the NAD+/NADH ratio, in the generation of oxidative stress confirming 
the oxidative stress theory of aging and AD. 
Hence, these new insights support the concept that mitochondrial bioenergetics is 
coordinated by mitochondrial architecture transitions and that Aβ induced a functional 
imbalance in the mitochondrial structure-function relationship, which might contribute already 
at an early disease state to AD pathogenesis. 
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Altogether, in the present thesis, we gained new insights on factors regulating 
mitochondrial dynamics and metabolism in health and disease states, e.g. AD. We firstly 
revealed that the circadian clock system, even in nondividing cells and tissues, regulates the 
phosphorylation of DRP1 resulting in cycles of fission and fusion that are essential for 
circadian oscillations in ATP production. These findings provide multiple implications into the 
understanding of metabolic homeostasis in human health as well as in disorders linked to 
impairments in circadian clock and/ or mitochondrial function. Secondly, we determined that 
neurosteroids are able to differentially modulate mitochondrial metabolism at the 
physiological state suggesting that these molecules might be considered as promising 
candidates in neuroprotective approaches to counterbalance mitochondrial deficiencies. 
Finally, we contributed to a better understanding of Aβ-induced neurotoxicity that is mediated 
by mitochondrial malfunctions further emphasizing the mitochondrial cascade hypothesis of 
AD. 
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INTRODUCTION
A. The circadian rhythm: the living clock making life tick. 
 Circadian rhythm is recognized as an evolutionarily conserved adaptation to 
periodical changes of the external environment that can be traced back to the earliest life 
forms [1]. This rhythm is a roughly-24-hour cycle that times/coordinates a wide range of 
metabolic, physiological and behavioral events of living beings, including plants, animals, 
fungi and cyanobacteria. These rhythmic processes are governed by an integrated system 
involving environmental cues, such as fluctuations in light intensity associated with food 
viability, an internal circadian timing system composed of a central pacemaker in the brain's 
suprachiasmatic nuclei (SCN) and subsidiary clocks in nearly every body cell, and the 
interaction between this timekeeping system and environmental signals on order to provide 
time information required for the control of behavior, physiology, and gene expression 
(Figure 1). 
 
 
Figure 1: The circadian system model. 
In order to maintain and generate a variety rhythmic behavior and functions, the circadian rhythm 
oscillators resynchronize themselves each day with external stimuli such as the brightness of the 
ambient light (adapted from [2]). 
 
 Briefly, to consider a biological rhythm as circadian, the endogenous rhythm 
generators have to present the ability to generate and maintain a “free-running” rhythm at 
periods slightly different than 24 hours. Moreover, circadian rhythms are characterized by 
two key features: they are self-sustained in absence of environmental cue (‘free-running 
conditions) and they can be entrained to daily changes in the environment (entrained 
conditions). To maintain their accuracy, the circadian rhythm generators are entrained or 
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synchronized to the environment by input pathways initiated from receptors perceiving and 
transmitting environmental cues (e.g. the most important being the light/dark cycle), 
commonly named “zeitgebers”. The output pathways translate then the oscillations into 
behavioral and physiological rhythms. Another fundamental feature of circadian clocks is the 
ability to counteract inappropriate signals and to be persistent under stable ambient 
conditions. The most well-known example is illustrated in the temperature compensation 
observed in all molecular and behavioral circadian rhythms. 
 Overall, circadian timekeeping system can be analyzed as an integrated system – 
beginning with genes related to the molecular clock machinery and leading ultimately to 
behavioral outputs. Moreover, circadian rhythms share common fundamental properties 
(Figure 2). The parameters include the free-running, or the length of one oscillation under 
constant environmental conditions and phase response/entrainment, the ability of the clock 
to alter its phase in response to external stimuli and the amplitude of the rhythm, that is the 
force of the oscillations. 
 
 
Figure 2: Parameters of an hypothetical rhythm. 
Three important parameters of circadian rhythm are indicated: phase, period and amplitude. The 
amplitude refers to the maximum absolute value of a periodically varying quantity. The period refers to 
the time spent between two peaks. The phase represents the position of a peak compared to the time 
unit. Under entrained conditions (standard light-dark cycles), the time of lights on usually defines 
zeitgeber time zero (ZT 0) for diurnal organisms and the time of lights off defines zeitgeber time twelve 
(ZT 12) for nocturnal animals. The circadian time refers to a standard of time based on the free-
running period of a rhythm. By convention, the onset of activity of diurnal organisms (or subjective day) 
defines circadian time zero (CT 0) under ‘free-running’ condition, while the onset of activity of 
nocturnal organisms (or subjective night) defines circadian time twelve (CT 12). LD, a regular 
alternation of light and darkness each day; DD, Constant darkness. 
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1. Clock genes and clock machinery 
 Generation and maintenance of circadian rhythms rely on complex interlaced 
feedback loops (positive and negative) based on transcriptional and posttranscriptional 
events involving clock genes and kinases that mandate fine-tuning of the clock and yet 
provide for its plasticity by which it can adjust to changes in the environment [3-5] (Figure 3). 
This mechanism of transcriptional-translational feedback loop (TTFL) that is at the basis of 
the mammalian circadian machinery is well conserved amongst many other species, such as 
bacteria (e.g. Cyanobacteria), plants (e.g. Arabidopsis thaliana) and animals (e.g. Drosophila 
melanogaster) beings [5, 6]. 
 
 
Figure 3: The molecular mechanism of the circadian clock in mammals. 
The core circadian clock consists in an autoregulatory transcription-translation feedback loop (TTFL) 
involving activators CLOCK/NPAS2 (Clk; green circle) and BMAL1 (red circle) which dimerize and bind 
to specific promoter sequences, E-Box leading to activation of the transcription of the negative 
elements Per (isoforms 1,2) and Cry (isoforms 1,2). Moreover, Rev-Erbα negatively regulates the 
expression of BMAL1, whereas RORs positively regulate the expression of BMAL1. As a 
consequence, also the negative key components CRY and PER and REV-ERBα decrease their own 
concentration in the cell. CLOCK: BMAL1 also regulates many downstream target genes known as 
clock-controlled genes (CCG) which provide a circadian output in physiology. P, phosphate; Cry, 
cryptochrome; Per, Period (adapted from [7]). 
 
 In mammals, the primary feedback loop is made up of the positive elements that 
include members of the basic helix-loop-helix (bHLH)-PAS (Period-Arnt-Single-minded) 
transcription factor family, CLOCK/NPAS2 (circadian locomotor output cycles kaput/neuronal 
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PAS domain protein 2) and BMAL1 (brain and muscle ARNT-1) [8, 9]. Both factors form a 
heterodimer that binds E-Box sequences (CACGTC) present in clock and clock-controlled 
gene (CCG, or circadian output genes) promoters. This binding initiates the transcription of 
period (Per) and cryptochrome (Cry) messenger RNA. PER and CRY mRNAs are translated 
into proteins in the cytoplasm. These proteins then form heteropolymeric complexes 
(PER/CRY and PER/PER) that enter the cell nucleus and interact with the CLOCK/BMAL1 
heterodimer inhibiting the transcription process and hence the production of PER and CRY. 
As a consequence cry and per mRNAs and proteins decrease in concentration and once the 
nuclear levels of the CRY–PER complexes are insufficient for auto-repression, a new cycle 
of Per and Cry transcription can start. 
 In addition to this core transcriptional feedback loop, expression of Rev-Erbα and 
retinoic-related orphan nuclear receptors (RORs), circadian-controlled metabolic transcription 
factors, is also induced by CLOCK:BMAL1 heterodimers [8, 9]. Contributing to the 
robustness of this molecular clockwork circuitry, REV-ERBα and RORα subsequently 
compete to bind retinoic acid-related orphan receptor response elements (ROREs) present in 
Bmal1 promoter. RORs activate transcription of Bmal1 [10-12], whereas REV-ERBs repress 
the transcription process [12, 13]. 
 At a posttranslational level, mechanisms such as phosphorylation and ubiquitination 
significantly contribute to keep the clocks ticking at a normal speed (~24 hours oscillations) 
by affecting the stability and nuclear translocation of aforementioned core clock proteins [8, 
14]. For instance, Casein kinase 1 epsilon and Casein kinase 1 delta (CK1ε and CK1δ) and 
AMP kinase (AMPK) are critical factors that regulate the core circadian protein turnover in 
mammals [8, 15, 16]. The kinases phosphorylate the PER and CRY proteins, respectively, to 
promote polyubiquitination by their respective ubiquitin ligase complexes, which in turn tag 
the PER and CRY proteins for degradation by the proteasome complex. 
 Additional genes with promoters containing E-box, D-box and retinoic acid responsive 
element (RRE) consensus sequences are also clock regulated and make up a large body of 
circadian clock–controlled genes (CCG). Genome-wide transcriptome profiling studies 
revealed that up to 10% of all mammalian genes display oscillations in their expression levels 
with a period of about 24 hours in the brain as well as in peripheral organs [17, 18]. Among 
these rhythmic genes, several regulatory genes and transcription factors are involved in 
metabolic processes such as carbohydrate, lipid, and cholesterol metabolism as well as 
detoxification mechanisms (for details, see section A.3. Circadian rhythms and Metabolism). 
In the liver, the transcription factors identified belong to the PAR bZip family such as DBP, 
TEF, and HLF that bind to D-elements, the PAR bZip-related repressor E4BP4, the Krüppel-
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like factors KLF10 and KLF15 , and nuclear receptors (review in [2]). All these transcription 
factors are known to be linked remotely or closely to the metabolic homeostasis. 
 Although the TTFL is well recognized as essential for the timekeeping in the SCN and 
virtually in cells of the body, recent studies may revise the typical view of how the rhythmicity 
is sustained within the cells. Interestingly, it has been demonstrated that transcription is not 
required for circadian oscillations in human red blood cells which have no nucleus (or DNA) 
and, therefore, cannot perform transcription and non-transcriptional events seem to be 
sufficient to sustain cellular circadian rhythms [19, 20]. Moreover, these rhythms are 
entrainable (that is, tunable by environmental stimuli) and temperature-compensated, both 
key features of circadian rhythms. Consequently the idea that oscillations persist in absence 
of nucleus suggests a more complex view of the circadian timing system where other players 
act as critical modulators (e.g: metabolites) of the biological timekeeping (see also section 
A.3. Circadian rhythms and metabolism). 
 
2. Organization of the circadian timing system 
 A highly refined circadian system is already present in invertebrates such as 
arthropods and insects, but the most complex organization of the circadian system is found 
in mammals and humans. The mammalian circadian system is organized in a hierarchical 
manner that consists of the central circadian rhythm generator, also known as the conductor 
of the circadian orchestra or the ‘master clock’, and all the subsidiary clocks in the other parts 
of the brain as well as in nearly every body cell (Figure 4). 
2.1. Suprachiasmatic nuclei, the conductor(s) of the circadian orchestra 
 In mammals, the master circadian clock resides in the suprachiasmatic nuclei (SCN), 
a pair of distinct and bilateral groups of neurons (~20 000 neurons) located above the optic 
chiasm at the basis of the hypothalamus. In the 1970’s, lesion studies in rodents conducted 
almost simultaneously by two laboratories identified the exact location of the master clock 
which was shown to be both necessary and sufficient for the generation of circadian activity 
rhythms [21, 22]. In a nutshell, lesion of the SCN abolished circadian rhythmicity in entrained 
condition and resulted in the loss of corticosterone rhythms as well as in the disruption of the 
locomotor activity. Moreover, the tract tracing experiment revealed a bilateral projection from 
the retina to the hypothalamus named the retinohypothalamic tract (RHT). Inversely, when 
SCN-lesioned hamsters were transplanted with fetal SCN tissue into the third ventricle, 
circadian locomotor activity was restored (review in [23]). Furthermore, rhythms in SCN-
lesioned wild-type hamsters were reestablished but with a shortened period length 
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characteristic of the Tau mutant hamsters displaying circadian rhythmicity [24]. Overall, these 
results converged nicely to support the idea that the SCN as the master circadian clock is 
synchronized by the environmental light. 
 
 
Figure 4: Circadian rhythm hierarchy in humans. 
The circadian system is composed of a central circadian rhythm generator and subsidiary clocks. 
Environmental light is detected by the retina that, through the retina-hypothalamic tract, sends signals 
to the master clock, the suprachiasmatic nucleus (SCN) of the hypothalamus. SCN elaborates this 
light information and synchronizes its circadian rhythm with the external light-dark rhythm. Moreover, 
through neuronal and hormonal output pathways, SCN synchronizes virtually all cells of the body. Like 
feeding rhythms, body temperature rhythms appear to play an important role in the coordination of 
peripheral clocks. 
 
 To maintain its accuracy, the central biological clock resynchronizes itself each day 
with external stimuli such as the brightness of the ambient light, by means of the optic 
nerves, which bring this information to the SCN from ganglion cells in the retina through the 
RHT. While SCN is structurally and functionally heterogeneous at the single-cell level [7, 25-
27], SCN can generate and maintain a basic and independent rhythm as a network in which 
the SCN cells are mutually coupled and oscillate in a consistent manner, even if the external 
cues of the cycle of day and night are eliminated [27, 28]. When the SCN were isolated as 
explant or when single SCN neurons were cultured in vitro (review in [23]), electrical activity 
remained circadian and individual neurons showed circadian firing rhythms, even after three 
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weeks in culture demonstrating that the robustness of the SCN network oscillatory system is 
critically dependent of the intracellular coupling of SCN neurons. 
 To function as a pacemaker and synchronizer for other brain and peripheral clocks, 
the intrinsic timekeeping signal from the SCN has to be transmitted once the SCN has 
integrated the time-related information from the environmental inputs. SCN uses both signals 
and neural efferents to convey timing information (i.e, entrain, synchronize) to other parts of 
the brain (e.g. hypothalamic nuclei) and the periphery. In fact, SCN get directly involved into 
the sleep/arousal, reproductive and endocrine systems in part through neuroanatomic 
connections by which the SCN can synchronize peripheral clocks, e.g. by inducing the 
release of glucocorticoids [29]. Inversely, activity rhythms as well as circadian outputs from 
other tissues can feed back on the SCN and on other peripheral oscillators. 
2.2. Peripheral clocks: keeping up with the master clock 
 Although it was initially believed that the SCN is the only mammalian tissue capable 
of circadian rhythm generation, the identification of core genetic component of the 
mammalian circadian clock suggested that virtually all cell types can be considered as 
circadian oscillators by sharing the same molecular mechanism [30]. Therefore, cell 
autonomous and self-sustained circadian rhythms are found outside the SCN [31] and even 
outside the brain [32] in many peripheral organs and tissues [33] in the body such as 
oesophagus, lung, liver, pancreas, spleen, thymus and the skin; the cells constituting these 
tissues are called peripheral oscillators [34, 35]. First evidence was described by Tosini and 
Menaker in cultured mammalian retina where melatonin (the so called ‘night hormone’, 
mainly produced by pineal gland) was secreted in a circadian fashion [36]. Following studies 
revealed that all examined peripheral tissues (with the exception of testis) virtually transcribe 
main clock genes (mBmal1, mNpas2, mReverbα, mDbp, mRev-erbβ, mPer3, mPer1 and 
mPer2) in a cyclic fashion, however, with a mRNA peak occurring 4 hours later than those in 
the central pacemaker, SCN [13, 32, 37, 38]. 
 Many circadian overt output cycles of the circadian timing system involve circadian 
clocks in peripheral cell types (3-10% of all mRNAs in a given tissue) [7, 30]. However, the 
expression of these CCG is largely nonoverlapping in each tissue, reflecting the necessity for 
temporal modulation peculiar to each single cell type. As a result, a large number of key 
biological processes, including many aspects of metabolism [39], glucose homeostasis [40] 
and lipogenesis [41] is subject to control of the circadian clock. The liver is the most well-
known organs in term of circadian transcription with close to 1000 circadian transcripts 
identified encoding key enzymes involved in metabolic pathways, energy homeostasis, food 
processing and detoxification (review in [23]). 
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 Given the hierarchical organization of the circadian system, peripheral circadian 
clocks, and thus daily physiology and behavior, are coordinated by systemic cues emanating 
from the SCN, such as neuronal signals and circulating hormones or metabolites, and/or by 
local peripheral oscillators synchronized by the SCN [2, 7, 23]. Moreover, although the SCN 
serves as the master synchronizer of the entire system, food intake or body temperature 
change can uncouple peripheral clocks from control by the SCN [2]. Such a system has the 
potential benefit of temporary uncoupling between SCN and peripheral clocks. For instance, 
changes in feeding schedule lead to the alteration in the phase relationship between the 
central clock in the SCN and the clocks in the liver, suggesting that changes in metabolism 
caused by alterations in feeding rhythm may affect the circadian system [42]. Understanding 
the complexity of tissue-specific circadian expression patterns remains a major challenge. 
Several mechanisms have been proposed to explain the tissue-specific rhythm generation: 
(1) variations of the core clock across different tissues, (2) tissue-specific rhythmically 
expressed transcription factors and co-factors, (3) and systemic cues such as hormone 
secretion, sympathetic innervation, body temperature, and activity rhythms (review in [43]). 
 Unlike the SCN explants, the peripheral cell or tissue rhythms tend to damp out within 
a few cycles until restarted by a wide range of resetting stimuli, including serum shock, 
glucocorticoids, cold pulses, and even medium changes in cell culture models [44-47]. The 
difference in damping between SCN and other tissues appears to be quantitative rather than 
qualitative. It has been observed that damping of the circadian rhythms is explained by loss 
of coupling among cells rather than damping of individual cell rhythms [48-50]. Individual 
fibroblast cells are capable of functioning as independently phased circadian oscillators that 
are self-sustained for many days in vitro. In fact, their circadian function appears very similar 
to SCN neurons assayed on multielectrode arrays for rhythms of neuronal firing [27]. It is 
thus possible to use peripheral oscillator as model to study molecular mechanisms of 
circadian rhythms. 
2.3. How to study circadian timing system: from bench to bedside 
 It is believed that the intrinsic period length of the SCN affect the phase of diurnal 
behavior. Mammalian circadian system can be investigated at different levels from molecular 
and cellular processes to behavior in a whole organism. 
 In rodents, locomotor activity is mostly used to determine the circadian rhythm [51]. In 
human, many physiological, biochemical and neuroendocrine parameters such as 
sleep/wake cycle, body temperature, melatonin, cortisol, heart rate, and blood pressure are 
broadly used as circadian output [52]. The analyses of the circadian rhythms of these 
markers can give hints about circadian parameters, such as amplitude, phase and period 
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length (for details, see Figure 2). However, the major concerns in circadian studies are that 
endogenous circadian clocks are not only determined by the biological clock and the sleep 
homeostasis but also zeitgebers such as light exposure, temperature, body position and food 
intake [53]. Therefore, these factors can have direct or indirect effects on many functions, so-
called “masking” effects. To overcome these difficulties, it was necessary to develop 
protocols that control or at least attenuate for masking effects. Principally, the individuals are 
placed in constant and controlled conditions (e.g. constant darkness, short or long sleep 
time) in order to elucidate the characteristics of the endogenous circadian pacemaker [54]. 
Nevertheless, measurement of the circadian period length, normally accomplished by 
prolonged subject observation, remains difficult and costly in humans. 
 Since it is believed that SCN and most cells of the body virtually share the same cell-
intrinsic mechanism of the biological clock [32, 37], several circadian studies developed ex-
vivo protocols using cells - skin, blood, or hair root cells - or explants from animal or human 
tissue that can be obtained easily. Although the period length of circadian behavior in rodents 
is straightforwardly determined by analysis of wheel-running behavior in constant darkness 
[54], success in developing transgenic animals in which the luciferase gene has been fused 
to a circadian reporter permits to complement wheel-running behavioral analyses by 
measuring the period length of circadian genes in vitro [55, 56]. Furthermore, explants from 
different tissues as well as cultured mouse fibroblasts from these animals were used to 
analyze the circadian rhythm by real-time measurement of light output [48, 57]. As 
anticipated, the circadian oscillators of these cells are self-sustained and cell-autonomous, 
similar to those operative in SCN neurons. 
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Figure 5: Protocol to study circadian rhythms in human skin fibroblasts. 
Punch skin biopsy is (1) harvested and cultivated under sterile conditions. Fibroblasts that grow 
around the biopsy are isolated, amplified and (2) infected with a circadian reporter coding for firefly 
luciferase under a clock gene promoter, i.e. Bmal1. The infected cells are selected and then, (3) after 
synchronization of circadian rhythms, (4) the light emitted by the cells is measured in the Lumicycle 
(Actimetrics) or in a home-made device able to detect and measure bioluminescence. 
 
 Likewise, it has been reported that the period of human circadian behavior is mostly 
driven by cellular clock properties in normal individuals and can be approximated by 
measurement in peripheral cells such as fibroblasts using lentivirally-delivered circadian 
reporter vectors (Figure 5) [49, 58]. For example, the cellular clocks of early chronotypes 
(i.e., “larks”) have shorter circadian periods than those of later chronotypes (“owls”) [59], and 
circadian period length in vitro is proportional to physiological period in vivo [58]. 
 Except for the damping tendency of peripheral clocks which can be counteracted with 
a wide range of resetting stimuli in vitro including serum shock, glucocorticoids, cold pulses, 
and even medium changes in cell culture models [44-47], primary cells are a good model to 
study circadian aspects for their accuracy in circadian characteristics, such as the period 
length, even isolating in vitro oscillators. Moreover, the ability to transfect peripheral 
oscillators such as fibroblasts with dominant-negative constructs is another important tool 
that can be used to investigate particular aspects of circadian rhythm. In this way, it was 
possible to ensure that circadian genetic differences are reflected in the rhythms of fibroblast 
gene expression [49]. Overall, in vitro studies on isolated peripheral oscillators can be 
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associated to in vivo studies to investigate a circadian question from more points of view, in 
both physiological and pathological states. 
 
3. Circadian rhythms and metabolism 
 Circadian rhythms control a wide range of physiological events, including metabolism, 
in all organisms. Over the last decades, accumulating evidence has revealed that, from 
metabolites to transcription factors, circadian rhythms and metabolism converge to optimize 
energy harvesting and utilization across the light/ dark cycle [60, 61]. While the regulation of 
metabolic pathways is well known to be achieved by the circadian clock, it has also been 
suggested that various hormones, nutrient sensors, redox sensors and metabolites are not 
only clock output but can also regulate in turn the biological clock by acting as an input signal 
[57, 62] (Figure 6). Moreover, as demonstrated by individuals working night or rotating, but 
also by rodent models of circadian arrhythmia, circadian cycle is strongly associated with 
metabolic imbalance among the living organisms [63-65]. Understanding more the interplay 
between these two systems will provide not only needed insights about circadian physiology 
and metabolic mechanisms but also novel knowledge about the pathophysiologic 
consequences of disruption of this molecular interplay. 
 The interplay between circadian and metabolic cycles has been described in recent 
studies showing that the circadian clock exerts its control over metabolism by (i) controlling 
the expression of ascertained genes and enzymes involved in metabolic processes, (ii) 
intertwining nuclear receptors and nutrient sensors (e.g. SIRT1 and CLOCK, AMPK and 
CRY1) with the clock machinery, and/ or (iii) regulating metabolite levels (e.g. NAD+, cAMP) 
[66, 67]. Of note, various hormones, nutrient sensors, redox sensors and metabolites are not 
only clock output but can also regulate in turn the biological clock by acting as an input 
signal. 
 As mentioned above, in addition of transcription factors known to regulate genes 
involved in metabolism, a large fraction of rhythmic genes transcripts encode for important 
metabolic regulators. However, a much larger percent of the proteome oscillates in either 
expression or activity [60]. This implies that, in order to achieve a well time-coordinated 
expression, a powerful and cyclic mechanism of chromatin remodeling has to be partly 
involved in order to response rapidly and adequately to specific cues. This is likely to be 
obtained through rhythmic alterations in histone modifications such as phosphorylation or 
acetylation associated directly with circadian clock proteins [68-70]. Interestingly, CLOCK 
itself contains histone acetyltransferase activity which contributes to the rhythmic acetylation 
of histone of its binding partner, BMAL1 [71]. 
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Figure 6: The circadian clock and metabolism converge. 
The core clock requires the transcription- translation feedback loop (TTFL) that synchronizes diverse 
metabolic processes through both direct and indirect outputs, including oxidative metabolism. 
Reciprocally, inputs from the byproducts of metabolism processes (e.g. NAD
+
, ATP/AMP) are 
transferred back to the clock through nutrient signaling pathways (including SIRT1 and AMPK) which 
act as rheostats to couple metabolic flux with daily cycles of sleep/ wakefulness and fasting/ feeding, 
especially in peripheral tissues. NAMPT, nicotinamide phosphorribosyltransferase; SIRT1, Sirtuin 1; 
AMPK adenosine monophosphate-dependent protein kinase; LKB, serine–threonine kinase liver 
kinase (adapted from [61]). 
 
 Over the last years, a growing body of evidence highlighted that metabolic byproducts 
(e.g.: NAD+, ATP) display 24 h oscillation and can in turn regulate the clock. Thus it has 
become clearer that the relationship between the clock machinery and metabolism is not only 
unilateral but reciprocal. One of the earliest study supporting the concept that metabolism 
can affect the clock machinery investigated the role of cellular redox translated by the couple 
NAD+/NADH and NADP+/NADPH [72]. When the oxidized forms (NAD+ and NADP+) are 
predominant, the DNA binding of the Clock:BMAL1 and NPAS2:BMAL1 heterodimers is 
strongly diminished whereas the reduced forms enhance. Interestingly, these observations 
can be nicely correlated with observations made in human red blood cells where transcription 
is not required for circadian oscillations in, and non-transcriptional events such as redox state 
changes seem to be sufficient to sustain cellular circadian rhythms [19, 20]. The most known 
byproduct is nicotinamide adenine dinucleotide (NAD+) which is, among others, involved in 
cellular redox reactions as key cofactors. Importantly, recent data reveal that NAD+ produced 
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by the salvage pathway oscillates in a circadian manner in peripheral tissues such as liver 
and adipose tissue, even when animals are maintained in constant darkness [73-75]. The 
circadian biosynthesis of NAD+ in mammals relies on the activity of the rate-limiting enzyme 
nicotinamide phosphorribosyltransferase (NAMPT) whose its expression is controlled by 
CLOCK–BMAL1 activator complex in conjunction with NAD+- activated SIRT1, a histone 
deacetylase involved to the translation from the cellular energy states to chromatin 
remodeling. 
 The activation of AMPK (adenosine monophosphate-dependent protein kinase) by 
the variation of ratio ATP/AMP, key metabolites, is central for the transmission of nutrient and 
energy-dependent signals to the molecular clock (review in [16]). It has been reported that 
when AMP levels are elevated, structural changes in AMPK, a nutrient sensor, enhance 
phosphorylation by liver kinase B1 (LKB1), resulting in regulation of circadian rhythm, energy 
metabolism and gene expression in isoform- and tissue-specific manners [76]. Then AMPK 
can directly modulate the core clock machinery by phosphorylation of the clock repressor 
proteins CRY and PER, targeting them for proteasomal degradation (for detailed 
mechanisms see section A.1. Clock genes and clock machinery) [77, 78]. 
Although extensive evidence shows a tight and mutual connection between the clock and 
the metabolism, the implication of the mitochondrion which is yet at the crossroad of cellular 
metabolism is only starting to arise. Reports on circadian oscillations in mitochondrial 
dynamics started surfacing last year first in macrophages [79] and more recently in liver [80]), 
but the underlying molecular mechanisms by which these changes occur remain mostly 
elusive. 
 
 
B. Keeping mitochondria in shape: a matter of life and death 
 Present in almost all eukaryotes cells (except in erythrocyte), mitochondria are highly 
dynamic organelles that participate in energy conversion, metabolism, intracellular signaling, 
cell migration and synaptic plasticity [81, 82]. To fulfill their multiple tasks, mitochondrial 
network come in varied morphologies and ultrastructures to ensure the energy supply, stored 
in the form of adenosine triphosphate (ATP), by oxidative reactions from nutritional sources 
[83, 84]. While mitochondria are essential for cell survival, the mitochondrial network 
participates actively to apoptotic signaling pathways through release of a stream of harmful 
compounds such as reactive oxygen species (ROS) [85]. 
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1. Mitochondria: powerhouses of the cell 
 Unlike any other organelle, except for chloroplasts, mitochondria are thought to have 
originated from an endosymbiosis accompanied by gene transfers when a nucleated cell 
engulfed an aerobic prokaryote about 1.5 billion years ago [86]. Owing to their ability to 
generate ATP through respiration, they became a driving force in the evolution [87]. 
Consequently, several characteristics sustain the endosymbiotic theory making mitochondria 
unique (Figure 7). 
1.1. Mitochondrial features 
Mitochondria are rode-shaped organelles characterized by a double-membrane 
organization which divides the mitochondrion in four compartments, distinct in appearance 
and in composition, thus determining the biochemical function of each compartment (Figure 
7). These compartments or regions include the outer membrane (OMM), the intermembrane 
space (IMS), the inner membrane (IMM), and mitochondrial matrix. 
 
 
Figure 7: Mitochondrion, unique organelle. 
(A) Diagram of mitochondrion showing the inner and outer membranes, the matrix, the circular 
mitochondrial DNA (mtDNA) and the folded cristae. (B) Schematic representation of the mammalian 
mitochondrial genome (16,569 bp). Mitochondrial DNA encodes 22 tRNA genes (light-orange), two 
ribosomal RNA genes (dark-orange) and 13 genes encoding polypeptides of complex I (ND1-ND6), 
complex III (cytB), complex IV (COX1-3) and complex V (ATP6/8) (Courtesy of F. Wanner and 
adapted from [88]) 
 
 The porous OMM fully encompasses the IMM, with the IMS in between. The OMM is 
widely permeable due to the high presence of many protein-based pores that are big enough 
to allow the passage of ions and molecules as large as a small protein (up to 5000Da) [89]. 
In opposition to the permeable OMM, the IMM does not contain porin, thus this membrane is 
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highly impermeable to the stream of small molecules and ions, much like the plasma 
membrane of the cell [90]. The IMM houses numerous proteins involved in apoptosis such as 
cytochrome c [91] and apoptosis-inducing factor (AIF) [92], in the electron transport chain 
and ATP synthesis as well as in mitochondrial fusion and fission [93, 94]. The presence of 
numerous folds, also called cristae, provides a large amount of surface area of the IMM, 
enhancing its ability to produce ATP. Finally, the mitochondrial matrix, which is surrounded 
by the IMM, contains a wide range of enzymes for metabolic pathways including the 
tricarboxylic acid (TCA) cycle, also known as the Krebs cycle or citric acid cycle and the 
beta-oxidation of fatty acids which generates acetyl CoA that enters the TCA cycle [95, 96]. 
 Although most of a cell's DNA is contained in the cell nucleus, the mitochondrion has 
its own independent genome and the machinery to manufacture their own RNAs and 
proteins in the mitochondrial matrix (Figure 7). Each mitochondrion possesses 2-10 copies of 
mitochondrial DNA (mtDNA) [97]. The mtDNA copy number as well as the number 
mitochondria per cells vary depending on the energy requirements: tissues with a high 
capacity to perform aerobic metabolic functions such as brain or skeletal muscle will have a 
larger number of mitochondria [98]. The mtDNA is a circular double-stranded DNA inherited 
solely from the mother in most species, including humans, and is organized into compact 
particles named nucleoids [99]. The human mtDNA encodes 37 genes including 13 genes 
which are integrated into the inner mitochondrial membrane, along with proteins encoded by 
nuclear genes, to achieve the mitochondrial respiratory capacity. It comprises 7 of 46 
subunits of complex I (ND1, 2, 3, 4, 4L, 5 and 6), one of 11 subunit of complex III 
(cytochrome b (Cyt b)), 3 of 13 subunits of complex IV (Cytochrome c oxidase (COX) I, II and 
III), 2 of 17 subunits of complex V (ATPase 6 and ATPase 8). Subunits of complexes I, III, IV 
and V are encoded by both mtDNA and nDNA, while subunits of complex II is solely 
originates from nDNA (nucleoids). In addition, the mitochondrial genome contains the genes 
encoding for 2 rRNAs (12S and 16S) and 22 tRNAs (one-letter code) required for 
intramitochondrial protein synthesis [97]. Unlike nDNA, mtDNA lacks histones [100] making it 
more susceptible to injury, such as oxidative stress [101], and its mutation rate is about 10-
fold higher than that of nDNA [102], especially in tissues with a high ATP demand like the 
brain. Because both nDNA and mtDNA are essential to mitochondrial function, it is not 
surprising that a disruption of both nuclear and mitochondrial genes may therefore result in 
(pathological) alterations in mitochondrial function leading to aging and mitochondrial 
diseases once a certain threshold (“threshold effect”) is reached [103]. 
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1.2. Mitochondrial respiratory capacity 
 Although mitochondria house many biosynthetic and major enzymatic systems, ATP 
is the major energy currency molecule of the cell. More than 90% of our cellular energy is 
synthetized within the mitochondria through two metabolic pathways: the Krebs cycle (TCA) 
and the oxidative phosphorylation system (OxPhos) (Figure 8). 
 
 
Figure 8: The mammalian oxidative phosphorylation system (OxPhos). 
Complexes I (NADH:ubiquinone oxidoreductase) and II (succinate dehydrogenase, belongs to the 
tricarboxylic acid cycle called TCA) receive electrons from NADH and FADH2 respectively. Electrons 
are then driven from complexes by the mobile carrier molecules coenzyme Q/ubiquinone (UQ) and 
cytochrome c (Cyt c) to the final acceptor, molecular oxygen (O2). Transfer of electrons along ETC 
maintains the membrane potential via proton pumping into the IMS. The resulting proton gradient is 
harvested by complex V to generate ATP. The number of protein subunits encoded by mitochondrial 
(mtDNA) and nuclear (nDNA) genomes are indicated. mtDNA, mitochondrial DNA; nDNA, nuclear 
DNA; IMS, intermembrane space; IMM, inner mitochondrial membrane. (adapted from [97]) 
 
 Once the cytosolic glycolytic reactions are completed to break down one molecule of 
glucose, the two produced pyruvate molecules cross the mitochondrial membrane into the 
matrix where they can be catabolized to acetyl-CoA which then enters the citric acid cycle 
(TCA or Krebs cycle), resulting in the generation of two molecules of ATP and the cofactors 
nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2). These 
two compounds ensure the transport of free energy via electron into the mitochondrial 
respiratory machinery (OxPhos). 
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 Also known as the mitochondrial respiratory chain, the last step in cellular respiration 
is composed of the electron transport chain (ETC) consisting of four multisubunit protein 
complexes (complex I to IV) as well as the F1F0-ATP synthase (complex V) inserted in the 
IMM with an enrichment in the cristae. It was demonstrated that these complexes can 
assemble into supramolecular assemblies called “supercomplexes” or respirasomes [104]. 
The five complexes are functionally connected by mobile electron acceptors and donors: 
ubiquinone and cytochrome c. The electrons are also transferred along the ETC in a serie of 
oxidation reduction steps via cytochromes, iron-sulfur clusters and copper centres. Briefly, 
electrons carried away from the TCA by NADH and FADH2 are used to power complex I 
(NADH dehydrogenase) and complex II (Succinate dehydrogenase) respectively. These 
electrons are then passed freely through the IMM by coenzyme Q/ubiquinone (UQ) from both 
complexes to complexes III (Ubiquinol cytochrome c oxidoreductase). Cytochrome c 
eventually transports the electrons from complex III to IV (Cytochrome c oxidase) leading to 
the conversion of oxygen to water. It has been estimated that about 90% of mammalian 
oxygen consumption is mitochondrial, which primarily serves to synthesize ATP, although in 
variable levels according to the tissue considered and the organism’s activity status [105]. As 
electrons are carried along the ETC, protons are translocated from the matrix into the IMS 
resulting to the generation of a proton electrochemical gradient across the IMM. Two 
components define the proton electrochemical gradient: a difference in the concentration of 
protons (ΔpH, alkaline inside) and a difference in the electrical potential (negative inside: Δψ: 
−150 to −180 mV). This redox energy is finally used by the F1F0- ATP synthase. ATP 
synthase has been first described as rotary molecular motor by John Walker and Paul Boyer, 
(review in [106]) where F0 is the transmembrane element ferrying the protons from the matrix 
back to the IMS to power the rotor activity of F1, the catalytic component, where one ATP is 
synthetized with each turn via the addition of inorganic phosphate (Pi) to ADP. The net gain 
of OxPhos is typically 32 ATPs from one molecule of glucose.  
 
2. Mitochondria: paradoxical organelles 
 When mitochondria fulfill their physiological function, it is as if Pandora’s box has 
been opened, as this vital organelle contains potentially harmful proteins and biochemical 
reaction centers; mitochondria are the major producers of reactive oxygen species (ROS) at 
the same time being susceptible targets of ROS toxicity [107] (Figure 9). 
Although approximately 90% of O2 utilized by the cells is reduced to water during ATP 
generation, O2 can instead react with a small portion of electrons (up to 2%) escaping the 
ETC, mostly at complex I and III, and is incompletely reduced to give the superoxide radical 
(O2
-.) which can be converted into other ROS such as hydrogen peroxide (H2O2) and the 
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highly reactive hydroxyl radical (OH.) through enzymatic and non-enzymatic reactions [108, 
109]. Besides ETC as the major source, ROS can be generated by peroxisomes as well as a 
variety of cytosolic enzymes systems (e.g. xanthine oxidase, mitochondrial monoamine 
oxidase (MAOA and MAOB), nitric oxide synthase (NOS), and NADPH oxidase) [110]. 
 
 
Figure 9: Pathways of reactive oxygen species (ROS) generation and their enzymatic 
detoxification. 
Complexes I and III generate superoxide anion radical (O2
-.
) during the electron transfer process. O2
-.
 
can interact with NO
.
, produced by nitric oxidase synthase (NOS), to generate peroxynitrite (ONOO
-
). 
The enzymatic activity of mitochondrial manganese superoxide dismutase (SOD) converts O2
-.
 to 
hydrogen peroxide (H2O2), which may then diffuse to the cytoplasmic compartment where glutathione 
peroxidase (GPX) and catalase convert H2O2 to H2O. H2O2 can interact with Fe
2+
 or Cu
+
 to generate 
hydroxyl radical (OH
.
), a highly reactive free radical, that can induce as well as ONOO
-
, lipid 
peroxidation and oxidative damage to proteins and DNA. Of note, NO and its derivates (reactive 
nitrogen species or RNS) belong also to the group of ROS. 
 
 Given the reactivity and toxicity of ROS at high levels, cells are equipped with 
endogenous antioxidants regulatory strategies to counteract excessive ROS (Figure 9). First, 
O2
-.is detoxified to H2O2 by manganese superoxide dismutase (MnSOD) or copper/zinc 
superoxide dismutase (Cu/Zn SOD) and then to water by glutathione peroxidase (GPX) or 
catalase (CAT) [111]. Interestingly, it has been found that the redox state of the ETC as well 
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as the proton electrochemical gradient Δψ are major determinant of ROS production [108] 
For instance, recent data suggest that neuronal UCP proteins by regulating mitochondrial 
biogenesis, calcium flux, free radical production and local temperature [112], may reduce 
ROS production. 
 When the endogenous antioxidant systems are overwhelmed, unstable ROS are 
capable of damaging many types of mitochondrial components; this includes oxidative 
deterioration of mtDNA, lipids of the mitochondrial membrane, and mitochondrial proteins, 
and it is thought that this damage that may accumulate over time from ROS generated from 
aerobic respiration may play a significant role in aging [113]. Moreover, it was previously 
demonstrated that nitrosative stress evoked by increased nitric oxide synthesis also leads to 
protein oxidation as well as mitochondrial and DNA damage, which are common 
mechanisms occurring in the elderly [107]. All in all, oxidative damages of the mitochondrial 
compounds lead to a shutdown of energy production [114], which in turn, leads to a depletion 
of antioxidant defense (e.g. GSH) and the enhancement of ROS triggering the vicious cycle 
of oxidative stress, mitochondrial dysfunction and apoptosis. 
 Whereas ROS have been traditionally thought of as toxic metabolic byproducts that 
cause cellular damage, a constant growing body of evidence highlights the role of ROS in 
cellular signaling regulating various cellular events such as proliferation, differentiation, 
metabolic adaptation and the regulation of adaptive and innate immunity [115, 116] (for 
details see section B.3.3. Biological functions of mitochondrial dynamics). 
 
3. From mitochondria to mitochondrial network 
 Once perceived as solitary structures, mitochondria are now recognized as highly 
mobile along cytoskeletal tracks and dynamic organelles that continually fuse and divide 
[117] (Figure 10). Mitochondrial dynamics comprise all processes relating to the biogenesis, 
subcellular distribution and correct spatial recruitment, as well as the defined morphology of 
this organelle. The control and maintenance of mitochondrial dynamics requires a tight 
regulation by three large GTPases and their interacting factors. These mediators constitute 
the core machinery of mitochondrial dynamics which is well conserved from yeast to 
mammals (Figure 11). 
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.  
Figure 10: Different shapes of the mitochondrial network. 
 (adapted from [118]) 
 
 Moreover, the balance between fission and fusion rates varies in response to 
metabolic, cellular and environmental changes in order to maintain the bioenergetic 
homeostasis [118-120]. For instance, a shift towards fusion favours a tubular network which 
is beneficial in metabolically active cells. In contrast, quiescent cells have numerous small 
spherical mitochondria which are often referred as fragmented network. At cellular level, 
mitochondrial dynamics has been connected to several functions including mtDNA stability, 
respiratory capacity and apoptosis [121, 122]. Because of these functions, mitochondrial 
dynamics play a central role in the quality control of mitochondria and therefore, even mild 
defects can lead to disease [123]. 
3.1. Mitochondrial fusion 
 In mammals, the core mitochondrial fusion machinery consists of three large 
GTPases named mitofusins (MFN1/2) and optic atrophy 1 (OPA1) (Figure 11). Mitofusins 1 
and 2 are transmembrane GTPase proteins of 741 and 757 residues, respectively [124]. 
Both mitofusins are characterized by a GTPase domain associated to a coiled- coil domain 
(also name heptad repeat domain) in the NH2-terminal part to ensure the GTP binding. A 
second heptad repeat domain in the COOH-terminal side is required for the first step of the 
mitochondrial fusion, namely, the tethering of two adjacent mitochondria through a dimeric 
antiparallel coiled-coil structure. Although MFN1 is exclusively present in the OMM, it has 
been reported that MFN2 is also located in the endoplasmic reticulum (ER) and controls ER 
morphology and its tethering with mitochondria [125]. 
 OPA1 is a transmembrane dynamin-related GTPase protein of 960 to 1015 amino 
acids, located in the mitochondrial intermembrane space in soluble forms or is tightly 
attached to the IMM [124]. Whereas OPA1 sequence presents similar functional domains as 
mitofusins, OPA1 contains an NH1-terminal mitochondrial targeting sequence enriched in 
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positively charged amino acids which confer the mitochondrial localization of OPA1 and a 
region that is alternatively spliced (exons 4, 4b and 5b, 149-208 amino acids). Because of 
differential RNA splicing and protein processing, OPA1 can be processed from 8 distinct 
splice precursors into a long isoform or a short isoform. Although, under physiological 
conditions, the membrane fusion requires a combination of both long and short isoforms, the 
long isoform alone appears to be sufficient to enhance mitochondrial fusion under stress 
conditions [126]. 
 Since mitochondria have double membranes, mitochondrial fusion is a two-step 
process, where the outer and inner mitochondrial membranes fuse by sequential events 
[127]. First, MFN1 and MFN2 on the outer membrane of adjacent mitochondria form 
complexes in-trans that bring the opposing OMM to within approximately 100 Å of each other 
and tether mitochondria together [128]. This event induces outer-membrane fusion, followed 
by fusion of the inner membrane mediated by OPA1. Manipulation of mitochondria in vitro 
demonstrated that the fusion events are depending of GTP content and of mitochondrial 
membrane potential (MMP). Under limiting GTP concentrations, only the fusion of the OMM 
occurs and dissipation of the MMP disrupts the OMM fusion but not the IMM membrane 
fusion [129]. 
 Targeted deletion of any of the three fusion genes results in embryonic lethality, a 
dramatic reduction of mitochondrial fusion activity, impaired mitochondrial functions such as 
oxidative metabolism and disturbance in mitochondrial axonal transport [124]. Consequently, 
mutations in MFN2 or OPA1 are responsible for several human diseases such as obesity, 
Type 2 diabetes, Charcot-Marie-Tooth type 2A and autosomal dominant optic atrophy 
(review in [124]). 
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Figure 11: The core machinery of mitochondrial dynamics in mammals. 
(A) Schematic of main molecules involved in mitochondrial fusion and fission. The lengths of human 
proteins (numbers of amino acids) are indicated. Proteins are not drawn to scale. (B) Mitochondrial 
fusion is a highly regulated process that requires the coordination of both the inner mitochondrial 
membrane (IMM) and the outer mitochondrial membrane (OMM). The OMM uses proteins such as 
mitofusin 1 and mitofusin 2 (MFN1/2), which are GTPase proteins, whereas the IMM uses optic 
atrophy 1 (OPA1) to coordinate the joining of the membrane. Mitochondrial fission factor (Mff) and 
Fission-1 (FIS1) are anchored to the outer mitochondrial membrane where they recruit cytosolic Drp1, 
which then oligomerises and forms a ring-like structure around the mitochondria to constrict and divide 
them into multiple smaller mitochondria. TPR, tetratricopeptide repeat. 
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3.2. Mitochondrial fission 
 The main factor for controlled noncytokinetic mitochondrial division is a member of 
the conserved dynamin large GTPase superfamily covering diverse membrane fission 
functions termed DRP1 in mammals [130] (Figure 11). The typical dynamin domains of 
mammalian DRP1 (isoform 3, 699 residues) consist of multiple motifs including GTPase, 
middle and GTPase effector domains that are important for both intramolecular and 
intermolecular interactions. This isoform is broadly expressed in the organism including 
skeletal muscle, heart, kidney and liver with high to low levels of expression [124]. 
Interestingly, the brain is known to express a specific isoform derived from the insert of 37 
amino acids by alternative splicing of DRP1 mRNA (isoform 1, 736 residues) [124]. Under 
normal conditions, the localization of DRP1 is predominantly cytoplasmic, but an extensive 
pool of this protein is also associated to the OMM into spiral structures ringing the organelle, 
which, upon GTP hydrolysis, becomes constricted, thereby facilitating mitochondrial scission 
[130]. DRP1 is recruited to the mitochondrial membrane by receptor-like receptors including 
FIS1 and mitochondrial fission factor (Mff) on the OMM [131] (Figure 11). Surprisingly, Fis1 
inhibition by RNA interference does not disrupt the mitochondrial localization of DRP1 [132], 
whereas knockdown of Mff reduces the amount of DRP1 that is recruited to mitochondria 
[133], suggesting that Mff may play a dominant role in mitochondrial fission.  
 Although the exact mechanism remains mostly unresolved, multiple posttranslational 
modifications, including phosphorylation, ubiquitination and sumoylation, have been 
implicated in the regulation of DRP1 function and thereby of various activities during 
mitochondrial fission [120, 134]. For instance, three distinct phosphorylation sites have been 
described with contrary effects on fission activity (review in [120]). Cyclin B-dependent kinase 
promotes mitochondrial fission during mitosis through DRP1 phosphorylation at residue 
Ser585 whereas DRP1 phosphorylation at residue Ser637 through cAMP-dependent kinase 
(PKA) is thought to inhibit GTPase activity thereby promoting fusion. Calcineurin is the 
phosphatase responsible for the dephosphorylation of Ser637. The third site has been only 
reported in the Drp1 isoform 3 which is phosphorylated at residue Ser600 by the Ca2+/ 
calmodulin-dependent protein kinase Iα upon the induction of a calcium influx. 
 Inhibition of DRP1 function, either by expression of a dominant-negative variant or 
RNA interference, results in very elongated mitochondria that entangle and collapse [130, 
132]. Because DRP1 is essential for embryonic development and synapse formation, 
targeted deletion of DRP1, as for the three fusion genes, results in embryonic lethality due to 
abnormal brain development (review in [122]). 
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3.3. Biological functions of mitochondrial dynamics 
 During mitochondrial life, the shape, length and number of mitochondria are regulated 
by functional connection existing between mitochondrial dynamics and mitochondrial 
turnover comprising mitochondrial biogenesis and the segregation of impaired mitochondria 
by mitophagy [135]. These events are related to mitochondrial quality control in order to limit 
mitochondrial damage and ensure the integrity of a healthy mitochondrial population within 
the cells but also the integrity of the cell itself [136] (Figure 12). 
 
 
Figure 12: Biological functions of mitochondrial dynamics. 
The mitochondrial life cycle begins with growth and division of pre-existing organelles (biogenesis) and 
ends with selective sequestration and subsequent degradation of the dysfunctional or surplus 
mitochondrion by mitophagy (adapted from [115, 118]). 
 
 When mitochondria fuse with each other under normal condition, the outer 
membranes, the inner membranes and the intramitochondrial contents including mtDNA and 
metabolic byproducts (e.g. ATP, NAD+) are exchanged to unify the mitochondrial 
compartment which allows the complementation of contents from healthy and dysfunctional 
mitochondria (e.g. containing mtDNA with ROS-induced mutations) (review in [137, 138]). 
However a complete fusion is not always necessary. Mitochondrial fusion assays using 
photoactivatable green fluorescent protein indicate that organelles can undergo exchange of 
contents necessary for proper functioning while maintaining a desired morphology [139]. This 
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type of fusion event has been termed “kiss-and run”. The high frequency of such content 
exchange events implies that they are functionally important. 
 In contrast to fusion, mitochondrial division frequently generates two uneven daughter 
organelles. While one maintains an intact mitochondrial membrane potential (high MMP) and 
is able to re-fuse with the mitochondrial network, the second might be depolarized with a low 
respiration activity, depleted of OPA1 as well as high accumulation of mtDNA ROS-induced 
mutations, thereby preventing further cycles of fusion and subsequently leading to mitophagy 
[140-142]. In addition to the control of mitochondrial shape, fusion and fission are also 
important for the bioenergetic function of mitochondria [143, 144]. Fibroblasts that lack both 
MFN1 and MFN2 have reduced respiratory capacity, and individual mitochondria show great 
heterogeneity in shape and membrane potential. Cells that lack OPA1 show similar defects, 
with an even greater reduction in respiratory capacity [145, 146]. 
 The changes in the shape of mitochondrial network are also believed to affect the 
ability of cells to distribute their mitochondria to specific subcellular locations correlated to the 
specific bioenergetic requirements of the cell. This function is especially important in highly 
polarized cells, such as neurons (review in [147]). When DRP1 function is disrupted in 
neurons, it results in drastically reduced numbers of synaptic and dendritic mitochondria and, 
as a consequence, disruption of sustained neurotransmission and dendritic morphogenesis, 
respectively [148, 149]. 
 Along with the important consequences for mitochondrial integrity, mitochondrial 
morphology transitions have been described to be involved in retrograde signaling pathways 
through the production and release of metabolic byproducts from mitochondria to the 
cytoplasm and nucleus [118]. Retrograde signaling including calcium ions, ROS, 
ATP/ADP/AMP and NAD+/NADH is believed, at least under certain physiological states, to 
trigger adaptive cellular responses orchestrated by activating nutrient or redox sensors to 
coordinate changes in gene expression [150, 151]. While mitochondrial morphology 
transitions, via their effect on intracellular signaling pathways, can significantly impact cellular 
function and survival, other byproducts are involved in the initiation of apoptosis (review in 
[152]). Cells undergoing extensive network fragmentation resulting from disruption of 
mitochondrial fission are more susceptible to apoptotic cell death through mechanisms 
possibly involving the mitochondrial permeability transition pore (mPTP) by regulating the 
release of intermembrane-space proteins (e.g. cytochrome c, calcium ions) into the cytosol 
[84, 132]. 
 A growing body of evidence revealed an interesting functional connection between 
the machinery of mitochondrial dynamics and other organelles such as the endoplasmic 
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reticulum and peroxisomes in order to coordinate theirs activities in common such as steroid 
production and beta-oxidation of fatty acids, respectively [153, 154].  
 While mitochondrial dynamics are fundamental processes necessary for the health 
and the functional state of mitochondria, it becomes clear that the integration of mitochondrial 
shape changes into other cellular pathways is critically important for cellular function. Of 
note, a major unsolved issue is to understand how the bidirectional relationship between 
mitochondrial dynamics and the rest of cell is precisely coordinated in health. This point is 
particularly challenging in the explication of many pathological cases (e.g. Alzheimer’s 
disease, Parkinson’s disease) in order to establish clear cause-effect relationship. 
 
4. Circadian clock regulation of mitochondrial functions 
 Because of the close-fitting relationship between circadian rhythms and metabolism, it 
has been suggested that numerous mitochondrial functions may be regulated remotely or 
closely by the circadian clock, and therefore possibly may serve as the pivotal constituent in 
the interplay between the clock and cellular energy metabolism [155]. 
 With the emergence of the –omics technology (metabolomic, transcriptomic, genomic 
and proteomic), circadian databases provide evidences supporting circadian oscillations in 
mitochondrial functions in various tissues from mice including the SCN and the liver [156]. It 
has been reported that mRNA of several nuclear-encoded mitochondrial proteins involved in 
mitochondrial oxidative phosphorylation as well as key bioenergetic parameters (e.g.: 
mitochondrial membrane potential, cytochrome c oxidase activity and Ca2+ homeostasis) 
display circadian oscillations [17, 157, 158]. Together, these findings support the concept of 
temporal organization of mitochondrial metabolism and bioenergetics within important brain 
regions. 
 Accumulating evidence also supports circadian and/or diurnal oscillations in 
mitochondrial energy metabolism and associated oxidative pathways in peripheral tissues 
(review in [159]). Nevertheless, the underlying mechanism of the contributions of the 
molecular clock in mitochondrial functions remains mostly unclear. To better understand the 
molecular interplay, emerging data have been performed using tissues, cells and/ or isolated 
organelles from mice deficient in core clock components [160]. Outstandingly it is suggested 
that the mitochondrial metabolism seems rather to be controlled in a multilevel manner by the 
biological clock, including both transcriptional and post-transcriptional mechanisms. 
Furthermore, it has been reported that the clock transcription feedback loop produces cycles 
of NAD+ biosynthesis which in turn influence mitochondrial oxidative function through 
INTRODUCTION 
 
 
31 
modulation of rhythmic mitochondrial protein acetylation [160]. This rhythmicity of acetylation 
event is related to the circadian activation of the mitochondrial NAD+-dependent deacetylase 
sirtuin 3 (SIRT3). In support of, several reports show a correlation between circadian 
alterations in liver metabolome and differentially acetylated mitochondrial proteins supporting 
the idea that the circadian clock regulates mitochondrial energy metabolism, in part, by a 
nontranscriptional mechanism (e.g.: acetylation) [161]. SIRT3 can also activate or repress 
transcription of genes regulated by peroxisome proliferator-activated receptor gamma 
coactivator 1α (PGC-1α), a master regulator of mitochondrial biogenesis suggesting a 
circadian control of the mitochondrial biogenesis (review in [159, 161]). 
 Although compelling evidence arises regularly that normal mitochondrial respiratory 
chain function and bioenergetics are dependent on the molecular clock to meet daily 
fluctuations in cellular energy demands, the implication of the clock remains unresolved in 
the cellular mitochondrial network (governed by mitochondrial fusion and fission) considering 
that alterations in mitochondrial dynamics also impact cellular bioenergetics. Thus, 
perturbations in the circadian clock may be a key initiating factor in diseases linked to 
mitochondrial impairment such Alzheimer’s disease. 
 
 
C. Mitochondrial dysfunction: Aging, Amyloid β, and tau – a deleterious trio 
 AD is the most common neurodegenerative disorder among elderly individuals. It 
accounts for up to 80% of all dementia cases and ranks as the fourth leading cause of death 
among those above 65 years of age [162]. With the increasing average life span of humans, 
it is highly probable that the number of AD cases will dangerously rise since aging is the 
primary risk factor for major human pathologies, including cancer, diabetes, cardiovascular 
disorders, and neurodegenerative diseases [163]. The pathology of AD characterized by 
abnormal formation of amyloid plaques (aggregates of amyloid- β [Aβ]) and neurofibrillary 
tangles (NFT; aggregates of tau) was shown to be accompanied by mitochondrial 
dysfunction. However, the mechanisms underlying this dysfunction are poorly understood. 
Within the past few years, several cell culture models as well as single, double and, more 
recently, triple transgenic mouse models have been developed that reproduce diverse 
aspects of AD. These models help in understanding the pathogenic mechanisms that lead to 
mitochondrial failure in AD, and in particular the interplay of AD-related cellular modifications 
within this process [107, 164]. 
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1. Etiological factors and clinical symptoms 
 AD is a progressive, neurodegenerative disorder, characterized by an age-dependent 
loss of memory and an impairment of multiple cognitive functions [165]. From a 
histopathological point of view, AD encompasses reduced synaptic density, neuronal loss in 
selected brain areas, as well as Aβ-containing plaques and neurofibrillary tangles (NFTs) 
(Figure 13). Interestingly, positron emission tomography (PET) measurements demonstrate 
reduced energy metabolism in affected brain regions of AD patients and suggest that a 
cellular energy deficit may precede cognitive symptoms [166] (Figure 13). In addition, mood 
disorders and behavioral abnormalities such as circadian disruption are frequently 
associated with aging, depressive disorders and Alzheimer’s disease (AD). Nevertheless, a 
complete diagnosis is achieved only during post-mortem examination where the presence of 
Aβ-containing plaques and NFTs is confirmed in the brain region involved in learning and 
memory. 
 From a genetic point of view, AD can be classified into two different forms: rare 
familial forms (FAD) where the disease onset is at an age below 60 years (< 1% of the total 
number of AD case) and the vast majority of sporadic AD cases where onset occurs at an 
age over 60 years [167]. Genetic studies in FAD patients have identified autosomal dominant 
mutations in three different genes, encoding the APP (over 20 pathogenic mutations 
identified) and the presenilins PS1 and PS2 (more than 130 mutations identified) [168]. 
These mutations are directly linked to the increased production of Aβ from its precursor 
protein APP, suggesting a direct and pathological role for Aβ accumulation in the 
development of AD. 
 Although NFTs are a major hallmark in AD, mutations in the microtubule-associated 
protein tau (MAPT), protein responsible of NFTs formation, have not been yet linked to AD. 
Nevertheless, genetic studies showed that patients with fronto-temporal dementia (FTD) with 
Parkinsonism carry mutations linked to chromosome 17 (FTDP-17) [168]. Overall the findings 
that, in the FAD and FTDP, the genes encoding the proteins that are deposited in plaques 
and NFTs (APP and MAPT, respectively) are mutated suggested a causal role for these 
proteins in disease and led to generation of transgenic animal models with the aim to better 
understand the underlying mechanisms in the initiation and progression of the pathology. 
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Figure 13: The pathology of Alzheimer's disease. 
 (A) In comparison to normal brain (left panel), AD results in shrinkage of brain regions involving in 
learning and memory combined with major reductions in cellular energy metabolism in living patients 
(right panel: AD brain picture and Positron Emission Tomography). (B) The pathology of AD is 
characterized by two histopathological hallmaks: abnormal formation of amyloid plaques (aggregates 
of amyloid- β [Aβ]) and neurofibrillary tangles (NFT; aggregates of hyperphosphorylated tau) resulting 
in dysfunctional neuron and thus neurodegeneration (adapted from [166]). 
 
2. Histopathological Alzeihmer’s Disease related-features 
 Histopathologically, the brain of AD patients displays two hallmark lesions: 
extracellular Aβ-containing plaques and intracellular neurofibrillary tangles made of 
abnormally hyperphosphorylated tau [169, 170]. 
2.1. Cleavage pathway of APP and Aβ deposits 
 According to the first description of a “peculiar substance” by Alois Alzheimer, 
extensive evidence suggests that extracellular deposits composed of peptides of 39–43 
amino acids called amyloid beta (Aβ) protein play a pivotal role in the pathogenesis of AD. 
Aβ is derived from a larger precursor transmembrane protein called amyloid precursor 
protein (APP) (Figure 14.A.). Although still elusive, the role of APP has been suggested to be 
critical in neuron growth, survival, synaptic plasticity, cell adhesion and post-injury repair 
[171, 172]. APP is a type 1 integral 110–130 kDa glycoprotein, from 695 to 770 amino acids, 
with a large extracellular glycosylated amino-terminus, a shorter cytosplamic carboxy-
terminus and is partly inserted through its Aβ fragment in the plasma membrane as well as in 
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several organelles, such as endoplasmic reticulum (ER), Golgi apparatus, and possibly 
mitochondria [173]. APP can be proteolytically processed by α-, β- and γ-secretases involved 
in two pathways: a nonamyloidogenic pathway and an amyloidogenic pathway. 
 The non-amyloidogenic pathway is initiated by three enzymes (ADAM 9, ADAM10 
and ADAM17) belonging to ADAM family, a disintegrin- and metalloprotease- family enzyme 
with α-secretase activity. The cleavage occurs in the middle of the Aβ sequence, and results 
in two fragments: sAPPα (secreted ectodomain of APP) and a C-terminal small membrane-
anchored fragment (C83). The APPsα fragment is secreted and acts as a neurotrophic 
protein, whereas the CTFα is subsequently internalized and degraded by γ-secretase, a 
multimeric complex of the presenilin proteins PS1 and PS2, nicastrin, anterior pharynx 
defective 1, and presenilin enhancer 2, to form a short fragment termed p3 and Aβ 
intracellular cytoplasmic domain (AICD) [168, 173]. Furthermore, α-secretase is involved in 
the nonamyloidogenic pathway by cleaving APP within the Aβ domain, thus precluding Aβ 
formation. The amyloidogenic pathway involves sequential cleavages by β-secretase (BACE-
1) and γ-secretase (presenilins) and leads to release of neurotoxic Aβ peptides and AICD. 
BACE-1 initially mediates the cleavage of APP at a position located 99 amino acids from the 
C-terminus, forming a 99 amino acid membrane-anchored fragment termed C99 and βAPPs. 
While βAPPs is released into the extracellular space, C99 is subsequently cleaved by γ-
secretase producing Aβ and AICD. Since the γ–secretase can cleave C99 between residues 
38 and 43, Aβ peptides released exist in varying length. In healthy individuals, the 
predominant full-length Aβ peptide produced by brain cells throughout life is Aβ40 whereas 
the more amyloidogenic form Aβ42 is merely generated at a ratio of 10:1 [174, 175]. 
Interestingly, Aβ42 is more hydrophobic [176] and therefore is more readily to aggregate and 
form fibrils and induce neurotoxicity than the shorter form [177]. Nevertherless, in AD, both 
Aβ variants may form oligomeric aggregates, protofibrils and fibrils which eventually deposit 
as plaques. Although Aβ under the form of monomer does not appear toxic, the oligomer 
form has been described as the earliest pathological and toxic form by acting on oxidative 
stress, impairing the Ca2+ homeostasis and synaptic plasticity, driving to neuronal death [166, 
178]. 
INTRODUCTION 
 
 
35 
 
Figure 14: APP processing and tau phosphorylation. 
 (A) The amyloid-β (Aβ) peptide is derived by proteolytic cleavage from the amyloid precursor protein 
(APP). To liberate the Aβ species, APP must undergo two sequential endoproteolytic steps that are 
mediated by distinct enzymatic activities known as β- and γ-secretase. The first cleavage relases an 
ectodomain (βAPPs), and the last 99 amino acids of APP (C99) remains within the membrane. C99 is 
subsequently cleaved by γ -secretase complex, which generates Aβ40 and Aβ42 as well as AICD. (B) 
In AD, abnormally hyperphosphorylated tau contributes to a destabilized microtubule network, 
impaired axonal transport, and ultimately in neurofibrillary tangle (NFT) formation and neuronal death. 
 
2.2. Phosphorylation of tau and development of neurofibrillary lesions 
 Alois Alzheimer observed in the brain of his original patient a second lesion which co-
occurs with Aβ plaques. But unlike Aβ deposits, this protein aggregates were present 
intraneuronally. In the late 1980s, it was discovered that they are composed of abnormally 
hyperphosphorylated microtubule-associated protein tau [179, 180] (Figure 14.B.). 
 Human tau proteins belong to the family of microtubule-associated protein (MAP) that 
promote the assembly and the stabilization of the microtubular network, essential for normal 
axonal transport, cell polarity and shape as well as for normal crosstalk between 
mitochondria, cytoskeletal elements and plasma membrane [181]. Under physiological 
conditions, tau is predominantly localized to the axon for stabilization of microtubule, 
although partially present in soma but almost totally absent in dendrites. 
 Structurally, human tau proteins consist of a heterogeneous combination of six 
isoforms ranging from 50 to 70kDa and from 352 to 441 residues [182]. The isoforms are 
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derived by alternative mRNA splicing from a single gene (16 exons) located on chromosome 
17. Tau is also a phosphoprotein owing to its high numbers of phosphorylation sites (almost 
20% of the molecule, mostly due to high frequency of serine and threonine residues). 
Moreover its open structure affords easy access to many kinases including glycogen 
synthase kinase-3β (GSK-3β), cyclin-dependent kinase 5 (cdk5), extracellular signal-
regulated kinase 2 (ERK2), protein kinase A and C, calcium-calmodulin dependent protein 
kinase II (CaMKII), and mitogen-associated protein affinity-regulating kinases (MARK) 
(review in [183]). 
 As consequence of a high rate of easy accessible phosphorylation sites near the 
regions of the microtubules binding domains, tauopathies including AD and FTDP-17 are 
commonly distinguished by the hyperphosphorylation of tau combined with conformational 
changes that results in the dissociation of tau from microtubules, causing them to 
depolymerize, while tau is deposited in aggregates such as neurofibrillary tangles (NFTs). 
Indeed, hyperphosphorylated tau has been shown to interfere with neuronal functions, such 
as mitochondrial respiration and axonal transport which eventually lead to neurodegeneration 
[170]). While no mutations in the gene encoding tau have been identified in patients with AD, 
the phosphorylation rate in AD brains was shown to be three- to four- fold higher compared 
to normal human brains. 
 
3. Age-related Aβ and tau effects on mitochondria in AD. 
 Aging is an inevitable biological process that results in a progressive structural and 
functional decline, as well as biochemical alterations that altogether lead to reduced ability to 
adapt to environmental changes. Although aging is almost universally conserved among all 
organisms, the molecular mechanisms underlying this phenomenon still remain unclear. 
There are several theories of aging, in which free radical (oxidative stress), DNA, or protein 
modifications are suggested to play the major causative role [184, 185]. A growing body of 
evidence supports mitochondrial dysfunction as a prominent and early, chronic oxidative 
stress-associated event that contributes to synaptic abnormalities in aging and, ultimately, 
increased susceptibility to age-related disorders including Alzheimer’s disease (AD) [186]. A 
growing body of evidence supports that, on the one hand, mitochondrial decline observed in 
brain aging is a determinant and early chronic oxidative stress-associated event in the onset 
of AD and, on the other hand, the close interrelationship of this organelle with Aβ and tau is 
crucial in the pathogenic process underlying AD contributing to synaptic abnormalities and, 
ultimately, selective neuronal degeneration in AD (Figure 15). 
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Figure 15: Aging, Amyloid-Beta and tau: toxic consequences on mitochondria. 
The aging process may weaken the mitochondrial OxPhos (oxidative phosphorylation) system in a 
more general way by the accumulation of ROS-induced damage over many years thereby sowing the 
seeds for specific and destructive effects of Aβ and tau. ROS induce peroxidation of several 
mitochondrial macromolecules, such as mtDNA and mitochondrial lipids, contributing to mitochondrial 
impairment in the mitochondrial matrix. In AD, mitochondria were found to be a target of Aβ toxicity, 
which may act directly or indirectly on several proteins, leading to mitochondrial dysfunction. Indeed, 
Aβ was found in the OMM and IMM as well as in the matrix. The interaction of Aβ with the OMM might 
affect the transport of nuclear encoded mitochondrial proteins, such as subunits of the ETC CIV, into 
the organelle via the TOM import machinery. Aβ seems to be able to enter into the mitochondrial 
matrix through TOM and TIM or could be derived from mitochondria-associated APP metabolism. The 
interaction of Aβ with the IMM would bring it into contact with respiratory chain complexes with the 
potential for myriad effects on cellular metabolism. It may be that Aβ by these interactions affects the 
activity of several enzymes decreasing the ETC enzyme CIV, reducing the amount of hydrogen that is 
translocated from the matrix to the intermembrane space, thus impairing the MMP. The dysfunction of 
the ETC leads to a decreased CV activity and so to a lower ATP synthesis, in addition to an increased 
ROS production. Interestingly, deregulation of CI is mainly tau dependent, while deregulation of CIV is 
Aβ dependent, at both the protein and activity level. Aβ, amyloid-β; AD, Alzheimer’s disease; APP, 
amyloid precursor protein; CI, complex I; CII, complex II; CIII, complex III; CIV, complex IV; CV, 
complex V, Cu/Zn-SOD, copper/zinc superoxide dismutase; cyt c, cytochrome c; ETC, electron 
transport chain; IMM, inner mitochondrial membrane; MMP, mitochondrial membrane potential; 
MnSOD, manganese superoxide dismutase; mtDNA, mitochondrial DNA; OMM, outer mitochondrial 
membrane; ROS, reactive oxygen species; TIM, translocase of the inner membrane; TOM, 
translocase of the outer membrane. (adapted from [107]). 
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3.1. Mitochondrial aging—the beginning of the end in AD? 
 As mentioned above, within the cell, metabolism is a highly dynamic process where 
mitochondrial network is a prominent actor in regulation of both energy metabolism and 
apoptotic pathways. Although commonly termed as `powerhouses of cells`, mitochondria are 
rather paradoxical organelles by being major sources of ROS and at the same time being 
susceptible targets of ROS toxicity (see section B.2. Mitochondria: paradoxical organelles). 
Therefore, it is believed that accumulation of ROS-induced damages within the cells may 
contribute significantly in aging [187-189]. Given that mtDNA is more susceptible to ROS-
induced damages, especially in tissues with a high ATP demand like the brain and muscles 
[184, 190, 191], it has been described that accumulation of ROS-related mtDNA mutations 
can eventually result in the synthesis of mutant ETC proteins that, in turn, can lead to the 
leakage of more electrons and increased ROS production. This so-called ‘‘vicious cycle’’ is 
hypothesized to play a critical role in the aging process according to the mitochondrial theory 
of aging. However, age-associated change in mtDNA abundance seems to be tissue 
specific, as several studies have reported no change in mtDNA abundance with age in other 
than muscular tissues in both man and mouse [192, 193]. Many investigators have 
developed models for studying mitochondrial-related aging [194]. Among them senescence-
accelerated mice (SAM) strains are especially useful models to understand the mechanisms 
of the age-related mitochondrial decline (review in [107]). In addition to behavioral studies 
showing deficits in learning and memory, several research groups highlighted an age-related 
impairment of mitochondrial functions including a decrease of COX activity, mitochondrial 
ATP content, as well as a dysbalance of the protective antioxidant machinery inside 
mitochondria at a relatively early age [195-200]. Besides the progressive mitochondrial 
decline and increased oxidative stress, an age-related increase in mRNA and protein levels 
of amyloid-β precursor protein (APP), followed by formation of amyloid plaques, as well as 
tau hyperphosphorylation were also observed at an early age in the brain of SAMP8 mice 
[201-203]. Altogether, these data indicate that mitochondrial dysfunction is a highly relevant 
event in the aging process, which is also known as the primary risk factor for AD and other 
prevalent neurodegenerative disorders. 
3.2. Separate modes of Aβ and tau toxicity on mitochondria 
 Mitochondria were found to be a target for APP toxicity as both the full-length protein 
and Aβ accumulate in the mitochondrial import channels, and both lead to mitochondrial 
dysfunction [204-207]. Several evidences from cellular and animal AD models indicate that 
Aβ triggers mitochondrial dysfunction through a number of pathways such as impairment of 
OxPhos, elevation of ROS production, interaction with mitochondrial proteins, and alteration 
of mitochondrial dynamics followed by mitochondrial depletion from axons and dendrites and, 
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subsequently, synaptic loss [164, 173]. 
 Using neuronal PC12 cells and neuroblastoma cells SH-SY5Y overexpressing APP, 
several studies demonstrated that the extensive expression of APP leads to an enhanced 
mitochondrial impairment counting impaired mitochondrial respiration followed by a decrease 
in ATP generation, impaired MMP and complex IV activity in correlation with an increase of 
ROS content (review in [164]). When intracellular Aβ production is prevented by a γ-
secretase inhibitor, this restores nitric oxide and ATP levels, indicating a direct involvement 
of Aβ in these mechanisms. In addition, Aβ toxicity to native SH-SY5Y neuroblastoma was 
assessed by iTRAQ quantitative proteomics where numerous proteins, a quarter of which are 
involved in mitochondrial function and energy metabolism, were deregulated, indicating the 
key role of Aβ toxicity in the onset of mitochondrial dysfunction [208]. 
 From the first APP mice model (called PDAPP) bearing the human ‘‘Indiana’’ mutation 
of the APP gene (V171F) established in 1995 [209] to the most aggressive models, double-
transgenic APPS/L/PS1 (APPSwedish/London/PS1M141L) mice [210, 211], success in 
developing single and double transgenic mouse models that mimic the amyloid pathogenesis 
has greatly facilitated the understanding of physiopathological mechanisms underlying AD 
(review in [107, 164]). Interestingly, although each transgenic model is different in the 
mutation construction, they all displayed an age-related amyloid plaques formation combined 
with cognitive deficits as wells as mitochondrial dysfunction including mitochondrial 
membrane potential, decreased complex IV activity, depletion of ATP content and antioxidant 
defense mechanisms as well as an escalation of oxidative stress. 
 Since mitochondrial function relies heavily on its morphology and distribution (see 
section A.3), alterations of which have been increasingly implicated in neurodegenerative 
diseases, such as AD. Indeed, abnormal mitochondrial dynamics have been identified in 
sporadic and familial AD cases [212, 213] as well as in AD mouse model [214]; a distortion 
probably mediated by altered expression of dynamin-like protein 1 (DRP1), regulator of 
mitochondrial fission and distribution, due to elevated oxidative and/or Aβ-induced stress. 
This modification can disturb the balance between fission and fusion of mitochondria in favor 
of mitochondrial fission followed by mitochondrial depletion from axons and dendrites and, 
subsequently, synaptic loss [213]. 
 In its hyperphosphorylated form, tau, which forms the NFTs, the second hallmark 
lesion in AD, has been shown to block mitochondrial transport, which results in energy 
deprivation and oxidative stress at the synapse and, hence, neurodegeneration [215-217]. 
Based on the mutation in MAPT observed in FTD with Parkinsonism, a robust mouse model 
for tau pathology was created in 2001 [218]. The P301L tau–expressing pR5 mice (longest 
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four-repeat 4R2N) are characterized by an age-related occurrence of NFTs but also display 
several mitochondrial impairments. A mass spectrometric analysis of the brain proteins from 
these mice revealed mainly a deregulation of mitochondrial respiratory chain complex 
components (including complex V), antioxidant enzymes, and synaptic protein space [219]. 
The functional analysis demonstrated age-related mitochondrial dysfunction, together with 
reduced NADH ubiquinone oxidoreductase (complex I) activity as well as age-related 
impaired mitochondrial respiration together with depleted ATP content in pR5 mice model. 
Mitochondrial dysfunction was also associated with higher levels of ROS and the 
upregulation of antioxidant enzymes in response to oxidative stress in aged transgenic mice. 
Thus, this evidence demonstrated for the first time that not only Aβ but also tau pathology 
leads to metabolic impairment and oxidative stress by distinct mechanisms from that caused 
by Aβ in AD. Although Aβ impacts the mitochondrial dynamics in favor of mitochondrial 
fission, expression of human tau results in abnormal elongated mitochondrial architecture 
and distribution in cellular model as well as in both drosophila and mouse neurons [181, 220, 
221]. Furthermore, mitochondrial shape imbalance was consistent with impairment of 
mitochondrial function including substantial complex I deficit accompanied by decreased ATP 
levels and increased susceptibility to oxidative stress [222]. 
 Overall, these evidences highlighted new insights on the potential role of tau in 
disruption of mitochondrial dynamics and subsequently in mitochondrial metabolism 
observed in AD. Since not only Aβ but also tau pathology act on mitochondrial network 
integrity by distinct mechanisms in AD, both hallmarks should be investigated together in 
order to understand the likely interplay between them involved in the AD pathogenesis. 
3.3. Synergistic modes of Aβ and tau toxicity on mitochondria 
 Although Aβ and tau pathologies are both known hallmarks of AD, the question 
whether these two molecules could synergistically affect mitochondrial integrity have 
remained unresolved until recently. Several studies suggest that Aβ aggregates and 
hyperphosphorylated tau may block the mitochondrial carriage to the synapse leading to 
energy deficiency and neurodegeneration [223]. Remarkably, intracerebral Aβ injections 
amplify preexisting tau pathology in several transgenic mouse models [224-226], whereas 
lack of tau abrogates Aβ toxicity [170, 216]. Consistent with the in vivo evidence, incubation 
of isolated mitochondria from pR5 mice with either oligomeric or fibrillar Aβ species caused 
an impairment of the mitochondrial membrane potential and respiration [227]. While both 
oligomeric and fibrillar Aβ species are toxic, they exert different degrees of toxicity on 
mitochondria – aged-related mitochondrial sensitivity to oligomeric species being more 
significant. 
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 Additionally, in recent years triple transgenic mouse models have been established 
that combine Aβ and tau pathologies. In these models the contribution of both AD-related 
proteins on the mitochondrial respiratory machinery and energy homeostasis has been 
investigated in vivo (review in [107]). In a novel triple transgenic mouse model 
(pR5/APPSw/PS2 N141I)—the tripleAD mouse, mitochondrial dysfunction was investigated 
using proteomics followed by functional validation [228]. Particularly, deregulation of activity 
of complex I was found to be tau dependent, whereas deregulation of complex IV was Aβ 
dependent, in 10-month-old tripleAD mice. The convergent effects of Aβ and tau led already at 
the age of 8 months to a depolarization of mitochondrial membrane potential in tripleAD mice. 
Additionally, age-related oxidative stress also plays a significant part in the deleterious 
vicious cycle by exaggerating Aβ- and tau-induced disturbances in the respiratory system 
and ATP synthesis, finally leading to synaptic failure. 
 These evidence complement those obtained in another triple transgenic mouse model 
3xTg-AD (P301Ltau/APPSw/PS1 M146L) exhibiting mitochondrial dysfunction including age-
related decrease in the activity of regulatory enzymes of OxPhos such as COX, or of the 
Krebs cycle such as pyruvate dehydrogenase [229, 230]. Importantly, mitochondrial 
bioenergetics deficits were found to precede the development of AD pathology in the 3xTg-
AD mice. Extensive evidences support that AD-specific changes including cognitive 
impairments, Aβ accumulation, Aβ plaques, and mitochondrial dysfunction seem to occur at 
an earlier onset from single, double up to triple AD transgenic mice models. Together, the 
findings highlight the key role of mitochondria in AD pathogenesis and consolidate the notion 
that a synergistic effect of tau and Aβ enhances the pathological weakening of mitochondria 
at an early stage of AD. 
3.4. The Alzheimer’s disease mitochondrial cascade hypothesis 
 Until recently, the leading AD molecular paradigm, the “amyloid-β cascade 
hypothesis”, was the main pathogenetic model of AD based on studies of rare autosomal 
dominant variants representing less than 1 % of the AD patients and its role in the majority of 
sporadic AD cases is unclear. In 2004, Swerdlow and Kahn proposed an alternative 
paradigm where mitochondria play a prominent role since morphological, biochemical and 
genetic abnormalities of the mitochondria that have been extensively reported in several AD 
tissues over the last decade [231, 232] (Figure 16). Accumulation of somatic mtDNA 
mutation over an individual’s lifespan may cause mitochondrial decline leading to energy 
failure and increased oxidative stress. Eventually, once the age-related mitochondrial decline 
reaches a threshold, it may affect APP expression and processing as well as accumulation of 
Aβ, which in a vicious cycle may reinforce the mtDNA damage and the oxidative stress. Aβ 
directly triggers mitochondrial dysfunction through interaction with different mitochondrial 
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targets including the outer mitochondrial membrane, inter-membrane space, inner 
mitochondrial membrane, and the matrix (review in [173, 233]). In parallel, Aβ can influence 
the rate of hyperphosphorylation of tau and NFTs formation that in turn disturb mitochondrial 
trafficking and function within the cell. Overall, several vicious cycles are interconnected 
within a larger vicious cycle where mitochondria play a key role in the cascade of events 
leading to AD. All of them, once set in motion, amplify their own processes, thus accelerating 
the development of AD. Finally, the critical role of mitochondria in the early pathogenesis of 
AD may make them attractive as a preferential target for treatment strategies. 
 
 
Figure 16: The AD mitochondrial cascade hypothesis. 
As age-associated mitochondrial decline progresses, Aβ production increases and accumulation of Aβ 
reinforces in turn mitochondrial dysfunction, ROS production and neurofibrillary tangles (NFT) 
formation. All the intermediate vicious cycles are interconnected within a larger vicious cycle which 
amplify their own processes and eventually lead to synaptic failure and neurodegeneration. 
 
4. Mitochondria: potential target of neurosteroids 
 In 1981, Baulieu and coworkers first demonstrated that steroid production also occurs 
within the nervous system itself, independently of peripheral glands [234]. In contrast to 
steroid hormones produced by endocrine glands, this category of molecules was named 
neurosteroids and defined as neuroactive molecules acting on the nervous system in an 
auto/paracrine manner. Neurosteroids exhibit several biological functions that are essential 
during the development as well as in adult brain [235]. Given their ability to easily cross 
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cellular membrane, neurosteroids can act on nuclear receptors and therefore induce gene 
transcription. They can also interact with membrane receptors such as GABAA [236] and 
NMDA [237] receptors. The subsequent negative or positive allosteric modulation is specific 
to neurosteroids involved. 
 Taking place in mitochondria and endoplasmic reticulum (ER), neurosteroidogenesis 
encompasses several criss-cross biochemical pathways leading to generation of several 
neurosteroids derived from cholesterol and other blood-borne steroidal precursors. The first 
step, which is also the limiting step in the production of neurosteroids, is the transfer of 
molecules of cholesterol from the outer membrane to the inner mitochondrial membrane. The 
first enzyme, the cytochrome P450 cholesterol side chain cleavage enzyme (P450scc), is 
located at the inner side of the mitochondrial membrane which permits the conversion of 
cholesterol to pregnenolone (PREG), precursor of all steroid hormones. PREG is then 
carried to the ER where the steroid is subsequently converted into neuroactive steroids. 
Additionally, recent findings demonstrated that mitochondrial fusion precedes and is required 
for steroid biosynthesis [154]. It has been suggested that mitochondrial fusion, through 
regulation of MFN2 expression, promotes the association of mitochondria with mitochondria-
associated membranes (MAM). This association might then facilitate a non-vesicular traffic of 
PREG between the two compartments. 
 In the recent years, compelling evidence has shown that neurosteroids interact with 
mitochondria to counteract oxidative stress occurring in age-related diseases such as 
Alzheimer’s disease (AD). In particular, estrogen treatment was shown to alleviate 
mitochondrial deficits including impairment of mitochondrial respiration and enhanced ROS 
level as well as excitotoxicity caused by imbalance in Ca2+ homeostasis, but also to enhance 
antioxidant defense in humans, animals and cellular models (review in [238]). 
 More recently, it has been reported that a mitochondrial enzyme named Aβ- binding 
alcohol dehydrogenase (ABAD), which is involved in the conversion of estradiol into estrone, 
is up-regulated in brains of AD mice [239] and AD patients [240]. It has been suggested that 
ABAD is directly modulated by Aβ peptide exacerbating mitochondrial dysfunction induced by 
Aβ (Figure 17). Moreover, to counteract the Aβ-ABAD interaction, new treatments with decoy 
peptide or ABAD-specific compound inhibitor (AG18051) were able to restore mitochondrial 
deficits (mitochondrial respiration, activity of mitochondrial respiratory complexes and ROS 
levels) in cellular and animal models [107, 241, 242] (for further details see Appendix D). 
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Figure 17:Aβ–ABAD interaction and estradiol level in mitochondria. 
 (A) Mitochondrial estradiol content is very low compared with total estradiol level in SH-SY5Y 
neuroblastoma cells. Unpaired t-test, ***p < 0.001. (B) Estradiol level is differently influenced by Aβ 
peptide in the cytosol and in mitochondria. Paired t-test, *p < 0.05, ***p < 0.0001. (C) Aβ1-42 peptide is 
able to modulate ABAD function by binding directly to this mitochondrial enzyme. This results in the 
decrease of ABAD-induced conversion of estradiol into estrone with a concomitant increase of ROS 
levels and an impairment of the ETC in mitochondria. ABAD, Aβ -binding alcohol dehydrogenase 
(adapted from [107]) (for further details see Appendix A). 
 
 Although the neuroprotective effect of estrogen on mitochondria has been widely 
investigated, the potential role of other neurosteroids on mitochondria is rather poorly 
understood. The need to better understand the separate but as well the potential synergistic 
effects of different neurosteroids on mitochondrial function is considered as an emerging 
research field in the context of new drug development for AD management. 
 
5. Circadian disruption in aging and AD 
 Aging is an inevitable biological process that results in a progressive loss of 
physiological integrity, as well as biochemical alterations that altogether lead to reduced 
ability to adapt to environmental changes and to increased vulnerability to death. Although 
aging is almost universally conserved among all organisms, the molecular mechanisms 
underlying this phenomenon still remain unclear. There are several theories of aging, in 
which free radical (oxidative stress), DNA, or protein modifications are suggested to play the 
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major causative role [163, 184, 185]. A growing body of evidence supports mitochondrial 
dysfunction as a prominent and early, chronic oxidative stress-associated event that 
contributes to synaptic abnormalities in aging and, ultimately, increased susceptibility to age-
related disorders including Alzheimer’s disease (AD) [186]. In situations of both physiological 
and pathological aging such as AD, several lines of evidence indicate an alteration of the 
circadian machinery, worsened in AD patients, leading to an increased number of nocturnal 
awakenings, a higher proportion of night-time wakefulness, reduced sleep efficiency and a 
reduction in rapid eye movement (REM) sleep [243-245]. Recent research suggests that 
hormonal changes during aging may influence negatively both homeostatic and circadian 
sleep regulatory [246, 247]. Although basic clock properties (e.g. period length, amplitude 
and phase) of peripheral cells did not change during aging, when in the presence of human 
serum from older donors, peripheral cells displayed shortened period length and advanced 
the phase of cellular circadian rhythms, indicating that a circulating factor might alter human 
chronotype [246]. Overall these evidences highlighted the bidirectional relationship between 
aging and daily “circadian” behavior in humans which in the case of disruption may contribute 
to pathological processes as AD. 
 In addition to circadian behavioral disruption, AD is associated with the deposition of 
aggregates named Aβ plaques and neurofibrillary tangles in the brain (for details see section 
B). Interestingly, Holtzman and colleagues demonstrated that Aβ dynamics is regulated by 
orexin and the sleep- wake cycle suggesting a key role of the sleep- wake cycle in the Aβ 
aggregation process in AD [248]. While it is known that progression and worsening of 
cognitive impairment are paralleled by circadian disturbances in AD patients, the underlying 
mechanisms of when and how circadian rhythms influence the pathogenesis of AD, 
particularly the aggregation processes, remain mostly unresolved [249]. Of note, alterations 
of the circadian rhythms can already be observed in patients with mild AD, exhibiting an 
increased sleep propensity during daytime. Recent studies suggest that “sleep problems” 
already correlated with “subjective cognitive slowing” in Mild Cognitive Impairment (MCI) 
patients [250]. 
 Degeneration of brain nuclei that contain sleep circuits and circadian clock-regulating 
circuits in the SCN [251], hypothalamus [252], basal forebrain [253] and brainstem [254] is 
one of the possible causes of sleep defects in patients with neurodegenerative diseases 
(review in [244]). Furthermore, it is believed that one of the main features of 
neurodegenerative disease is increased oxidative stress which leads to an increased 
accumulation of DNA oxidation product causing thus amplification of the processes and 
eventually synaptic failure and neurodegeneration (see section B. 2. Mitochondria: 
paradoxical organelles). As mentioned above in section A.3. Circadian rhythms and 
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metabolism, circadian clock and metabolism are closely linked. Indeed, disruption of the 
circadian clock leads to numerous defects in metabolism and to the development of 
metabolic syndromes, which are known to be associated with increased oxidative damage. 
 Taken together, this evidence of the correlation between neurodegeneration and 
circadian clock dysfunction raises important question. What comes first and when? The egg 
or the chicken? Given the AD mitochondrial cascade hypothesis, it is possible that circadian 
disturbance in both aging and AD belong to its own vicious cycle that amplify its own process 
along the vicious cycles involved in the AD mitochondrial cascade hypothesis. Of note, given 
that mitochondrial metabolism was connected, on the one hand, with circadian rhythms and, 
on the other hand with the pathogenesis of AD, it would be a thrilling challenge to highlight 
the impending interplay between mitochondrial network, circadian rhythm in both 
physiological and pathological conditions in order to expand our perspective on the cell 
biology common to neurodegenerative diseases. 
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Summary
Circadian clocks are tightly connected to metabolic processes through reciprocal 
regulation from metabolites to transcription factors. Here, we demonstrate evidence of a 
novel coupling mechanism via mitochondrial morphology that is essential for circadian 
production of adenosine triphosphate (ATP). Within the cell, the mitochondrial network is a 
prominent actor in regulation of energy metabolism. Both in vivo and in vitro, mitochondrial 
fission-fusion dynamics are strongly clock-controlled, as well as all other aspects of 
mitochondrial bioenergetic homeostasis, including oxidative phosphorylation, generation of 
ATP and reactive oxygen species (ROS). We show that circadian control of the activity of the 
dynamin-related protein 1 (DRP1) is required for circadian oscillations of the mitochondrial 
network. Genetic or pharmacological abrogation of DRP1 activity abolished circadian 
mitochondrial network dynamics and mitochondrial respiratory activity, as well as eliminated 
circadian ATP production. Our findings provide new insights into a crosstalk governing the 
interplay between mitochondrial dynamics and circadian cycles. 
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Highlights:
· The circadian clock controls rhythmic mitochondrial dynamics and metabolic flux. 
· The key protein regulating cell cycle-based mitochondrial morphology, DRP1, is 
phosphorylated in circadian fashion. 
· Genetic or pharmacological suppression of DRP1 activity eliminates circadian ATP 
production. 
· Blockade of DRP1 leads to an impaired core circadian clock. 
 
eTOC Blurb/ In Brief: 
The circadian clock globally regulates energy metabolism and mitochondrial 
morphology. Even in nondividing tissues, it co-opts cell cycle-based rhythmic control of 
DRP1 phosphorylation to direct circadian mitochondrial morphology. This control is essential 
for circadian production of ATP, and it furthermore feeds back to influence the core circadian 
clock. 
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Introduction
The circadian clock is a hierarchical network of oscillators that synchronize a wide 
variety of metabolic pathways to the optimal time of day, anticipating periodic changes of the 
external environment for all living organisms, from cyanobacteria and fungi (Brunner and 
Schafmeier, 2006) to insects (Rosato et al., 2006) and mammals (Gachon et al., 2004). 
Over the years, a growing body of evidence suggested specifically that energy 
metabolism and cellular mechanisms defending against oxidative damage are coordinated 
by the circadian clock (Bailey et al., 2014, Kalsbeek et al., 2011, Langmesser and Albrecht, 
2006). Conversely, disruption of the clock impairs metabolic homeostasis (Bugge et al., 
2012, Cho et al., 2012, Marcheva et al., 2010, Turek et al., 2005). This close relationship 
between circadian and metabolic cycles has been verified in studies demonstrating that the 
circadian clock exerts its control over metabolism by (i) controlling the expression of genes 
and enzymes involved in metabolic processes (Eckel-Mahan et al., 2012, Feng et al., 2011, 
Vollmers et al., 2009), (ii) intertwining nuclear receptors and nutrient sensors with the clock 
machinery, e.g. PER2/CLOCK and SIRT1 (Asher et al., 2008, Nakahata et al., 2008), PER2 
and PPARα/REV-ERBα (Schmutz et al., 2010), CRY1 and AMPK/GCR (Lamia et al., 2011, 
Lamia et al., 2009), REV-ERBα and HDAC3 (Zhang et al., 2015), and/or (iii) regulating 
metabolite levels (e.g. NAD+/NADH, ATP/ADP, cAMP) (Nakahata et al., 2009, O'Neill et al., 
2008, Peek et al., 2013, Ramsey et al., 2009). In reverse, various hormones, nutrient 
sensors, redox sensors and metabolites not only act as clock output but can in turn also 
regulate the biological clock by acting as input signals (reviewed in (Bass, 2012, Eckel-
Mahan and Sassone-Corsi, 2013)). 
Within this network, the mechanistic relationship between the clock and the 
mitochondrial network remains mostly elusive. Mitochondria are highly dynamic cellular 
organelles playing a major role in cellular energy metabolism and homeostasis via 
generation of several metabolites including ATP (Scheffler, 2001). Several studies have 
shown diurnal oscillations in key mitochondrial bioenergetic parameters including expression 
of genes involved in mitochondrial respiration, membrane potential, and cytochrome c 
oxidase activity in the suprachiasmatic nuclei (Isobe et al., 2011, Panda et al., 2002). 
Moreover, one regulatory node for mitochondrial oxidative metabolism is the level of 
NAD+/NADH which regulates the activity of mitochondrial sirtuins and thereby mitochondrial 
protein acetylation (Nakahata et al., 2009, Peek et al., 2013). However, in the other systems 
global control of mitochondrial function is strongly coordinated with morphology. For 
example, in response to cues from the cell cycle, a tightly regulated equilibrium between 
opposing mitochondrial fusion and fission activities is required to meet changing demands for 
energy production and adjust mitochondrial function (Frank, 2006, Mishra and Chan, 2014, 
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Westermann, 2010). In this paper, we show that this cell cycle-mediated control is in effect 
co-opted by the circadian clock: even in nondividing cells and tissues, circadian regulation of 
dynamin-related protein 1 (DRP1) results in cycles of fission and fusion that are essential for 
circadian oscillations in ATP production. Our findings are consistent with the existence of a 
crosstalk between the clock and the mitochondrial network that maintains bioenergetic 
homeostasis in response to circadian metabolic changes. 
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Results
The circadian clock regulates cellular metabolic state. 
Extensive circadian transcriptomic and metabolomic profiling has revealed the 
existence of a mutual and dynamic relation between the timing of the molecular clock and the 
network of metabolic pathways modulating energy charge and redox state. These studies 
were performed in different organs and matrices of both mice and men (Dallmann et al., 
2012, Eckel-Mahan et al., 2012, Minami et al., 2009, Patel et al., 2012). To eliminate 
potential systemic and environmental influences upon metabolic measurements, we 
rigorously examined the influence of the circadian clock on metabolic flux in cultured cells in 
vitro. Global metabolomic profiles were obtained in cultured U2OS cells over the course of 24 
hours after synchronizing circadian clocks with dexamethasone (Balsalobre et al., 2000), 
while the temporal pattern of selected metabolites including ATP, NAD+/NADH and reactive 
oxygen species (ROS) was determined in cultured human fibroblasts after synchronizing 
circadian clocks with serum shock (Balsalobre et al., 1998). Using gas and liquid 
chromatography with a mass spectrometer (GC/LC-MS) as previously (Dallmann et al., 
2012), we identified a total of 228 metabolites in cell pellets from cultured U2OS cells (Fig.1, 
Table S1). Consistent with but more dramatic than previous findings (Dallmann et al., 2012, 
Eckel-Mahan et al., 2012, Minami et al., 2009), periodic analysis of cellular data (Hughes et 
al., 2010) showed that ~29% of these metabolites (67 of 228) displayed circadian rhythmicity 
(P<0.05) (Fig. 1B-D, Table S1). The majority of these identified metabolites are related to 
numerous metabolomic pathways involved in redox state and energy metabolism, including 
glycolysis and the TCA cycle, branched amino-acid metabolism and GSH/GSSG metabolism 
(Fig. 1E-G). In support of previous findings (Peek et al., 2013), we particularly observed 
robust circadian rhythmicity in total ATP content (Fig. 2A), in NAD+ and NADH levels (Fig. 
S1A, C), and in mitochondrial ROS content (Fig. S2). These circadian fluctuations occurred 
with a peak at 16 hours post-shock and a trough at 28 hours post-shock in cultured 
fibroblasts. Similarly, these metabolites displayed a circadian pattern in brain homogenates 
from wildtype mice, with maximal levels near the beginning of the resting period (circadian 
time CT4) and a trough occurring at CT16 (start of the activity period) (Fig. 2B and Fig. S1B, 
D). The role of core molecular clock transcription factors on ATP rhythmicity was further 
confirmed in mouse embryonic fibroblasts (MEFs) isolated from mice deficient in the clock 
transcriptional repressors (PER1 and PER2) that displayed completely abolished ATP 
rhythms compared to control MEFs, establishing a role for the circadian clock in cellular ATP 
oscillations (Fig. 2C). 
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Together, these metabolomics data show that circadian regulation of mitochondrial 
function likely extends across multiple steps within the oxidative phosphorylation process, 
and we therefore began to dissect the sources of this control. 
 
Circadian clock synchronizes mitochondrial ATP oscillations via oxidative 
metabolism. 
As ATP molecules are produced by two main pathways, cellular glycolysis and 
mitochondrial oxidative phosphorylation (OxPhos), we monitored ATP content in 
synchronized fibroblasts in the presence of an ATP synthase inhibitor (oligomycin, 2 μM) or 
glycolysis inhibitor (2-deoxy-glucose, 4.5 g/L) in order to determine which pathway is causally 
involved in ATP oscillations (Fig. 3A). We observed that the circadian oscillations in ATP 
were significantly dampened in the presence of oligomycin. In contrast, only the amplitude 
was decreased in the presence of 2-deoxy-glucose. These findings reveal that the circadian 
rhythm of ATP is primarily generated from mitochondrial oxidative phosphorylation rather 
than through glycolytic contributions. 
In order to confirm that the observed ATP oscillations are not associated with 
synchronous cell cycle (Marcussen and Larsen, 1996), we evaluated ATP content in 
synchronized fibroblasts treated with cytosine β-D-arabinofuranoside (AraC, 100 μM) to 
eliminate cell division (Fig 3B). The AraC-induced inhibition of the cell cycle was confirmed 
at 24 hours post-shock using a BrdU Cell Proliferation Assay (Fig. S3A). Although 
pharmacological disruption of cell division with AraC led to a somewhat decreased level of 
rhythmic ATP content compared to untreated controls, no alteration in the amplitude of 
circadian ATP production was observed (Fig. 3B). To ensure that cell division could play no 
role in the oscillations we observed, and also demonstrate the significance of our findings in 
vivo, we further examined circadian ATP levels in adult brain, where dividing cells represent 
a tiny minority. Here, too, ATP levels were circadian (Fig. 2B). Together, these results 
demonstrate that circadian fluctuations in ATP levels mainly originated from mitochondrial 
oxidative metabolism, independent of the cell cycle. 
To examine potential sources of circadian ATP levels, we further examined clock-
related regulation of mitochondrial oxidative metabolism using a Seahorse Bioscience XF24 
Flux Analyzer, measuring real-time oxygen consumption rate (OCR) in synchronized 
fibroblasts at 16 hours post-shock, corresponding to the total ATP peak, and at 28 hours 
post-shock, corresponding to the total ATP trough (Fig. 3C). OCR was assessed by 
sequential injection of (i) the ATP synthase inhibitor oligomycin (1μM) to determine the OCR 
devoted to ATP synthesis counterbalancing against ATP consumption (also called ATP 
turnover), (ii) an uncoupling agent, FCCP [carbonyl cyanide p (trifluoromethoxy) 
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phenylhydrazone] (0.7μM) to measure maximal respiration in the absence of a proton 
gradient, and (iii) inhibitors of activities of complexes I-III rotenone (2μM) and antimycin A 
(4μM), respectively, to evaluate the OCR of non-mitochondrial respiration (Fig. 3C). In 
parallel with the rhythmic oscillations in ATP content that we documented, we observed a 
lower OCR in the basal and maximal respiration (~19% and ~14%, respectively) as well as in 
ATP turnover (~24%) at 28 hours post-shock compared to the OCR measured at 16 hours 
post-shock (Fig. 3D). The spare respiratory capacity as a measure of the cellular ability to 
respond to an energetic demand as well as reflecting how closely to its theoretical maximum 
a cell is to respiring, was higher (~48%) at 28 hours post-shock compared to 16 hours post-
shock (Fig. S3B). By contrast, the rates of oxygen consumption were not coupled to ATP 
production – i.e. those required to overcome the natural proton leak across the inner 
mitochondrial membrane (Fig. S3C), and those related to glycolysis indicated by the 
extracellular acidification rate (ECAR) (Fig. S3D) - were unchanged at different time points. 
Finally, we plotted the bioenergetic profile of synchronized human skin fibroblasts, 
representing OCR (basal respiration) versus ECAR (glycolysis) at 16 hours and 28 hours 
post-shock (Fig. 3E). Matching with the rhythmic oscillations in the ATP content, cells 
switched between a metabolically active state corresponding to 16 hours post-shock and a 
metabolic resting state corresponding to 28 hours post-shock, independently of glycolysis. 
Global circadian oscillations at every level of the mitochondrial function might be explained 
by a variety of mechanisms. It is formally possible that circadian control of expression of a 
key rate-limiting mitochondrial enzyme would be sufficient. We show in Fig. S4 circadian 
oscillations of gene expression in mitochondrial subunits of Complexes I (Fig. S4A), IV (Fig. 
S4B) and V (ATP synthase, Fig. S4C) in human fibroblasts. A second more persuasive idea 
is that circadian control of NAD+/NADH levels feeds back to control mitochondrial output 
(Asher and Schibler, 2011, Nakahata et al., 2009, Peek et al., 2013). Recently, it has been 
shown that changed NAD+/NADH levels can affect activity of the mitochondrial deacetylase 
SIRT3, thereby affecting global mitochondrial protein acetylation. Elegantly, such a 
mechanism could also account for non-circadian feeding driven oscillations in mitochondrial 
function (Peek et al., 2013). A third idea relates to mitochondrial morphology: in the case of 
the cell cycle, direct regulation of mitochondrial morphology itself regulates all aspects of 
oxidative respiration (Mishra and Chan, 2014, Westermann, 2010), and mitochondria from 
liver deficient in the clock gene Bmal1, or from worms deficient in the Bmal1 homolog aha-1, 
are swollen and dysfunctional (Jacobi et al., 2015). 
 
Variations in mitochondrial architecture are mediated by circadian clock. 
As we discuss above, one way in which mitochondrial function is globally controlled is 
via morphological dynamics. Yet, only very recently evidence demonstrating circadian control 
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of this aspect has started surfacing, for example in peritoneal macrophages during infection 
(Oliva-Ramirez et al., 2014), and in comparing mitochondrial morphology and function 
between wildtype and Bmal1 knockout mice (Jacobi et al., 2015). Since mitochondria are 
highly dynamic organelles (Detmer and Chan, 2007, Westermann, 2010), we investigated 
whether the circadian clock intervenes globally in control and maintenance of the 
mitochondrial network architecture (Fig. 4). Hence, we visualized mitochondrial morphology 
in Mitotracker CMXROS-treated synchronized human primary skin fibroblasts by confocal 
microscopy (Fig. 4A). We observed that mitochondrial network morphology displayed a 
circadian rhythmicity with three distinct states (tubular, intermediate or fragmented at 8, 16 or 
24 hours post-shock, respectively). In parallel, we investigated the relationship between clock 
and mitochondrial architecture in brain and liver sections from wildtype mice at CT0 (onset of 
subjective day or rest period) and CT12 (onset of subjective night or activity period) by 
immunohistochemical labeling of VDAC (voltage-dependent anion channel), an outer 
mitochondrial membrane porin (Fig. 4B). Consistent with our in vitro observations, the 
mitochondrial network in both central and peripheral tissues exhibited a tubular morphology 
at CT0 (beginning of the rest period), while mitochondria appeared in a fragmented state at 
CT12 (beginning of the activity period). 
 
Clock control of DRP1 activity modulates mitochondrial metabolism. 
To understand how the circadian clock might control mitochondrial dynamics, we first 
analyzed circadian transcript levels of genes important for mitochondrial fusion (mitofusins 1 
and 2, MFN1 and 2; optic atrophy 1, OPA1) and fission (dynamin-related protein1, DRP1; 
human fission protein 1, hFIS1) (Benard and Karbowski, 2009, Youle and van der Bliek, 
2012). None of the genes displayed a circadian expression pattern in clock-synchronized 
fibroblasts (Fig. 4C, S5), suggesting that 24-hour oscillations observed in the mitochondrial 
network architecture in vitro and in vivo might be controlled by post-transcriptional 
modifications of mitochondrial shaping proteins. 
In the case of the cell cycle, oscillations in mitochondrial fusion and fission are 
regulated via phosphorylation and activation / inactivation of DRP1 protein by cyclin-
dependent kinases (Santel and Frank, 2008). Therefore, we next considered a potential 
contribution of the biological clock in the post-translational modification of DRP1 by 
phosphorylation at the key serine residue 637 (S637) using immunoblotting against DRP1 
and phosphorylated DRP1 in lysates from synchronized confluent human primary skin 
fibroblasts (Fig. 5A). Again to demonstrate that the results were not cell-division-dependent, 
and to show their relevance in vivo, the same experiment was performed using extracts from 
brain of wild-type mice maintained in constant darkness (Fig. 5B). While total DRP1 protein 
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did not display circadian oscillation in both cell lysates and brain lysates, Ser637 
phosphorylated DRP1 exhibited ~24hour rhythms with peaks occurring at 16 hours post-
shock and at CT12 (onset of the subjective night), respectively. Taken together, these results 
suggest that the in vitro and in vivo mitochondrial network remodeling is controlled by the 
circadian clock, accompanied by the same post-translational modulation of DRP1 protein that 
directs such remodeling in other contexts. To determine whether circadian modulation of 
mitochondrial fission and fusion might directly regulate circadian mitochondrial output, we 
first took a pharmacological approach, treating clock-synchronized cells with the 
mitochondrial division inhibitor, mdivi-1 (50 μM). Surprisingly, treatment with this drug 
completely abolished ATP oscillation compared to untreated human skin fibroblasts (Fig. 
6A). To further confirm whether inhibition or absence of DRP1 is able to impact ATP 
oscillation, we evaluated ATP content in MEFs from Drp1-/- mice as well as in hippocampi of 
adult Drp1-/- mice kept in constant darkness (Fig.6B-C) (Oettinghaus et al., 2015). MEFs 
lacking DRP1 did not display ATP oscillations compared to control MEFs (Fig 6B). In 
addition, ATP content was evaluated at CT4, near the beginning of the rest period and at 
CT16, the beginning of the activity period. Consistent with our in vitro observations, ATP 
measured in Drp1-/- mouse hippocampi did not display a significant change between CT4 and 
CT16 compared to control hippocampi (Fig. 6C). Therefore, both in vivo and in vitro, 
circadian activation of DRP1 plays a central role in coupling circadian and mitochondrial 
metabolic cycles. 
 
Feedback from mitochondrial morphology to the core clock. 
A key aspect of previously documented modes of circadian regulation of oxidative 
respiration is their ability to feed back to the circadian clock: NAD+ is itself a cofactor of 
SIRT1, a nuclear deacetylase directly affecting circadian clock function (Asher et al., 2008, 
Nakahata et al., 2008); and purine nucleotide levels modulate AMPK activity to regulate 
phosphorylation of CRY clock proteins (Jordan and Lamia, 2013). If the morphology-driven 
circadian control mechanism that we have uncovered indeed affected circadian mitochondrial 
function and ATP levels, then it would be predicted that they should also signal back to 
influence circadian function. To address this question, first we characterized the circadian 
period length of dexamethasone-synchronized fibroblasts after disturbing either 
mitochondrial respiration or the mitochondrial network by infecting the cells with a circadian 
reporter construct (Bmal1 promoter-driven expression of firefly luciferase)-harboring lentivirus 
(Fig.7A,B). Rotenone, oligomycin or FCCP were used to inhibit mitochondrial respiration, 
leading to ATP depletion (Fig. 3A, 7A). Notably, cells had a significantly longer period length 
in the presence of mitochondrial respiration inhibitors compared to controls. Moreover, 
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disruption of mitochondrial division by mdivi-1 treatment significantly increased period length 
(Fig.7B). These findings are consistent with the idea that DRP1-mediated mitochondrial ATP 
oscillations may also signal in retrograde fashion to the clock. 
We further analyzed gene expression of the core clock activator Bmal1 and 
repressors Per1 and Per2 in serum-shocked human skin fibroblasts treated with mdivi-1 
(50mM) (Fig. 7C-E) and in serum-shocked DRP1-deficient MEFs (Fig. 7F-H). When the 
mitochondrial network was pharmacologically disrupted through inhibition of DRP1, we 
observed a suppression of circadian variation in the gene expression of clock activator 
Bmal1 and repressors Per1 and Per2 (Fig. 7C-E), similar to results obtained in DRP1-
deficient MEFs (Fig. 7F-H). These findings indicate that disruption of circadian mitochondrial 
dynamics leads to an impaired core circadian clock. 
 
Discussion 
A wide range of metabolic processes follows the rhythmicity of the circadian cycle to 
anticipate energetic requirements of diverse cellular functions in response to cellular and 
environmental constraints. Yet, only a few studies have characterized the mechanisms 
involved, demonstrating coupling via cyclic redox metabolite levels (e.g: NAD+), mitochondrial 
protein acetylation and chromatin modification (Asher and Schibler, 2011, Feng et al., 2011, 
Masri et al., 2013, Nakahata et al., 2009, Peek et al., 2013). Here, we identify and 
characterize a third, mitochondrial dynamics-based regulatory connection between the 
circadian clock and metabolism, and show that this connection is absolutely essential for 
circadian regulation of cellular ATP levels. 
Mitochondrial morphology has previously been demonstrated to regulate nearly every 
aspect of mitochondrial function: mitochondrial fusion to form more extensive tubular 
networks results in global upregulation of oxidative respiration and all other functions, while 
fission of mitochondria into smaller fragments causes opposite effects (Westermann, 2010). 
Such regulation at the level of morphology has been extensively characterized within the 
context of the cell cycle, with different phases of the cell division process requiring specific 
energetic needs (Martinez-Diez et al., 2006, Mishra and Chan, 2014). 
The first clues that similar global regulation of mitochondrial function might be 
operational can be gleaned from circadian “-omics” analyses and studies of individual 
metabolite levels. Metabolic flux analysis and supplementary analyses presented here (Fig. 
1, 2) showed that many metabolites displayed circadian rhythmicity even in isolated cells, 
and the major circadian pathway signatures of the cellular metabolome that we have 
identified are consistent with those previously described in rodents (Eckel-Mahan et al., 
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2012, Minami et al., 2009) and humans (Ang et al., 2012, Dallmann et al., 2012, Davies et 
al., 2014, Kasukawa et al., 2012). Fully half of rhythmic compounds identified were amino 
acids and associated metabolites known to be engaged in mitochondrial energetic 
homeostasis through branched-chain amino acid metabolism, glycolysis and TCA cycle to 
provide energetic substrates such as pyruvate for ATP generation through oxidative 
phosphorylation. Another large compound group was linked to glutathione metabolism 
(where, interestingly, molecular abundance varied more dramatically than redox state per 
se), processing of ROS, and redox homeostasis, or was metabolic byproducts of 
mitochondrial metabolism (i.e. ATP, the couple NAD+/NADH). Interestingly, the group of 
mostly mitochondrial fuels showed peak expression levels about six hours earlier than the 
“byproduct” group. 
Overall, mitochondrial oxygen consumption analyses showed time-of-day-dependent 
variation in each measurable step of the mitochondrial respiratory chain (Fig. 3, see also 
(Isobe et al., 2011, Peek et al., 2013). When in resting state (low ATP), the cells exhibited a 
higher spare respiratory capacity. Remarkably, the bioenergetic profile showed that only 
mitochondrial respiration varied in a circadian manner over time, whereas glycolysis 
remained constant. 
Taken together, the pervasive circadian regulation of metabolic flux, even in cultured 
cells, suggested global regulation of mitochondrial function. Remarkably, such global and 
dynamic regulation has also been observed in the cellular metabolic regulation by the cell 
cycle (Martinez-Diez et al., 2006, Mishra and Chan, 2014). Once perceived as solitary 
structures, mitochondria are now recognized as highly mobile (along cytoskeletal tracks), 
dynamic organelles that continually fuse and divide to upregulate and downregulate 
respiration in response to cellular energy requirements (Kasahara and Scorrano, 2014). Our 
findings demonstrate that the circadian mitochondrial bioenergetic is governed by circadian 
mitochondrial dynamics in vivo and in vitro. This coupling is completely independent of the 
cell cycle (in which it was initially characterized), both because it continues in the presence of 
cell cycle inhibitors in vitro, and because it equally occurs in mostly nondividing tissues like 
brain and liver. Moreover, it is functionally essential for circadian ATP production because its 
inhibition, either pharmacologically or genetically, abolishes circadian oscillations in ATP 
levels. 
A well-defined set of proteins regulates mitochondrial fission and fusion, including 
mitofusins and dynamin-related proteins. Although another recent study has found circadian 
oscillation of these genes at a transcriptional level in liver (Jacobi et al., 2015), expression 
levels of these genes did not exhibit any circadian oscillations in cultured cells. Instead, we 
find that both phosphorylation of the protein DRP1 and its stability are regulated in a 
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circadian manner. An identical regulatory mechanism has been described for synchronizing 
mitochondrial function to the cell cycle: phosphorylation of DRP1 at serine 637 by cyclin 
B/CDK1 complexes is essential to cell cycle - coupled mitochondrial respiration (Cribbs and 
Strack, 2007, Kashatus et al., 2011, Santel and Frank, 2008). Our genetic and 
pharmacological inhibition experiments demonstrate that mitochondrial dynamics are also 
essential for circadian regulation in nondividing cells: analysis of regulation of DRP1 revealed 
that phosphorylation of serine 637 followed a circadian pattern, and pharmacological or 
genetic interference with DRP1 activity abolishes the circadian production of ATP. It has 
been suggested that DRP1 S637 phosphorylation is directed by protein kinase A (PKA), 
while DRP1 S637 dephosphorylation is mediated by calcineurin (Cereghetti et al., 2008, 
Cribbs and Strack, 2007). Moreover, it has been described that the activity of calcineurin, but 
not its protein expression, is under circadian regulation (Huang et al., 2012), suggesting that 
the oscillation of DRP1 phosphorylation may be dependent on calcineurin`s phosphatase 
activity. 
Importantly, the mitochondrial regulatory cascade that we uncover can feed back to 
modulate the circadian clock itself. When mitochondrial fission was pharmacologically 
inhibited, we observed not only dampening of mitochondrial ATP rhythm but also an increase 
of circadian period in human skin fibroblasts and a strong decrease in the circadian 
amplitude of clock gene transcription in fibroblasts. These results could be explained via two 
previously published feedback mechanisms from respiration to the circadian clock: on the 
one hand, ATP synthesis affects the balance of purine nucleotides in the cell, thereby 
modulating the activity of the nutrient-sensitive kinase AMPK in phosphorylation of the 
cryptochrome clock (Lamia et al., 2009, Um et al., 2011). On the other hand, circadian 
modulation of NAD+ and NADH levels affects the activity of the SIRT1 histone deacetylase, 
which can target both clock proteins and histones (Asher et al., 2008, Chang and Guarente, 
2013, Nakahata et al., 2008, Nakahata et al., 2009). Consistent with either feedback loop, 
inhibition of mitochondrial flux in multiple different ways showed effects upon circadian clock 
properties and upon clock gene expression in fibroblasts. Therefore, the mitochondrial 
network acts as a central node in coupling circadian and metabolic cycles. 
In summary, consistent with the growing body of evidence integrating cellular 
metabolism with circadian clocks (Rey and Reddy, 2013, Eckel-Mahan and Sassone-Corsi, 
2013, Bass, 2012, Bass and Takahashi, 2010), our findings establish a molecular link 
between circadian control of the mitochondrial architecture and mitochondrial oxidative 
metabolism, suggesting a key role for global circadian regulation of mitochondrial function in 
controlling circadian metabolism. Our findings could have multiple implications in the context 
of metabolic homeostasis, both with respect to human health and disease, and with respect 
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to impairment in circadian clock and/ or mitochondrial function. Perturbations in the clock 
may be a key initiating factor for diseases linked to compromised mitochondrial function, 
including neurodegenerative disorders such as Alzheimer’s disease. 
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Figures 
 
Figure 1: Circadian clock regulates globally the cellular metabolic flux. 
(A) Heat plots for all identified metabolites in synchronized human U2OS cells. (B) Percentage of non-circadian and circadian metabolites based on JTK_CYCLE analysis (six time 
points, n=2 for each). Metabolites were considered circadian at a p-value cutoff of 0.05. Out of the 228 measured and identified, 67 metabolites exhibited circadian pattern. (C, D) 
Pathway analyses (C) and time-of-day distribution of peak phases (D) of rhythmic metabolites. (E-H) Accumulation profiles of oscillating metabolites involved in branched-chain 
amino acids metabolism (E), in GSH/GSSG metabolism (F), in glycolysis (G) and in TCA cycle (H), presented as mean ± SEM. Pathways are color-coded as follows: amino acids, 
blue; carbohydrates, red; cofactors & vitamins, violet; energy, brown; lipids, orange; nucleotides, pink; peptides, green. See also Table 1. 
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Figure 2: Cellular bioenergetic variations are driven by the circadian clock. 
(A) Relative total ATP levels from serum-shocked human skin fibroblasts measured at the indicated time points (6 
time points, n=6 for each, JTK_Cycle, P<0.05). Right panel displays relative total ATP level at 16 hours post-
shock (peak of ATP content) and at 28 hours (trough of ATP content) in fibroblast cultures (One-way ANOVA, 
ATP variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, ***, P < 0.001). (B) Relative total ATP 
levels measured in brain of non-fasted wildtype mice kept in constant darkness (WT Brain) every 4 hours for 24 
hours (7 time points, n=4 for each). Right panel displays relative total ATP level at circadian time 4 (CT4) (peak of 
ATP content) and at circadian time 16 (CT16) (trough of ATP content) in control and treated conditions (One-way 
ANOVA, ATP variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, ***, P < 0.001). (C) Relative total 
ATP level measured in serum-shocked Per1/2−/− MEFs (KO P1P2) compared to WT MEFs (WT P1P2) (6 time 
points, n=6 for each, JTK_Cycle, PWT P1P2<0.05). Right panel displays relative total ATP level measured in serum-
shocked Per1/2−/− MEFs (KO P1P2) compared to WT MEFs (WT P1P2) at 16 hours post-shock (peak of ATP 
content) and at 28 hours (trough of ATP content) (One-way ANOVA, ATP variation pattern in WT MEFs, 
P<0.0001; post hoc Tukey; 16 versus 28 hours, **,P < 0.01). 
All data are represented as mean ± SEM of at least three independent samples. See also Figures S1, S2. 
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Figure 3: Circadian ATP oscillations result from mitochondrial respiratory activity. 
(A) Relative total ATP levels from serum-shocked human skin fibroblasts treated with 2 - deoxy-D-glucose (2DG, 
4.5g/L) or oligomycin (OLIGO, 2 μM) compared to non-treated cells (CTRL) measured at the indicated time points 
(6 time points, n=6 for each, JTK_Cycle, PCTRL<0.05, P2DG<0.05). Right panel displays relative total ATP level at 
16 hours post-shock (peak of ATP content) and at 28 hours (trough of ATP content) in control and treated 
conditions (One-way ANOVA, ATP variation pattern in control cells, P<0.0001; post hoc Tukey; 16 versus 28 
hours, ***, P < 0.001; ATP variation pattern in 2DG-treated cells, P<0.0001; post hoc Tukey; 16 versus 28 hours, 
°°, P < 0.001). (B) Relative total ATP contents from serum-shocked human skin fibroblasts treated with cytosine 
β-D-arabinofuranoside (AraC, 100 μM) compared to non-treated cells (CTRL) measured at the indicated time 
points in cells (6 time points, n=6 for each, JTK_Cycle, PCTRL<0.05, PAraC<0.05). Right panel displays relative total 
ATP level at 16 hours post-shock (peak of ATP content) and at 28 hours (trough of ATP content) in control and 
treated conditions (One-way ANOVA, ATP variation pattern in control cells, P<0.0001; post hoc Tukey; 16 versus 
28 hours, ***, P < 0.001; ATP variation pattern in 2DG-treated cells, P<0.0001; post hoc Tukey; 16 versus 28 
hours, °°, P < 0.01). All data are represented as mean ± SEM of at least three independent samples. (C) Oxygen 
Consumption Rate (OCR) was evaluated in serum-shocked fibroblasts treated sequentially with oligomycin (Oligo, 
2 μM), FCCP (0.7 μM), rotenone (ROT, 2 μM) and antimycin A (AA, 4 μM) at 16 and 28 hours post-shock, 
respectively. (D) Bioenergetic profile of synchronized fibroblasts at 16 and 28 hours post-shock, respectively. 
Basal respiration, ATP turnover and maximal respiration are determined after normalization to OCR allocated to 
non-mitochondrial respiration measured after antimycin A/rotenone injection (One-way ANOVA, OCR variation 
pattern P<0.0001; post hoc Tukey; 16 versus 28 hours, **, P< 0.01, ***, P < 0.001). (E) Cellular bioenergetic 
profile (OCR versus ECAR) evaluated at 16 and 28 hours post-shock, respectively in human skin fibroblasts. The 
red arrow corresponds to the metabolic switch from a metabolic active (16 hours) to a resting state (28 hours). All 
data are represented as mean ± SEM of three independent samples (2 time points, n= 11 replicates for each, 
three independent experiments). 
See also Figures S3, S4.  
MANUSCRIPT A 
 
 
76 
 
Figure 4: Dynamic mitochondrial architecture is controlled by the circadian clock. 
(A) Mitochondrial network morphology assessed in serum-shocked human skin fibroblasts at 8, 16 and 24 hours. 
The three distinct states (tubular, intermediate and fragmented network) correspond to 8, 16 and 24 hours, 
respectively. Scale bars, 7.5 μm. (B) Mitochondrial network morphology assessed in (i) brain and (ii) liver from 
non-fasted wild-type mice kept in darkness condition at CT0 and CT12. The tubular and fragmented states 
correspond to CT0 and CT12, respectively. Scale bars, brain, 50 μm; liver, 25 μm. (C) Relative mRNA expression 
of nuclearly-encoded genes related to mitochondrial fusion (MFN1, MFN2 and OPA1) and fission (DRP1 and 
hFIS1) measured at 16 hours and 24 hours in serum-shocked human skin fibroblasts (2 time points, n=6 for 
each). All data are represented as mean ± SEM of at least three independent samples. 
See also Figure S5. 
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Figure 5: DRP1 mediates clock control of mitochondrial architecture. 
(A, B) Phosphorylation of DRP1 on serine 637 (P-DRP1) and total DRP1 evaluated at the indicated time points in 
serum-shocked human skin fibroblasts (6 time points, n=6 for each, JTK_Cycle, P<0.05) (A) and in brain 
homogenate of non-fasted wildtype mice kept in constant darkness (7 time points, n=4 for each, JTK_Cycle, 
P<0.05) (B). Right panels display relative DRP1 phosphorylation measured in serum-shocked human skin 
fibroblasts (A) and in brain homogenate of non-fasted wildtype mice kept in constant darkness (B). 
All data are represented as mean ± SEM of at least three independent samples. 
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Figure 6: Mitochondrial metabolism is dependent to DRP1-related clock regulation. 
(A) Relative total ATP level from serum-shocked human skin fibroblasts treated with mdivi-1 (50 μM) compared to 
non-treated cells (CTRL) measured at the indicated time points (6 time points, n=6 for each, JTK_Cycle, 
PCTRL<0.05). Right panel displays relative total ATP level at 16 hours post-shock (peak of ATP content) and at 28 
hours (trough of ATP content) in control and treated conditions. (One-way ANOVA, ATP variation pattern in 
control cells, P<0.0001; post hoc Tukey; 16 versus 28 hours, ***, P < 0.001). (B) Relative total ATP levels from 
Drp1 
-/-
 MEFs compared to Drp1lox/lox MEFs measured at the indicated time points (6 time points, n=6 for each, 
JTK_Cycle, PDrp1lox/lox<0.05). Right panel displays relative total ATP level at 16 hours post-shock (peak of ATP 
content) and at 28 hours (trough of ATP content) in Drp1lox/lox MEFs and Drp1 -/- MEFs (One-way ANOVA, ATP 
variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, ***,P < 0.001). (C) Total ATP levels from cortex 
and hippocampus of non-fasted Drp1 -/- mice compared to Drp1lox/lox mice kept in constant darkness measured at 
CT4 (peak of ATP content) and at CT16 (trough of ATP content) (2 time points, n=4 cortex for each). (One-way 
ANOVA, ATP variation pattern, P<0.0001; post hoc Tukey; CT4 versus CT12, ***,P < 0.001). 
All data are represented as mean ± SEM of at least three independent samples. 
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Figure 7: Mitochondrial network feeds back into the molecular core clock. 
(A) Circadian period length determined in dexamethasone - synchronized human skin fibroblasts transfected with 
Bmal1::luciferase reporter in presence of rotenone (ROT, 1 μM), oligomycin (OLIGO, 2 μM) or FCCP (4 μM) 
compared to control (CRTL). (B) Circadian period length determined in dexamethasone - synchronized human 
skin fibroblasts transfected with Bmal1::luciferase reporter in presence of Mdiv-1 (50 μM) compared to control 
(CRTL). Bars represent the mean of three independent measurements ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 
for Student’s two-tailed t test comparing single time points. (C-E) Relative mRNA expression of BMAL1 (C), PER1 
(D) and PER2 (E) evaluated in serum-shocked human skin fibroblasts treated with mdivi-1 (50μM) compared to 
control cells (CTRL) at 12 hours and 24 hours (2 time points, n=6 for each) (One-way ANOVA, Bmal1 mRNA 
variation pattern, P<0.0001, post hoc Tukey; 12 versus 24 hours, °°°,P < 0.001; Per1 mRNA variation pattern, 
P=0.0001, post hoc Tukey; 12 versus 24 hours, °°°,P < 0.001 Per2 mRNA variation pattern, P=0.0008, post hoc 
Tukey; 12 versus 24 hours, °°,P < 0.01; Two-way ANOVA, group effect: control versus mdivi-1, PBmal1<0.0001, 
post hoc Bonferroni, ***, PBmal1<0.001; group effect: control versus mdivi-1, PPer1= 0.0011, post hoc Bonferroni, 
***, PPer1<0.001; group effect: control versus mdivi-1, PPer2=0.0034, post hoc Bonferroni, ***, PPer2<0.001). (F-H) 
Relative mRNA expression of Bmal1 (F), Per1 (G) and Per2 (H) evaluated from in Drp1 -/- MEFs compared to 
Drp1
lox/lox MEFs at 12 hours and 24 hours (2 time points, n=6 for each) (One-way ANOVA, Bmal1 mRNA variation 
pattern, P=0.0010, post hoc Tukey; 12 versus 24 hours, °,P < 0.001; Per1 mRNA variation pattern, P=0.0008, 
post hoc Tukey; 12 versus 24 hours, °°,P < 0.01 Per2 mRNA variation pattern, P=0.0010, post hoc Tukey; 12 
versus 24 hours, °°°,P < 0.01;Two-way ANOVA, group effect: WT versus KO, PBmal1=0.0002, post hoc Bonferroni, 
***, PBmal1<0.001; group effect: WT versus KO, PPer1= 0.0028, post hoc Bonferroni, ***, PPer1<0.001; group effect: 
WT versus KO, PPer2=0.0265, post hoc Bonferroni, ***, PPer2<0.001). 
All data are represented as mean ± SEM of at least three independent samples. 
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Supplemental Data 
Table S1: Complete list of all identified metabolites in serum-shocked U2OS. 
All values are normalized (mean±SEM). Rhythmic compounds are indicated in red color. Abbr.: RI: retention index, HMDB: identification numbers 
of biochemicals in Human Metabolome Database, PT-p: p-values computed with the permutation test as described in Methods, Per: Period, LAG: 
peak phases, Amp: amplitude of oscillation, defined as the maximum divided by the minimum level of a particular biochemical in the first 24hrs of 
the experiment. Phase: Phase of the peak for rhythmic biochemicals. 
 
BIOCHEMICAL PATHWAY PLATFORM RI MASS HMDB_ID PT-p PER LAG AMP 
Post- Schock (hours) 
12 16 20 24 28 32 
mean SEM mean SEM mean SEM mean SEM mean SEM mean SEM 
10-heptadecenoate (17:1n7) Lipid LC/MS Neg 5558 267.3   1.0000 24 13 0.08 0.85 0.11 1.15 0.11 0.88 0.05 1.07 0.04 2.70 0.01 0.47 0.02 
10-nonadecenoate (19:1n9) Lipid LC/MS Neg 5775 295.4   1.0000 24 13 0.06 0.84 0.10 1.16 0.14 0.92 0.06 1.03 0.02 1.91 0.13 0.53 0.04 
1-arachidonoylglycerophosphoethanolamine* Lipid LC/MS Neg 5731 500.3 HMDB11517 1.0000 24 15 0.05 1.27 0.41 1.29 0.36 0.83 0.24 1.43 0.53 2.42 0.02 0.67 0.14 
1-methylnicotinamide Cofactors and vitamins LC/MS Pos 688 137.1 HMDB00699 0.0009 24 2 0.34 1.38 0.07 1.24 0.03 0.97 0.11 0.75 0.06 0.46 0.06 1.04 0.11 
1-myristoylglycerophosphocholine Lipid LC/MS Pos 5481 468.3 HMDB10379 0.5770 24 0 0.29 1.05 0.37 1.00 0.03 0.75 0.07 0.82 0.14 0.68 0.00 1.37 0.05 
1-octadecanol Lipid GC/MS 1957.7 327.3 HMDB02350 1.0000 24 11 0.00 1.08 0.37 1.22 0.03 0.92 0.10 0.78 0.20 1.81 0.38 0.69 0.17 
1-oleoylglycerol (1-monoolein) Lipid GC/MS 2181.2 397.4 HMDB11567 1.0000 24 11 0.22 0.68 0.00 1.31 0.12 1.05 0.17 0.71 0.42 3.69 1.35 0.39 0.24 
1-oleoylglycerophosphocholine Lipid LC/MS Pos 5700 522.4   0.2485 24 0 0.09 1.52 0.40 0.95 0.12 0.87 0.07 0.51 0.05 3.47 0.30 1.00 0.00 
1-oleoylglycerophosphoethanolamine Lipid LC/MS Neg 5928 478.3 HMDB11506 1.0000 24 17 0.32 1.54 0.86 1.28 0.68 0.61 0.03 1.66 0.34 2.74 0.09 0.48 0.17 
1-palmitoylglycerol (1-monopalmitin) Lipid GC/MS 2119.5 371.3   1.0000 24 11 0.24 0.66 0.25 1.25 0.16 1.11 0.26 1.04 0.24 2.30 0.90 0.51 0.03 
1-palmitoylglycerophosphocholine Lipid LC/MS Pos 5671 496.4   0.2485 24 0 0.19 1.69 0.55 1.12 0.18 0.85 0.02 0.61 0.15 3.98 0.01 1.00 0.00 
1-palmitoylglycerophosphoethanolamine Lipid LC/MS Neg 5940 452.3 HMDB11503 1.0000 24 17 0.21 1.18 0.43 1.06 0.57 0.55 0.11 1.20 0.20 1.98 0.13 0.49 0.05 
1-stearoylglycerol (1-monostearin) Lipid GC/MS 2186.6001 399.4   0.6640 24 13 0.41 0.65 0.41 1.26 0.45 0.84 0.10 1.30 0.00 2.28 0.51 0.64 0.07 
1-stearoylglycerophosphocholine Lipid LC/MS Pos 5844 524.4   0.2485 24 0 0.33 3.31 2.29 1.32 0.33 0.77 0.07 0.56 0.00 2.21 0.14 1.15 0.30 
1-stearoylglycerophosphoethanolamine Lipid LC/MS Neg 6200 480.4 HMDB11130 1.0000 24 11 0.19 1.50 1.00 1.18 0.58 0.53 0.12 1.61 0.26 1.55 0.14 0.35 0.02 
1-stearoylglycerophosphoglycerol Lipid LC/MS Neg 5826 511.4   1.0000 24 17 0.09 0.62 0.20 0.83 0.21 1.24 0.21 0.35 0.00 2.56 0.02 0.77 0.23 
1-stearoylglycerophosphoinositol Lipid LC/MS Neg 5800 599.4   1.0000 24 15 0.32 1.03 0.42 1.00 0.04 0.50 0.12 1.34 0.00 7.70 0.11 0.43 0.09 
2-aminoadipate Amino acid GC/MS 1686.5 260.1 HMDB00510 0.0730 24 4 0.45 0.94 0.11 1.38 0.12 1.32 0.30 0.61 0.01 0.14 0.01 1.60 0.62 
2-arachidonoylglycerophosphocholine* Lipid LC/MS Pos 5524 544.3   1.0000 24 13 0.07 0.95 0.10 0.82 0.06 1.09 0.14 0.93 0.17 3.26 0.44 0.76 0.01 
2-arachidonoylglycerophosphoethanolamine* Lipid LC/MS Pos 5525 502.3   1.0000 24 11 0.01 1.20 0.18 0.99 0.05 1.05 0.08 0.71 0.13 3.68 0.63 0.85 0.05 
2'-deoxyinosine Nucleotide LC/MS Neg 1700 251.1 HMDB00071 0.3533 24 7 0.08 0.93 0.04 1.23 0.22 1.07 0.16 1.21 0.22 0.87 0.00 1.01 0.14 
2-docosahexaenoylglycerophosphocholine* Lipid LC/MS Pos 5507 568.3   1.0000 24 15 0.02 1.48 0.61 1.09 0.53 0.96 0.01 0.85 0.29 2.54 0.79 0.89 0.11 
2-docosahexaenoylglycerophosphoethanolamine* Lipid LC/MS Pos 5512 526.2   1.0000 24 13 0.10 0.93 0.04 1.06 0.03 1.00 0.17 0.85 0.32 3.47 0.62 0.75 0.04 
2-docosapentaenoylglycerophosphoethanolamine* Lipid LC/MS Pos 5548 528.2   1.0000 24 11 0.06 1.38 0.31 1.19 0.29 1.20 0.37 0.43 0.01 3.47 0.76 0.82 0.10 
2-hydroxyglutarate Lipid GC/MS 1576 247 HMDB00606 0.1702 24 5 0.33 0.92 0.00 1.40 0.40 1.35 0.26 0.60 0.02 0.42 0.00 1.17 0.03 
2-hydroxypalmitate Lipid LC/MS Neg 5508 271.3   0.0044 24 21 0.53 1.67 0.75 0.83 0.25 0.51 0.02 0.90 0.01 1.31 0.02 1.63 0.16 
2-hydroxystearate Lipid LC/MS Neg 5705 299.4   0.0730 24 21 0.57 1.76 0.86 0.73 0.28 0.53 0.06 0.96 0.04 1.44 0.04 1.51 0.11 
2-linoleoylglycerophosphocholine* Lipid LC/MS Pos 5544 520.4   0.0592 24 18 0.14 0.80 0.26 0.89 0.02 0.93 0.03 0.77 0.23 2.27 0.46 1.25 0.15 
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BIOCHEMICAL PATHWAY PLATFORM RI MASS HMDB_ID PT-p PER LAG AMP 
Post- Schock (hours) 
12 16 20 24 28 32 
mean SEM mean SEM mean SEM mean SEM mean SEM mean SEM 
2-linoleoylglycerophosphoethanolamine* Lipid LC/MS Neg 5650 476.4   1.0000 24 17 0.07 1.00 0.41 0.96 0.45 0.62 0.10 1.15 0.15 2.09 1.58 0.69 0.18 
2-methylbutyroylcarnitine Amino acid LC/MS Pos 2439 246.1 HMDB00378 0.00004 24 4 0.66 1.55 0.12 1.69 0.03 1.18 0.20 0.69 0.19 0.33 0.03 1.00 0.02 
2-myristoylglycerol (2-monomyristin) Lipid GC/MS 2040 285.2   1.0000 24 15 0.79 0.45 0.00 0.45 0.00 0.58 0.13 0.45 0.00 1.44 0.15 0.45 0.00 
2-myristoylglycerophosphocholine* Lipid LC/MS Pos 5450 468.3   0.8804 24 20 0.07 1.01 0.00 0.97 0.03 0.96 0.06 0.68 0.23 3.37 0.74 1.14 0.18 
2-oleoylglycerol (2-monoolein) Lipid GC/MS 2170 410.1   1.0000 24 11 0.16 0.37 0.00 2.21 0.11 0.94 0.15 0.82 0.09 3.79 1.85 0.57 0.19 
2-oleoylglycerophosphocholine* Lipid LC/MS Pos 5640 522.4   1.0000 24 13 0.04 1.20 0.15 0.94 0.06 1.00 0.07 0.50 0.10 3.51 0.51 0.99 0.01 
2-oleoylglycerophosphoethanolamine* Lipid LC/MS Pos 5625 480.2   1.0000 24 13 0.03 1.35 0.19 0.98 0.03 0.96 0.09 0.70 0.27 3.98 0.47 0.95 0.04 
2-oleoylglycerophosphoinositol* Lipid LC/MS Neg 5571 597.5   1.0000 24 17 0.18 0.70 0.57 0.96 0.17 0.36 0.22 1.07 0.20 2.13 0.12 0.16 0.02 
2'-O-methylguanosine Nucleotide LC/MS Neg 1901 296.2   1.0000 24 9 0.14 0.82 0.00 0.92 0.08 0.82 0.00 1.50 0.27 0.82 0.00 0.82 0.00 
2-palmitoleoylglycerophosphocholine* Lipid LC/MS Pos 5482 494.3   1.0000 24 13 0.09 1.05 0.14 1.00 0.11 0.93 0.10 0.62 0.16 3.93 0.47 1.02 0.05 
2-palmitoleoylglycerophosphoethanolamine* Lipid LC/MS Pos 5487 452.1   0.8804 24 20 0.23 1.01 0.12 0.85 0.04 1.01 0.21 0.49 0.28 4.48 1.22 1.15 0.04 
2-palmitoylglycerol (2-monopalmitin) Lipid GC/MS 2108 129   0.8804 24 13 0.20 0.76 0.04 1.33 0.22 1.13 0.20 1.00 0.06 2.36 0.43 0.78 0.13 
2-palmitoylglycerophosphocholine* Lipid LC/MS Pos 5604 496.3   0.8804 24 9 0.00 1.08 0.08 0.91 0.09 0.96 0.05 0.50 0.01 3.76 0.49 1.05 0.06 
2-palmitoylglycerophosphoethanolamine* Lipid LC/MS Pos 5598 454.2   0.5770 24 19 0.00 0.92 0.25 0.83 0.17 0.66 0.00 0.66 0.00 2.94 0.17 0.69 0.03 
3-(4-hydroxyphenyl)lactate Amino acid LC/MS Neg 1395 181.1 HMDB00755 0.0931 24 7 0.19 0.90 0.10 1.18 0.20 1.26 0.22 0.93 0.15 0.78 0.00 0.84 0.06 
3-dehydrocarnitine* Lipid LC/MS Pos 1020 160.2 HMDB12154 0.4899 24 3 0.26 1.00 0.04 1.05 0.27 1.07 0.20 0.69 0.05 0.64 0.00 1.46 0.22 
3'-dephosphocoenzyme A Cofactors and vitamins LC/MS Neg 2010 686.2 HMDB01373 1.0000 24 13 0.10 1.79 0.69 1.10 0.43 0.53 0.00 0.86 0.14 3.15 1.41 0.59 0.07 
4-hydroxybutyrate (GHB) Lipid GC/MS 1277 233.1 HMDB00710 0.0214 24 8 0.46 0.71 0.27 1.09 0.09 1.34 0.27 1.20 0.22 0.44 0.00 0.62 0.18 
5-methyltetrahydrofolate (5MeTHF) Cofactors and vitamins LC/MS Neg 1838 458.2 HMDB01396 1.0000 24 5 0.08 0.83 0.08 1.06 0.10 0.99 0.10 0.97 0.12 0.75 0.00 1.17 0.13 
5-methylthioadenosine (MTA) Amino acid LC/MS Pos 2427 298.1 HMDB01173 0.0001 24 4 0.24 1.10 0.03 1.26 0.09 1.09 0.09 0.40 0.02 0.30 0.07 0.96 0.04 
5-oxoproline Amino acid LC/MS Neg 744 128.2 HMDB00267 0.0021 24 4 0.48 1.61 0.29 1.47 0.22 1.30 0.18 0.72 0.09 0.22 0.04 0.84 0.04 
6-phosphogluconate Carbohydrate LC/MS Neg 588 275.1 HMDB01316 0.4216 24 14 0.19 0.85 0.00 1.05 0.34 1.61 0.64 1.12 0.12 1.94 0.90 0.78 0.08 
7-alpha-hydroxycholesterol Lipid GC/MS 2300 456.2 HMDB01496 0.8804 24 17 0.21 0.93 0.24 1.20 0.29 0.77 0.03 1.07 0.25 1.88 0.31 1.00 0.01 
7-beta-hydroxycholesterol Lipid GC/MS 2340 456.4 HMDB06119 0.2485 24 5 0.18 1.10 0.04 1.42 0.03 1.27 0.33 0.85 0.08 1.10 0.36 0.89 0.01 
acetyl CoA Cofactors and vitamins LC/MS Neg 1900 808.1 HMDB01206 1.0000 24 15 0.03 0.73 0.07 0.98 0.12 0.88 0.01 1.38 0.12 0.65 0.00 1.71 0.06 
acetylcarnitine Lipid LC/MS Pos 1203 204.2 HMDB00201 0.4899 24 2 0.36 1.01 0.01 1.11 0.11 0.97 0.17 0.51 0.03 0.25 0.08 1.52 0.02 
acetylphosphate Energy GC/MS 1263 211 HMDB01494 1.0000 24 9 0.01 0.84 0.26 1.40 0.05 0.85 0.14 1.16 0.20 1.05 0.04 0.91 0.06 
adenine Nucleotide GC/MS 1804.2 264 HMDB00034 0.0004 24 4 0.38 1.15 0.15 1.26 0.04 1.11 0.04 0.32 0.03 0.11 0.03 0.88 0.12 
adenosine Nucleotide LC/MS Pos 1650 268.1 HMDB00050 1.0000 24 13 0.08 0.80 0.03 1.06 0.11 0.92 0.20 1.01 0.06 1.20 0.04 0.86 0.19 
adenosine 3'-monophosphate (3'-AMP) Nucleotide LC/MS Neg 1268 346.1 HMDB03540 0.5770 24 16 0.17 0.90 0.10 0.90 0.07 0.86 0.05 1.59 0.25 3.00 1.01 0.81 0.00 
adenosine 5'-diphosphate (ADP) Nucleotide LC/MS Neg 800 426.1 HMDB01341 1.0000 24 9 0.08 0.89 0.14 1.00 0.10 0.93 0.17 0.90 0.10 0.15 0.00 1.23 0.04 
adenosine 5'diphosphoribose Cofactors and vitamins LC/MS Neg 964 558.1 HMDB01178 1.0000 24 17 0.65 0.77 0.00 0.77 0.00 0.77 0.00 0.77 0.00 1.00 0.23 0.77 0.00 
adenosine 5'-monophosphate (AMP) Nucleotide LC/MS Pos 1210 348.1 HMDB00045 0.1702 24 3 0.17 1.09 0.05 1.08 0.07 0.86 0.13 0.79 0.06 0.54 0.09 1.17 0.04 
adenylosuccinate Nucleotide LC/MS Pos 1870 464.1 HMDB00536 1.0000 24 7 0.08 0.28 0.02 0.87 0.44 1.13 0.13 0.26 0.00 0.41 0.15 1.26 0.03 
adrenate (22:4n6) Lipid LC/MS Neg 5684 331.3 HMDB02226 1.0000 24 15 0.14 0.95 0.23 1.05 0.19 0.79 0.10 1.16 0.05 2.19 0.04 0.54 0.00 
agmatine Amino acid GC/MS 1528 174 HMDB01432 0.6640 24 2 0.68 1.60 1.10 0.83 0.03 1.47 0.33 0.30 0.03 0.27 0.00 1.70 0.32 
alanine Amino acid GC/MS 1147.6 115.9 HMDB00161 0.4899 24 7 0.11 1.05 0.11 1.07 0.15 1.17 0.23 1.13 0.07 0.46 0.07 0.96 0.12 
alanylleucine Peptide LC/MS Pos 2150 203   0.6640 24 13 0.48 0.71 0.03 1.19 0.14 0.91 0.45 5.73 4.78 6.62 2.19 0.40 0.08 
alanylthreonine Peptide LC/MS Neg 827 189   0.3009 24 16 1.28 0.11 0.00 0.11 0.00 0.13 0.02 0.56 0.44 1.16 0.12 0.11 0.00 
allantoin Nucleotide GC/MS 1809.8 518.3 HMDB00462 0.8804 24 1 0.12 1.40 0.82 0.63 0.12 1.46 0.85 0.51 0.00 0.51 0.00 1.67 0.42 
alpha-tocopherol Cofactors and vitamins GC/MS 2305.3999 502.5 HMDB01893 0.3009 24 2 0.25 1.30 0.24 1.28 0.12 0.92 0.00 0.49 0.08 0.98 0.57 0.68 0.26 
arachidonate (20:4n6) Lipid LC/MS Neg 5525 303.4 HMDB01043 1.0000 24 15 0.00 1.00 0.00 1.03 0.00 0.84 0.03 1.05 0.14 2.30 0.07 0.51 0.03 
arginine Amino acid LC/MS Neg 728 173.2 HMDB00517 0.0272 24 10 0.34 0.82 0.07 1.13 0.10 1.00 0.44 1.40 0.03 1.03 0.05 0.52 0.10 
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asparagine Amino acid GC/MS 1651.2 231 HMDB00168 0.0272 24 4 0.30 1.21 0.04 1.20 0.32 1.10 0.02 0.40 0.12 0.04 0.00 1.21 0.29 
aspartate Amino acid GC/MS 1529.7 232 HMDB00191 0.0272 24 4 0.15 1.09 0.06 1.15 0.10 1.00 0.06 0.54 0.03 0.07 0.01 1.13 0.17 
aspartylphenylalanine Peptide LC/MS Pos 2538 281.1 HMDB00706 1.0000 24 9 0.10 0.90 0.12 1.21 0.05 1.49 0.85 0.86 0.13 1.54 0.43 0.54 0.16 
beta-alanine Amino acid GC/MS 1451.8 174 HMDB00056 0.0454 24 4 0.25 1.53 0.65 1.82 0.57 0.82 0.18 0.71 0.19 0.07 0.00 1.18 0.11 
betaine Amino acid LC/MS Pos 721 118.2 HMDB00043 0.0156 24 4 0.41 1.34 0.06 1.21 0.10 1.11 0.30 0.73 0.07 0.37 0.01 1.00 0.06 
butyrylcarnitine Lipid LC/MS Pos 2007 232.2 HMDB02013 1.0000 24 7 0.12 0.90 0.07 1.15 0.13 2.01 0.85 0.50 0.08 0.87 0.06 2.75 0.00 
caprate (10:0) Lipid LC/MS Neg 5092 171.2 HMDB00511 0.3533 24 13 0.19 0.79 0.03 1.05 0.01 0.87 0.08 1.14 0.06 3.29 0.14 0.81 0.10 
caprylate (8:0) Lipid LC/MS Neg 4367 143.2 HMDB00482 1.0000 24 11 0.05 0.60 0.00 0.97 0.23 0.81 0.18 0.80 0.20 1.97 1.38 0.81 0.21 
carnitine Lipid LC/MS Pos 702 162.2 HMDB00062 0.4899 24 4 0.14 1.00 0.02 1.10 0.01 0.96 0.17 0.76 0.12 0.40 0.02 1.27 0.02 
C-glycosyltryptophan* Amino acid LC/MS Pos 1912 367.1   1.0000 24 7 0.06 0.96 0.03 1.17 0.17 0.90 0.11 1.02 0.29 0.55 0.00 1.15 0.10 
cholesterol Lipid GC/MS 2316.8999 329.3 HMDB00067 1.0000 24 17 0.03 0.84 0.03 1.10 0.03 0.91 0.10 0.99 0.01 2.10 0.27 0.96 0.16 
choline Lipid LC/MS Pos 674 104.2 HMDB00097 1.0000 24 7 0.09 1.19 0.01 1.14 0.14 0.99 0.09 0.80 0.05 1.16 0.17 0.82 0.03 
choline phosphate Lipid LC/MS Pos 695 184.1 HMDB01565 0.0085 24 3 0.24 1.71 0.00 1.48 0.01 1.25 0.21 0.87 0.06 0.84 0.00 0.92 0.04 
cis-vaccenate (18:1n7) Lipid GC/MS 1987 339.3   1.0000 24 13 0.10 0.73 0.19 1.13 0.12 0.84 0.18 1.09 0.11 2.19 0.42 0.47 0.06 
citrate Energy GC/MS 1763.4 273.1 HMDB00094 1.0000 24 15 0.09 0.64 0.10 1.30 0.32 0.96 0.02 0.82 0.19 1.52 0.28 1.69 0.09 
coenzyme A Cofactors and vitamins LC/MS Neg 1600 766.1 HMDB01423 0.4899 24 5 0.18 1.23 0.20 1.31 0.09 0.81 0.01 1.30 0.15 0.48 0.08 0.78 0.19 
creatine Amino acid LC/MS Pos 758 132.1 HMDB00064 0.0021 24 3 0.27 1.23 0.06 1.16 0.05 1.00 0.07 0.62 0.02 0.60 0.05 0.99 0.07 
cyclo(gly-phe) Peptide GC/MS 1830 257   0.0454 24 11 0.46 0.59 0.04 1.28 0.19 1.34 0.58 1.83 0.36 0.91 0.21 0.67 0.25 
cystathionine Amino acid GC/MS 1979.6 218.1 HMDB00099 0.0004 24 5 0.44 1.07 0.01 1.73 0.13 1.22 0.12 0.67 0.05 0.45 0.08 0.89 0.05 
cysteine Amino acid GC/MS 1560.1 218 HMDB00574 0.0454 24 6 0.25 1.00 0.04 1.44 0.21 1.22 0.38 1.00 0.12 0.17 0.02 0.90 0.17 
cysteine sulfinic acid Amino acid GC/MS 1662 252 HMDB00996 0.0044 24 6 0.30 0.93 0.12 1.59 0.64 1.34 0.05 1.00 0.23 0.62 0.00 0.67 0.05 
cysteinylglycine Peptide GC/MS 1763 257 HMDB00078 0.0021 24 4 0.36 1.26 0.07 1.29 0.18 1.00 0.02 0.55 0.01 0.11 0.01 1.08 0.13 
cytidine Nucleotide LC/MS Pos 1065 244 HMDB00089 1.0000 24 13 0.67 0.55 0.05 1.68 0.94 0.85 0.40 2.14 0.29 6.98 0.17 0.36 0.09 
cytidine 5'-diphosphocholine Lipid LC/MS Pos 777 489.1 HMDB01413 0.0001 24 4 0.32 1.17 0.02 1.26 0.08 1.00 0.06 0.69 0.01 0.68 0.00 0.77 0.09 
cytidine 5'-monophosphate (5'-CMP) Nucleotide LC/MS Pos 887 324 HMDB00095 0.8804 24 3 0.11 1.08 0.00 1.27 0.29 0.85 0.17 0.98 0.17 0.76 0.16 0.92 0.12 
cytidine-5'-diphosphoethanolamine Lipid LC/MS Pos 765 447 HMDB01564 0.2485 24 4 0.05 1.01 0.03 1.00 0.01 1.04 0.13 0.62 0.01 0.61 0.00 1.02 0.00 
deoxycarnitine Lipid LC/MS Pos 759 146.1 HMDB01161 0.6640 24 7 0.12 1.00 0.09 1.12 0.04 0.91 0.06 0.81 0.22 0.56 0.08 1.47 0.10 
dihomo-linoleate (20:2n6) Lipid LC/MS Neg 5722 307.3   1.0000 24 15 0.10 0.86 0.14 1.13 0.13 0.82 0.12 1.15 0.12 2.49 0.08 0.52 0.00 
dimethylarginine (SDMA + ADMA) Amino acid LC/MS Pos 812 203.2 
HMDB01539, 
 HMDB03334 
0.2485 24 11 0.36 0.76 0.02 1.00 0.01 1.03 0.50 1.29 0.00 1.32 0.07 0.56 0.11 
docosadienoate (22:2n6) Lipid LC/MS Neg 6017 335.4   1.0000 24 13 0.08 0.88 0.14 1.13 0.21 0.91 0.14 1.08 0.10 1.88 0.02 0.55 0.01 
docosahexaenoate (DHA; 22:6n3) Lipid LC/MS Neg 5518 327.3 HMDB02183 1.0000 24 11 0.04 0.96 0.00 1.16 0.04 1.02 0.02 0.98 0.02 2.13 0.09 0.72 0.00 
docosapentaenoate (n3 DPA; 22:5n3) Lipid LC/MS Neg 5574 329.4 HMDB01976 1.0000 24 11 0.00 0.97 0.06 1.13 0.05 0.95 0.08 0.95 0.02 2.04 0.03 0.50 0.01 
eicosapentaenoate (EPA; 20:5n3) Lipid LC/MS Neg 5442 301.3 HMDB01999 1.0000 24 15 0.02 0.96 0.08 1.11 0.02 0.88 0.09 1.02 0.17 3.19 0.12 0.61 0.04 
eicosenoate (20:1n9 or 11) Lipid LC/MS Neg 5955 309.4 HMDB02231 1.0000 24 13 0.07 0.89 0.17 1.11 0.17 0.84 0.10 1.10 0.04 1.92 0.04 0.53 0.02 
erythronate* Carbohydrate GC/MS 1546.9 292.1 HMDB00613 0.1417 24 2 0.48 1.08 0.08 0.89 0.32 0.85 0.17 0.23 0.11 0.19 0.06 1.24 0.18 
ethanolamine Lipid GC/MS 1074 102 HMDB00149 0.0272 24 4 0.65 1.29 0.39 1.30 0.04 1.52 0.08 0.45 0.06 0.15 0.03 1.00 0.03 
flavin adenine dinucleotide (FAD) Cofactors and vitamins LC/MS Neg 2413 784.1 HMDB01248 0.8804 24 14 0.06 0.82 0.10 1.07 0.06 0.94 0.10 1.02 0.03 1.45 0.06 0.90 0.05 
fumarate Energy GC/MS 1382.1 245 HMDB00134 0.6640 24 6 0.04 0.88 0.07 1.12 0.25 1.27 0.16 0.92 0.20 0.40 0.08 1.15 0.09 
gamma-aminobutyrate (GABA) Amino acid GC/MS 1539.7 304.1 HMDB00112 0.0454 24 3 0.51 1.32 0.48 1.97 0.33 0.61 0.04 0.53 0.21 0.33 0.00 1.42 0.26 
gamma-glutamylcysteine Peptide LC/MS Pos 1274 251.1 HMDB01049 0.0021 24 2 0.37 1.13 0.01 1.19 0.12 0.73 0.09 0.51 0.08 0.43 0.00 1.01 0.08 
gamma-glutamylglutamate Peptide LC/MS Pos 1036 277.1   0.0730 24 3 0.85 1.77 0.02 1.43 0.41 1.27 0.77 0.41 0.19 0.37 0.00 1.22 0.24 
gamma-glutamylisoleucine* Peptide LC/MS Pos 2644 261.2 HMDB11170 0.3533 24 2 0.28 1.01 0.09 1.09 0.07 0.97 0.00 0.65 0.02 0.63 0.00 1.48 0.19 
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gamma-glutamylleucine Peptide LC/MS Pos 2744 261.2 HMDB11171 1.0000 24 5 0.08 0.84 0.01 1.09 0.02 1.11 0.17 0.89 0.01 0.82 0.00 1.41 0.20 
gamma-glutamylphenylalanine Peptide LC/MS Pos 2846 295.1 HMDB00594 1.0000 24 7 0.08 0.99 0.20 1.05 0.07 1.15 0.15 0.74 0.00 1.22 0.48 0.88 0.13 
gamma-glutamylvaline Peptide LC/MS Pos 2040 247.2 HMDB11172 1.0000 24 7 0.01 0.84 0.06 1.09 0.18 1.00 0.09 0.99 0.11 0.77 0.00 1.76 0.06 
glucose Carbohydrate GC/MS 1866.8 204.1 HMDB00122 0.0272 24 14 0.23 0.80 0.07 1.00 0.20 1.22 0.22 1.27 0.27 5.64 1.39 0.96 0.03 
glucose 1-phosphate Carbohydrate GC/MS 1853 217.1 HMDB01586 0.4899 24 12 0.21 0.45 0.22 1.36 0.69 1.23 0.14 2.05 0.27 0.23 0.00 0.76 0.15 
glutamate Amino acid LC/MS Pos 700 148.1 HMDB03339 0.0156 24 3 0.37 1.29 0.05 1.11 0.02 1.07 0.28 0.42 0.03 0.36 0.01 1.00 0.03 
glutamate, gamma-methyl ester Amino acid LC/MS Pos 1062 162.1   0.4899 24 7 0.19 0.73 0.07 1.06 0.08 1.34 0.24 0.91 0.12 0.66 0.00 0.98 0.18 
glutamine Amino acid GC/MS 1731.4 156 HMDB00641 0.0730 24 4 0.22 1.16 0.00 1.03 0.31 1.01 0.05 0.44 0.15 0.07 0.01 1.35 0.31 
glutathione, oxidized (GSSG) Amino acid LC/MS Pos 1535 613.1 HMDB03337 0.00004 24 4 0.37 1.23 0.14 1.42 0.16 1.13 0.09 0.66 0.07 0.39 0.12 0.87 0.10 
glutathione, reduced (GSH) Amino acid LC/MS Pos 1274 308.1 HMDB00125 0.00004 24 4 0.32 1.19 0.05 1.28 0.07 1.03 0.04 0.69 0.00 0.14 0.02 0.95 0.07 
glycerol 3-phosphate (G3P) Lipid GC/MS 1719.7 357.1 HMDB00126 0.0156 24 22 0.28 1.88 0.04 0.96 0.09 0.93 0.28 0.80 0.05 0.91 0.04 3.83 1.27 
glycerophosphoethanolamine Lipid GC/MS 1906 357.1 HMDB00114 0.2485 24 1 0.90 1.57 0.24 0.56 0.41 0.91 0.12 0.24 0.11 0.13 0.00 3.06 1.16 
glycerophosphorylcholine (GPC) Lipid LC/MS Pos 694 258.1 HMDB00086 0.0454 24 19 0.54 1.30 0.11 0.63 0.19 0.54 0.07 0.56 0.09 2.33 0.07 1.50 0.29 
glycine Amino acid GC/MS 1166 101.9 HMDB00123 0.0156 24 4 0.21 1.12 0.07 1.11 0.14 1.07 0.04 0.67 0.09 0.18 0.02 1.02 0.13 
glycylglycine Peptide GC/MS 1757.9 174 HMDB11733 0.2485 24 7 0.59 0.97 0.33 1.61 0.23 1.09 0.58 1.61 0.15 0.44 0.03 0.57 0.13 
glycylisoleucine Peptide LC/MS Pos 2080 189.1   0.2485 24 13 0.65 0.54 0.03 1.19 0.40 1.04 0.57 2.00 0.79 1.96 0.12 0.49 0.13 
glycylleucine Peptide LC/MS Pos 2236 189.1 HMDB00759 0.2485 24 13 0.69 0.51 0.03 1.18 0.47 1.06 0.53 2.36 1.07 2.09 0.15 0.52 0.16 
glycylphenylalanine Peptide LC/MS Neg 2193 221.2   0.2485 24 13 0.46 0.59 0.06 1.26 0.40 0.91 0.35 2.42 1.29 1.93 0.08 0.54 0.16 
glycylproline Peptide LC/MS Pos 1115 173.1 HMDB00721 0.7722 24 8 0.51 0.62 0.09 1.36 0.06 1.10 0.55 1.12 0.21 1.02 0.55 0.73 0.27 
glycylserine Peptide GC/MS 1854 174.1 HMDB00678 0.1702 24 10 0.66 0.97 0.19 1.88 0.16 1.66 1.12 2.65 0.31 0.69 0.14 0.63 0.11 
glycyltyrosine Peptide LC/MS Pos 1728 239.1   0.0454 24 14 0.65 0.46 0.11 1.05 0.53 1.00 0.20 1.78 0.47 1.76 0.10 0.45 0.21 
glycylvaline Peptide LC/MS Pos 1572 175.1   0.1132 24 13 0.62 0.25 0.00 0.89 0.37 0.83 0.35 1.54 0.54 1.31 0.05 0.39 0.09 
guanine Nucleotide GC/MS 1942.3 352.1 HMDB00132 0.0454 24 6 0.50 1.43 0.18 1.56 0.73 1.23 0.67 1.26 0.09 0.21 0.01 0.66 0.11 
guanosine Nucleotide LC/MS Pos 1676 284 HMDB00133 0.0272 24 7 0.52 0.90 0.09 1.51 0.17 1.17 0.17 1.30 0.16 0.39 0.16 0.43 0.02 
guanosine 5'- monophosphate (GMP) Nucleotide LC/MS Pos 1300 364   1.0000 24 13 0.18 0.90 0.07 1.11 0.07 0.78 0.00 1.29 0.15 1.25 0.10 0.64 0.12 
guanosine 5'-diphospho-fucose Nucleotide LC/MS Neg 797 588.1   0.0454 24 6 0.16 0.94 0.12 1.08 0.08 1.04 0.04 0.88 0.15 0.73 0.00 0.88 0.04 
histidine Amino acid LC/MS Neg 757 154.1 HMDB00177 0.0454 24 6 0.21 1.03 0.11 1.28 0.12 1.26 0.41 1.19 0.12 0.29 0.05 0.81 0.08 
hypotaurine Amino acid GC/MS 1598.5 188 HMDB00965 0.0085 24 4 0.22 1.78 0.63 1.68 0.51 0.97 0.03 0.76 0.18 0.14 0.03 1.21 0.21 
hypoxanthine Nucleotide LC/MS Neg 1313 135.1 HMDB00157 0.0454 24 6 0.26 1.34 0.23 1.30 0.29 1.09 0.30 1.05 0.06 0.41 0.06 0.85 0.11 
inosine Nucleotide LC/MS Neg 1630 267.2   0.0009 24 6 0.41 1.07 0.06 1.34 0.05 1.14 0.15 0.89 0.15 0.34 0.08 0.64 0.06 
inosine 5'-monophosphate (IMP) Nucleotide LC/MS Pos 1310 349 HMDB00175 0.0009 24 8 0.64 0.75 0.08 1.87 0.04 1.61 0.49 1.00 0.05 0.37 0.00 0.44 0.07 
inositol 1-phosphate (I1P) Lipid GC/MS 2057.8 318.1 HMDB00213 1.0000 24 17 0.01 0.76 0.21 1.20 0.18 1.02 0.22 0.95 0.03 1.97 0.18 0.88 0.26 
Isobar: UDP-acetylglucosamine, 
 UDP-acetylgalactosamine 
Carbohydrate LC/MS Neg 661 606.1   0.1132 24 4 0.48 1.99 0.43 1.46 0.06 1.06 0.18 0.89 0.17 0.76 0.17 0.64 0.11 
isobutyrylcarnitine Amino acid LC/MS Pos 1941 232.2 HMDB00736 0.0003 24 4 0.60 1.47 0.11 1.70 0.06 1.23 0.33 0.62 0.11 0.60 0.09 0.93 0.07 
isoleucine Amino acid LC/MS Pos 1614 132.1 HMDB00172 0.0730 24 7 0.21 0.96 0.05 1.30 0.02 1.25 0.37 1.10 0.05 0.57 0.08 0.89 0.10 
isovalerylcarnitine Amino acid LC/MS Pos 2533 246.2 HMDB00688 0.0004 24 4 0.51 1.46 0.16 1.49 0.03 0.99 0.13 0.60 0.09 0.51 0.00 0.86 0.02 
lactate Carbohydrate GC/MS 1102.8 116.9 HMDB00190 0.0085 24 6 0.12 0.97 0.01 1.19 0.02 1.05 0.03 1.09 0.01 0.04 0.01 0.88 0.02 
lactose Carbohydrate GC/MS 2134 204 HMDB00186 0.0454 24 7 0.87 0.92 0.04 2.29 0.05 1.78 0.74 2.22 0.60 0.19 0.05 0.46 0.03 
laurate (12:0) Lipid LC/MS Neg 5288 199.3 HMDB00638 0.4899 24 13 0.15 0.80 0.00 1.09 0.08 1.07 0.08 1.06 0.12 5.00 0.37 0.96 0.02 
leucine Amino acid LC/MS Pos 1674 132.2 HMDB00687 0.0454 24 8 0.26 0.98 0.06 1.33 0.03 1.23 0.40 1.22 0.05 0.88 0.07 0.80 0.12 
leucylleucine Peptide LC/MS Pos 3012 245.1   0.5770 24 13 0.56 0.32 0.05 1.08 0.23 0.44 0.17 1.65 0.49 1.77 0.43 0.46 0.18 
linoleate (18:2n6) Lipid LC/MS Neg 5533 279.3 HMDB00673 0.4899 24 13 0.36 0.78 0.10 1.10 0.06 0.84 0.11 1.25 0.05 3.17 0.09 0.59 0.01 
linolenate [alpha or gamma; (18:3n3 or 6)] Lipid LC/MS Neg 5450 277.3 HMDB01388 0.4899 24 13 0.25 0.71 0.02 1.06 0.01 0.83 0.12 1.08 0.00 2.75 0.16 0.55 0.00 
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lysine Amino acid GC/MS 1836.7 317.2 HMDB00182 0.1702 24 6 0.38 0.92 0.30 1.58 0.27 1.06 0.47 1.65 0.17 0.23 0.00 0.66 0.12 
malate Energy GC/MS 1502 233 HMDB00156 0.0085 24 5 0.38 1.00 0.02 1.31 0.09 1.34 0.05 0.73 0.02 0.14 0.00 1.06 0.09 
margarate (17:0) Lipid GC/MS 1951.6 327.3 HMDB02259 1.0000 24 11 0.12 0.78 0.10 1.29 0.17 0.98 0.17 0.84 0.29 2.39 0.24 0.57 0.03 
mead acid (20:3n9) Lipid LC/MS Neg 5642 305.4 HMDB10378 1.0000 24 15 0.18 0.94 0.19 1.00 0.13 0.68 0.06 1.25 0.10 2.02 0.09 0.71 0.02 
methionine Amino acid LC/MS Pos 1252 150.1 HMDB00696 0.0454 24 8 0.27 0.98 0.06 1.27 0.07 1.25 0.43 1.15 0.02 0.69 0.06 0.82 0.14 
methylphosphate Nucleotide GC/MS 1221 240.9   1.0000 24 13 0.01 0.66 0.00 1.14 0.19 1.14 0.00 0.88 0.01 1.07 0.26 1.13 0.09 
myo-inositol Lipid GC/MS 1924.9 217 HMDB00211 0.1702 24 4 0.09 1.03 0.01 1.34 0.35 0.98 0.17 0.82 0.08 0.14 0.05 1.05 0.00 
myristate (14:0) Lipid LC/MS Neg 5439 227.3 HMDB00806 0.4899 24 13 0.23 0.78 0.15 1.17 0.17 0.90 0.10 1.17 0.01 3.17 0.24 0.64 0.01 
myristoleate (14:1n5) Lipid LC/MS Neg 5338 225.3 HMDB02000 1.0000 24 13 0.01 0.76 0.03 1.09 0.05 1.08 0.11 0.94 0.01 2.80 0.23 0.99 0.05 
N1-methyladenosine Nucleotide LC/MS Pos 1356 282.1 HMDB03331 0.3009 24 7 0.20 0.81 0.05 1.14 0.10 0.93 0.29 1.12 0.12 0.64 0.00 0.70 0.06 
N6-acetyllysine Amino acid LC/MS Pos 1134 189.1 HMDB00206 0.1702 24 8 0.26 0.93 0.08 1.30 0.14 1.24 0.60 1.19 0.19 0.91 0.12 0.58 0.09 
N-acetylalanine Amino acid LC/MS Neg 882 130.1 HMDB00766 0.0272 24 6 0.24 1.05 0.13 1.22 0.18 1.03 0.18 0.92 0.08 0.67 0.00 0.83 0.16 
N-acetylaspartate (NAA) Amino acid LC/MS Neg 620 174.1 HMDB00812 0.00001 24 4 0.36 1.14 0.09 1.31 0.04 1.04 0.01 0.72 0.02 0.31 0.00 0.86 0.11 
N-acetyl-aspartyl-glutamate (NAAG) Amino acid LC/MS Pos 1563 305 HMDB01067 0.3533 24 5 0.01 0.96 0.01 1.13 0.03 1.00 0.03 0.93 0.11 0.31 0.05 1.09 0.07 
N-acetylglutamate Amino acid GC/MS 1720.6 156 HMDB01138 0.1417 24 6 0.23 0.87 0.13 1.58 0.31 1.02 0.12 1.13 0.38 0.75 0.00 0.90 0.09 
N-acetylmethionine Amino acid LC/MS Pos 2588 192.1 HMDB11745 0.1702 24 8 0.48 0.80 0.01 1.44 0.01 1.45 0.41 1.55 0.05 0.56 0.00 0.85 0.11 
N-acetylserine Amino acid GC/MS 1526 218 HMDB02931 0.2485 24 7 0.15 0.83 0.16 1.11 0.11 1.17 0.12 0.99 0.09 0.26 0.07 0.98 0.19 
N-acetylthreonine Amino acid LC/MS Neg 846 160.1   0.4899 24 2 0.04 1.19 0.18 0.98 0.00 1.04 0.08 1.02 0.23 0.79 0.00 1.05 0.08 
n-Butyl Oleate Lipid GC/MS 2045 265.3   0.3009 24 16 0.25 0.65 0.06 0.99 0.40 0.93 0.31 0.96 0.11 2.21 0.20 0.81 0.19 
N-formylmethionine Amino acid LC/MS Neg 1541 176.1 HMDB01015 0.0085 24 6 0.14 1.02 0.23 1.30 0.00 1.07 0.12 0.97 0.08 0.79 0.00 0.86 0.00 
nicotinamide Cofactors and vitamins LC/MS Pos 1267 123.1 HMDB01406 0.1702 24 5 0.13 1.00 0.09 1.18 0.08 1.12 0.17 0.89 0.12 0.35 0.02 1.04 0.06 
nicotinamide adenine dinucleotide (NAD+) Cofactors and vitamins LC/MS Pos 1370 664 HMDB00902 0.1132 24 4 0.07 1.03 0.04 1.29 0.28 0.98 0.05 0.65 0.18 0.07 0.00 1.24 0.03 
nicotinamide adenine dinucleotide phosphate (NADP+) Cofactors and vitamins LC/MS Pos 1330 743.9 HMDB00217 0.0009 24 5 0.26 1.06 0.00 1.50 0.02 1.06 0.12 0.80 0.01 0.69 0.00 0.76 0.07 
nicotinamide adenine dinucleotide reduced (NADH) Cofactors and vitamins LC/MS Neg 1554 664.1 HMDB01487 0.3533 24 3 0.29 0.94 0.13 1.26 0.33 0.90 0.20 0.66 0.05 0.61 0.00 1.34 0.03 
oleate (18:1n9) Lipid GC/MS 1984.4 339.2 HMDB00207 1.0000 24 11 0.16 0.72 0.12 1.23 0.03 0.84 0.23 1.05 0.13 2.13 0.36 0.49 0.04 
oleoylcarnitine Lipid LC/MS Pos 5202 426.4 HMDB05065 0.5770 24 1 0.43 1.00 0.16 1.02 0.27 1.72 0.72 0.22 0.04 0.45 0.27 7.25 2.04 
ornithine Amino acid GC/MS 1763.8 141.9 HMDB03374 0.1702 24 6 0.08 0.82 0.17 1.52 0.23 1.02 0.01 1.77 0.07 0.51 0.25 0.91 0.01 
palmitate (16:0) Lipid LC/MS Neg 5619 255.3 HMDB00220 0.8804 24 13 0.30 0.91 0.19 1.01 0.11 0.78 0.01 1.23 0.09 2.32 0.05 0.59 0.01 
palmitoleate (16:1n7) Lipid LC/MS Neg 5477 253.3 HMDB03229 0.8804 24 13 0.19 0.76 0.07 1.14 0.08 0.84 0.10 1.10 0.01 2.97 0.15 0.45 0.01 
palmitoyl sphingomyelin Lipid GC/MS 2524 311.3   1.0000 24 13 0.08 0.72 0.08 1.08 0.03 0.93 0.16 0.97 0.10 1.59 0.33 0.83 0.13 
pantothenate Cofactors and vitamins LC/MS Pos 2218 220.1 HMDB00210 0.1702 24 8 0.32 0.61 0.02 1.18 0.18 2.14 0.27 0.66 0.00 0.44 0.00 1.19 0.14 
pelargonate (9:0) Lipid LC/MS Neg 4847 157.2 HMDB00847 0.8804 24 13 0.06 0.77 0.03 1.06 0.05 0.93 0.10 0.98 0.08 3.16 0.16 0.86 0.12 
pentadecanoate (15:0) Lipid GC/MS 1853.5 299.2 HMDB00826 1.0000 24 17 0.15 1.01 0.75 0.68 0.42 0.82 0.56 0.71 0.20 1.32 0.06 0.57 0.13 
phenylacetylglycine Amino acid LC/MS Neg 2377 192.1 HMDB00821 0.0730 24 4 0.44 1.07 0.20 1.15 0.13 1.26 0.32 0.57 0.02 0.55 0.00 1.02 0.04 
phenylalanine Amino acid LC/MS Pos 2056 166.1 HMDB00159 0.1132 24 7 0.15 0.95 0.04 1.22 0.05 1.14 0.31 1.06 0.01 0.57 0.06 0.87 0.13 
phosphate Energy LC/MS Neg 627 195 HMDB01429 0.8804 24 13 0.11 0.91 0.06 1.08 0.06 0.91 0.05 1.11 0.07 2.69 0.31 0.85 0.03 
phosphoethanolamine Lipid GC/MS 1577.3 299.1 HMDB00224 0.1702 24 5 0.43 1.22 0.11 1.28 0.00 1.13 0.25 0.65 0.15 0.14 0.03 0.89 0.48 
pro-hydroxy-pro Peptide LC/MS Pos 960 229.2 HMDB06695 1.0000 24 5 0.30 0.62 0.09 0.96 0.08 1.14 0.04 0.52 0.00 0.52 0.00 1.06 0.10 
proline Amino acid LC/MS Pos 796 116.1 HMDB00162 0.0272 24 4 0.18 1.12 0.05 1.08 0.11 1.05 0.03 0.61 0.02 0.29 0.00 1.06 0.08 
prolylleucine Peptide LC/MS Pos 2334 229.2   0.3533 24 11 0.24 0.82 0.07 1.43 0.44 1.29 0.69 2.15 1.14 1.18 0.16 0.56 0.21 
propionylcarnitine Lipid LC/MS Pos 1589 218.2 HMDB00824 0.0454 24 4 0.16 1.02 0.04 1.15 0.01 0.93 0.18 0.74 0.14 0.44 0.10 1.14 0.13 
pseudouridine Nucleotide LC/MS Neg 1104 243.1 HMDB00767 0.1132 24 6 0.55 0.81 0.01 1.49 0.04 1.00 0.16 1.83 0.22 0.34 0.00 0.36 0.02 
putrescine Amino acid GC/MS 1705.8 174 HMDB01414 0.0009 24 2 0.34 2.67 1.37 2.14 0.87 0.88 0.02 0.84 0.01 0.08 0.03 1.15 0.05 
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BIOCHEMICAL PATHWAY PLATFORM RI MASS HMDB_ID PT-p PER LAG AMP 
Post- Schock (hours) 
12 16 20 24 28 32 
mean SEM mean SEM mean SEM mean SEM mean SEM mean SEM 
pyroglutamine* Amino acid LC/MS Pos 764 129.2   0.0363 24 0 0.61 1.35 0.35 1.15 0.19 0.70 0.15 0.43 0.12 0.86 0.55 1.63 0.19 
pyrophosphate (PPi) Energy GC/MS 1642.3 451 HMDB00250 0.2485 24 13 0.21 0.46 0.19 1.10 0.23 0.87 0.28 1.44 0.31 1.10 0.09 0.91 0.07 
pyruvate Carbohydrate GC/MS 1130.6 217 HMDB00243 1.0000 24 5 0.12 1.00 0.02 1.29 0.20 0.99 0.48 1.29 0.39 0.70 0.21 1.07 0.42 
ribitol Carbohydrate GC/MS 1692.4 217 HMDB00508 0.0272 24 4 0.25 0.91 0.14 1.31 0.23 1.00 0.04 0.69 0.06 0.63 0.00 1.16 0.43 
ribose Carbohydrate GC/MS 1639.2 204 HMDB00283 0.1417 24 6 0.44 1.43 0.43 1.51 0.12 1.65 0.90 0.74 0.09 0.95 0.36 0.61 0.01 
ribulose Carbohydrate GC/MS 1662 306.1 
HMDB00621, 
 HMDB03371 
0.0592 24 6 0.25 1.28 0.14 1.28 0.31 1.13 0.44 0.89 0.11 0.70 0.00 0.71 0.01 
S-adenosylhomocysteine (SAH) Amino acid LC/MS Pos 1480 385.1 HMDB00939 0.0454 24 7 0.25 0.97 0.06 1.34 0.01 1.30 0.36 1.31 0.01 0.71 0.02 0.94 0.03 
scyllo-inositol Lipid GC/MS 1893.8 318.2 HMDB06088 0.0021 24 3 0.70 1.83 0.02 1.59 0.07 1.00 0.02 0.54 0.01 0.10 0.05 1.19 0.27 
serine Amino acid GC/MS 1389.1 204 HMDB03406 0.0730 24 6 0.20 1.03 0.07 1.36 0.18 1.29 0.47 1.06 0.15 0.22 0.02 0.84 0.20 
sorbitol Carbohydrate GC/MS 1843 319.1 HMDB00247 0.0454 24 3 0.50 1.10 0.37 1.19 0.19 0.86 0.14 0.41 0.07 0.16 0.00 1.20 0.17 
spermidine Amino acid LC/MS Pos 533 146.2 HMDB01257 0.0156 24 4 0.16 1.03 0.05 1.17 0.02 1.00 0.05 0.79 0.07 0.55 0.02 1.13 0.11 
sphinganine Lipid LC/MS Pos 5175 302.3 HMDB00269 0.1702 24 19 0.26 1.00 0.01 0.83 0.22 0.84 0.14 0.58 0.29 2.38 0.08 1.53 0.32 
sphingosine Lipid LC/MS Pos 5197 300.2 HMDB00252 0.0730 24 20 0.35 1.00 0.03 0.86 0.18 0.69 0.14 0.65 0.29 2.86 0.07 1.30 0.23 
stearate (18:0) Lipid LC/MS Neg 5886 283.4 HMDB00827 1.0000 24 15 0.14 0.92 0.21 1.05 0.12 0.75 0.04 1.16 0.08 1.97 0.10 0.57 0.01 
stearoyl sphingomyelin Lipid GC/MS 2645 311.3 HMDB01348 0.2485 24 12 0.23 0.74 0.29 0.95 0.07 1.01 0.21 1.48 0.34 1.36 0.39 0.71 0.11 
succinate Energy GC/MS 1348 247 HMDB00254 0.0454 24 5 0.29 0.87 0.04 1.30 0.09 1.11 0.01 0.55 0.13 0.26 0.00 1.18 0.18 
succinyl CoA Energy LC/MS Neg 1800 866.1 HMDB01022 1.0000 24 11 0.00 0.70 0.00 1.09 0.40 0.70 0.00 0.92 0.23 0.70 0.00 0.77 0.08 
thiamin (Vitamin B1) Cofactors and vitamins LC/MS Neg 1699 263.1 HMDB00235 0.0085 24 4 0.16 1.02 0.08 1.11 0.09 0.96 0.11 0.81 0.00 0.81 0.00 0.95 0.05 
threonine Amino acid GC/MS 1412.3 218.1 HMDB00167 0.0454 24 4 0.15 1.03 0.08 1.22 0.21 1.31 0.31 0.77 0.14 0.19 0.01 1.16 0.17 
thymidine 5'-monophosphate Nucleotide LC/MS Neg 924 321.1 HMDB01227 0.0156 24 6 0.16 1.00 0.12 1.30 0.11 1.00 0.02 0.97 0.15 0.82 0.00 0.85 0.04 
trans-4-hydroxyproline Amino acid GC/MS 1537 140 HMDB00725 0.8804 24 2 0.51 1.04 0.04 1.13 0.22 1.18 0.27 0.41 0.14 0.16 0.00 2.29 0.26 
tryptophan Amino acid LC/MS Pos 2445 205.1 HMDB00929 0.1132 24 5 0.09 0.95 0.07 1.24 0.14 1.24 0.39 1.00 0.02 0.39 0.04 0.91 0.11 
tyrosine Amino acid LC/MS Pos 1516 182.1 HMDB00158 0.0454 24 6 0.19 1.00 0.08 1.30 0.11 1.27 0.39 1.10 0.04 0.50 0.04 0.84 0.10 
UDP-glucuronate Carbohydrate LC/MS Neg 594 579.1 HMDB00935 0.0004 24 6 0.53 1.18 0.18 1.46 0.07 1.10 0.10 0.91 0.10 0.25 0.01 0.58 0.01 
uracil Nucleotide GC/MS 1370.4 241 HMDB00300 0.0156 24 6 0.41 1.09 0.09 1.38 0.25 1.07 0.35 1.08 0.08 0.14 0.03 0.54 0.06 
uridine Nucleotide LC/MS Neg 1467 243.1 HMDB00296 0.8804 24 10 0.17 0.65 0.06 1.24 0.20 1.02 0.06 0.97 0.19 1.56 0.25 0.41 0.02 
uridine 5'-monophosphate (UMP) Nucleotide LC/MS Pos 1079 325 HMDB00288 0.0021 24 4 0.33 1.38 0.11 1.46 0.09 1.01 0.18 0.92 0.05 0.71 0.01 0.92 0.11 
uridine 5'-triphosphate (UTP) Nucleotide LC/MS Neg 639 483 HMDB00285 1.0000 24 9 0.09 0.69 0.00 0.95 0.27 1.32 0.32 0.91 0.15 0.68 0.00 1.01 0.04 
valine Amino acid LC/MS Pos 1040 118.1 HMDB00883 0.0730 24 7 0.31 1.00 0.01 1.33 0.08 1.22 0.38 1.15 0.13 0.65 0.03 0.80 0.10 
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Figure S1, related to Figure 2: The couple NAD
+
/NADH is driven by the circadian clock 
(A) Total NAD+ measured in serum-shocked human skin fibroblasts at the indicated time points (6 time points, 
n=6 for each, JTK_Cycle, P<0.05). Right panel displays relative total NAD+ level at 16 hours post-shock (peak) 
and at 28 hours (trough) (One-way ANOVA, NAD+ variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 
hours, **,P < 0.01). (B) Total NAD+ content assessed from brain of non-fasted wild-type mice kept in constant 
darkness every 4 hours for 24 hours (7 time points, n= 4 for each, JTK_Cycle, P<0.05). Right panel displays 
relative total NAD+ level at CT4 (peak) and at CT16 (trough) (One-way ANOVA, NAD+ variation pattern, 
P<0.0001; post hoc Tukey; 16 versus 28 hours, **,P < 0.01). (C) Total NADH measured in serum-shocked human 
skin fibroblasts at the indicated time points (6 time points, n=6 for each, JTK_Cycle, P<0.05). Right panel displays 
relative total NAD+ level at 16 hours post-shock (peak) and at 28 hours (trough) (One-way ANOVA, NADH 
variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, **,P < 0.01). (D) Total NADH content assessed 
from brain of non-fasted wild-type mice kept in constant darkness every 4 hours for 24 hours (7 time points, n= 4 
for each, JTK_Cycle, P<0.05). Right panel displays relative total NAD+ level at CT4 (peak) and at CT16 (trough) 
(One-way ANOVA, NADH variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, **,P < 0.01). 
All data are represented as mean ± SEM of at least three independents samples. 
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Figure S2, related to Figure 2: Circadian clock regulates mitochondrial reactive oxygen species 
(A) Cytosolic (cROS) and mitochondrial (mROS) reactive oxygen species levels were evaluated in serum-
shocked human skin fibroblasts (6 time points, n= 4 for each, JTK_Cycle, PmROS<0.05). Right panel displays 
cROS and mROS levels at 16 hours post-shock (peak) and at 28 hours (trough) (One-way ANOVA, mROS 
variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, ***,P < 0.001). (B) Superoxide anions level were 
evaluated in serum-shocked human skin fibroblasts (6 time points, n= 4 for each, JTK_Cycle, P<0.05). Right 
panel displays superoxide anions level at 16 hours post-shock (peak) and at 28 hours (trough) (One-way ANOVA, 
superoxide anions variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, ***,P < 0.001). 
All data are represented as mean ± SEM of at least three independents samples. 
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Figure S3, related to Figure 3: Circadian regulation of intrinsic mitochondrial function 
(A) Percentage of BrdU- positive cells in absence and presence of AraC at 24 hours post-shock (student t-test, 
control versus AraC, ***, P<0.0001). (B) Percentage of OCR linked to spare respiratory capacity (SRC) at 16 
hours post-shock and 28 hours post-shock in human skin fibroblast (One-way ANOVA, OCR variation pattern, 
P<0.0001; post hoc Tukey; 16 versus 28 hours, *,P < 0.05). (C) OCR related to the proton leak (independent to 
ATP production) at 16 hours post-shock and 28 hours post-shock in human skin fibroblast. (D) Extracellular 
Acidification Rate (ECAR) corresponding to glycolytic rate at 16 hours post-shock and 28 hours post-shock 
evaluated in human skin fibroblast. 
All data are represented as mean ± SEM of three independents samples (2 time points, n= 11 replicates for each, 
three independent experiments). 
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Figure S4, related to Figure 3: Circadian control of mitochondrial biogenesis 
(A) Circadian profiles of relative mRNA expression of complex I subunits (NDUFA2, NDUFB5, NDUFC1, and 
NDUFV2) in serum-shocked human skin fibroblasts (6 time points, n= 4 for each, JTK_Cycle, P<0.05). (B) 
Relative mRNA expression of complex I subunits at 16 hours post-shock (corresponding to the peak in gene 
expression) and 28 hours post-shock (corresponding to the trough in gene expression) (One-way ANOVA, mRNA 
variation pattern, P<0.0001; post hoc Tukey; 16 versus 28 hours, *, P<0.05, **, P<0.01, ***,P < 0.001). (C) 
Circadian profiles of relative mRNA expression of complex IV subunits (COX4I1, COX6A1, COX7A2 and COX7B) 
in serum-shocked human skin fibroblasts (6 time points, n= 4 for each, JTK_Cycle, P<0.05). (D) Relative mRNA 
expression of complex IV subunits at 16 hours post-shock (corresponding to the trough in gene expression) and 
28 hours post-shock (corresponding to the peak in gene expression) (One-way ANOVA, mRNA variation pattern, 
P<0.0001; post hoc Tukey; 16 versus 28 hours, *, P<0.05, **, P<0.01, ***, P < 0.001). (E) Circadian profiles of 
relative mRNA expression of complex V subunits (ATP5G2, ATP5L and ATP5C1) in serum-shocked human skin 
fibroblasts (6 time points, n= 4 for each, JTK_Cycle, P<0.05). (F) Relative mRNA expression of complex V 
subunits at 20 hours post-shock and 32 hours post-shock (corresponding respectively to the peak and trough in 
gene expression) (One-way ANOVA, mRNA variation pattern, P<0.0001; post hoc Tukey; 20 versus 32 hours, *, 
P<0.05, **, P<0.01, ***, P < 0.001). 
All data are represented as mean ± SEM of at least three independents samples. 
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Figure S5, related to Figure 4: Circadian clock influences mitochondrial morphology 
(A) Number of cells displaying one of the mitochondrial network states (tubular, intermediate and fragmented) 
determined in serum-shocked human skin fibroblasts from 8 hours post-shock every 8 hours over the course of 
48 hours (mean of 3 independent experiments, 100 cells counted per conditions). (B) Profile of relative mRNA 
expression of nuclearly-encoded genes related to (B) mitochondrial fusion (MFN1, MFN2 and OPA1) was 
evaluated in serum-shocked human skin fibroblasts (6 time points, n=6 for each). (C) Profile of relative mRNA 
expression of nuclearly-encoded genes related to fission (DRP1 and hFIS1) was evaluated in serum-shocked 
human skin fibroblasts (6 time points, n=6 for each). 
All data are represented as mean ± SEM of at least three independents samples. 
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Figure S6: Schematic representation of the relationship between the core molecular clock and 
mitochondrial dynamics. CI, complex I; CII, complex II; CIII, complex III; CIV, complex IV; CV, complex V; 
∆Ψ, mitochondrial membrane potential; IMS, intermembrane space; IMM, inner mitochondrial membrane; Q, 
ubiquinone; Cyt C, cytochrome c; ROS, reactive oxygen species; Cry, cryptochrome; Per, Period; TCA, 
tricarboxylic acid cycle.  
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Experimental Procedures 
Mice 
Male C57BL/6, Male Drp1flx/flx CreERT2 (Ishihara et al., 2009) and mPer1/mPer2 (Bae et al., 
2001) double-mutant mice were housed for one week on a 12:12 light-dark cycle prior to 
placement in DD 5 days before the beginning of the experiment with free access to food and 
water. Circadian time 0 (CT0) is the start of subjective daytime and CT12 is the start of 
subjective night-time, under constant dark conditions, over 24 hours. All brain homogenate 
samples were normalized on 5 mg/ml of protein before ATP content measurement and on 1 
mg/ml for NAD+/NADH content determination. See Supplemental Experimental Procedures.
Cell culture  
Human osteosarcoma U2OS cell and human skin fibroblasts infected with lentiviral circadian 
reporter mice Bmal1::luciferase were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 1% penicillin/streptomycin (Sigma), 1% Glutamax (Sigma) and 
20% fetal bovine serum (FBS) (Sigma) as described previously (Brown et al., 2005, Pagani 
et al., 2010). Metabolic profiles also were obtained from dexamethasone-synchronized U2OS 
cells. Small-Molecule Determination Metabolon analyzed metabolites in dexamethasone-
synchronized U2OS cells, as described previously (Dallmann et al., 2012, Lawton et al., 
2008). 
Drp1lox/lox MEFs were prepared from E13.5 Drp1lox/lox embryos and cultured as previously 
described (Ishihara et al., 2009). Drp1-/- MEFs were subsequently generated by expression of 
Cre recombinase. The MEFs were maintained in (DMEM) supplemented with 1% 
penicillin/streptomycin (Sigma), 1% Glutamax (Sigma), 10% fetal bovine serum (FBS) and 1x 
non-essential amino acids. 
MEFs lacking mPer1 and mPer2 isolated from double knockout mice were generated from 
E12 embryos as previously described (Nagoshi et al., 2004, Zheng et al., 2001) and cultured 
in DMEMc containing 10% FCS. 
For measurements of nucleotide level, cell proliferation, ROS, oxygen consumption rate and 
mitochondrial morphology, cells were synchronized by serum shock treatment (50% horse 
serum supplemented DMEMc) for 2 hours at 37 °C. For period length determination, cells 
were synchronized by addition of 100 nM dexamethasone (Sigma) in DMEMc + 20% FBS. 
See Supplemental Experimental Procedures. 
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Nucleotide Measurements 
Total ATP content from synchronized cell cultures and mice brain homogenates was 
determined using bioluminescence assay (ViaLighTM HT; Cambrex Bio Science) according 
to the instruction of the manufacturer. For measurement of NAD+ and NADH from 
synchronized fibroblasts and mice brain homogenates, NAD+ and NADH were separately 
extracted using an acid-base extraction (HCL 0.1 mol/l – NAOH 0.1 mol/l). For complete 
protocol, please refer to the Supplemental Experimental Procedures. 
ROS level 
The formation of cytosolic (cROS), mitochondrial (mROS) reactive oxygen species and 
superoxide anions in synchronized fibroblasts were measured using, the fluorescent probe 
H2DCF-DA (DCF) (10 μM, 15 min), the non-fluorescent dihydrorhodamine-123 (DHR) (10 
μM, 15 min) and the Red Mitochondrial Superoxide Indicator (MitoSOX, 5 μM, 30 min), 
respectively. See Supplemental Experimental Procedures. 
Oxygen Consumption Rate (OCR) Measurements 
OCR was measured in synchronized fibroblasts using a Seahorse Bioscience (North 
Billerica, MA, USA) XF24 Analyzer as previously described (Invernizzi et al., 2012). 
Experiments were performed at 16 hours post-shock and 28 hours post-shock. For complete 
protocol, please refer to the Supplemental Experimental Procedures. 
Quantitative Real-Time PCR 
Total RNA was extracted from lysates of synchronized fibroblasts using RNeasy Mini KIT 
(Qiagen). cDNA was generated using Ready-to-Go You-Prime First-Strand Beads (GE 
Healthcare). For data analysis, human Cdk4 was used as an endogenous control. Data are 
expressed as relative expression for each individual gene normalized to their corresponding 
controls using the comparative CT method. The primers used were purchased from Applied 
Biosystems and Microsynth (Probe ID: see Supplemental Experimental Procedures). Data 
are expressed as relative expression for each individual gene normalized to their 
corresponding controls. 
Mitochondrial Morphology 
Mitochondrial staining was performed on serum-shocked fibroblasts with the mitochondrial 
membrane potential-sensitive dye Mitotracker® Red CMX ROS (75nM, 579/599, Life 
technologies). Sytox Green (167nM, 504/523, Invitrogen) was used as nuclei staining 
according to the manufacturer’s recommendation. 
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For immunohistochemistry on brain and liver slices from C57BL/6 mice at CT0 (onset of 
subjective day or rest period) and CT12 (onset of subjective night or activity period), antibody 
against the outer mitochondrial membrane porin, Voltage-Dependent Anionic Channel 
(VDAC, 1:75, Cell Signaling) was used for determining mitochondrial morphology. A FITC-
labeled anti-rabbit IgG (1:160, Sigma, 490/525) was used as secondary antibody. TO-PRO-
3iode (1uM, 642/661, Invitrogen) was used as nuclei staining according to the manufacturer’s 
recommendation. 
For complete protocol, please refer to the Supplemental Experimental Procedures. 
Protein Gel Electrophoresis and Immunoblotting 
Lysates from serum-shocked fibroblast cultures and brain homogenate were prepared and 
protein expression levels were measured by standard western blot procedure. We used 
primary antibodies to DRP1 (1:500, Cell Signaling), ser637-phosphorylated DRP1 (1:500, 
Cell Signaling) and VDAC (1:500, Cell Signaling) and horseradish peroxidase-coupled IgG 
as secondary antibody (1:160, Sigma). Signals were detected by enhanced 
chemiluminescence using SuperSignal™ West Dura Chemiluminescent Substrate (Thermo 
Scientific). For complete protocol, please refer to the Supplemental Experimental 
Procedures. 
Circadian period length determination 
In human skin fibroblast transfected with the lentiviral circadian reporter mice 
Bmal1::luciferase (Brown et al., 2005), light output was measured in homemade light-tight 
atmosphere-controlled boxes for at least 5 days. For complete protocol, please refer to the 
Supplemental Experimental Procedures. 
Statistical Analysis 
Data were presented as mean ± S.E.M. Statistical analyses were performed using the 
Graph Pad Prism software. For statistical comparisons, One-way ANOVA followed by 
Tukey’s multiple comparison test or Two-way ANOVA followed by Bonferroni's multiple 
comparison test was used respectively. Rhythmicity of metabolites and genes expression 
was assessed using an algorithm previously described for rhythmic transcripts. The JTK-
cycle algorithm was used as implemented in R by Kronauer as previously described 
(Dallmann et al., 2012, Hughes et al., 2010). A window of 24 h was used for the 
determination of circadian periodicity and a P value of <0.05 was considered as statistically 
significant. Metabolites profiles were crosschecked by visual inspection and false positive 
were excluded.  
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Supplemental Experimental Procedures 
Mice 
Drp1flx/flx CreERT2 mice [20] were obtained by crossing Drp1flx/flx mice with mice 
expressing an inducible Cre recombinase transgene under the control of the 
CamKIIα promoter (Cre+), which is active in the hippocampus and the cortex of adult 
mice (from the European Mouse Mutant Archive EMMA strain 02125) (Ishihara et al., 
2009). At 8 weeks of age mice were injected intraperitoneally with 1 mg tamoxifen 
(Sigma) twice daily for five consecutive days to induce recombination of the Drp1 
locus (Oettinghaus et al., 2015). 
Brain Homogenate Preparation  
Brains were dissected on ice and washed in ice-cold buffer (210 mM mannitol, 70 
mM sucrose, 10 mM Hepes, 1 mM EDTA, 0.45% BSA, 0.5 mM DTT, and Complete 
Protease Inhibitor mixture tablets (RocheDiagnostics). After removing the cerebellum, 
tissue samples were homogenized in 2 ml of buffer with a glass homogenizer (10–15 
strokes, 400 rpm). We used 10μl of the suspension for protein concentration 
determination 
Human Skin Fibroblast  
Fibroblasts were isolated from biopsies, infected with lentiviral circadian reporter mice 
Bmal1::luciferase and cultured in DMEM/1% penicillin/streptomycin (Sigma)/1% 
Glutamax (Sigma) (DMEMc)/20% FBS (Sigma) as described previously (Brown et al., 
2005, Pagani et al., 2010). For measurements of nucleotide level, cell proliferation 
(BrdU assay), ROS, oxygen consumption rate and mitochondrial morphology in 
human skin fibroblasts, circadian rhythms were synchronized by serum shock 
treatment (50% horse serum supplemented DMEMc) for 2 hours at 37 °C. For period 
length determination, circadian rhythms were synchronized by 100 nM 
dexamethasone (Sigma) in DMEMc + 20% FBS. DMEMc without phenol red was 
supplemented with 0.1 mM luciferin (Molecular Probes) and 10% FBS to obtain the 
counting medium (CM). 
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U2OS Cells Metabolome 
Small-Molecule Determination. Metabolon was used to analyze metabolites in 
dexamethasone-synchronized U2OS cells, as described previously (Dallmann et al., 
2012, Lawton et al., 2008). 
Oxygen Consumption Rate (OCR) Measurements 
OCR was measured in synchronized fibroblasts as recommended as previously 
described (Invernizzi et al., 2012). Briefly, human skin fibroblasts were seeded at the 
density of 3x104 cells/100 μl per well on Seahorse Biosciences 24-well culture plates 
one day prior to the beginning of assay. After serum shock synchronization, medium 
was exchanged to 500 μl of assay medium (glucose-free RPMI-1640 medium 
containing 2% FBS, 2 mM sodium pyruvate, pH ~ 7.4). Prior to measurements the 
microplates were equilibrated in a CO2 free incubator at 37 °C for 60 minutes. The 
drug injections ports of the XF Assay Cartridge were loaded with the assay reagents 
at 10X in assay medium. 55 μl of oligomycin (10 μM), 62 μl of FCCP (7 μM), 68μl of a 
mix of antimycin A (40 μM) and rotenone (20 μM) were added to ports A, B and C 
respectively. Experiments were performed at 16 hours post-shock and 28 hours post-
shock. 
Nucleotides Measurement 
Total ATP content from synchronized human skin fibroblasts, Drp1lox/lox and Drp1-/- 
MEFs, Per1/2+/+ and Per1/2-/- MEFs and mice brain homogenates was determined 
using bioluminescence assay (ViaLighTM HT; Cambrex Bio Science) according to 
the instruction of the manufacturer. The enzyme luciferase, which catalyzes the 
formation of light from ATP and luciferin was used. The emitted light is linearly related 
to the ATP concentration and is measured using a luminometer (VictorX5, Perkin 
Elmer). To define the origin of ATP oscillation, DMEMc without phenol red + 2% FBS 
supplemented with 2-Deoxy-D-glucose (4.5 g/l) a glycolysis inhibitor or oligomycin (2 
μM), an ATP synthase inhibitor was added on synchronized human skin fibroblasts. 
To test the possibility that rhythmic ATP is a byproduct of rhythmic cell division, 
pharmacological disruption of the cell cycle was accomplished with the inhibitor AraC, 
an anticancer drug that prevents cell division (100 μm; Sigma). AraC was added to 
human skin fibroblasts cultures 3 hours after the seeding, directly after the medium 
exchange following the synchronization and then every 24 hours to assure continued 
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block of cell division. To verify if AraC treatment had an impact on cell cycle and 
blocked cell proliferation, the BrdU Cell Proliferation Assay (Calbiochem, Darmstadt, 
Germany) was used following the instructions of the manufacturer. To investigate the 
role of clock- regulated Drp1 in mitochondrial bioenergenetics, mitochondrial fission 
was abolished by selective inhibition of mitochondrial division dynamin, Drp1, in 
presence of mdivi-1 (50 μM, Sigma). 
For measurement of NAD+ and NADH from synchronized fibroblasts and mice brain 
homogenates, NAD+ and NADH were separately extracted using an acid-base 
extraction (HCL 0.1 mol/l – NAOH 0.1 mol/l). The determination of both NAD+ and 
NADH was performed using an enzyme cycling assay based on passing the electron 
from ethanol trough reduced pyridine nucleotides to MTT (3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) in a PES- (phenazine ethosulfate) coupled 
reaction resulting in a purple formazan product that can be quantitatively measured at 
a wavelength of 595 nm (VictorX5, Perkin Elmer). Experiments were performed 
starting from 12 hours post-synchronization time point and measured at 4 hours 
intervals for 6 time points. 
Circadian period length determination 
In fibroblast transfected with the lentiviral circadian reporter mice Bmal1::luciferase 
(Brown et al., 2005), light output was measured in homemade light-tight atmosphere-
controlled boxes for at least 5 days. To measure the fibroblast basal circadian 
rhythms, CM was supplemented with 10% FBS; to determine the influence of ATP on 
circadian period length, CM was supplemented with mitochondrial respiration 
inhibitors: rotenone, a complex I inhibitor (1 μM), oligomycin, ATP synthase inhibitor 
(2 μM) or carbonyl-cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), an 
uncoupler of proton gradient (4 μM). To determine the role of Drp1-regulated 
mitochondrial bioenergenetics, CM was supplemented with mdivi-1 (50 μM, Sigma), 
a mitochondrial division inhibitor. 
ROS Level 
Synchronized fibroblasts were loaded for 15 min with 10 μM DCF or 15 min with 10 
μM DHR at 37 °C. After washing twice with HBSS, the formation of the reduced 
fluorescent product dichlorofluorescein was detected using the VictorX5 multilabel 
reader (PerkinElmer Life Sciences) at 485 nm (excitation)/535 nm (emission). DHR, 
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which is oxidized to cationic rhodamine 123 which localizes in the mitochondria and 
exhibits green fluorescence, was detected using the VictorX5 multilabel reader at 490 
nm (excitation)/590 nm (emission). The levels of superoxide anion radical were also 
assessed using the Red Mitochondrial Superoxide Indicator (MitoSOX, 5 μM, 30 
min). MitoSOX, which is specifically oxidized by mitochondrial superoxide, exhibits a 
red fluorescence detected at 535 nm (excitation)/595 nm (emission). The intensity of 
fluorescence was proportional to mROS levels or superoxide anion radicals in 
mitochondria. Experiments were performed starting from 12 hours post-
synchronization time point and measured at 4 hours intervals. 
Primer sequences 
The primer sequences purchased from Applied Biosystems were: MFN1, 
Hs00250475_m1; MFN2, Hs00208382_m1; OPA1, Hs00323399_m1; DRP1, 
Hs00247147_m1; hFIS1; Hs00211420_m1; NDUFA2, Hs00159575_m1; NDUFB5, 
Hs00159582_m1; NDUFC1, Hs00159587_m1; NDUFV2, Hs00221478_m1; COX4I1, 
Hs00971639_m1; COX6A1, Hs01924685_g1; COX7A2, Hs01652418_m1; COX7B, 
Hs00371307_m1; ATP5G2, Hs01096582_m1; ATP5C1, Hs01101219_g1, ATP5L, 
Hs00758883_s1; Bmal1, Mm00500226_m1; Per1, Mm00501813_m1; Per2, 
Mm00478113_m1. The primer sequences purchased from Microsynth were: hBmal1 
forward, 5'-GAAGACAACGAACCAGACAATGAG-3', hBmal1 reverse, 5'-
ACATGAGAATGCAGTCGTCCAA-3', hBmal11 probe, 5'-Yakima Yellow-
TGTAACCTCAGCTGCCTCGTCGCA-BHQ1-3'; hPer1 forward, 5'-
CGCCTAACCCCGTATGTGA-3'', hPer1 reverse, 5'-
CGCGTAGTGAAAATCCTCTTGTC-3', hPer1 probe, 5'-Yakima Yellow-
CGCATCCATTCGGGTTACGAAGCTC-BHQ1-3'; hPer2 forward, 5'-
GGGCAGCCTTTCGACTATTCT-3', hPer2 reverse, 5'-
GCTGGTGTCCAACGTGATGTACT-3', hPer2 probe, 5'-Yakima Yellow-
CATTCGGTTTCGCGCCCGGG-BHQ1-3'. 
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Abstract
 
The brain has high energy requirements to maintain neuronal activity. Consequently impaired 
mitochondrial function will lead to disease. Normal aging is associated with several 
alterations in neurosteroid production and secretion. Decreases in neurosteroid levels might 
contribute to brain aging and loss of important nervous functions, such as memory. Up to 
now, extensive studies only focused on estradiol as a promising neurosteroid compound that 
is able to ameliorate cellular bioenergetics, while the effects of other steroids on brain 
mitochondria are poorly understood or not investigated at all. Thus, we aimed to characterize 
the bioenergetic modulating profile of a panel of seven structurally diverse neurosteroids 
(progesterone, estradiol, estrone, testosterone, 3α-androstanediol, DHEA and 
allopregnanolone), known to be involved in brain function regulation. Of note, most of the 
steroids tested were able to improve bioenergetic activity in neuronal cells by increasing ATP 
levels, mitochondrial membrane potential and basal mitochondrial respiration. In parallel, 
they modulated redox homeostasis by increasing antioxidant activity, probably as a 
compensatory mechanism to a slight enhancement of ROS which might result from the rise 
in oxygen consumption. Thereby, neurosteroids appeared to act via their corresponding 
receptors and exhibited specific bioenergetic profiles. Taken together, our results indicate 
that the ability to boost mitochondria is not unique to estradiol, but seems to be a rather 
common mechanism of different steroids in the brain. Thus, neurosteroids may act upon 
neuronal bioenergetics in a delicate balance and an age-related steroid disturbance might be 
involved in mitochondrial dysfunction underlying neurodegenerative disorders. 
 
Keywords: Mitochondria, Neurosteroid, Bioenergetics, Amyloid-β peptide, tau protein. 
 
Abbreviations:  
3α-A, 3α-androstanediol; AD, Alzheimer’s disease; APP, amyloid-β precursor protein; AP, 
allopregnanolone; D, DHEA (dihydroepiandrosterone); DHR, dihydrorhodamine 123; DMSO, 
dimethylsulfoxide; E1, estrone; E2, 17β-estradiol; E3, estriol; ECAR, extracellular 
acidification rate; ETC, electron transport chain; MAS, mitochondrial assay solution; MPP, 
mitochondrial membrane potential; mtROS, mitochondrial reactive oxygen species; OCR, 
oxygen consumption rate; OXPHOS, Oxidative phosphorylation; P, progesterone; PD, 
Parkinson’s disease; PMP, plasma membrane permeabilizer; RCR, respiratory control ratio; 
roGFP, redox sensitive green fluorescent protein; ROS, reactive oxygen species; SRA, 
steroid receptor antagonist; T, testosterone; TCA, tricyclic acid.  
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1. Introduction
 The brain is a highly differentiated organ with high energy requirements, mainly in the 
form of adenosine triphosphate (ATP) molecules. Despite its small size, it accounts for about 
20% of the body’s total basal oxygen consumption (1). As a result, the brain is more sensitive 
to neuronal damage during hypometabolic states and impaired redox homeostasis, as 
observed in normal aging and in neurodegenerative diseases associated with a decline in 
energy production and changes in the redox status (2). In this context, mitochondria, small 
organelles that are present in almost all cell types playing a predominant role in cellular 
bioenergetics, are particularly important in the nervous system because of its high energy 
demand. Mitochondria are not only the “powerhouses of the cell”, providing the main source 
of cellular energy via ATP generation through oxidative phosphorylation, but they also 
contribute to plenty of cellular functions, including apoptosis, intracellular calcium 
homeostasis, alteration of the cellular reduction–oxidation (redox) state and synaptic 
plasticity (3; 4). Thus, it is more and more recognized that mitochondrial dysfunction is a 
significant and early event of neurodegeneration, and that the pathophysiological 
mechanisms of a range of neurodegenerative diseases, including Alzheimer’s (AD) and 
Parkinson’s disease (PD), are associated with a decline in bioenergetic activity and an 
increase in oxidative stress, particularly in mitochondria themselves (5-10). 
Steroid hormones are molecules involved in the control of many physiological 
processes in the periphery, from reproductive behavior to the stress response. They are 
mainly produced by endocrine glands, such as the adrenal glands, gonads and placenta, but 
in 1981 Baulieu and co-workers were the first to demonstrate the production of steroids 
within the nervous system itself (11). This last category of molecules is now called 
“neurosteroids” and is defined as steroids that are synthetized within the nervous system 
independently of peripheral endocrine glands. Neurosteroid levels remain elevated even after 
adrenalectomy and castration (12; 13) and are involved in brain-specific functions. Since the 
ability to produce neurosteroids is conserved during vertebrate evolution, one can suggest 
that this family of molecules is important for living things and that the modulation of their 
biosynthesis plays an important role in the pathophysiology of neurodegenerative disorders. 
Studies performed in humans, animals, and cellular models have shown alterations in 
the synthesis of neurosteroids that declined during brain aging paralleled by a loss of 
important nervous functions, such as memory, and were further associated with PD and AD 
(14-16). Thus, several neurosteroids have been quantified in various brain regions of aged 
AD patients and aged non-demented controls. This showed a general trend toward lower 
steroid levels in AD patients compared to controls, associated with a negative correlation 
between neurosteroid levels and amyloid-β (Aβ) and phospho-tau in some brain regions (17). 
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In accordance with these observations, previous data from our groups provided first evidence 
that, vice versa, Aβ and hyperphosphorylated tau differentially impacted 
neurosteroidogenesis (Fig. 1) (18-20). Indeed, a decrease of progesterone and 17-
hydroxyprogesterone production was observed in amyloid precursor protein (APP)/Aβ-
overexpressing cells, while 3α-androstanediol and estradiol levels were increased (19). 
Moreover, in vitro treatment of human neuroblastoma cells with “non-toxic” Aβ concentrations 
(within the nanomolar range) revealed an increase in estradiol production, whereas toxic Aβ 
concentrations (within the micromolar range) showed the opposite effect (18). 
Overexpression of human wild type tau (hTau40) protein induced an increase in production 
of progesterone, 3α-androstanediol, and 17-hydroxyprogesterone, in contrast to the 
abnormally hyperphosphorylated tau bearing the P301L mutation that led to decreased 
production of these neurosteroids (19).  
Moreover, a growing body of evidence has highlighted neuroprotective effects of 
steroids, particularly estradiol, against AD-related injury (reviewed in (21)). Because the drop 
of estrogen in a post-menopausal woman is considered as a risk factor in AD (two-thirds of 
AD patients are women), the neuroprotective action of estrogen has been widely investigated 
(reviewed in (22)). One in vivo study showed that estradiol treatment of ovariectomized 
female rats up-regulated enzymes involved in glycolysis and oxidative phosphorylation, and 
increased ATP synthase expression which was translated into an increased mitochondrial 
respiration (23). These findings were additionally confirmed in an AD mouse model by Yao 
and coworkers (24). 
However, there is little evidence that other steroids are also able to act on 
mitochondrial function, and to our knowledge, no study has aimed to compare the effects of 
neurosteroids besides estradiol on cellular bioenergetics and redox environment in neuronal 
cells. Thus, the objective of our study was to investigate the effects of different neurosteroids 
on bioenergetic activity in vitro. For this purpose, we selected seven neurosteroids - 
progesterone, estradiol and estrone, belonging to the estrogen family; testosterone and 3α-
androstanediol, belonging to androgen family; and DHEA and allopregnanolone - known to 
be involved in brain function regulation (12; 13; 25; 18; 19; 17). Neurosteroid effects on ATP 
production, mitochondrial membrane potential (MMP), mitochondrial respiration, glycolysis 
and the consequences on the modulation of the redox environment were investigated in 
neuronal cells.  
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2. Materials and methods
2.1. Chemicals and reagents 
 Dulbecco’s-modified Eagle’s medium (DMEM), RPMI-1640 medium, fetal calf serum 
(FCS), penicillin/streptomycin, progesterone, 17β-estradiol, estrone, 3α-androstanediol, 
DHR, TMRM, ADP, pyruvate, succinate and malate were from Sigma-Aldrich (St. Louis, MO 
USA). Glutamax, MitoSOX, DPBS, Neurobasal medium and B27 were from Gibco Invitrogen 
(Waltham, MA, USA). DHEA and allopregnanolone were from Calbiochem (Billerica, MA, 
USA). PMP and XF Cell Mitostress kit were from Seahorse Bioscience (North Billerica, MA, 
USA). Testosterone was from AppliChem (Darmstadt, Germany). Horse serum (HS) was 
from Amimed, Bioconcept (Allschwil, Switzerland). RU-486, ICI-187.780, and 2-hydroxy 
flutamide were from Cayman Chemical (Ann Arbor, MI, USA). 
 
2.2. Cell culture 
 Human SH-SY5Y neuroblastoma cells were grown at 37 °C in a humidified incubator 
chamber under an atmosphere of 7.5% CO2 in DMEM supplemented with 10% (v/v) heat-
inactivated FCS, 5% (v/v) heat-inactivated HS, 2 mM Glutamax and 1% (v/v) 
penicillin/streptomycin. Cells were passaged 1-2 times per week, and plated for treatment 
when they reached 80–90% confluence.  
 
2.3. Primary neuronal cultures 
 Mouse cortical neurons were prepared from E15 embryos according to the French 
guidelines, as previously described (26). Cells were plated in poly-L-lysine-coated plates at a 
density of 1.5 × 104 cells/well for ATP measurement (white 96-well plate) or 5 × 104 
cells/well for measurement with the Seahorse XF24 Analyser (XF24 cell culture microplate). 
After 7 days at 37 °C, 50% of the medium was replaced with fresh medium every third day. 
ATP level, oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were 
investigated in this primary neuronal culture after a 24 h treatment with the different 
neurosteroids. 
 
2.4.  Treatment paradigm  
 Assessment of cell viability was performed on SH-SY5Y neuroblastoma cells to 
determine the potential toxic concentration range of neurosteroids (from 10 nM to 1000 nM, 
data not shown) and steroid receptor antagonists (SRA, from 1 nM to 1 μM, data not shown) 
using a MTT reduction assay (Roche, Basel, Switzerland). On the basis of the MTT results, 
the concentrations 10 nM and 100 nM of steroids were then selected and used in all assays. 
SH-SY5Y cells were treated one day after plating either with DMEM (untreated control 
condition) or with a final concentration of 10 nM and 100 nM of progesterone, 17β-estradiol, 
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estrone, testosterone, 3α-androstanediol, DHEA or allopregnanolone made from a stock 
solution in DMSO for 24 h (final concentration of DMSO < 0.002%, no effect of the vehicle 
solution (DMSO) alone compared to the untreated condition). In the experiment using SRA, 
cells were pre-treated for 1 h. with 100 nM of RU-486 and ICI-187.780, and 1 μM of 2-
hydroxy flutamide (2OH-flutamide), and then treated for 24 h with the corresponding 
neurosteroids. To limit cell growth and to optimize mitochondrial respiration, treatment 
medium contained only a low amount of fetal calf serum (5% FCS) as well as glucose (1 g/l) 
and was supplemented with 4 mM pyruvate. Each assay was repeated at least 3 times. 
 
2.5. ATP levels 
 Total ATP content of SH-SY5Y cells was determined using a bioluminescence assay 
(ViaLighTM HT, Cambrex Bio Science, Walkersville, MD, USA) according to the instruction of 
the manufacturer, as previously described (27). SH-SY5Y cells were plated in 5 replicates 
into a white 96-wells cell culture plate at a density of 1.5 × 104 cells/well. The bioluminescent 
method measures the formation of light from ATP and luciferin by luciferase. The emitted 
light was linearly related to the ATP concentration and was measured using the multilabel 
plate reader VictorX5 (Perkin Elmer). 
  
2.6.  Cell proliferation assay  
 To verify if our treatment had an impact on cell cycle and induced proliferation, the 
BrdU Cell Proliferation Assay (Calbiochem, Darmstadt, Germany) was used following the 
instructions of the manufacturer. Briefly, SH-SY5Y cells were plated in 6 replicates into a 96-
wells cell culture plate at a density of 1 × 104 cells/well. During the final 12 h of neurosteroid 
treatment, BrdU was added to the wells and incorporated into the DNA of dividing cells. The 
detection of BrdU was performed using an anti-BrdU antibody recognized by a horseradish 
peroxidase-conjugated anti-mouse. After addition of the substrate (TMB), the color reaction 
was quantified using the multilabel plate reader VictorX5 at 450nm. Values are proportional 
to the number of dividing cells.  
 
2.7. Determination of mitochondrial membrane potential 
 The MMP was measured using the fluorescent dye tetramethylrhodamine, methyl 
ester, and perchlorate (TMRM). SH-SY5Y cells were plated in 6 replicates into a black 96-
well cell culture plate at a density of 1.5 × 104 cells/well. Cells were loaded with the dye at a 
concentration of 0.4 μM for 15 min. After washing twice with HBSS, the fluorescence was 
detected using the multilabel plate reader VictorX5 (PerkinElmer) at 530 nm (excitation)/590 
nm (emission). Transmembrane distribution of the dye was dependent on MMP.  
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2.8. Oxygen consumption rate and extracellular acidification rate 
 The Seahorse Bioscience XF24 Analyser was used to perform a simultaneous real-
time measurement of oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR). XF24 cell culture microplates (Seahorse Bioscience) were coated with 0.1% 
gelatine and SH-SY5Y cells were plated at a density of 2.5 × 104 cells/well in 100 μl of the 
treatment medium containing 5% FCS, 1 g/l glucose and 4 mM pyruvate. After neurosteroid 
treatment, cells were washed with PBS and incubated with 500 μl of assay medium (DMEM, 
without NaHCO3, without phenol red, with 1g/l glucose, 4 mM pyruvate, and 1% L-glutamine, 
pH 7.4) at 37 °C in a CO2-free incubator for 1 h. The plate was placed in the XF24 Analyser 
and basal OCR and ECAR were recorded during 30 min. For primary neuronal culture, the 
same conditions were kept, except the medium; here DMEM was replaced by RPMI-1640 
medium. 
 
2.9.  Mitochondrial respiration 
 The investigation of mitochondrial respiration was performed using the Seahorse 
Bioscience XF24 analyser. XF24 cell culture microplates were coated with 0.1% gelatine and 
cells were plated at a density of 2.5 × 104 cells/well in 100 μl of treatment medium containing 
5% FCS, 1 g/l glucose and 4 mM pyruvate. After neurosteroid treatment, cells were washed 
with 1× pre-warmed mitochondrial assay solution (MAS; 70 mM sucrose, 220 mM mannitol, 
10 mM KH2PO, 4.5 mM MgCl2, 2 mM HEPES, 1 mM EGTA and 0.2% (w/v) fatty acid-free 
BSA, pH 7.2 at 37 °C) and 500 μl of  pre-warmed (37 °C) MAS containing 1 nM XF plasma 
membrane permeabilizer (PMP, Seahorse Bioscience), 10 mM pyruvate, 10 mM succinate 
and 2 mM malate was added to the wells. The PMP was used to permeabilize intact cells in 
culture, which circumvents the need for isolation of intact mitochondria and allows the 
investigation of the OCR under different respiratory states induced by the sequential injection 
of: i) ADP (4 mM) to induce state 3; ii) Oligomycin (0.5 μM) to induce state 4o; iii) FCCP (2 
μM) to induce state 3 uncoupled (3u); and iv) Antimycin A/rotenone (0.5 μM and 1 μM 
respectively) to shut down mitochondrial respiration. Data were extracted from the Seahorse 
XF24 software and the respiratory control ratio (RCR: State 3/State 4o), which reflects the 
mitochondrial respiratory capacity, was calculated. 
 
2.10. GABAA receptor expression 
 Cells were lysed and total RNA was extracted using the RNeasy Mini Kit from Qiagen 
(Venlo, Netherlands), according to the instructions of the manufacturer to measure GABAA 
receptor (subunits α1 and β2) mRNA levels. The first cDNA strand was synthesized using all 
RNA extracted by reverse transcription in a final volume of 30 μl using the Ready-to-Go You-
Prime First-Strand Bead cDNA synthesis kit (GE Healthcare, Little Chalfont, UK) according to 
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the supplied protocol. After reverse transcription, the cDNA was diluted 1:3 and 3 μl were 
amplified by real-time PCR (StepOne™ System) in 20 μl using DyNAmy Flash Probe qPCR 
Kit (Thermo Scientific, Waltham, MA, USA) with conventional Applied Biosystems cycling 
parameters (40 cycles of 95°C, 5 s, and 60°C, 1 min). Primers for human and mouse GABAA 
receptor subunit α1 and β2 were obtained from Life Technologies (Waltham, MA, USA). 
References of the primers are: GABRA1: Hs00971228_m1; GABRB2: Hs00241451_m1; 
gabra1: Mm00439046_m1; and gabrb2: Mm00433467_m1. After amplification, the size of 
the quantitative real-time PCR products was verified by electrophoresis on 2% (wt/vol) 
ethidium bromide-stained agarose gel. CDK4 was used as control housekeeping gene to 
assess the validity of the cDNA mixture and the PCR reaction. The gene expression of CDK4 
was clearly detected in SH-SY5Y (data not shown), but not that of GABAA receptor. 
 
2.11. Reactive oxygen species detection 
 Total level of mitochondrial reactive oxygen species (mtROS) and specific level of 
mitochondrial superoxide anion radicals were assessed using the fluorescent dye 
dihydrorhodamine 123 (DHR) and the Red Mitochondrial Superoxide Indicator (MitoSOX), 
respectively. SH-SY5Y cells were plated in 6 replicates into a black 96-well cell culture plate 
at a density of 1.5 × 104 cells/well. After neurosteroid treatment, cells were loaded with 10 
μM of DHR for 15 min or 5 μM of MitoSOX for 90 min at room temperature in the dark on an 
orbital shaker. After washing twice with HBSS (Sigma), DHR, which is oxidized to cationic 
rhodamine 123 localized within the mitochondria, exhibits a green fluorescence that was 
detected using the multilabel plate reader VictorX5 at 485 nm (excitation)/538 nm (emission). 
MitoSOX, which is specifically oxidized by mitochondrial superoxide, exhibits a red 
fluorescence detected at 535 nm (excitation)/595 nm (emission). The intensity of 
fluorescence was proportional to mtROS levels or superoxide anion radicals in mitochondria.  
 
2.12. MnSOD activity  
 The DetectX Superoxide Dismutase (SOD) Activity Kit (Ann Arbor, MI, USA) was 
used to quantitatively measure manganese SOD (MnSOD) activity following the instructions 
of the manufacturer. Briefly, 1 × 106 SH-SY5Y cells were collected for protein extraction. 
After a short sonication in PBS, the cellular homogenate was centrifuged at 1.500 × g for 10 
min at 4 °C. The supernatant was then centrifuged at 10,000 × g for 15 min and the obtained 
cell pellet was treated with 2 mM potassium cyanide, and assayed for MnSOD activity. 
 
2.13. Mitochondrial redox environment  
 To investigate changes in mitochondrial redox environment, SH-SY5Y cells were 
transfected with a plasmid coding for a redox sensitive green fluorescent protein with a 
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mitochondrial targeting sequence (pRA305 in pEGFP-N1). In an oxidized environment the 
absorption increases at short wavelengths (390 nm) at the expense of absorption at longer 
wavelengths (485 nm). The fluorescence ratio indicates oxidation/reduction, i.e., the redox 
environment in the mitochondria (28). Cells were plated in 6 replicates into a black 96-well 
cell culture plate at a density of 1.5 × 104 cells/well. After neurosteroid treatment, cells were 
washed twice with PBS and placed in a HEPES buffer (130 mM NaCl, 5 mM KCl, 1 mM 
CaCl2, 10 mM D-glucose, and 20 mM HEPES). The ratio 390 nm/485 nm was measured 
using the multilabel plate reader VictorX5 detecting fluorescence at 390 nm or 485 nm 
(excitation)/510 nm (emission). An increase of the ratio indicates a more oxidized 
environment. 
 
2.14. Statistical Analysis 
 Data are given as the mean ± SEM, normalized to the untreated control group 
(=100%). Statistical analyses were performed using the Graph Pad Prism software. For 
statistical comparisons of more than two groups, One-way ANOVA was used, followed by a 
Dunnett's multiple comparison test versus the control. For statistical comparisons of two 
groups, Student unpaired t-test was used. P values < 0.05 were considered statistically 
significant. Statistical correlations were determined using Pearson’s correlation coefficients. 
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3. Results
3.1. Neurosteroids modulate mitochondrial bioenergetics 
 To investigate the effects of neurosteroids on cellular bioenergetic activity, we first 
studied the SH-SY5Y cell line, a commonly used neuronal culture in vitro model that 
expresses a variety of neuronal receptors, including steroid receptors (progesterone, 
estrogen and androgen receptors) (29; 30). Cells were treated with different neurosteroids: 
progesterone (P), estradiol (E2), estrone (E1), testosterone (T), 3α-androstanediol (3α-A), 
DHEA (D) or allopregnanolone (AP), at two physiologically relevant concentrations, 10 nM 
and 100 nM (31-35) , and ATP level was measured after 24 h of treatment. All neurosteroids, 
except allopregnanolone, were able to significantly increase ATP level (Fig. 2A), ranging 
from a 10% increase after 3α-A treatment (10 nM) up to a 22% increase induced by 
progesterone (100 nM) compared to the untreated control.  
 A pre-treatment for 1 h with different steroid receptor antagonists (SRA) including the 
progesterone receptor antagonist RU-486 (assay concentration 100 nM), the estrogen 
receptor antagonist ICI-182.780 (assay concentration 100 nM), and the androgen receptor 
antagonist 2OH-flutamide (assay concentration 1 μM) completely abolished the action of P, 
E2 and E1, as well as T and 3α-A, respectively (Fig. 2B). The SRAs alone were devoid of the 
effects of ATP production. These results indicate that the action of neurosteroids may be 
mediated by nuclear receptors via gene regulation, at least for those neurosteroids that act 
via these receptors (progesterone, estrogens, and androgens).  
 To exclude that this rise in ATP was due to enhanced cell proliferation, we 
investigated the effects of the different neurosteroids. Of note, only allopregnanolone at 100 
nM induced a significant increase of cell division by about 6% compared to the control (Table 
1). Thus, our results indicate that the neurosteroid-induced up-regulation of cellular energy 
levels was independent of cell proliferation demands. 
 To verify whether the increase of ATP levels was directly linked to mitochondrial 
activity, we investigated the effects of neurosteroids on MMP, an indicator of the proton 
motive force necessary for ATP synthesis by the mitochondrial ATP synthase (36). Our 
results show that, at least for one of the two concentrations tested, neurosteroids induced a 
significant increase in MMP (Fig. 2C). The low concentration of 10 nM was particularly 
effective, ranging from an 18% increase after estradiol treatment up to a 32% increase 
induced by DHEA. Again, allopregnanolone was not able to significantly modulate the MMP. 
Thus, the observed increase in ATP is consistent with the finding of a slight hyperpolarization 
of the MMP. 
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 Because molecules of ATP are produced by two main pathways, the cellular 
glycolysis and oxidative phosphorylation (OXPHOS) in mitochondria, we determined whether 
and which of those neurosteroids were able to modulate one or both pathways. For this 
purpose, we simultaneously monitored in real-time the extracellular acidification rate (ECAR), 
an indicator of glycolysis, and the oxygen consumption rate (OCR), an indicator of basal 
respiration, using a Seahorse Bioscience XF24 Analyser (Fig. 3A-C). On the one hand, 
despite a slight general increase, only estradiol and DHEA were able to significantly 
modulate the ECAR after 24 h of treatment (about 16.4% and 19.4% respectively) (Fig. 3A). 
On the other hand, our findings demonstrate that estradiol, estrone, testosterone, 3α-A and 
DHEA significantly increased the OCR, with the most pronounced effect detected after a 
testosterone treatment at 100 nM (+26.5% compared to the control) (Fig. 3B). To compare 
the action of neurosteroids on glycolysis and basal respiration, we characterized the 
bioenergetic profile of SH-SY5Y neuroblastoma cells, representing OCR versus ECAR under 
the different treatment conditions (Fig. 3C). Notably, after treatment with the neurosteroid 
panel cells were switched to a metabolically more active state, with a tendency to increase 
both, glycolytic activity (ECAR) and basal respiration (OCR).  
 A Pearson correlation was performed to study whether the ATP levels correlated with 
OCR, ECAR or MMP (Fig. 4). A positive linear correlation between ATP level and OCR (Fig. 
4A), but not between ATP and ECAR (Fig. 4B) or MMP (Fig. 4C) was detected, suggesting 
that the improvement in ATP production was preferentially linked to an increase of 
mitochondrial respiration (oxygen consumption). 
 To investigate more deeply the effects of neurosteroids on mitochondrial OXPHOS, 
OCR was measured using permeabilized SH-SY5Y cells, which allows the evaluation of 
different respiratory states and the respiratory control ratio (RCR=state 3/state 4) (Fig. 5). 
Especially testosterone significantly up-regulated the mitochondrial respiratory capacity by 
increasing the respiratory state 3 (ADP-dependent), state 3 uncoupled (in the absence of 
proton gradient after injection of FCCP) and the RCR (Fig. 5A-C). The treatment with DHEA 
(10 nM) showed a similar effect on the RCR under these experimental conditions (Table 1), 
while the rest of the tested steroid compounds had no beneficial effect on RCR. Thus, our 
findings suggest that neurosteroids primarily act on basal respiration in neuroblastoma cells, 
and that testosterone and DHEA are additionally able to increase the capacity for substrate 
oxidation (high RCR), which is important when cells have specific or high energy demands.
 Since SH-SY5Y cells and other cell lines are not as highly dependent on OXPHOS as 
primary cell cultures to produce ATP (37), we investigated the action of neurosteroids on 
primary cell cultures from mouse brain cortex. Data demonstrate that, except for the 
treatment with progesterone, the level of ATP was significantly increased with at least one of 
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the two concentrations tested, ranging from a 27% increase after treatment with estrone (100 
nM) up to a 59% induced increase by DHEA (10 nM) (Fig 6A). Compared to the data 
obtained with SH-SY5Y neuroblastoma cells (Fig. 2A), the magnitude of the rise in ATP 
concentration was higher in the primary cortical cell culture (maximal increase of 22.6% in 
SH-SH5Y cells versus 59.2% in primary neurons). This result implies that primary cell 
cultures have a greater capacity to produce ATP than neuroblastoma cells. Moreover, both 
concentrations of allopregnanolone were able to increase ATP level in primary cells, which 
was not the case in SH-SY5Y cells. Allopregnanolone mainly acts as an allosteric positive 
modulator of GABAA receptor (GABAA-R). To verify the implication of this receptor, we first 
investigated whether it was expressed in both cell types. We found that SH-SY5Y cells do 
not express the GABAA-R subunits α1 and β2 that are involved in the allopregnanolone 
binding site (38), in contrast to primary cortical neurons (Suppl. Fig. 1), indicating that 
GABAA-R may be involved in the modulation of bioenergetics by allopregnanolone in 
neurons. 
 To determine whether the increase in ATP level was due to an improvement of 
glycolytic activity or mitochondrial respiration in this cellular model, we again performed a 
simultaneous real-time monitoring of the ECAR and the OCR (Fig. 6B-D). We measured a 
significant effect on the OCR for most of the neurosteroids tested, starting with a 59% 
increase after treatment with testosterone (10 nM) up to a 128% increase induced by 3α-A 
(10 nM) (Fig. 6B). Again, the magnitude of change was higher compared to the 
neuroblastoma cell line (maximal increase of 26.5%). In parallel, we measured a slight, but 
not significant, decrease in the glycolytic activity, except for the treatment with progesterone 
at 100 nM which in contrast induced a huge increase in the ECAR (+51.% compared to the 
control condition) (Fig. 6C). The bioenergetic profile (OCR versus ECAR) revealed that after 
treatment with neurosteroids, the primary cortical neurons had the general tendency to 
switch to a more aerobic state (Fig. 6D) by increasing their oxygen consumption (OCR) and 
decreasing their glycolytic activity (ECAR), especially at the low concentration of 10 nM. 
 Taken together, these data indicate that in primary mouse neurons, most of the 
neurosteroids from the tested panel were able to increase ATP production via improvement 
of mitochondrial respiration. 
 
3.2.  Neurosteroids modulate the redox homeostasis  
 The increase of OXPHOS is often coupled with an increase in mitochondrial reactive 
oxygen species (mtROS) production (39; 40). Since neurosteroids were able to significantly 
increase mitochondrial respiration, we investigated whether ROS levels were also increased 
within mitochondria (mtROS) by measuring the oxidation of the fluorescent dye 
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dihydrorhodamine 123 (DHR). All neurosteroids induced a significant dose-dependent 
increase in mtROS levels, ranging from a 43% increase after DHEA treatment (10 nM) up to 
a 111.3% increase induced by testosterone (100 nM) (Fig. 7A). Moreover, the specific 
measure of mitochondrial superoxide anion radicals revealed that some of the ROS 
produced were indeed superoxide anions (Table 1). However, the extent of mtROS 
production, which in excess can lead to massive oxidative stress, and finally cell death, did 
not seem to be sufficient to trigger cell death under those experimental conditions (data not 
shown).  
 Therefore, we next tested the antioxidant defense system in mitochondria. We 
quantitatively measured the activity of the manganese superoxide dismutase activity 
(MnSOD), which is present within the mitochondrial matrix. Indeed, MnSOD activity was 
significantly increased (Fig. 7B) after treatment with the whole panel of neurosteroids, 
ranging from a 28.6% (progesterone, 100 nM) up to a 49.3% increase (testosterone, 100 
nM). The increase in mtROS was paralleled by an increase of antioxidant activity. In addition, 
mtROS level and MnSOD activity correlated with one another (Fig. 7C), suggesting that the 
increase of MnSOD activity was substrate-dependent.  
 Finally, to verify whether the mitochondrial redox environment was impacted by this 
increase of ROS versus increase of antioxidant defenses, SH-SY5Y cells stably transfected 
with a reporter gene coding for a redox sensitive green fluorescent protein (AR305 roGFP) 
located within mitochondria were treated with our panel of neurosteroids (28). Figure 7D 
displays the oxidation/reduction state in mitochondria, and indicates that, despite a slight 
switch toward a more oxidized state, only testosterone (100 nM) and DHEA (100 nM) 
significantly modified the redox environment in mitochondria.  
 Taken together, our data indicate that neurosteroids increased mitochondrial activity, 
which was paralleled by an enhancement in mtROS levels. However, cell viability was still 
unchanged and the raise of mtROS appeared to be at least in part compensated by an 
increase in antioxidant activity, which in turn led to a slight switch to an oxidized state within 
mitochondria. 
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4. Discussion
 The aim of our study was to investigate the effects of seven neurosteroids on cellular 
bioenergetics and redox homeostasis in neuronal cells. The key findings were that: i) the 
majority of these steroids increased energy metabolism, mainly via an up-regulation of the 
mitochondrial activity and at least in part via receptor activation, and ii) neurosteroids 
regulated redox homeostasis by increasing the antioxidant activity as a compensatory 
mechanism to the ROS level enhancement which might result from the acceleration in 
oxygen consumption accompanied by a greater electron leakage from the electron transport 
chain. Additionally, each neurosteroid seems to have a specific bioenergetic profile. The 
single profiles are delineated as pie charts for SH-SY5Y (Fig. 8A) and mouse primary cortical 
neurons (Fig. 8B). 
Remarkably, each steroid doesn’t seem to act in the same way on both cell types. For 
example, allopregnanolone, which had no effects on ATP level and basal respiration in SH-
SY5Y cells, appeared to increase those two parameters in primary neuronal cells. On the 
contrary, progesterone was able to increase ATP production in SH-SY5Y cells, but showed a 
significant effect only on glycolysis in primary cells. One explanation could be that SH-SY5Y 
cells and primary neuronal culture may exhibit steroid receptor expression profiles that are 
slightly different. Steroid receptor expression, such as that of progesterone, estrogen and 
androgen receptors, has already been demonstrated in both SH-SY5Y cells (29; 30) and in 
mouse neurons (41-43), respectively. It is known that allopregnanolone doesn’t bind to a 
conventional steroid receptor but mainly acts as a positive GABAA receptor (GABAA-R) 
allosteric modulator that strengthens the effects of GABA. We found that SH-SY5Y cells do 
not express GABAA-R unlike in primary neurons (Suppl. Fig. 1). This indicates that 
allopregnanolone may act via GABAA-R to increase ATP level especially in primary neurons 
and explains the lack of effect on ATP in SH-SY5Y cells. Furthermore, other signaling 
pathways and receptors may be involved in the effects of allopregnanolone upon 
bioenergetics in primary cortical neurons, such as the newly characterized pregnane 
xenobiotic receptor (44). 
 Moreover, it is known that proliferative cells and tumors have a net tendency to use 
the cellular glycolysis to produce ATP instead of the OXPHOS system. This phenomenon is 
called “Warburg effect” (37). On the contrary, primary neurons, which are differentiated cells, 
rely almost exclusively on the OXPHOS system to produce ATP and glycolysis is really low 
(raw data not shown). Indeed, in the latter model, ATP level appeared to be strictly coupled 
with the basal respiration. The bioenergetic profile of primary cortical cells revealed that 
neurosteroids preferentially increased mitochondrial respiration and not the glycolytic 
pathway, while both pathways were increased in SH-SY5Ycells (Fig. 3C, Fig. 6D). 
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 In the recent years, neurosteroids have emerged as new potential therapeutic tools 
against neurodegeneration (45). Among the steroids, the family of sex steroid hormones is 
the most widely studied. They are in the focus of research on neurodegenerative diseases 
since cognitive decline and the risk to develop AD appear to be associated with an age-
related loss of sex hormones (e.g. estradiol, testosterone but also progesterone) in both, 
women and men (46; 25), a hypothesis largely supported by epidemiological evidence (47). 
In vitro and in vivo studies demonstrated neuroprotective effects of sex hormones, 
particularly with mitochondria proposed as the primary site of action of estradiol (48; 32; 49; 
24). Indeed, estrone (E1), estradiol (E2), and estriol (E3), are known to play a fundamental 
role in the regulation of the female metabolic system (50). It has been reported that 
estrogens can regulate mitochondrial metabolism by increasing the expression of glucose 
transporter subunits and by regulating some enzymes involved in the tricarboxylic acid cycle 
(TCA cycle) and glycolysis, which leads to an improvement in glucose utilization by cells 
(reviewed in (21)). Estrogens seem also able to up-regulate genes coding for some electron 
transport chain components such as subunits of mitochondrial complex I (CI), cytochrome c 
oxidase (complex IV), and the F1 subunit of ATP synthase. In line with these findings, our 
data demonstrated that both female sex hormones, estradiol (E2) and estrone (E1), were 
able to increase ATP levels, basal respiration, and MMP in neuroblastoma cells (Fig. 8A). Of 
note, the increase of ATP levels induced by E2 and E1 was abolished in the presence of ICI-
182.780, an estrogen receptor (α and β) antagonist (Fig. 2B) suggesting that estrogens, such 
as E2 and E1, may act via these receptors to up-regulate genes involved in cellular 
bioenergetics, as mentioned above. Estradiol seemed to be more potent that estrone, 
because both concentrations (10 nM and 100 nM) were effective to increase ATP levels and 
mitochondrial respiration. In addition, estradiol was able to regulate glycolysis. This 
difference can be explained by the observation that, despite estrone’s capability as an 
estrogenic compound, it is about 10 times less estrogenic than estradiol (21). The same 
finding was observed in primary neurons (Fig. 8B).  
 Regarding the predominantly male hormone testosterone, we witnessed an increase 
in ATP levels, basal respiration and mitochondrial membrane potential in neuroblastoma 
cells (Fig. 8A). Moreover, testosterone was also the only steroid besides DHEA inducing an 
acceleration of the respiratory control ratio (RCR), an indicator of the capacity for substrate 
oxidation (high RCR), which is important when cells have specific or high energy demands. 
The role of androgens on mitochondrial function, especially testosterone, has received little 
attention up to now, compared to the estrogens. Only one study demonstrated a similar 
effect of testosterone on MMP (51). Furthermore, it has been proposed that estradiol and 
testosterone can regulate energy production by inducing nuclear and mitochondrial OXPHOS 
genes, since the subunits of mitochondrial chain complexes are encoded by the nuclear and 
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the mitochondrial genome, respectively, and both contain hormone responsive elements 
(52). Again, those findings are in line with our results, since we have shown that the increase 
of ATP levels was blocked in the presence of estrogen and androgen receptor antagonists 
(Fig. 2B). 
 Progesterone is the second main female sex hormone but it is also a precursor for 
estrogens and androgens. Progesterone, and its 3α-5α-derivate allopregnanolone (or 3α, 5α-
tetrahydroprogesterone) as well as 3α-androstanediol, seem to play a role in mood 
modulation. Their therapeutic potential for the treatment of depression, anxiety (53-55) and 
more recently AD is currently under investigation (35). In the present study, we demonstrated 
that progesterone increased ATP levels and MMP without significant effects on basal 
respiration in neuroblastoma cells (Fig. 8A). An increase in glycolysis was also observed 
after treatment in the primary neurons (Fig. 8B). Again, the up-regulatory effect of 
progesterone on ATP levels was shut down in the presence of the progesterone receptor 
antagonist RU-486 (Fig. 2B), suggesting that progesterone also modulates cellular 
bioenergetics by regulating gene expression via a progesterone nuclear receptor. Studies 
performed on ovariectomized rats revealed that a 24 h treatment with progesterone 
(subcutaneous injection, 30 μg/kg) increased OXPHOS capacity in isolated mitochondria, in 
part by enhancing cytochrome c oxidase activity and expression (32). Interestingly, the 
increase of OXPHOS capacity was suppressed by a co-treatment with estradiol and 
progesterone, suggesting a competitive mode of action between both steroids. Another study 
using wobbler ALS (amyotrophic lateral sclerosis) model mice showed that progesterone was 
able to normalize the deficits in mitochondrial complex I activity observed in motor neurons of 
the cervical spinal cord (56). Because progesterone seems to have different functional 
effects, one can speculate that its action on mitochondrial respiration may be distinct to 
specific nerve cell populations.  
 Allopregnanolone and 3α-androstanediol have a distinct mode of action compared to 
sex hormones because they mainly act on membrane receptors (allosteric modulator of 
GABAA-R) and not nuclear receptors (57). Their effects on mitochondrial bioenergetics 
cannot be explained by a direct regulation of genes involved in the OXPHOS system as 
previously proposed for sex hormones. In our study, 3α-androstanediol showed a similar 
effect compared to progesterone in the neuronal cell line, but was also able to significantly 
increase the basal respiration (at 100 nM) (Fig. 8A). Both concentrations were effective to 
increase ATP and respiration in primary cells (Fig. 8B). Allopregnanolone significantly 
regulated ATP levels and basal respiration only in primary neurons, whereas no effect was 
detected in the neuroblastoma cell line. Based on those observations, we can speculate that: 
i) GABAA-R is involved in the up-regulatory effect of allopregnanolone on ATP levels in 
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primary cells because no increase was observed in SH-SY5Y cells lacking of this receptor 
(Suppl. Fig. 1); and ii) 3α-androstanediol could act via androgen receptor because its effect 
on ATP levels was abolished in the presence of an androgen receptor antagonist (Fig. 2B). 
However, further investigations will be required to understand the exact underlying 
mechanisms. Besides, due to the high complexity of the neurosteroid pathway synthesis, it is 
difficult to conclude that the effect which we observed on bioenergetics is due to the tested 
neurosteroid itself, or to one of its metabolites, because they all belong to crisscross 
pathways (Fig. 1). However, since blocking progesterone, estrogen and androgen receptors 
abolishes the effects of their respective agonists, we have good evidence that the 
neurosteroids themselves exhibit the mode of action. In the same way, we can exclude that 
progesterone is acting via its metabolite allopregnanolone because the latter has no effects 
on bioenergetics in SH-SY5Y cells. Nevertheless, it is also possible that 3α-androstanediol 
doesn’t act directly on androgen receptors but is converted in dihydrotestosterone, another 
testosterone metabolite which has high affinity for this receptor. In a similar way, DHEA can 
be converted in androgens and estrogens and may act via the corresponding steroid nuclear 
receptor. 
 DHEA (dehydroepiandrosterone) was the first neurosteroid identified in 1981 (11), 
and its physiological action involves both genomic and non-genomic mechanisms, in part via 
activation of androgen/estrogen receptors and allosteric modulation of NMDA receptors, 
respectively (58). Human studies showed an age-related decrease in DHEA levels in the 
brain and in the blood in relation to the age-associated cognitive decline (59; 17). In vitro, we 
showed that DHEA enhanced ATP levels and basal respiration in primary neurons (Fig. 8B). 
A similar effect was observed in the neuronal cell line with an additional increase in MMP, 
glycolysis and RCR (Fig. 8A, Table 1). In agreement with our findings, DHEA was able to 
improve mitochondrial respiration in the brain of old rats (18-24 months) which exhibited a 
decline in mitochondrial function when compared to young rats (8-10 weeks) (60). More 
specifically, DHEA stimulated the respiratory state 3 in old rats which consequently was 
similar to that of untreated young rats. Furthermore, DHEA increased cytochrome c content 
in young and old mouse brains and enhanced mitochondrial dehydrogenase activities.  
 Thus, the different bioenergetic profiles we observed after treatment with our panel of 
steroids could be explained by their distinct abilities to directly or indirectly regulate the 
transcription of genes involved in glycolysis and oxidative phosphorylation (probably, via 
steroid nuclear receptors), but also the content and activity of mitochondrial respiratory 
complexes. Further investigations are required to determine in more detail which genes are 
involved in these processes. 
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 Mitochondria are known to be paradoxical organelles. They can be compared to a 
double-edged sword that, on one hand, produces the energy necessary for cell survival, and 
on the other hand, induces the formation of ROS that can be harmful for cells when produced 
in excess with mitochondria as the first target of toxicity (39; 40). In our study, the increase in 
ATP appeared to be coupled to an increase in MMP and improved basal respiration (Fig. 
8A). In parallel, we detected higher mitochondrial ROS levels, supporting the hypothesis that 
increased mitochondrial activity generates more ROS. The only exception was observed 
after treatment with allopregnanolone where we detected more ROS but no increase in ATP 
level, MMP, or basal respiration. We can speculate that, in this model, allopregnanolone 
might be able to increase ROS-producing metabolic functions via other mechanisms. But 
with regard to the other neurosteroids, the increase of mitochondrial ROS was paralleled by 
an increase in MnSOD activity. The MnSOD is located in the mitochondrial matrix and 
represents one of the first antioxidant defenses against ROS produced by OXPHOS (61). Its 
improved activity could be in part explained by an up-regulation of gene expression and 
protein level of MnSOD. Indeed, in studies which focused on antioxidant effects of steroids in 
ovariectomized female rats, an increase of MnSOD protein level has been observed after 
treatment with estradiol or progesterone (32), whereas DHEA preferentially up-regulated the 
expression of Cu/ZnSOD (31). In orchiectomized male rats, testosterone was also able to 
increase MnSOD protein level compared to the control (sham operated) (62). A similar 
observation was made in the wobbler ALS mouse model, where MnSOD expression was 
elevated after treatment with progesterone (56).  
 In our study, the correlation between mitochondrial ROS level and MnSOD activity 
implies that the increase of enzymatic SOD activity might be preferentially substrate-
dependent, but can be explained, at least in part, by an up-regulation of gene expression.  
 Based on our observation, one can speculate that pre-treatment with neurosteroids 
may exert a protective action against oxidative stress, possibly through a preconditioning 
mechanism via their ability to increase antioxidant defenses (i.e. MnSOD activity). However, 
in an already oxidized environment, the presence of neurosteroids may be deleterious for 
cells because they also appear to further increase ROS production. This observation 
reinforces the “critical window hypothesis” of the therapeutic use of steroids as debated 
recently with regard to the hormone replacement therapy in post-menopausal women (63) 
and implies that this kind of therapy should begin at an age when the redox system is still 
balanced, thus favoring the reference postulating early onset administration. 
 It is known that some neurosteroid levels decline during aging and are further 
modified in neurodegenerative conditions (i.e. AD and PD). In addition, mitochondrial 
dysfunction has been well-documented in aging and age-related neurodegenerative diseases 
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(64). Steroids offer interesting therapeutic opportunities for promoting successful aging 
because of their pleiotropic effects in the nervous system. Our findings highlight, for the first 
time, up-regulatory effects of neurosteroids upon the neuronal bioenergetic activity via up-
regulation of the mitochondrial oxygen consumption as a common mechanism underlying 
neurosteroid action. In addition, these steroids can modulate the redox homeostasis, by 
balancing the increase of ROS production via improved mitochondrial antioxidant activity 
(Fig. 9). Thus, our results provide new insights in re-defining the biological model of how 
neurosteroids control neuronal functions. Because each steroid appeared to have a specific 
profile in bioenergetic outcome and redox homeostasis, the underlying mechanisms have to 
be elucidated in more details in the future, as well as those in models of neurodegenerative 
diseases, such as AD. 
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Table 1: Effects of neurosteroids on cellular bioenergetics in neuroblastoma cells. 
  
Progesterone Estradiol Estrone Testosterone 
3α-
androstanediol 
DHEA 
Allo-
pregnanolone 
  
10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 10 nM 100 nM 
ATP level 113.9* 122.6* 113.4* 114.6* 116* 120.4* 110.7* 118* 110.1* 111.4* 107.6* 112.4* 95.8 100.3 
Cell proliferation 98.7 100.9 98.2 100.3 97.2 99.2 97.9 102.1 100.1 103.8 97.6 103.7 101.7 106.2* 
MMP 120* 108.2 118.5* 118.8* 120* 119.2* 128.1* 119.9* 123.2* 109.8 132.2* 119.9* 111.5 114.2 
Glycolysis 115.4 102.7 119.4* 116.1* 113.8 111.1 108.1 105.5 105.7 106.6 106.2 116.4* 102.2 101.6 
Mitochondrial 
respiration 
Basal 111 105.9 118.3* 123.2* 110.9 118.1* 115.1* 126.5* 106.9 114.1* 110.8* 106.7 99.6 109.6 
RCR 97.9 98.7 93.7 89.6 100.6 102.8 132.7* 116.5* 95.3 104 120.3* 97.81 105.7 102.1 
Mitochondrial 
ROS 
Total 108.4 151.7* 122.9 160.8* 121.8 171.3* 145.2* 211.3* 148.4* 182.8* 143.9* 200.6* 151* 207.2* 
Superoxide 100.7 104* 103 106.2* 102.8 108* 103.6* 105.8* 103.8* 105.9* 105* 106.4* 103.6* 107.4* 
MnSOD activity 110.6 128.6* 120.7 136.6* 128.7 141.9* 137.4* 149.3* 134.7* 127.6 135.3* 128.1* 128.7* 147.4* 
Mitochondrial redox state 105.7 110.6 108.1 108.9 104.1 109.2 109.9 113.6* 109.8 109.1 104.2 113.3* 91.7 102.5 
Values represent the mean normalized on 100% of the control group (untreated). * indicates when the percentage is significantly different from the control group. MMP; 
mitochondrial membrane potential, RCR; respiratory control ration, ROS; reactive oxygen species, MnSOD; manganese superoxide dismutase. 
 
MANUSCRIPT B 
 
 
125 
FIGURES
 
 
Fig. 1: Schematic representation of the main biochemical pathways for neurosteroidogenesis 
in the vertebrate brain. Boxes represent neurosteroids tested in our study. * indicates neurosteroids whose 
synthesis is impacted in AD. PREG; pregnenolone, PROG; progesterone, 17OH-PREG; 17-
hydroxypregnenolone, 17OH-PROG; 17-hydroxyprogesterone, DHEA; dehydroepiandrosterone, DHP; 
dihydroprogesterone, ALLOPREG; allopregnanolone, DHT; dihydrotestosterone, P450scc; cytochrome P450 
cholesterol side chain cleavage, P450c17; cytochrome P450c17, 3β-HSD; 3β-hydroxysteroid dehydrogenase, 5α-
R; 5α-reductase, Arom.; aromatase, 21-OHase; 21-hydroxylase, 3α-HSOR; 3α-hydroxysteroid oxydoreductase, 
17β-HSD; 17β- hydroxysteroid dehydrogenase  
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Fig. 2. Neurosteroids increase ATP level in SH-SY5Y neuroblastoma cells. (A) ATP level was 
significantly increased after neurosteroid treatment for 24 h at a concentration of 10 nM (white boxes) or 100 nM 
(gray boxes). (B) ATP level was measured after pre-treatment of cells for 1 h with either progesterone receptor 
antagonist RU-486 (100 nM), or estrogen receptor antagonist ICI-182.780 (100 nM), or androgen receptor 
antagonist 2OH-flutamide (1 μM) and then treated for 24 h with the corresponding steroid agonist. (C) 
Mitochondrial membrane potential (MMP) was significantly increased after neurosteroid treatment for 24 h at a 
concentration of 10 nM (white boxes) or 100 nM (gray boxes). (A-C) Values represent the mean ± SEM; n=12-18 
replicates of three independent experiments. One-way ANOVA and post hoc Dunnetts' multiple comparison test 
versus control (untreated), *P<0.05; **P<0.01; ***P<0.001. Student unpaired t-test, && P<0.01; &&&P<0.001. P; 
progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α-A; 3α-androstanediol, D; dihydroepiandrostanedione 
(DHEA), AP; allopregnanolone, RU; RU-486, ICI; ICI-182.780, flut.; 2OH-flutamide. 
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Fig. 3. Neurosteroids positively regulate bioenergetic activity in SH-SY5Y neuroblastoma cells. 
(A) Extracellular acidification rate (ECAR) and (B) oxygen consumption rate (OCR) were measured 
simultaneously using a Seahorse Biosciences XF24 Analyser in the same experimental conditions. (C) 
Bioenergetic profiling of SH-SY5Y cells (OCR versus ECAR) revealed increased metabolic activity after treatment 
with neurosteroids. Values represent the mean of each group (mean of the ECAR in abscissa/mean of the OCR in 
ordinate) normalized to the untreated control group (=100%). (A-C) Values represent the mean ± SEM; n=12-18 
replicates of three independent experiments. One-way ANOVA and post hoc Dunnetts' multiple comparison test 
versus control (untreated), *P<0.05; **P<0.01; ***P<0.001; P; progesterone, E2; estradiol, E1; estrone, T; 
testosterone, 3α-A; 3α-androstanediol, D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone. 
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Fig. 4. ATP levels did correlate with basal mitochondrial respiration. Graph representing ATP levels 
in abscissa versus (A) OCR or (B) ECAR or (C) MMP in ordinate. Values represent the mean of each treatment 
group normalized to the control group (=100%). Pearson correlation r=0.5074, R2=0.2575, P=0.0032. OCR; 
oxygen consumption rate, ECAR; extracellular acidification rate; MMP; mitochondrial membrane potential. 
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Fig. 5. Testosterone increased mitochondrial respiratory capacity. (A) Oxygen consumption rate 
(OCR), was measured on permeabilized SH-SY5Y cells after treatment with testosterone for 24 h, using a XF24 
Analyser (Seahorse Bioscience). The sequential injection of mitochondrial inhibitors is indicated by arrows (see 
details in the Materials and Methods section). (B) Values corresponding to the different respiratory states are 
represented as mean ± SEM (n= 15-18 replicate of three independent experiments/group) and were normalized to 
the basal respiration of the control group (=100%). (C) The respiratory control ratio (RCR= State 3/State 4o), 
which reflects the mitochondrial respiratory capacity, was increased by testosterone. Student unpaired t-test, 
*P<0.05. T 10 nM; testosterone at a concentration of 10 nM, T 100 nM; testosterone at a concentration of 100 nM, 
O; oligomycin, F; FCCP, R/A; rotenone/antimycin A. 
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Fig. 6. Neurosteroids up-regulated the bioenergetic activity in primary cortical cells. (A) ATP 
level was significantly increased after neurosteroid treatment (24 h) at a concentration of 10nM (white boxes) and 
100nM (gray boxes). (B) Oxygen consumption rate (OCR) and (C) extracellular acidification rate (ECAR) were 
measured simultaneously using a Seahorse Biosciences XF24 Analyser under the same experimental conditions. 
(D) Bioenergetic profile of primary cortical cells (OCR versus ECAR) revealed an increased aerobic activity (O2 
consumption) after treatment with neurosteroids. Values represent the mean of each group (mean of the ECAR in 
abscissa / mean of the OCR in ordinate) and were normalized to the control group (100%). (A-C) Values 
represent the mean ± SEM, n=4-6 replicates of three independent experiments / group, and were normalized to 
the control group (=100%). One-way ANOVA and post hoc Dunnetts' multiple comparison test versus control 
(untreated), *P<0.05; **P<0.01; ***P<0.001; P; progesterone, E2; estradiol, E1; estrone, T; testosterone, 3α-A; 
3α-androstanediol, D; dihydroepiandrostanedione (DHEA), AP; allopregnanolone. 
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Fig. 7. Neurosteroids modulate the mitochondrial redox environment in SH-SY5Y 
neuroblastoma cells. (A) Mitochondrial reactive oxygen species (mtROS) levels were significantly increased 
after neurosteroid treatment (24 h) at a concentration of 10 nM (white boxes) and 100 nM (gray boxes). (B) This 
increase was accompanied by an up-regulation of manganese superoxide dismutase activity (MnSOD). (C) A 
positive correlation was observed between ROS levels and MnSOD activity. (D) Using a reporter gene coding for 
a redox sensitive green fluorescent protein (AR305 roGFP) located within mitochondria, the mitochondrial redox 
state underwent a switch to a more oxidized state after neurosteroid treatment compared to the untreated control. 
(A, B) Values represent the mean ± SEM and were normalized to the corresponding untreated control group 
(=100%). (C) Values represent the mean of each group (mean of the mitochondrial ROS level in abscissa / mean 
of the MnSOD activity in ordinate) normalized to the untreated control group (=100%). Pearson correlation 
r=0.7096, R2=0.5035, P=0.0022. (D) Values represent the mean ± SEM of the ratio “oxidized state/reduced 
state”, n=8-15 replicates of three independent experiments/group. Values were normalized to the control group 
(=100%). One-way ANOVA and post hoc Dunnett’s multiple comparison test versus control (untreated), *P<0.05; 
**P<0.01; ***P<0.001; P; progesterone, E2; estradiol, E1; estrone, T; testosterone, 3a-A; 3a-androstanediol, D; 
dihydroepiandrostanedione (DHEA), AP; allopregnanolone, Ox.; oxidized environment, Red.; reduced 
environment.  
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Fig. 8. Different action profile of neurosteroids on cellular bioenergetics. Representative diagrams 
of the effects of neurosteroids on the bioenergetic activity (ATP level, basal respiration, glycolysis, MMP) and the 
modulation of mitochondrial redox environment (mtROS levels, MnSOD activity, redox state) in SH-SH5Y 
neuroblastoma cells (A), and the bioenergetic activity in primary cortical cells (B). No effect is represented in 
white color. A significant increase of the respective parameter is marked either in yellow (significant only at 10 
nM), blue (significant only at 100 nM), or green (significant at both concentrations). mtROS; mitochondrial reactive 
oxygen species, MMP; mitochondrial membrane potential, MnSOD; manganese superoxide dismutase activity. 
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Fig. 9. Schematic representation of the effects of neurosteroids on mitochondrial bioenergetics 
and redox environment in SH-SH5Y neuroblastoma cells. * indicates that the effect was similar to that 
observed in primary cortical cells. ETC; electron transport chain, TCA; tricyclic acid, MnSOD; manganese 
superoxide dismutase, ROS; reactive oxygen species, MMP; mitochondrial membrane potential. 
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Suppl. Fig. 1. PCR analysis of GABAA receptor in SH-SY5Y human neuroblastoma cells and 
mouse primary cortical cells. Total RNA obtained from both cell types was amplified with the corresponding 
primers for human and mouse GABAA receptor subunits α1 and β2. GABRA1; human subunit α1 (82 bp), 
GABRB2; human subunit β2 (143 bp), gabra1; mouse subunit α1 (98 bp), mouse; gabrb2; mouse subunit β2 (115 
bp). 
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Abstract: 
 Mitochondria are the major bioenergetic provider of eukaryotic cells. They form a 
highly dynamic network that in response to metabolic, cellular and environmental changes 
adapts its architecture by fission and fusion processes to maintain the cellular bioenergetic 
homeostasis. Mitochondrial functions are impaired in aging and neurodegenerative diseases 
including Alzheimer’s disease (AD) for which age is the highest risk factor. Deposition of 
amyloid-β (Aβ) represents one of the histopathological hallmarks of AD, and while Aβ impairs 
mitochondrial function, it is not clearly understood how dysfunctions in mitochondrial 
dynamics and bioenergetics are coupled and contribute to the AD pathogenesis. Here we 
report that, under normal physiological conditions, the morphology of the mitochondrial 
network oscillates between three distinct states: tubular, intermediate and fragmented. 
Interestingly, during the transition from a tubular via an intermediate to a fragmented 
mitochondrial network, the ATP level displayed an inverted “U”-shape along with a higher 
oxygen consumption rate (OCR) in the basal respiration and maximal respiration at its peak. 
Aβ abolished the oscillations in the mitochondrial network organization which were 
associated with a decline in mitochondrial metabolism including reduced ATP level and OCR. 
Our results indicate firstly that mitochondrial function is tightly coupled to mitochondrial 
morphology, and secondly that Aβ-induced abnormal mitochondrial dynamics is likely to 
contribute to the decay of mitochondrial energy metabolism. Thus, an imbalance in the 
mitochondrial structure-function relationship may play a crucial role in the deleterious 
mitochondrial cascade of AD. 
 
Keywords:  
Alzheimer’s disease, amyloid-β, bioenergetic balance, energetic state, mitochondria, 
mitochondrial dynamics. 
 
Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; ATP, adenosine tri-phosphate; 
DRP1, dynamin-related protein 1; ECAR, extracellular acidification rate; hFIS1, human 
fission protein 1; MFN1/2, mitofusin 1/2; NAD+, nicotinamide adenine dinucleotide, oxidized 
form; NADH, nicotinamide adenine dinucleotide, reduced form; OCR, oxygen consumption 
rate; OxPhos, oxidative phosphorylation; OPA1, optic atrophy 1. 
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1. Introduction
Once thought to be solitary and rigidly structured, mitochondria are now recognized to 
constitute a population of highly dynamic organelles that participate in energy conversion, 
metabolism, intracellular signalling, cell migration and synaptic plasticity [1]. To achieve the 
integrity of a healthy mitochondrial population within cells but also the integrity of the cell 
itself, the mitochondrial network comes in varied morphologies and ultrastructures, ranged 
from fragmented to forming a tubular network, such as to meet the ever-changing 
requirements for energy production and additional mitochondrial functions [2]. This requires a 
tightly regulated equilibrium between opposing mitochondrial fusion and fission activities, 
with these activities collectively termed 'mitochondrial dynamics' [3, 4]. Since mitochondrial 
function relies heavily on the morphology and distribution of this organelle, alterations to the 
mitochondrial architecture will have severe consequences on neuronal activity and survival, 
which can, at least in part, contribute to the development of neurodegenerative disorders 
including Alzheimer’s disease (AD). 
AD is an age-related progressive neurodegenerative disorder. Over the last decade, 
extensive evidence from both cellular and animal models has led to the view that alterations 
in mitochondrial bioenergetics, including a reduced mitochondrial membrane potential, 
decreased complex activities, depletion of ATP content and antioxidant defence mechanisms 
as well as an escalation of oxidative stress, are associated with the pathogenesis of AD [5, 
6]. Additionally, abnormal mitochondrial dynamics has been identified in sporadic and familial 
AD cases [7, 8] as well as in AD mouse models [9-12]. By assessing both protein and 
transcript levels, in general, levels of fission transcripts/proteins were found to be increased, 
and those of fusion transcripts/proteins decreased [7]. In one study, reduced levels of DRP1 
and an increased mitochondrial length were found in AD fibroblasts [8]. Taken together, 
these findings indicate that a decline in both mitochondrial bioenergetics and dynamics is 
prominent and represents an early hallmark of Amyloid-β (Aβ)-induced neuronal 
degeneration in AD. Nevertheless, the underlying mechanism in how mitochondrial dynamics 
and bioenergetics are coupled in AD is not understood. Thus, we addressed the question of 
whether mitochondrial metabolism is directly connected to mitochondrial shape transitions in 
a physiological context and whether Aβ-related alterations of mitochondrial dynamics are a 
direct cause of the bioenergetic decline observed in AD by impairing the integrity of the 
mitochondrial structure–function relationship. For this purpose, we investigated mitochondrial 
dynamics in parallel with the oxidative metabolism in cell cycle-synchronized human primary 
skin fibroblast, an already established model for studies of mitochondrial dynamics in AD [8], 
under both physiological and pathological conditions. Our findings are consistent with the 
concept that mitochondrial bioenergetics is coordinated by transitions in the mitochondrial 
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architecture and that Aβ impairs this functional balance. This disruption of the synchronized 
transition of the mitochondrial architecture may have an important role in AD pathogenesis.
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2. Materials and Methods
2.1. Chemicals and reagents 
Dulbecco’s-modified Eagle medium (DMEM), RPMI-1640 medium, foetal calf serum 
(FCS), penicillin/streptomycin, NAD+, NADH, MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) and PES (phenazine ethosulfate) were from Sigma-Aldrich (St. 
Louis, MO, USA). Glutamax and DPBS were from Life Technologies (Waltham, MA, USA). 
XF Cell Mitostress kit was from Seahorse Bioscience (North Billerica, MA, USA). Horse 
serum (HS) was from Amimed, Bioconcept (Allschwil, Switzerland). 
2.2. Cell culture 
Human fibroblasts were isolated from biopsies cultured in DMEM/1% penicillin-streptomycin 
(v/v)/1% Glutamax (v/v) (DMEM complete (DMEMc))/20% heat-inactivated FBS (v/v) as 
described previously [13]. Prior to the assessment of nucleotide levels, oxygen consumption 
rate (OCR) and mitochondrial morphology in human primary fibroblast culture, serum shock 
treatment (DMEMc supplemented with 50% heat-inactivated horse serum (v/v)) was 
performed for 2 hours at 37 °C to synchronize the cells [14, 15]. After serum shock treatment, 
the medium was exchanged to DMEM without phenol red/ 1% penicillin-streptomycin 
(v/v)/1% Glutamax (v/v)/2% FBS (v/v) for reduce cell growth.  
2.3. Amyloid-beta peptide preparation and treatment 
The amyloid-β (Aβ) peptide Aβ1-42 (Bachem, Bubendorf, Switzerland) was rapidly 
dissolved in sterile PBS 1x, pH~7.4 (stock concentration 500 μM) and stored as aliquots at -
80 °C until needed. One day before treatment with Aβ peptide was initiated, a 50 μM working 
solution was prepared in PBS 1x, pH~7.4. After securing the cap with parafilm, the tube was 
incubated on a table-top thermomixer (Eppendorf, Hamburg, Germany) at 1000 rpm (~250 x 
g) at 37°C for 24 hours in order to induce aggregation of the Aβ peptide into fibrils. 
Fibroblasts were then treated with 500 nM Aβ in DMEM/1% penicillin-streptomycin (v/v)/1% 
Glutamax (v/v) (DMEMc)/20% FBS (v/v) for five days until analyzed. 
2.4. Mitochondrial Morphology 
To determine mitochondrial dynamics in synchronized fibroblasts, cells were seeded on 
collagen - coated coverslip (0.05 mg/ml, Corning, NY, USA) at a cell density sufficient to 
reach 50% confluency on the following day. After the serum shock treatment, the medium 
was exchanged to DMEMc without phenol red + 2% FBS (v/v) containing 75 nM Mitotracker® 
Red CMX ROS (579/599, Life Technologies, Waltham, MA, USA), a red-fluorescent dye that 
stains mitochondria in live cells and whose accumulation requires an intact membrane 
potential. From 8 hours post-synchronization and at 8 hour-intervals over the course of 24 
hours, cells were fixed with 4% paraformaldehyde/PBS for 30 minutes at room temperature. 
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After extensive washes, the fixed cells were permeabilized with 0.15% Triton X-100 prior to 
staining the nuclei with Sytox Green (504/523, Life Technologies, Waltham, MA, USA) 
according to the manufacturer’s recommendations. After mounting the coverslips, images 
were processed using a confocal microscope (60x oil objective, Leica). 
2.5. Nucleotides Measurements 
The total ATP content from synchronized human skin fibroblasts was determined using a 
bioluminescence assay (ViaLighTM HT; Cambrex Bio Science, Walkersville, MD USA) 
according to the instruction of the manufacturer. Cells were plated in 8 replicates into a 96-
wells cell culture plate at a cell density sufficient to reach 40-50% of confluency on the 
following day. The enzyme luciferase, which catalyzes the formation of light from ATP and 
luciferin was used. The emitted light is linearly related to the ATP concentration and is 
measured using a multilabel plate reader VictorX5 (Perkin Elmer). The data were obtained at 
8, 16 and 24 hours after cell synchronization. 
To measure NAD+ and NADH, the two molecules were separately extracted using an 
acid-base extraction method (HCL 0.1 mol/l – NAOH 0.1 mol/l). To determinate both NAD+ 
and NADH, an enzyme cycling assay was used that is based on passing the electron from 
ethanol through reduced pyridine nucleotides to MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) in a PES (phenazine ethosulfate)-coupled reaction resulting in 
the formation of a purple precipitate (formazan) that, once dissolved, can be quantified at 595 
nm (VictorX5, Perkin Elmer). The data were obtained at 8, 16 and 24 hours after cell 
synchronization. 
2.6. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
The OCR and ECAR were evaluated in synchronized fibroblasts as previously described 
[16]. Briefly, human skin fibroblasts were seeded at the density of 3x104 cells/100 μl per well 
on Seahorse Biosciences 24-well culture plates one day prior to the beginning of the assay. 
After serum shock synchronization, the medium was exchanged to 500 μl of assay medium 
(glucose-free RPMI-1640 medium containing 2% FBS (v/v), 2 mM sodium pyruvate, pH~ 
7.4). Prior to measurements, the microplates were equilibrated in a CO2-free incubator at 37 
°C for 60 minutes. The plate was placed in the Seahorse XF24 Analyzer and the OCR and 
ECAR were recorded in real-time over 75 min. The Mitostress Kit was used according to the 
instructions of the manufacturer to determine the OCR allocated to basal respiration, ATP 
turnover, proton leak, maximal respiration and non-mitochondrial respiration by sequential 
injection of oligomycin (1 μM), FCCP [carbonyl cyanide p (trifluoromethoxy) 
phenylhydrazone] (0.7 μM), a mix of antimycin A (4 μM) and rotenone (2 μM). Experiments 
were performed at 16 and 24 hours after synchronization. 
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2.7. Quantitative Real-Time PCR 
Total RNA was extracted from lysates of synchronized fibroblasts using the RNeasy mini 
kit (Qiagen, Venlo, Netherlands). cDNA was generated using Ready-to-Go You-Prime First-
Strand Beads (GE Healthcare, Little Chalfont, UK). For data analysis, human Cdk4 was used 
as an endogenous control. After reverse transcription, the cDNA was diluted 1:3 and 
amplified in the presence of the corresponding primers by real-time PCR using the DyNAmy 
Flash Probe qPCR kit (Thermo Scinetific, Waltham, MA USA). Conventional Applied 
Biosystems cycling parameters (40 cycles of 95°C, 5 seconds, and 60°C, 30 seconds) were 
used. Data were expressed as relative expression for each individual gene normalized to 
their corresponding controls using the comparative CT method. The primers used were 
purchased from Applied Biosystems (Life Technologies, Waltham, MA, USA) (Probe ID: see 
Primer sequences section for details). Experiments were performed at 8, 16 and 24 hours 
after cell synchronization. 
2.8. Primer sequences 
 Primer Probe ID (Applied Biosystems) 
Fusion MFN1 Hs00250475_m1 
 MFN2 Hs00208382_m1 
 OPA1 Hs00323399_m1 
Fission DRP1 Hs00247147_m1 
 FIS1 Hs00211420_m1 
OxPhos NDUFA2 (complex I) Hs00159575_m1 
 NDUFB5 (complex I) Hs00159582_m1 
 NDUFC1 (complex I) Hs00159587_m1 
 NDUFV2 (complex I) Hs00221478_m1 
 COX4I1 (complex IV) Hs00971639_m1 
 COX6A1 (complex IV) Hs01924685_g1 
 COX7A2 (complex IV) Hs01652418_m1 
 COX7B (complex IV) Hs00371307_m1 
 ATP5G2 (ATP synthase) Hs01096582_m1 
 ATP5C1 (ATP synthase) Hs01101219_g1 
 ATP5L (ATP synthase) Hs00758883_s1 
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2.9. Statistical analysis 
Data were presented as mean ± S.E.M. Statistical analyses were performed using the 
Graph Pad Prism software. For statistical comparisons, unpaired Student’s two-tailed t-test, 
One-way ANOVA followed by Tukey’s multiple comparison test or Two-way ANOVA followed 
by Bonferroni's multiple comparison test was used respectively. P values less than 0.05 were 
considered statistically significant. 
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3. Results
3.1. Ab impairs the mitochondrial network organization 
To analyze the impact of Aβ on the mitochondrial network state, we first examined the 
mitochondrial morphology in Aβ1-42-treated human skin fibroblasts compared to untreated 
cells under cell division-synchronized conditions. Images were processed by confocal 
microscopy (Fig. 1A). We observed that under physiological conditions the mitochondrial 
network displayed three distinct states at the three time points chosen after cell 
synchronization (8, 16 and 24 hours) that were defined as tubular, intermediate and 
fragmented states, respectively. Of note, after 5 days of Aβ1-42-treatment, only the 
fragmented network was detected suggesting that Ab promotes mitochondrial fission events 
by interfering with the equilibrium of fusion and fission thereby affecting the network 
architecture of mitochondria. 
As mitochondrial dynamics is tightly regulated, we next investigated whether Ab 
impacts the expression of the different fusion genes (mitofusins 1 and 2, MFN1 and 2; optic 
atrophy 1, OPA1) and fission genes (dynamin-related protein1, DRP1; human fission protein 
1, hFIS1) that are tightly regulated to maintain the integrity of the mitochondrial system (Fig. 
1B-F). Relative quantification of mRNAs isolated from Aβ1-42-treated human skin fibroblasts 
showed that Ab-treatment significantly diminished the expression of the fusion gene OPA1 
(Two-way ANOVA, group effect: control versus Aβ, P < 0.001) (Fig. 1D) and the fission gene 
DRP1 (Two-way ANOVA, group effect: control versus Aβ, P < 0.001) (Fig. 1E), while 
expression of the fission gene hFIS1 was significantly increased (Two-way ANOVA, group 
effect: control versus Aβ, P < 0.001) (Fig. 1F). No change was observed in the expression of 
the fusion genes MFN1 and 2 (Fig. 1B, C). 
Consistent with previous observations in cultured neurons [17, 18], our findings 
indicate that Ab is capable of destabilizing the mitochondrial network by disturbing the 
equilibrium between fusion and fission, at least at the gene expression level, collectively 
promoting mitochondrial fragmentation. 
 
3.2. Ab-related mitochondrial morphology alterations negatively impact mitochondrial 
homeostasis 
As ATP is primarily generated via mitochondrial oxidative phosphorylation (OxPhos), 
we monitored whole cell ATP content as readout of OxPhos in Aβ1-42-treated compared with 
untreated human skin fibroblasts for the three time-points corresponding to tubular, 
intermediate and fragmented mitochondrial network states. Surprisingly, we found that total 
ATP levels displayed an inverted “U”-shape in control cells (One-way ANOVA, variation of 
ATP level in control cells, P<0.0001) during the transition from a tubular via an intermediate 
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to a fragmented network (with the peak at 16 hours corresponding to the intermediate 
mitochondrial network), whereas ATP levels in the Ab-treated cells remained unaltered and 
were significantly reduced (Two-way ANOVA, group effect: control versus Ab, P<0.0001) 
(Fig. 2A). These findings suggest that large mitochondrial networks of fused mitochondria 
are a prerequisite for enabling a maximal energy supply for the cells, which is then 
transferred, with a short delay, from the mitochondrial pool of ATP to the cytosolic pool of 
ATP during the intermediate state [19].  
To further investigate the Ab-induced imbalance in mitochondrial homeostasis, we 
next evaluated the NAD+/NADH ratio as an oxidative stress readout in Ab-treated human skin 
fibroblasts compared to untreated cells at the same three time-points (Fig. 2B). We observed 
that the NAD+/NADH ratio was significantly augmented by Aβ1-42 treatment with the highest 
level at that time point (at 16 hours) (One-way ANOVA, variation of NAD+/NADH ratio in Ab-
treated cells, P=0.0136), when we had observed a maximum ATP peak but only in control 
cells. In contrast, the NAD+/NADH ratio was lower (Two-way ANOVA, group effect: control 
versus Ab, P<0.0001) and did not exhibit a variation pattern in control cells as detected for 
mitochondrial morphology and ATP These findings indicate that, while the cellular defence 
systems are capable of perfectly stabilizing the oxidative stress generated by normally 
functioning mitochondria, Ab provokes a shift in the redox homeostasis toward a more 
oxidized state, with the peak at 16 hours. However, this increase in NAD+/NADH ratio does 
not seem to relate on the mitochondrial architecture oscillations, since they are abolished by 
Ab, but may rather be dependent on the activation of cytosolic antioxidant defence enzymes. 
Together, our findings suggest that Ab triggers a decline of mitochondrial 
bioenergetics including an abolishment of variations in ATP levels coupled to a shift in the 
redox homeostasis. 
 
3.3. Alterations in Ab-related mitochondrial morphology lead to mitochondrial respiratory 
defects 
Since mitochondria were found to be a target of Aβ [20], leading to mitochondrial 
dysfunction including a decline in OxPhos, we further investigated the impact of Ab on 
mitochondrial oxidative metabolism and glycolysis. For this purpose, we monitored the real–
time oxygen consumption rate (OCR), an indicator of mitochondrial respiration, and the 
extracellular acidification rate (ECAR), an indicator of the glycolytic state, in Ab-treated 
human skin fibroblasts compared to untreated cells at 16 hours corresponding to the ATP 
peak and at 24 hours related to the ATP trough using the Seahorse Bioscience XF24 Flux 
Analyzer (Fig. 2A, 3).  
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In untreated cells, the OCR was significantly decreased in general at the condition of 
an ATP trough and fragmented network (at 24 hours) compared to that of an ATP peak and 
intermediate network (at 16 hours) over the entire OCR measurement period (runtime 2 – 57 
min; Two-way ANOVA, group effect: 16 versus 24 hours, P<0.0001) (Fig. 3A, left panel). 
This is further indicated by a lower OCR for the basal respiration (~20%) as well as for ATP 
turnover (~25%) and maximal respiration (~15%) at 24 hours compared to the OCR 
measured at 16 hours after cell cycle synchronization (Fig. 3B). Moreover, the spare 
respiratory capacity was higher (~42%) at 24 hours compared to that at 16 hours suggesting 
that the mitochondrial network is metabolically more plastic to respond to an energy demand 
whilst in resting state (Suppl. Fig. 1). In contrast, Ab1-42 treatment completely abolished the 
OCR difference between ATP peak and trough conditions (Fig. 3A right panel, 3B and 
Suppl. Fig. 1). In addition, the bioenergetic readouts such as basal respiration, ATP turnover 
and maximal respiration were significantly reduced in Ab-treated compared to untreated cells 
at the two time points (Two-way ANOVA, group effect: control versus Ab, P<0.0001) (Fig. 
3B) as well as the spare respiratory capacity at 24 hours after synchronization suggesting a 
mitochondrial inability to respond to an increasing metabolic demand in the presence of Ab 
(Two-way ANOVA, group effect: control versus Ab, P=0.0013) (Suppl. Fig. 1). 
No variation pattern was observed in the OCR of control cells allocated to leakage of 
proton and to non-mitochondrial respiration confirming that the biphasic changes in ATP 
levels are primarily dependent on the activity of the electron transport chain and ATP 
synthase (complex V) (Fig. 3B), while a decreased proton leakage in the Ab-treated human 
skin fibroblasts at both time points (Fig. 3B) might indicate a damage in the coupling 
efficiency of mitochondria that has been associated with aging and age-related diseases as 
AD [21]. Moreover, OCR coupled to non-mitochondrial respiration was also significantly 
decreased in Ab-treated human skin fibroblasts (Fig. 3B) suggesting that Ab, besides its 
effects on mitochondria, might also negatively impact on a subset of cellular enzymes that 
continue to consume oxygen after rotenone/ antimycin A addition. 
In parallel to determining the OCR, ECAR as an indicator of the glycolytic state, was 
assessed. The glycolytic rate remained unchanged in untreated control cells between both 
time points (16 and 24 hours) and seems therefore to be independent of a change in the 
mitochondrial network (Fig. 3C). Moreover, treatment of human primary fibroblast cultures 
with Ab1-42 resulted in a higher ECAR than for untreated cells, suggesting an Ab-induced 
metabolic switch favoring glycolysis which can be interpreted as a cellular mechanism to 
compensate for the mitochondrial respiration decay and depletion in ATP production (Fig. 
3C).  
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To compare the effects of Ab on glycolysis and mitochondrial respiration, we 
characterized the cellular bioenergetic profile of Ab-treated human skin fibroblasts compared 
to untreated cells, mapping OCR (basal respiration) versus ECAR (glycolysis) for the 
indicated time points (Fig. 4A). Remarkably, Ab-treated cells exhibited higher glycolytic 
states at the two time points corresponding to ATP peak and trough (16 and 24 hours), 
respectively, whereas untreated cells switched between a metabolically active state 
corresponding to the intermediate mitochondrial network (high ATP, 16 hours) and a 
metabolically resting state corresponding to the fragmented mitochondrial network (low ATP, 
24 hours). Of note, this phenomenon could be confirmed for all other mitochondrial 
respiratory states exhibiting decreased oxygen consumption rates after treatment with Ab 
(Suppl. Fig. 2). 
To determine whether the variations in ATP levels were due to the inverted “U”-
shaped variation in OCR or the glycolytic rate, ATP levels for each group were plotted 
against the corresponding basal OCR or ECAR (Fig. 4B and Suppl. Fig. 3). The inverted 
“U”-shaped changes in ATP levels seem to be correlated with OCR but not ECAR in control 
cells. The Ab-induced increase in ECAR, which was regardless associated with lower ATP 
level in Ab-treated cells, suggests that glycolysis does not seem to be sufficient to counteract 
the depletion in ATP levels. 
Together, these findings show that, after Ab1-42 treatment, mitochondria get stuck in a 
fragmented state coupled with a decrease in mitochondrial respiration, which consequently 
leads to a depletion in ATP levels. These findings further indicate that a balanced 
mitochondrial network might be a crucial precondition for the bioenergetic homeostasis as 
maintained under normal conditions. 
To better understand the impact of the Ab-related deterioration of mitochondrial 
morphology and cellular bioenergetic activity, we further examined whether Ab impacts 
directly the integrity of the electron transport chain (ETC). For this purpose, we determined 
the gene expression of subunits involved in oxidative phosphorylation, particularly in the 
electron transport chain (complexes I and IV) and in ATP generation (ATP synthase or 
complex V) (Fig. 5). Relative quantification of mRNAs isolated from Ab-treated human skin 
fibroblasts showed that Ab negatively impacted gene expression by decreasing the 
expression of OxPhos genes involved in the function of complex I (NDUFA2, NDUFB5, 
NDUFC1 and NDUFV2) and ATP synthase (ATP5C1, ATPG2 and ATP5L) (Fig. 5A, C). 
Interestingly, subunits of complex IV (COX4I1 and COX6A1) exhibited a significantly higher 
gene expression in Ab-treated human skin fibroblasts compared to untreated cells 
suggesting that cells develop compensatory responses to alleviate the deleterious effect of 
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Ab on mitochondrial function (Fig. 5B). The data show that Ab induced aberrant and 
differential expression of nuclearly encoded ETC subunits which can potentially contribute to 
an impairment in the assembly of mitochondrial ETC complexes leading to a decline in 
mitochondrial respiration. 
Taken together, these observations support the hypothesis that mitochondrial 
oxidative metabolism is dependent on the mitochondrial architecture and hence, that an Ab-
related imbalance of the mitochondrial network likely contributes to AD-related mitochondrial 
respiration deficiency, at least by disturbing the expression of ascertained OxPhos subunits. 
  
MANUSCRIPT C 
 
 
154 
4. Discussion
In our study, we aimed to investigate the changes in mitochondrial architecture at 
three time points (8, 16 and 24 hours) in synchronized fibroblasts under normal and Ab 
conditions. The two key findings of our study are that, (i) the mitochondrial oxidative 
metabolism as readout of normal mitochondrial activity displayed an inverted “U”-shaped 
pattern with a peak at 16 hours mirroring the pattern of the mitochondrial network under 
physiological conditions and, (ii) Ab provoked a shift in the mitochondrial architecture towards 
a fragmented network that negatively impacted several mitochondrial functions including 
bioenergetics along with an increase in oxidation.  
Although in recent years our perception of mitochondria has changed from that of a 
static and singular to that of a dynamic organelle, only few studies provide support for the 
existence of a direct relationship between mitochondrial morphology and function [22]. 
Remarkably, in our study, the parallel examination of mitochondrial morphology and oxidative 
metabolism in human skin fibroblast revealed that both mitochondrial features are tightly 
linked. Surprisingly, shortly after the mitochondrial network displayed a tubular architecture, 
mitochondrial respiration and ATP level increased during the transition from tubular to 
fragmented network which corresponds to the intermediate state. Conversely, when the cells 
were in resting state (at 24 hours mirroring the fragmented network, low mitochondrial 
respiration along with low ATP), the mitochondrial morphology was shifted towards a 
fragmented network. Our findings confirm previous observations that, when the expression of 
mitochondrial fusion and fission proteins is genetically manipulated in different cellular 
models including human fibroblasts, the incurring abnormal mitochondrial morphology 
induces a dysfunction in mitochondrial respiration, and possibly coupling efficiency as well as 
a depletion in ATP content [22, 23]. Furthermore, this mitochondrial structure/function 
relationship was reflected by the transcriptional profiling, with the expression of several ETC 
subunits as well as in the ATP synthase appearing to be modulated by the mitochondrial 
morphology state in human skin fibroblasts. It is believed that mitochondrial fission is 
essential in the formation of the cristae and the proper assembly of mitochondrial electron 
transport chain complexes [24, 25]. Altogether, our data show for the first time that under 
physiological conditions, transitions in mitochondrial architecture directly influence 
mitochondrial functions including respiration and ATP generation.  
Since both mitochondrial bioenergetics and dynamics are known as early and 
prominent features of AD-related neuronal toxicity induced by Aβ [24, 26], we examined the 
potential impact of Aβ on the integrity of the mitochondrial morphology/function relationship. 
We found, in contrast to the aforementioned observations, that Aβ treatment of fibroblasts 
completely abolished the variation pattern in the mitochondrial architecture by causing an 
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imbalance in fusion and fission proteins which led to a network frozen in a fragmented state. 
This is consistent with in vitro observations made in APPwt (APP wild-typ) and APPswe 
(APP with Swedish mutation) - expressing M17 cells where DRP1 and OPA1 became 
reduced, whereas Fis1 became significantly increased [18]. However, while AD neurons 
exhibit increased fragmentation [8], fibroblasts from AD patients show elongated and highly 
interconnected mitochondrial network [8, 12, 27] suggesting that a tissue-related pattern in 
the expression and/or in post-translational modifications might also be involved in the Aβ-
induced alterations in mitochondrial functions. Concomitantly, defects in mitochondrial 
dynamics induced a decline in mitochondrial metabolism including decreased mitochondrial 
respiration, depletion in ATP content and increased oxidative stress through drastic changes 
in the NAD+/NADH ratio. These findings are in agreement with previous observations from 
both animal models and AD patients that showed mitochondrial decline and elevated 
oxidative stress playing a crucial role in AD pathogenesis [25, 28, 29]. Additionally, an Aβ-
induced mitochondrial bioenergetic defect can be partly explained by the down-regulation of 
several nuclearly-encoded OxPhos subunits which was also observed in MCI and AD brains 
at early stage [30, 31]. In contrast, up-regulation in the gene expression of complex IV 
subunits might be the result of a functional compensation by the cells to maintain the proton 
gradient needed for the ATP production [21]. It is known that the impairment of OxPhos 
efficiency can also be triggered and amplified by Ab-related oxidative damage to 
mitochondrial membranes and proteins [32]. According to previous observations in 3xTg-AD 
neurons [26], the concurrent increase in glycolysis in Ab-treated cells could be interpreted as 
a compensatory mechanism in which the cells switch to glycolysis to try to rescue the 
depletion in mitochondrial respiration-related ATP production. Nevertheless, this mechanism 
was not sufficient to recover the Ab- induced decrease in ATP level in human primary 
fibroblast cultures. 
In summary, we gained new insights, on the one hand, into the relevance of the 
coupling between mitochondrial morphology and function and, on the other hand, into the 
deleterious cascade of events involved in the abnormal coupling of mitochondrial structure-
function mechanisms driven by Ab. Our findings further emphasize the relevance of the 
mitochondrial cascade hypothesis of AD [33].  
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FIGURES
 
Fig. 1: Aβ-induced imbalance of mitochondrial fission/fusion proteins causes abnormal 
mitochondrial fragmentation in human primary fibroblasts. (A) Whereas mitochondrial morphology in 
untreated control cells oscillated between 3 distinct states (tubular, intermediate and fragmented network) 
corresponding to 8, 16 and 24 hours after cell synchronization, respectively. Only mitochondrial fragmentation 
was observed Aβ-treated cells at 8, 16 and 24 hours after cell synchronization. Scale bars, 7.5 μm. (B-F) Relative 
mRNA expression of nuclearly-encoded genes related to mitochondrial fusion: (B) MFN1, (C) MFN2 and (D) 
OPA1, and fission: (E) DRP1 and (F) hFIS1 measured at 8, 16 and 24 hours in Ab-treated human skin fibroblasts 
(black bars) compared to control cells (white bars). Aβ-induced expression of OPA1 and DRP1 was significantly 
decreased, while expression of hFIS1 was significantly increased. (B-F) Values represent the mean ± SEM; n = 6-
9 replicates of three independents experiments (Two-way ANOVA, group effect: control versus Ab, post hoc 
Bonferroni, ***, P < 0.001).   
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Figure 2: Aβ-induced imbalance of mitochondrial dynamics is followed by a decline in 
bioenergetic homeostasis. (A) ATP levels were significantly reduced at 8, 16 and 24 hours after cell 
synchronization (Two-way ANOVA, group effect: control versus Ab, P<0.0001, post hoc Bonferroni, ***, 
P<0.0001) without variation pattern in Ab-treated human skin fibroblasts (black bars) compared to untreated cells 
(white bars) which expressed a variation pattern with a biphasic regulation of ATP content that peaks at 16 hours 
(One-way ANOVA, ATP variation pattern in control cells, P<0.0001; post hoc Tukey; 8 versus 16 hours, &&,P < 
0.01; 16 versus 24 hours, 
°°°
,P < 0.001). (B) The NAD+/NADH ratio was significantly enhanced in Ab-treated 
human skin fibroblasts compared to untreated cells (Two-way ANOVA, group effect: control versus Ab, P<0.0001, 
post hoc Bonferroni, **, P< 0.01, ***P < 0.001) and expressed a variation pattern (One-way ANOVA, NAD+/NADH 
ratio variation pattern in Ab-treated cells, P<0.0001; post hoc Tukey; 8 versus 16 hours,
 &&
,P < 0.01 ; 16 versus 24 
hours.,
°°°
,P < 0.001) that was absent in control cells. (A,B) Values represent the mean ± SEM; n=9-12 replicates 
of three independents experiments.  
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Figure 3: Aβ-induced imbalance of mitochondrial dynamics leads to an impairment of 
mitochondrial respiration. (A) The oxygen consumption rate (OCR) was evaluated in Ab-treated human skin 
fibroblasts (right panel) compared to untreated control cells (left panel) at 16 hours, corresponding to the 
intermediate mitochondrial network as well as ATP peak and 24 hours, corresponding to the fragmented 
mitochondrial network as well as ATP trough. The sequential injection of mitochondrial inhibitors is indicated by 
blue arrows (for experimental details, see Materials and Methods) (n= 11 replicates /group, three independent 
experiments). (B) Basal respiration, proton (H+) leak, ATP turnover and maximal respiration were determined 
after normalization to non-mitochondrial respiration. (C) Extracellular Acidification Rate (ECAR) corresponding to 
glycolytic rate was determined at the indicated time points in Ab-treated human skin fibroblasts compared to 
untreated cells. OCR and ECAR were measured simultaneously and in real time using a Seahorse XF24 analyzer 
under the same experimental conditions. (A-C) Values represent the mean ± SEM (n= 11 of three independent 
experiments) (Two-way ANOVA, group effect: CTRL versus Ab, post hoc Bonferroni, *, P < 0.1; **, P < 0.01;***, 
P< 0.001; group effect: variation pattern 16 versus 24 hours, post hoc Bonferroni, 
o
, P < 0.1; 
oo
, P < 0.01;
 ooo
, P< 
0.001). O, oligomycin; F, FCCP; R, rotenone; A, antimycin A; Basal, basal respiration; H+ leak, proton leak; Max. 
Resp., maximal respiration; Non-mito, non-mitochondrial respiration. 
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Figure 4: Aβ- treated fibroblasts exhibit decreased mitochondrial respiration and increased 
glycolysis. (A) OCR/ECAR: The basal oxygen consumption rates (OCR) corresponding to the intermediate (at 
16 hours) and fragmented (at 24 hours) networks are plotted against the respective glycolytic rates (ECAR) under 
control (white symbols) and Aβ conditions (black symbols). Values represent the mean for each group (mean of 
the ECAR in abscissa/ mean of the OCR in ordinate); n= 11 replicates /group for three independent experiments. 
(B) OCR/ATP: The basal OCR corresponding to the intermediate (at 16 hours) and fragmented (at 24 hours) 
networks are plotted against the respective ATP content in control (white symbols) and Aβ conditions (black 
symbols). Values represent the mean of each group (mean of the ATP levels in abscissa/ mean of the OCR in 
ordinate); n= 11-12 replicates /group of three independent experiments. The red arrows highlight the Aβ-induced 
metabolic shift at 16 and 24 hours after cell synchronization. 
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Figure 5: Aβ impairs the expression of genes with a role in mitochondrial oxidative 
metabolism. (A-C) Profiles of relative mRNA expression of nuclearly-encoded (A) complex I, (B) complex IV 
and (C) complex V-encoding subunits involved in the ETC and OxPhos in Ab-treated human skin fibroblasts 
(black bars) compared to untreated cells (white bars) at 8, 16 and 24 hours after cell synchronization. Values 
represent the mean ± SEM, n= 3. (A-C) Two-way ANOVA, group effect: control versus Ab, P<0.0001, post hoc 
Bonferroni, *, P < 0.1; **, P < 0.01;***, P< 0.001.  
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Supplementary Figure 1: Aβ-treated fibroblasts exhibit a decreased ability to respond to an 
energetic demand. The spare respiratory capacity was determined based on the measurements taken in Fig. 
3 (A). Values represent the mean ± SEM (n= 11 of three independent experiments) (One-way ANOVA, spare 
respiratory capacity variation pattern in control cells, P<0.0001; post hoc Tukey, 
°°°
, P < 0.001; Two-way ANOVA, 
group effect: control versus Ab, P=0.0013. post hoc Bonferroni;***, P< 0.001). 
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Supplementary Figure 2: Bioenergetic profiling (OCR/ECAR) of human primary fibroblast 
cultures at (A) 16 hours and (B) 24 hours. OCR corresponding to the intermediate network is plotted 
versus the respective glycolytic rate (ECAR) in control (white symbol) and Aβ conditions (black symbol). The 
circle lines highlight the cloud data for untreated and Aβ-treated cells. The bioenergetic profile was calculated 
during basal respiration and after sequential exposure to mitochondrial inhibitors (a) oligomycin, (b) FCCP and (c) 
rotenone/antimycin A. Values represent mean of each group (mean of the ECAR in abscissa/ mean of the OCR in 
ordinate) normalized to the basal respiration at 16 hours under control condition (=100%/100%). The red arrows 
highlight the Aβ-induced metabolic shift towards an increased glycolytic rate. 
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Supplementary Figure 3: Aβ-induced depletion in ATP production is independent of metabolic 
switch toward a glycolytic state. ECAR/ATP: The glycolytic rates (ECAR) corresponding to the 
intermediate (at 16 hours) and fragmented (at 24 hours) networks are plotted against the respective ATP content 
under control (white symbols) and Aβ conditions (black symbols). Values represent the mean of each group 
(mean of the ATP levels in abscissa/ mean of the ECAR in ordinate); n= 11-12 replicates /group for three 
independent experiments. The red arrows highlight the Aβ-induced metabolic shift towards an increased glycolytic 
rate.  
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Mitochondria are highly dynamic and essential organelles in cell survival and death by 
regulation of both energy metabolism and apoptotic pathways. To fulfill their multiple tasks, 
the mitochondrial network comes in varied morphologies and ultrastructures to ensure the 
energy supply, stored in the form of adenosine triphosphate (ATP), by oxidative reactions 
from nutritional sources. A well-defined set of proteins regulates mitochondrial fission and 
fusion, including mitofusins and dynamin-related proteins. Because mitochondria are 
considered as the ‘powerhouses’ of the cell, a fine-tuning of both mitochondrial dynamics and 
metabolism is imperative to maintain the integrity of a healthy mitochondrial population within 
the cell but also the integrity of the cell itself. Even though the molecular mechanisms 
involved in mitochondrial fusion/fission and their roles in mitochondrial homeostasis are well 
established, the regulatory mechanisms behind the global control of mitochondrial functions 
are still mostly elusive. Additionally, a greater comprehension of the mechanisms involved in 
the physiological regulation of mitochondrial functions might be of great relevance for the 
understanding of the implication of mitochondrial deficiencies in the pathogenesis of 
neurodegenerative disorders, e.g. Alzheimer’s disease (AD). 
Thus, the aim of the present thesis was firstly to gain novel insights into the role of (i) 
the circadian clock and of (ii) neurosteroids on the modulation of mitochondrial homeostasis. 
In the second part (iii), we further investigated the consequence of Ab-induced abnormal 
mitochondrial morphology on mitochondrial bioenergetics to further underscore the 
mitochondrial cascade hypothesis of AD. 
 (i) A wide range of metabolic processes follows the rhythmicity of the circadian cycle 
to anticipate energetic requirements of diverse cellular functions in response to cellular and 
environmental constraints. Yet, only a few studies have characterized the mechanisms 
involved, demonstrating coupling via cyclic redox metabolite levels (e.g: NAD+), mitochondrial 
protein acetylation and chromatin modification. Combining morphological and functional 
assays, we identified and characterized a novel mitochondrial dynamics-based regulatory 
connection between the circadian clock and metabolism, and showed that this connection is 
absolutely essential for the circadian regulation of cellular ATP levels. Specifically, the 
circadian transitions of mitochondrial bioenergetics were directly coupled to clock-controlled 
changes in mitochondrial ultrastructure. This coupling was completely independent of the cell 
cycle (in which it was initially characterized), both because it remains in the presence of cell 
cycle inhibitors in vitro, and because it equally occurs in mostly nondividing tissues like brain 
and liver. Moreover, analysis of regulation of DRP1 revealed that phosphorylation of serine 
637 followed a circadian pattern and was functionally essential for circadian ATP production 
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because its inhibition, either pharmacologically or genetically, abolished circadian oscillations 
in ATP levels. Finally, inhibition of mitochondrial flux in multiple different ways showed effects 
upon circadian clock properties and upon clock gene expression in vitro. 
Overall, consistent with the growing body of evidence stating the importance to 
integrate the cellular metabolism with circadian clocks [1], our findings established a new 
molecular link in which the mitochondrial network acts as a central node in coupling circadian 
and metabolic cycles. Our results further underline the importance of a well-coordinated 
metabolic system in human health as well as in disorders linked to impairments in circadian 
clock and/ or mitochondrial function. Although the effect of aging on the circadian system and 
mitochondrial homeostasis has been known for many years [2-5], disruption between the 
circadian system and the mitochondrial network may be a key initiating factor for age-related 
diseases such as AD. 
 (ii) A growing body of evidence supports that, on the one hand, some neurosteroid 
levels decline during aging and, on the other hand, mitochondrial dysfunction is a prominent 
and early age-associated event [6]. Both deteriorations are known to contribute in a separate 
manner to energy failure and increased oxidative stress which, once a threshold is reached, 
ultimately increased susceptibility to age-related disorders including AD. The enhanced 
neuronal vulnerability might, at least in part, result from the loss of neurosteroid-mediated 
neuroprotection [7, 8]. Nevertheless, only few studies, which especially concentrated on 
estradiol, showed that mitochondrial dysfunction can be partially recovered by neurosteroids 
[6]. Thus, our findings highlight for the first time that, besides estradiol, several neurosteroids 
are able to enhance mitochondrial metabolic activities at least in part via the activation of 
their particular receptors. Specifically, the up-regulation of the mitochondrial activity of each 
neurosteroid was subtly divergent suggesting a more complex regulatory system on 
mitochondrial activities. In addition, these steroids can modulate the redox homeostasis by 
balancing the increase of ROS production via improved mitochondrial antioxidant activity. 
Altogether, our findings re-define the crucial importance of neurosteroids in the development 
of therapeutic strategies to counterbalance the age-related mitochondrial decline which may 
result from a depletion in neurosteroid contents. 
 Since circadian clock and neurosteroids impact positively mitochondrial metabolism in 
a distinct manner, the next challenge would be to investigate the potential crosstalk between 
circadian clock and neurosteroids and its synergistic effect on the vital organelle homeostasis 
including mitochondrial dynamics and bioenergetics. It has been demonstrated that the 
circadian clock influences the concentrations of progesterone and its metabolite 
allopregnanolone in the female whole mouse brain [9]. Therefore, a better understanding of 
the interplay between mitochondrial function, neurosteroids and the circadian machinery in 
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health state would help to deepen our knowledge about the underlying mechanisms 
contributing to neurodegenerative disorders such as AD. 
 (iii) Based on the aforementioned findings, we investigated the impact of Ab on the 
balance between mitochondrial structures and function since both mitochondrial dynamics 
and bioenergetics are crucial hallmarks of Aβ-induced neuronal toxicity in AD [4, 10]. In the 
line of evidence of previous findings [11, 12], we determined that Ab-treated cells undergo 
extensive network fragmentation. Concomitant with Ab-related alterations in mitochondrial 
dynamics, mitochondrial metabolism was drastically impaired including decreased 
mitochondrial respiration, depletion in ATP content and increased oxidative stress resulting 
from increased mitochondrial ROS levels and radical changes in NAD+/NADH ratio. Thus, 
our findings underline the AD mitochondrial cascade hypothesis which claims that 
bioenergetic defects ultimately trigger AD. Once the age-related mitochondrial decline 
reaches a critical threshold, it affects APP expression and processing as well as 
accumulation of Aβ, which can reinforce mtDNA damage and oxidative stress in a vicious 
cycle. Based on the complexity of the multifactorial nature of AD, the key role of 
mitochondrial dysfunction in the early pathogenic pathway by which Aβ leads to neuronal 
dysfunction in AD is particularly challenging with respect to establishing disease-modifying 
treatments. 
 Taken together, our results provide the first evidence that the time-of-day-dependent 
oscillations in metabolic homeostatic parameters are consequent to a complex interplay 
between the circadian clock and the coupled mitochondrial structure-function relationship. 
Furthermore, neurosteroids, in term of gender-oriented neuroprotective candidates, are key 
factors in the fine-tuning of mitochondrial function, particularly the mitochondrial bioenergetic 
homeostasis. Finally, we gain novel insights into the cascade of the molecular and functional 
events initiating AD pathogenesis according to the AD mitochondrial cascade hypothesis 
[13]. However, further investigations are needed to identify the remaining gaps in the 
interplay between mitochondrial function, neurosteroids and the circadian machinery in 
health state as well as in aging with regard to the development of interventions that prevent 
the progression of the age-related mitochondrial decline (Figure 18). 
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Figure 18 : A hypothetical sequence of the interplay between mitochondrial functions, the 
circadian clock and neurosteroids in health, aging and age-related diseases as AD. 
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2DG   2 deoxy-D-glucose 
3α-A   3α-androstanediol 
ABAD   Aβ binding protein alcohol dehydrogenase 
AD   Alzheimer’s disease 
ADAM   A disintegrin and metalloproteinase 
AICD   Aβ intracellular cytoplasmic domain 
AIF   Apoptosis-inducing factor 
AMPK   AMP-activated protein kinase 
AP   allopregnanolone 
APH1   Anterior pharynx-defective 1 
APP   Amyloid precursor protein 
ATP   Adenosine tri-phosphate 
AVP   Arginine vasopressin 
Aβ   Amyloid-beta peptide 
Bmal1   Brain and muscle ARNT-like protein 1 
C83   83-amino-acid Ct APP fragment 
C99   99-amino-acid Ct APP fragment 
CaMKII  Calcium-calmodulin dependent protein kinase II 
cAMP   Cyclic adenosine monophosphate 
CAT   Catalase 
CCG   Clock-controlled gene 
CLOCK  Circadian locomoter output cycles protein kaput 
CO2   Carbon dioxide 
COX   Cytochrome c oxidase 
cROS   cytosolic reactive oxygen species 
CRY   Cryptochrome 
Ct   Carboxy-terminal 
CT   Circadian time 
Cu/Zn SOD  Copper/zinc superoxide dismutase 
CYP   Cytochrome P 450 
D   DHEA (dihydroepiandrosterone) 
DD   Dark/dark 
DHEA   Dehydroepiandrosterone 
DHR   Dihydrorhodamine 123 
DRP1   Dynamin-related protein 1 
E1   Estrone 
E2   17β-estradiol 
E3   Estriol 
ECAR   Extracellular acidification rate 
ER   Estrogen-receptor 
ETC   Electron transport chain 
FAD   Familial Alzheimer’s disease form 
FADH2  Flavin adenine dinucleotide 
FTDP-17  Fronto-temporal dementia with Parkinsonism linked to chromosome 17 
GABA   g-aminobutyric acid 
GPX    Glutathione peroxidase 
GSH    Glutathione 
GSK-3β   Glycogen synthase kinase-3β 
H2O2    Hydrogen peroxide 
hFIS1   Human fission protein 1 
IMM    Inner mitochondrial membrane 
IMS    Intermembrane space 
LD   Light/dark 
MAOA   Monoamine oxidase A 
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MAOB   Monoamine oxidase B 
MARK   Mitogen-associated protein affinity-regulating kinases 
MCI   Mild cognitive impairment 
MDA   Malondialdehyde 
MEF   Mouse embryonic fibroblast 
MFN1/2  Mitofusin 1/ 2 
MMP   Mitochondrial membrane permeabilization 
MnSOD  Manganese superoxide dismutase 
mRNA   Messenger ribonucleic acid 
mROS   Mitochondrial reactive oxygen species 
mtDNA  Mitochondrial DNA 
NAD+   Nicotinamide adenine dinucleotide, oxidized form 
NADH   Nicotinamide adenine dinucleotide, reduced form 
NAMPT  Nicotinamide phosphoribosyltransferase 
nDNA   Nuclear DNA 
NFTs   Neurofibrillay tangles 
NMDA   N-methyl-D-aspartic acid 
NO   Nitric oxide 
NOS   Nitric oxide synthase 
Npas2   Neuronal PAS domain-containing protein 2 
NREM   Non rapid eye movement 
Nt   Amino-terminal 
O2-.   Superoxide anion 
OCR   Oxygen consumption rate 
OH.    Hydroxyl radical 
OMM   Outer mitochondrial membrane 
ONOO-  Peroxynitrite 
OPA 1   Optic atrophy 1 
OXPHOS  Oxidative phosphorylation; 
P   Progesterone 
PACAP  Pituitary adelylate cyclase–activating polypeptide 
PAS   PER-ARNT-SIM domain 
PD   Parkinson’s disease 
Per   Clock gene Period 
PET   Positron emission tomography 
PKA   Protein kinase A 
PKC   Protein kinase C 
PLC   Phopsholipase C 
pR5   P301L mutant tau transgenic pR5 mice 
PS1    Presenelin 1 
PS2   Presenelin 2 
REM   Rapid eye movement 
RHT   Retina-hypotalamic tract 
RNS   Reactive nitrogen species 
ROR   Retinoic-related orphan nuclear receptor 
RORE   Retinoic acid-related orphan receptor response element 
ROS   Reactive oxygen species 
SAD   Sporadic Alzheimer’s disease form 
SCN   Suprachiasmatic nucleus 
Ser637  Residue serine 637 
SIRT   Sirtuin 
SRA   Steroid receptor antagonist;  
T   Testosterone 
TCA   Tricarboxylic acid cycle 
TNF   Tumor necrosis factor 
TOM   Translocator outer membrane 
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UCPs   Uncoupling proteins 
VDAC   Voltage-dependant anion channels 
VDCC   Voltage-dependent Ca2+ channel 
VIP   Vasoactive intestinal peptide 
ZT   Zeitgeber time 
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Human aging is accompanied by dramatic changes in daily sleep–
wake behavior: Activity shifts to an earlier phase, and the consol-
idation of sleep andwake is disturbed. Although this daily circadian
rhythm is brain-controlled, its mechanism is encoded by cell-
autonomous circadian clocks functioning in nearly every cell of
the body. In fact, human clock properties measured in peripheral
cells such as ﬁbroblasts closely mimic those measured physiologi-
cally and behaviorally in the same subjects. To understand better
the molecular mechanisms by which human aging affects circadian
clocks, we characterized the clock properties of ﬁbroblasts culti-
vated from dermal biopsies of young and older subjects. Fibroblast
period length, amplitude, and phase were identical in the two
groups even though behavior was not, thereby suggesting that
basic clock properties of peripheral cells do not change during ag-
ing. Interestingly, measurement of the same cells in the presence of
human serum from older donors shortened period length and ad-
vanced the phase of cellular circadian rhythms compared with
treatment with serum from young subjects, indicating that a circu-
lating factor might alter human chronotype. Further experiments
demonstrated that this effect is caused by a thermolabile factor
present in serum of older individuals. Thus, even though the mo-
lecular machinery of peripheral circadian clocks does not change
with age, some age-related circadian dysfunction observed in vivo
might be of hormonal origin and therefore might be pharmacolog-
ically remediable.
chronobiology | peripheral oscillators | human behavior
Circadian clocks possess an endogenous periodicity of about24 h and play a key role in physiological adaptation to the
solar day for all living organisms, from cyanobacteria and fungi
(1) to insects (2) and mammals (3). Circadian clocks inﬂuence
nearly all aspects of physiology and behavior, including sleep–
wake cycles, body temperature, and the function of many organs
(3). During normal aging, clock function is attenuated, with
consequences both for health and quality of life. Older individuals
have an earlier phase of everyday activity compared with the
young (4). Not only is the consolidation of sleep and wake dra-
matically reduced (5, 6), but overall circadian amplitude of hor-
mones and body temperature are lower (7, 8), and many aging-
associated sleep–wake pathologies have been reported (9–11). As
a result, one in ﬁve healthy older individuals reports taking sleep
medications regularly (9). In cases of pathological aging, chro-
nobiological disturbance is even more acute: Huntington disease,
Parkinson disease, and Alzheimer’s disease are all associated with
profound alterations in sleeping patterns (10–12). These effects
of aging on circadian rhythms—diminished circadian amplitude,
earlier phase, shorter circadian period, and desynchronization of
rhythms in peripheral organs—have been observed widely in
several species of mammals (7, 13, 14). Paradoxically, however,
even though the behavioral phase is earlier in aged humans,
multiple studies conclude that the free-running period remains
unchanged (15–18). Thus, changes in phase have been ascribed
to alterations in overall circadian amplitude and changed sleep
architecture. However, the nature and mechanism of these
changes remains entirely unknown.
Mammalian circadian clocks are organized in a hierarchical
fashion: The suprachiasmatic nuclei (SCN) of the anterior hy-
pothalamus serve as a master clock, receiving light signals from
the external environment via the retina and retino-hypothalamic
tract and elaborating these stimuli into signals that are sent all
over the body to synchronize clocks in peripheral organs (3).
Interestingly, the clock mechanism itself is cell-autonomous and
involves interlocked feedback loops of transcription and trans-
lation. These loops are encoded by dedicated clock genes: For
example, in one loop the heterodimer formed by the two tran-
scription factors CLOCK and BMAL1 binds cis-acting E-box
sequences present in Per and Cry gene promoters to activate
their transcription. Subsequently, PER and CRY protein com-
plexes inhibit the activity of CLOCK–BMAL1. As a consequence,
Cry and Per mRNAs decrease in concentration, and a new cycle
can start (19).
At a cellular level, the SCN and peripheral oscillators share the
same molecular mechanism (20). Thus, cellular reporters com-
posed of clock gene promoters driving expression of luciferase or
GFP have proven to be very useful tools for the study of circadian
rhythms in the SCN as well as in peripheral oscillators (21, 22).
Using such reporters, we have shown previously that many dif-
ferences in human circadian behavior also can be seen at a mo-
lecular level in peripheral cells. For example, the cellular clocks of
early chronotypes (i.e., “larks”) have shorter circadian periods
than those of later chronotypes (“owls”) (23), and circadian pe-
riod length in vitro is proportional to physiological period in vivo
(24). Under entrained conditions in which cellular clocks are
constrained to 24 h via an entrainment protocol that mimics di-
urnal variations in mammalian body temperature (25), ﬁbroblasts
show the early or late circadian phases of their owners (23).
In principle, alterations in circadian behavior caused by aging
could arise by a variety of mechanisms. Changing neural networks
might perturb sleep–wake timing or alter the communication
between the SCN clock and other brain regions. Hormonal signals
critical for maintaining physiological homeostasis might be per-
turbed. On a cellular level, molecular changes associated with
aging (e.g., oxidative damage, telomere attrition) might alter basic
clock function. In this paper we have addressed the effects of
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aging on molecular circadian clock properties using a ﬁbroblast-
based assay. Our results are consistent with the hypothesis that
the molecular machinery of circadian rhythms in peripheral
oscillators is not altered by age but that molecules present in se-
rum might be responsible for some of the circadian changes that
occur in the elderly.
Results
Aging Changes Human Circadian Behavior in Vivo but Does Not Alter
Fibroblast Circadian Clocks in Vitro. To try to understand the mo-
lecular changes that might underlie modiﬁcations in daily be-
havior in elderly individuals, we characterized the circadian
rhythms of dermal skin ﬁbroblasts obtained from young and older
donors. Subjects were recruited based on age but also were asked
to give information about daytime preference (their preferred
waking time and bedtime both on workdays and during leisure) by
completing the Munich Chronotype Questionnaire (MCTQ)
(26). The 18 young and 18 older sex-matched subjects partici-
pating in our study are summarized in Table S1 and are described
individually in Table S2.
From the completed MCTQ, older subjects in our study dis-
played a signiﬁcantly earlier sleep phase compared with young
subjects (Fig.1A; unpaired t test; P < 0.01). This difference
reﬂected well the epidemiological trend that is observed in the
general population, e.g., as reported by Roenneberg and col-
leagues (27). To characterize possible cellular origins of these
differences, two 2-mm dermal punch biopsies were taken from
every subject. Primary ﬁbroblast cultures were isolated from the
biopsies and infected with a lentivirus that harbored a circadian
reporter construct (the Bmal1 promoter driving expression of the
ﬁreﬂy luciferase gene (28)). Circadian clocks in infected ﬁbroblast
cultures were synchronized with dexamethasone (29), and circa-
dian bioluminescence corresponding to Bmal1 promoter activity
was measured for at least 5 d under constant conditions in a cell-
culture incubator. The circadian oscillations from ﬁbroblasts from
young and elderly subjects then were examined systematically for
differences in period length, amplitude, and phase. It had been
shown previously that chronotype correlates negatively with pe-
riod length in vivo (30) and in vitro (23). Hence, if the origins of
aging-related differences were cell intrinsic, we hoped to see
correlations between clock properties in vitro and subject age.
The period length for each individual is shown in Fig. 1B. As we
have reported for other subject populations (28), ﬁbroblast period
differed signiﬁcantly among different individuals but not between
different biopsies from the same individual (Fig. S1A). No dif-
ferences were observed between the groups (Fig. 1B Inset; un-
paired t test; P > 0.05; and Table S1). Additionally, no correlation
was seen between period length and MCTQ sleep phase in either
older or younger subjects (Fig. S1B; linear regression: P > 0.05).
[Previous studies showing correlations between questionnaire-
based sleep–wake behavior and period length were based on
comparisons of extreme early vs. late chronotypes (23, 30).]
In addition to period length, other clock properties include
amplitude (the difference between peak and nadir expression
values) and phase (the relative timing of each cycle relative to
a periodic entraining stimulus). We also studied the circadian
amplitude of the oscillations that we observed in vitro. No cor-
relation with aging was observed, nor did amplitude correlate
with ﬁbroblast cell passage number (i.e., a longer or shorter time
in cultivation) (Fig. S2 A–C; unpaired t test; P > 0.05).
Theoretically and biologically, period and phase are tightly
coupled: A longer period leads to a later phase. Under certain
circumstances, amplitude and phase also are coupled, with lower
amplitude leading to earlier phase (23). Nevertheless, phase dif-
ferences also can be driven by rhythmic inputs from outside the
circadian oscillator (e.g., by the timing of light to the retina in
mammals). To measure circadian phase in ﬁbroblasts in vitro, we
entrained ﬁbroblast clocks to a 24-h daily cycle using periodic
oscillations of incubator temperature between 34 and 37 °C. After
6 d, ﬁbroblast daily rhythms entrained well to these cycles in both
young and old subjects regardless of their period lengths. On day
7, we measured the phase of reporter gene expression relative to
the temperature cycle. An earlier phase was not observed in older
vs. younger subjects (Fig. S2D; unpaired t test; P > 0.05), con-
ﬁrming the lack of effect of subject age on period and amplitude
that we already had observed. In total, none of the physiological
signs of human circadian aging could be detected or duplicated in
cultured ﬁbroblasts from elder subjects.
Human Sera Inﬂuence Fibroblast Circadian Period Length and Phase.
Even if the peripheral cells of elderly subjects do not differ from
younger subjects in their chronobiological properties, it is well
documented that the milieu in which these cells are found
undergoes dramatic changes as individuals age (7, 31), and pe-
ripheral organs certainly show altered function with aging (7, 13,
14, 17, 32), If cellular circadian properties per se do not change
with aging, we reasoned that age-related circadian alterations
might be provoked by a circulating factor. To test this possibility,
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Fig. 1. Inﬂuence of age on period length and chronotype. (A) Chronotype of young and old subjects, as measured by the MCTQ. The y axis shows subject
MSF-Sc. This statistic (the output of the MCTQ) is widely used as a reliable measure of human chronotype (27). Dataset variation is shown as a standard
boxplot (n = 18; unpaired t test; **P < 0.01). (B) Period length of the primary ﬁbroblasts of each subject participating in this study. For ease of display, data are
sorted on the basis of the period length. Data are mean of six independent measurements of the period length for every subject ± SEM. (Inset) Population
average of period lengths of skin ﬁbroblasts from young (Y) and older (O) subjects, shown as a standard boxplot. No statistical difference was observed
(n = 18; unpaired t test; P > 0.05).
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we replaced the normal standardized FBS used in our cell cul-
tures with human serum harvested from donors of different ages.
The circadian rhythms of four young (Y) and two old (O) cell
lines were measured in the presence of eight different media
containing human serum from young (YS) male donors and ﬁve
different media containing human serum from three older male
donors and two postmenopausal female donors (OS). Data re-
garding these blood donors are listed in Table S3. Fig. 2 A and B
shows representative data from one Y and one O ﬁbroblast cell
line tested with all sera. (The complete data set is shown in Fig
S3.) Fig. 2 C and D shows averages from all cell lines and all sera
collectively. Irrespective of whether the treated ﬁbroblasts were
from young or older subjects, cells measured in serum from older
donors had a signiﬁcantly shorter circadian period than cells
in serum from young donors (Fig. 2 C and D; unpaired t test;
PY < 0.001; PO < 0.001). In the presence of YS, cells from young
and older subjects showed a period length of 24.61 ± 0.18 h and
24.35 ± 0.18 h, respectively, whereas in the presence of OS cells
from young and older subjects showed a period length of 23.79 ±
0.16 h and 23.60 ± 0.33 h, respectively. Analyzed individually,
period measurements with different sera showed a strong corre-
lation between donor age and period length (Fig. 2E; P < 0.0001;
R2 = 0.91).
Because changes in period are coupled to changes in phase (as
described above), to verify these results we wanted to ensure that
the dramatic changes in circadian period that we observed were
mirrored by corresponding changes in phase. Using the tem-
perature entrainment paradigm described earlier to entrain
clocks in all cells to rhythms of 24 h, we measured the circadian
phase after temperature entrainment of two Y cell lines and two
O cell lines in the presence of two YS and two OS. Serum from
older subjects indeed phase-advanced the circadian rhythms of
cells from both young (Fig. 3A) and older (Fig. 3B) subjects,
compared with the same cells in YS (unpaired t test; P < 0.05),
and there was a strong correlation between period length and
phase shifting in individual sera (Fig. 3C; P= 0.0265; R2 = 0.66).
Therefore, the shortened period observed with sera from older
individuals manifested as earlier phase under entrained con-
ditions, at least in cells.
Inﬂuence of Human Serum on Period Length Is Caused by Heat-
Sensitive Substances in Sera from Older Subjects. Our results sug-
gested that one or more substances in human serum can re-
capitulate at a cellular level the differences in circadian phase
seen between younger and older subjects. In principle, such
effects could arise from substances either in YS or in OS. To
investigate further the nature of the substance(s) responsible
for the aging effects, we attempted to heat-inactivate four YS
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Fig. 2. Length of circadian period of skin ﬁbroblasts treated with media containing human serum. (A) Lengths of circadian period in one representative cell
line taken from a young subject (Y) measured in medium containing FBS (white) and media containing human serum from eight young (YS; gray) and ﬁve
older (OS; black) donors. Bars represent the mean of three independent measurements ± SEM. (B) Equivalent measurements from a representative cell line
from an older subject (O). (C) Bar graph showing the average differences in period length in four Y cell lines treated with YS and OS. Results are expressed
as average ± SEM. (D) Equivalent measurements for two O cell lines. In both cases, treatment with YS gave a highly different period length (unpaired t test;
***P < 0.001 compared with the treatment with OS in Y cell lines). (E) Average period length across experiments using human serum, as a function of the
age of the serum donor (linear regression: P < 0.0002; r2 = 0.6274).
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Fig. 3. Circadian phase of ﬁbroblasts in the presence of serum from young
and older subjects. (A) Phase of cell lines from young subjects (Y) was deter-
mined after temperature entrainment in the presence of serum from younger
subjects (YS) or from older subjects (OS). Results are expressed as phase dif-
ference (in h) between the two treatments. Each bar results from the average
of two different cell lines, each treated with two different sera, ± SEM. (B)
Equivalent data using cell lines from older subjects. In both cases, there was
a signiﬁcant advance in the phase of cells treated with OS compared with the
same cell lines treated with YS (unpaired t test; *P < 0.05). (C) Correlation
between phase-shift differences seen in this ﬁgure and differences in period
length seen in Fig. 2. Phase shifts are plotted relative to the average phase for
all sera from young subjects (linear regression: P = 0.0265; r2 = 0.6488).
7220 | www.pnas.org/cgi/doi/10.1073/pnas.1008882108 Pagani et al.
(YSHI) and four OS (OSHI). In this way the secondary structure
of proteins and unstable metabolites would be destroyed, and
a ﬁrst indicator of molecular identity would be given. The cir-
cadian period length from four cell lines (two Y and two O) were
analyzed in the presence of medium containing each of these
sera. Individual values for each serum in a single cell line are
shown in Fig. 4A. (The complete data set is shown in Fig S4.)
Average values for cell lines from younger and older individuals
are shown separately in Fig. 4B. Heat treatment had no effect on
YS: Measurements from cells with YSHI were not different from
measurements with YS [period Y = 24.61 ± 0.18 h (with YS) vs.
24.63 ± 0.27 h (with YSHI); period O = 24.35 ± 0.18 (with YS)
vs. 24.50 ± 0.45 (with YSHI); PY > 0.05; PO > 0.05]. Neverthe-
less, measurements with OSHI were signiﬁcantly longer than
with OS and were not signiﬁcantly different from those with YS
[period Y = 23.79 ± 0.16 (with OS) vs. 24.60 ± 0.14 (with OSHI);
period O = 23.60 ± 0.33 (with OS) vs. 24.32 ± 0.28 (with OSHI);
one-way ANOVA Tukey’s multiple comparison test: PY < 0.001;
PO < 0.01]. Thus, the longer periods observed with young sera
were rescued by the heat inactivation of OS, providing strong
evidence for heat-sensitive circulating factors present in serum
from older individuals that can shorten period. In support of this
hypothesis, iterative dilution of OS with FBS results in a pro-
gressive loss of this period-shortening effect (Fig S5A).
If the changes in period that we observe with OS are re-
sponsible for changes in phase, then it would be likely that heat-
inactivated OS also should no longer produce phase changes. We
tested this hypothesis by examining phase in a temperature en-
trainment protocol with two sera each from old and young
donors, tested on two cell lines each from old and young subjects.
As expected, heat treatment abolished the earlier phase pro-
duced by serum from older individuals (Fig. 4C).
Theoretically, either a diurnal factor or one constantly present
could achieve the effects that we observe. Multiple phase-shifting
activities are known to be present in serum, no matter what time
of day it is drawn (29). Two obvious labile circadian candidates
would be melatonin and cortisol, hormones widely used as cir-
cadian markers and known to phase-shift the circadian clock.
Melatonin would be barely present in serum at these times, al-
though cortisol would be abundant. We tested the levels of both
these substances explicitly in our sera: They were not signiﬁcantly
different in young and older blood donors at the time that these
sera were taken (ca. 2:00 PM) (Fig. S5 B and C; unpaired t test;
P > 0.05). Because a trend toward elevated cortisol was visible in
older subjects, we tested sera supplemented with different
amounts of cortisol to see whether this hormone could cause the
changes we observe. Because ﬁbroblasts treated with different
amounts of cortisol at levels found in the blood of these donors
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Fig. 4. Length of the circadian period of skin ﬁbroblasts treated with media containing normal or heat-inactivated human serum. For ease of analysis, data
for normal serum are replotted from Fig. 2. (A) Length of circadian period obtained from one representative cell line from a young subject (Y) measured in
media containing normal (YS or OS) or heat-inactivated (YSHI or OSHI) human serum from four young and seven older donors. Every bar shows the mean of
three independent measurements ± SEM. (B) (Upper) Graph showing the average period length from Y cell lines treated with normal and heat-inactivated
serum from both young and old subjects. Each bar represents the average of two different cell lines, each treated with four different sera, ± SE. (Lower)
Equivalent graph for cell lines from older subjects. In both cases, YSHI did not modify the period length compared with YS (one-way ANOVA Tukey’s multiple
comparison test: P > 0.05), whereas OSHI increased the period length compared with OS (one-way ANOVA Tukey’s multiple comparison test: *P < 0.05; **P <
0.01; ***P < 0.001) to a length equivalent to that obtained with YS (one-way ANOVA Tukey’s multiple comparison test: P > 0.05). (C) Under temperature-
entrained conditions, comparison of phase shifts obtained with untreated and heat-inactivated sera tested on two cell lines from young subjects and two
from older subjects. Results are expressed relative to phase obtained with young serum. No differences were observed in phase among YS, YSHI, and OSHI
(one-way ANOVA Tukey’s multiple comparison test: P > 0.05), but OS resulted in signiﬁcantly earlier phase (one-way ANOVA Tukey’s multiple comparison
test: *P < 0.05). (D) Model demonstrating why older subjects show altered circadian behavior. Blue, younger subjects. Red, older subjects. (1) In elderly
individuals, lower light levels caused by less light exposure and changed lens properties reduce the ability of light to entrain the central clock in SCN. (2) A
weakened circadian drive from the SCN results in fragmented sleep–wake cycles, which in turn affect self-selected light preferences. (3) Altered hormonal
balance in elderly individuals changes cellular clock properties and shifts phase earlier at sleep–wake centers but cannot entrain the SCN. In cells, only intrinsic
and hormonal inﬂuences are operative, resulting in shorter period and earlier phase in the presence of serum from older individuals.
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did not show differences in period length compared with un-
treated cells, we conclude that cortisol is not the factor re-
sponsible for our effects (Fig. S5D).
Discussion
In this study, we have shown that skin ﬁbroblasts taken from
young and older subjects do not differ in their circadian prop-
erties per se, but incubation of both cells in serum from older
subjects results in a shortening of circadian period and a shift to
earlier phase compared with incubation with serum from youn-
ger subjects. Moreover, the effects that we observe are caused by
a thermolabile activity in serum from older subjects. Our results
suggest that hormonal changes can alter cellular clocks, and
these changes in turn might underlie the differences in circadian
behavior caused by aging.
Various theories have been proposed to explain a shift toward
earlier behavior in elderly individuals. According to one hypoth-
esis, fragmentation of the sleep–wake cycle coupled with in-
creased daytime napping results in less nighttime sleep and a shift
to an earlier activity phase (6, 33). In this scenario, changes in
sleep structure alter self-selected timing of light, and thereby
circadian phase. Such changes in sleep structure might be caused
by age-related reduction in the evening circadian signal that
opposes homeostatic sleep pressure (15, 34). According to an-
other theory, changes in eye physiology with age (e.g., lens yel-
lowing and senile miosis or cataracts) and changes in behavior
(less time in direct sunlight outdoors) are thought to reduce the
entraining effects of solar light, exacerbating a circadian en-
trainment problem in elderly individuals (35). Recent studies
corroborate these hypotheses and demonstrate clearly that the
circadian system in the elderly is less sensitive to light (36, 37).
The results that we present provide an additional cellular ex-
planation for the shift toward earlier chronotype based on
changes in hormone balance in elderly individuals. The putative
causal factor could be constantly present in serum and use
asymmetry in phase-response curves to shift overall phase. In this
case, we would expect that the magnitude of the factor would be
different in older and younger individuals at all times of day.
Alternatively, if the factor were rhythmically secreted, it could
have the same amplitude but a different phase proﬁle in older and
younger individuals. In this case, the difference in abundance that
we saw by sampling at a single time would reﬂect different cir-
cadian dynamics of the putative clock-modifying substance in
older and younger individuals.
Nevertheless, there is one obvious problem with this idea:
Excellent studies suggest that the physiological period of human
beings does not change with age (15, 16, 38). If a circulating
hormone were shortening period, then why does free-running
physiological period remain unchanged? We propose that such
a factor might act upon non-SCN regions of the human brain and
periphery but not upon the SCN itself. This hypothesis would
explain our data and also would explain nicely why the phase of
sleep–wake timing is shifted earlier relative to the timing of the
endogenous circadian clock even in “forced desynchrony” labo-
ratory studies. In rodents, brain structures other than the SCN
(e.g., hippocampus, thalamus, and cortex) actually show an en-
trainment reminiscent of peripheral cells: They have a clock
phase 4 h later than the SCN, and they are entrained to feeding
and temperature-entrainment signals, whereas the SCN is not
(25, 39). Other types of decoupling of locomotor activity rhythms
from SCN clock phase (e.g., by methamphetamine in rats or by
darkness in certain mouse strains) also are accompanied by
alterations in the phase of clock gene expression in non-SCN
brain areas (40, 41).
Overall, compelling evidence exists for all three models, and it
is likely that each could contribute to the dramatic changes in
behavior seen in elderly individuals (a model is shown in Fig.
4D). Our ﬁndings open the possibility that circadian difﬁculties
associated with aging might be hormonally driven in part and
therefore might be pharmacologically treatable without recourse
to potentially addictive sleep aids. If so, this approach would
represent a major beneﬁt to health.
Materials and Methods
Subject Recruitment Criteria and Chronotype Determination. Eighteen healthy
young (age 21–30 y) and 18 healthy older subjects (age 60–88 y) were chosen
for participation based on age alone and were asked to ﬁll out the MCTQ.
MSF-Sc was calculated from this questionnaire and used as a measure of
chronotype (26). Subject statistics are shown in Table S1. Prior ethical con-
sent for the use of human skin tissues was given by the Ethical Committee of
Basel, and informed written consent for participation in this study was
obtained from all human subjects.
Tissue Isolation, Fibroblast Culture, and Viral Infection. Two cylindrical cuta-
neous biopsies (2 mm diameter) were taken from the buttocks of each
recruited healthy subjects. Fibroblasts were isolated from biopsies by 4-h di-
gestion of tissue in DMEM/1% penicillin streptomycin (Sigma)/1% Glutamax
(Sigma) (DMEMc)/20% FBS (Sigma)/87.5 ng/mL Liberase (Roche), and cultured
in DMEMc/20% FBS. Conﬂuent cells were infected using Bmal1::luciferase
lentivirus. Transfected cells were positively selected 3 d after infection (28).
Harvesting of Sera. At 2:00 PM, 45 mL of blood were collected from eight
healthy young male (age 25.5 ± 4.6 y) and ﬁve healthy older (three male and
two postmenopausal female; age 74.4 ± 9.8 y) subjects in clot-activator
vacutainers (BD Vacutainer System). Whole blood was incubated 30 min at
room temperature and then centrifuged 10 min at 2,000 × g. Serum was
harvested and stored at −20 °C. When speciﬁed, human serum was heat-
inactivated by treatment for 30 min at 56 °C.
Synchronization and Measurement of Circadian Period and Phase. Five days or
more after human ﬁbroblast infection, circadian rhythms were synchronized
by 100nMdexamethasone (Sigma) inDMEMc+20%FBS (42). DMEMcwithout
phenol red was supplemented with 0.1 mM luciferin (Molecular Probes)
to obtain the counting medium (CM), and light output was measured in
homemade light-tight atmosphere-controlled boxes for at least 5 d. To
measure the ﬁbroblast basal circadian rhythms, CM was supplemented with
10% FBS; to determine the inﬂuence of human serum on circadian period
length, CM was supplemented with 10% human serum; to determine the
inﬂuence of cortisol on period length, CM was supplemented with 10% FBS
or 10% FBS and 25 ng/mL cortisol (Sigma) or 10% FBS and 75 ng/mL cortisol;
to determine the inﬂuence of heat-inactivated human serum on period
length, CM was supplemented with 10% heat-inactivated human serum. For
phase determination experiments, cells in luciferin-supplemented medium
were synchronized by incubation for 6 d in a temperature-controlled in-
cubator under a 16 h/8 h 35 °C/37 °C daily temperature cycle. On day 7, cells
were transferred to the Lumicycle device at 37 °C, and bioluminescence was
measured for an additional 16 h. Cellular phase was determined by mea-
suring the time of the transcriptional maximum of reporter gene expression
in the smoothed and normalized dataset during this interval (23).
Melatonin Determination in Sera. A direct double-antibody RIA was used for
the melatonin assay, validated by gas chromatography-mass spectroscopy
(Buehlmann Laboratories). The minimum detectable dose of melatonin
(analytical sensitivity) was determined to be 0.2 pg/mL The functional least-
detectable dose using the <20% coefﬁcient of interassay variation criterion
was <0.65 pg/mL Melatonin concentrations in the sera were expressed as pg/
mL of serum.
Cortisol Determination in Sera. Quantiﬁcation of cortisol in sera was per-
formed using a Cortisol ELISA Kit (R&D) following the manufacturer’s in-
struction. Cortisol concentration in the sera was expressed as ng/mL of
serum, and the assays were performed in duplicate.
Statistical Methods. Details of statistical methods are given in SI Materials
and Methods.
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Statistical Methods: Period. For each luciferase measurement, the
period of oscillation was calculated by least-mean-squares ﬁtting
of dampened sine wave functions to the actual data. The period of
the sine wave with the best least-squares ﬁt to the data was as-
sumed to be the true period of oscillation. Because the period
length of the ﬁrst day after synchronization varied according to
the conditions of synchronization, it was not included in these
calculations; rather, period was determined by analyzing only days
2–5. For each period measurement, at least three separate ex-
perimental measurements were done for each biopsy, using two
biopsies from each individual. Period values are presented as
mean ± SE.
Statistical Methods: Relative Amplitude. The amplitudes of the
second and third cycles of circadian expression were obtained as
the difference between the peak and nadir expression values of
these cycles. These measurements then were normalized using the
absolute raw-data magnitude of the ﬁrst peak as an approximate
measure of reporter virus infection efﬁciency in each culture.
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Fig. S1. (A) Period lengths obtained from two different biopsies taken from three young females (YF), three young males (YM), three older females (OF), and
three older males (OM). Each bar represents the mean of three independent measurements per biopsy ± SEM. (B) Comparison between chronotype and in vitro
circadian period length for the two groups of subjects (Pall subjects = 0.3707; PY = 0.3785; PO = 0.9229). The x axis shows period length in hours. Period length
values are shown as the mean of six independent measurements ± SEM. The y axis shows subject mean sleep phase corrected for sex and cumulative sleep debt
(MSF-Sc). This statistic is the output of the Munich Chronotype Questionnaire and is widely used as a reliable measure of human chronotype.
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Fig. S3. Effects of individual sera upon individual cell lines from younger (A) and older (B) subjects used in our study. The length of the circadian period in each
cell line used in our study is shown, as measured in the presence of each sample of human serum from young individuals (YS, gray) or from older individuals
(OS, white). Bars represent the mean of three independent measurements ± SEM. Cell line designations refer to young (Y) or older (O) male (M) or female (F)
donors. Donors are described in detail in Table S2.
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Fig. S2. Inﬂuence of age on amplitude and phase of entrainment. (A) Schematic representation of the amplitude measurement. Amplitude of the ﬁrst three
peaks (ﬁrst peak = A1; second peak = A2; third peak = A3) was measured. Damping was approximated as the ratio A2/A1 or A3/A1, which produced equivalent
results (SI Materials and Methods). (B) Diagram showing the correlation between A2/A1 and A3/A1 for young and old subjects. Age did not inﬂuence either of
these ratios (unpaired t test: P > 0.05). (C) Graph reporting the inﬂuence of cellular senescence on the damping rate of peripheral oscillators. The x axis shows
the passage number of the measured cells; the y axis shows the damping rate A2/A1, normalized to the highest value obtained from each subject. There was no
difference in amplitude of ﬁbroblasts between young and old subjects with increasing passage number (unpaired t test: P > 0.05). (D) Graph showing
chronotype (MSF-Sc) vs. phase of entrainment of reporter expression for ﬁbroblasts from ﬁve young and six older subjects. Statistical analyses revealed no
signiﬁcant correlation between phase of entrainment, chronotype, and aging (PAll subjects = 0.3699; PY = 0.9462; PO = 0.0698).
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Fig. S4. Effects of individual normal and heat-inactivated sera on the individual cell lines used in our study. (For ease of analysis, data for normal serum are
replotted from Fig. S3.) Circadian period lengths of cell lines from young male (YSM) or female (YSF) donors (A) and from older male (OSM) and older female
(OSF) donors. (B) Cell lines, measured in media containing normal (OS, YS) or heat-inactivated (OSHI, YSHI) human serum from four young and four to eight
older donors. Every bar shows the mean of three independent measurements ± SEM.
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Fig. S5. (A) Period length measured in cell lines from two young subjects and from two older subjects in the presence of two sera from young donors (YS) and
two sera from older donors (OS), serially diluted with FBS as indicated. A signiﬁcantly shorter period is observed in the presence of OS (unpaired t test: P <
0.001); this effect gradually diminishes with increasing dilution. (B) Melatonin levels (pg/mL) in four YS and four OS. There was no statistical difference in
melatonin concentration between the two groups of sera (unpaired t test: P > 0.05). (C) Cortisol levels (ng/mL) in four YS and four OS. There was no statistical
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length were studied in more detail, as shown in D. (D) Period lengths of one cell line in serum supplemented with 0 ng/mL, 25 ng/mL, or 75 ng/mL cortisol. Every
point represents the mean of three independent measurements ± SEM. No signiﬁcant differences were observed (unpaired t test: P > 0.05).
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Table S1. Subject characteristics
Category N Age (y ± SD) Chronotype (MSF-Sc ± SD) Fibroblast period length (h ± SD)
Young 18 25.44 ± 3.58 4.98 ± 0.84 24.73 ± 0.32
Female 7 25.86 ± 2.48 4.86 ± 0.78 24.80 ± 0.38
Male 11 25.18 ± 4.24 5.06 ± 0.91 24.69 ± 0.29
Older 18 67.89 ± 7.32 3.88 ± 1.12 24.94 ± 0.37
Female 7 65.43 ± 4.12 4.01 ± 1.22 24.96 ± 0.35
Male 11 69.45 ± 8.61 3.79 ± 1.10 24.92 ± 0.40
MSF-Sc, mean sleep phase, corrected for sex and cumulative sleep debt. (Further details are given in the main
text and in the legend for Fig. S1.)
Table S2. Detailed subject information
Age (y) Sex Chronotype (MSF-Sc)
Fibroblast period length
Time (h) SD n
28 F 3.98 24.27 0.30 6
23 F 6.04 24.50 0.21 7
27 F 5.48 24.71 0.20 6
29 F 5.02 24.75 0.45 6
27 F 4.19 24.83 0.51 5
23 F 4.11 25.12 0.27 6
24 F 5.17 25.40 0.27 5
27 M 4.53 24.14 0.08 6
21 M 3.56 24.38 0.12 6
31 M 4.36 24.50 0.39 5
21 M 4.15 24.58 0.11 7
21 M 4.67 24.65 0.06 6
31 M 5.50 24.73 0.17 4
22 M 6.52 24.73 0.13 6
24 M 6.27 24.82 0.34 6
31 M 4.45 24.82 0.26 6
26 M 5.95 25.07 0.11 6
22 M 4.19 25.13 0.23 6
65 F 3.17 24.27 0.14 6
61 F 3.64 24.73 0.31 6
73 F 3.58 25.01 0.20 6
62 F 4.46 25.13 0.13 6
63 F 4.90 25.15 0.30 5
68 F 2.29 25.26 0.24 6
66 F 6.00 25.20 0.17 6
64 M 3.90 23.99 0.27 6
65 M 5.62 24.32 0.21 6
70 M 2.50 24.82 0.24 4
70 M 4.50 25.03 0.40 7
60 M 5.37 25.05 0.27 6
65 M 4.39 25.05 0.13 5
70 M 3.29 25.15 0.55 6
83 M 2.75 25.20 0.30 6
66 M 2.37 25.18 0.20 6
63 M 3.27 25.29 0.08 6
88 M 3.75 25.01 0.19 7
Subjects highlighted in gray also were the source of biopsied ﬁbroblasts
used in characterization of blood sera.
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Table S3. Blood donor characteristics
Blood donor Sex Age (y) Medications
Y1 M 21 No
Y2 M 20 No
Y3 M 32 Citalopram-hormosan (120 mg/d)
Y4 M 21 No
Y5 M 26 No
Y6 M 27 No
Y7 M 31 No
Y8 M 26 No
O1 M 81 Daﬂon (500 mg/d)
O2 F 83 Aspirine Cardio (100 mg/d); metoprolol (50 mg/d; perindopril/indapamin (4 mg/d/1.25 mg/d)
O3 F 67 No
O4 M 80 Aspirine Cardio (100 mg/d); amlodipine maleate (2.5 mg/d); chlorthalidone (12,5 mg/d)
O5 M 61 Aspirine Cardio (100 mg/d); simvastatin (40 mg/d)
O6 F 61 No
O7 M 63 No
O8 F 56 No
O9 M 61 No
O, old; Y, young.
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INTRODUCTION 
 
Increasing evidence suggests that disruption of 
circadian clock function – either genetically or 
environmentally – can exacerbate a wide range of age-
related pathologies, ranging from cataracts to cancer.  
An excellent review on this subject was published 
recently in this journal [1].  Equally relevant, however, 
and even more painfully obvious, is the impairment of 
circadian function that occurs as a natural process of 
aging.  The German language has invented the term 
“senile Bettflucht” (literally, senile bed evacuation) to 
describe the difficulty that elderly individuals have in 
sleeping at night, and the early hour at which they rise.  
Indeed, one in four aged persons reports regular use of a 
prescribed sleep medication [2].  Since such 
medications treat only the symptoms and are also 
potentially addictive, the origins of this sleep 
disturbance are an important public health question. 
 
Age-related sleeping difficulties are actually twofold.  
On the one hand, elderly individuals will rise and also 
go to bed an average of two hours earlier than young 
adults [3].  Secondly, their nighttime sleep is 
considerably more fragmented, and contains a much 
lower proportion of “deep” or slow-wave sleep (SWS) 
[4].  Whether these two phenomena are linked or 
independent remains a subject of debate.  Underlying 
causes are a matter of speculation. 
 
Recently, by using primary human fibroblast cells as a 
model system, our laboratories reported that serum-
borne factors (i.e. hormones) could play a role in age-
related circadian disturbances [5].  Rather than being a 
comprehensive review, this Perspective is an attempt to 
set our findings more explicitly within the context of 
other data in the field than was possible in the context 
of the original research communication. 
 
THE EXPERIMENT UNDER DISCUSSION 
 
Exploiting the fact that human circadian clocks are 
conserved in most cell types, Pagani et al. examined the 
circadian properties of primary fibroblasts from older 
and younger individuals.  Although the cells from both 
groups showed identical circadian properties (period, 
amplitude, entrained phase) when cultured identically, 
inclusion of serum from older individuals resulted in a 
shortening of circadian period and an earlier entrained 
phase in either cell type.  This change was likely due to 
a substance in the serum of older individuals, because 
heat treatment gave older persons’ sera the circadian 
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properties of younger persons’ sera, but did not change 
the properties of younger persons’ sera (Figure 1, 
bottom) [5]. 
 
Background 
 
In principle, sleep is regulated by two separable 
processes: a circadian one, which pushes diurnal species 
such as humans to sleep preferentially at night; and a 
homeostatic one, by which sleep drive increases with 
increasing time spent awake [6]. 
 
The circadian process is driven by a biological 
“circadian” clock.  In mammals, the central clock 
controlling diurnal behavior is located in the 
suprachiasmatic nucleus of the brain hypothalamus (the 
Figure 1: Top panel.  In vivo, a central clock in the suprachiasmatic nucleus (SCN) determines the timing of daily 
behavior, and communicates this timing to peripheral clocks in other tissues and brain loci that control sleep.  The 
timing of sleep influences clock phase by controlling when the eyes receive environmental light.  Inset graph, This 
light phase-shifts the clock differently at different times of day (Data reproduced from [11]).  Black stars, 
Feedback loops affecting sleep in the elderly.  1. A shorter period in the SCN would shift sleep earlier, but this has 
not been observed experimentally in humans.  2. Changes to sleep-wake structure, either by affecting 
homeostatic sleep or by affecting the circadian drive to sleep at night, 3. could feed back to affect light availability 
and therefore clock phase because of natural time-dependent differences in phase shifting.  4. Hormones could 
directly affect peripheral clocks at sleep-wake centers to affect sleep timing without altering the central clock in 
the SCN.  Bottom panel.  In vitro, treatment of primary human fibroblasts with serum from older subjects (OS) 
results in a shorter period and an earlier phase of cellular circadian rhythms than that obtained with serum from 
younger subjects (YS). Heat treatment (OSHI) abolished this effect. (Data reproduced from [5].) 
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 SCN).  Its mechanism is cell-autonomous, and is 
duplicated in “slave” clocks in nearly all the cells of the 
body.  The molecular mechanism of this clock has been 
reviewed previously, including in this journal [1].  
Numerous studies have demonstrated that its genetically 
encoded period length (the time taken for one complete 
cycle under constant conditions) directly affects the 
phase of human behavior and gene expression: 
individuals with longer periods have a later phase than 
those with shorter periods, looking either at human 
behavior or at gene expression [7-9]. 
 
In mammals, entrainment of the circadian clock to its 
environment is driven predominantly at the ocular level 
by environmental light.  Hence, blind individuals with 
an endogenous clock period significantly different from 
24 hours are unable to synchronize to the solar day [10].  
The response of the clock to light is asymmetric, and 
light at different times of the day or night will shift the 
clock in different directions and by different amounts 
(Figure 1, bottom inset).  As one might predict, evening 
light delays the clock, and morning light advances it 
[11]. 
 
The homeostatic process is much less well understood 
at the molecular level, but may be a fundamental 
property of neural assemblies [12].  It involves global 
synchronization of rhythmic thalamocortical firing 
patterns whose hallmark is a predominance of particular 
frequencies measured by EEG.  Sleep is divided into 
different “stages” characterized by different frequency 
bands, and an individual will typically alternate among 
these stages in a defined pattern for several episodes 
during the night.  The “intensity” of sleep is determined 
by time spent awake, by genetic factors, and by 
environmental disturbance, with more profound sleep 
characterized by a greater intensity of these EEG 
frequencies, indicative of more pervasive neuronal 
synchrony [13]. 
 
Theory 
 
Purely theoretically, based upon the mechanisms 
outlined above, numerous hypotheses can be advanced 
to explain the disruption of sleep in the elderly.  Let us 
consider the two features of this disruption separately.  
The earlier bedtime and waking time of elderly 
individuals could be a result of a shortening of 
endogenous circadian period.  It could also arise from a 
change in the way the clock changes phase in response 
to light: anything that resulted in a net gain of morning 
light or loss of evening light would result in an earlier 
phase.  Finally, the early phase of elderly individuals 
could arise from homeostatic effects: an increased sleep 
need would advance bedtime or delay wake time, and a 
decreased sleep need would advance wake time or delay 
bedtime. 
 
The second property of sleep in the elderly is its 
fragmentation.  Lower circadian amplitude would result 
in greater difficulty in sleeping at night, and greater ease 
of napping.  Alternatively, homeostatic processes could 
play a role: lower homeostatic sleep drive would also 
result in sleep fragmentation.  Greater susceptibility to 
environmental disturbance would have the same effect. 
 
By imagining age-related changes to both homeostatic 
and circadian mechanisms, it is possible to rationalize 
separately the earlier phase and the increased 
fragmentation of sleep that occur in elderly individuals 
[14].  However, explaining both effects with the same 
hypothesis is not simple.  One idea is that dampened 
circadian amplitude results in sleep fragmentation at 
night and daytime napping [15].  These changed sleep 
patterns would be reinforced by changes in the timing 
of light, which shifts phase earlier [16].  A second 
hypothesis suggests that reduction in homeostatic sleep 
drive could accomplish the same effect, fragmenting 
sleep directly and shifting phase via altered light choice 
[17].   These models are shown schematically in Figure 
1. 
 
OBSERVATIONS 
 
Although numerous behavioral studies have been 
conducted over the past decade to address these 
hypotheses, no clear picture has emerged.  Evidence to 
support and contradict each of them exists: 
 
Circadian period length:  Although a shortened 
behavioral period length as a consequence of age has 
been observed in some animals [18], careful studies of 
older humans under conditions of “forced desynchrony” 
show no hint of such changes.  In these experiments, 
subjects were kept under photoperiods so long (28h) 
that their endogenous circadian clocks could not adjust. 
Circadian period was determined under these “free-
running” conditions by measuring rhythmic expression 
of the hormone melatonin, or diurnal variation in body 
temperature [14].  Pagani et al. showed shortening of 
period in human fibroblasts, but only in the presence of 
blood serum from older individuals [5]. 
 
Phase shifting:  In humans, phase shifts in response to 
very bright light do not differ significantly between 
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 older and younger subjects, at least for phase delays 
[19, 20].  Phase advances were attenuated in some 
studies [19, 21], but this data would not explain earlier 
phases in older individuals.  Moreover, these studies 
used very bright light to obtain maximum phase-
shifting.  Whether these results can be generalized to 
dimmer light remains an open question, because 
considerable reduction in lens transmission occurs with 
age [22], and reduced phase delays in response to 
moderate light have been reported [23]. 
 
Circadian Amplitude: Changes in circadian amplitude 
are more difficult to measure.  Certainly, melatonin 
production has been shown in multiple studies to 
diminish with age [24], but it is not clear that this 
reflects a change in circadian amplitude per se:  size and 
calcification of the pineal gland that produces melatonin 
also diminish with age [25, 26].  Circadian rhythms of 
body temperature also decline with aging, but these are 
in part activity-determined [27]. 
 
Sleep fragmentation:  Changes in sleep patterns in the 
elderly have been well-documented, but ascribing them 
specifically to circadian or homeostatic changes are 
more difficult.  For example, a tendency toward 
shallow, fragmented sleep could be explained by a 
weakened circadian arousal signal at that time [15].  
Surprisingly, recent studies suggest that older adults 
have less daytime sleep propensity than younger ones 
[4].  At the same time, total sleep duration is reduced, 
and sleep fragmentation increases.  These results imply 
effects upon homeostatic control -- specifically, a 
reduction in sleep need has been documented in elderly 
individuals [28], accompanied by a reduction in sleep 
efficiency.  Partly contradicting this, the response to low 
sleep pressure in laboratory conditions is similar in 
younger and older individuals, suggesting an interplay 
between circadian and homeostatic effects [29]. 
 
UNCERTAIN CONCLUSIONS 
 
So far, little evidence exists to suggest that the period 
length of circadian behavior is changed in elderly 
individuals.  Moreover, although studies suggest that 
homeostatic sleep is affected in fundamental ways in 
older individuals, these observations are likely 
insufficient to explain the marked circadian changes 
observed.  In forced desynchrony studies that showed 
increased sleep fragmentation, investigators also 
observed an earlier sleep onset relative to the phase of 
the hormone melatonin [14].  Similarly, under constant 
routine studies under constant dim light, the phase of 
gene expression in blood cells is still advanced [30].  
Since the light cycle in these studies was not 
systematically affecting the circadian clock, these 
results imply that changes in circadian phase are 
unlikely to be explained via strictly homeostatic 
mechanisms affecting light choice.  Of course, 
homeostatic sleep mechanisms might also have more 
direct effects upon the circadian oscillator [31, 32], but 
these mechanisms remain to be explored. 
 
Against this context, Pagani et al. postulated that 
hormonal changes in elderly individuals could alter 
circadian period in peripheral cells.  In an environment 
entrained by the solar day, such changes would easily 
translate into changes in phase.  These observations do 
not, however, explain age-related changes in circadian 
amplitude or in homeostatic sleep.  Moreover, such an 
explanation presumes that nuclei in the brain directing 
sleep timing are affected by this hormone, but that the 
master clock in the suprachiasmatic nuclei is not (since 
no corresponding changes in human behavioral period 
have been documented).  Thus, it is at best a partial 
explanation.  What makes it attractive is that hormonal 
changes offer the likely possibility of pharmacological 
remedy. 
 
FUTURE DIRECTIONS 
 
This Perspective has confined itself (mostly) to 
discussion of specific theories about the interplay 
among aging, sleep, and the circadian clock.  Already, 
mutation and gene profiling studies have implicated 
specific clock genes in the ageing process [1, 33, 34].  
In fact, however, the best evidence for any model comes 
in the form of detailed mechanisms, and here is 
undoubtedly where future research will be directed.  For 
example, in rodent models, aging is correlated with 
losses of specific classes of neurons (orexin and CRH) 
that could affect sleep architecture [35].  Experiments to 
address whether these changes are necessary and 
sufficient to explain fragmented sleep -- and whether 
similar changes are observed in the aged human brain 
that correlate with sleep disturbance – will reinforce 
homeostatic models.  Similarly, it is well-known that 
human aging is accompanied by large alterations in 
hormone balance, both in the hypothalamic-pituitary-
adrenal axis and elsewhere [36].  If Pagani et al. wish to 
suggest that a hormone is in part responsible for age-
related circadian dysfunction, then the best evidence in 
their favor would be identification of the suspected 
factor and characterization of its effects. 
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Introduction
With the increasing average lifespan of humans, Alzheimer’s 
disease (AD) is the most common neurodegenerative 
disorder among elderly individuals. It accounts for up to 
80% of all dementia cases and ranks as the fourth leading 
cause of death amongst those above 65 years of age [1]. 
Although the hallmark lesions of the disease were already 
described by Alois Alzheimer in 1906 - amyloid-β (Aβ)-
containing plaques and microtubule-associated protein 
tau-containing neuroﬁ brillary tangles (NFTs) - the 
underlying molecular mechanisms that cause the forma-
tion of these end-stage lesions are not known [2]. 
Moreover, as only a small fraction of AD is caused by 
autosomal dominant mutations, this comes down to a 
question of what is causing the prevalent sporadic cases 
in the ﬁ rst place. A growing body of evidence supports 
mitochondrial dysfunction as a prominent and early, 
chronic oxidative stress-associated event that contributes 
to synaptic abnormalities and, ultimately, selective neur-
onal degeneration in AD [3-9]. Is oxidative stress 
accelerating the NFT and Aβ pathologies, are these 
lesions causing oxidative stress themselves, or are there 
other mechanisms involved? Within the past few years, 
several cell culture models as well as single, double and, 
more recently, triple transgenic mouse models have been 
developed that reproduce diverse aspects of AD. # ese 
models help in understanding the pathogenic mecha-
nisms that lead to mitochondrial failure in AD, and in 
particular the interplay of AD-related cellular modiﬁ -
cations within this process [10].
Mitochondria: paradoxical organelles
Mitochondria play a pivotal role in cell survival and death 
by regulating both energy metabolism and apoptotic 
pathways (Figure 1); they contribute to many cellular 
functions, including intracellular calcium homeostasis, 
the alteration of the cellular reduction-oxidation poten-
tial, cell cycle regulation and synaptic plasticity [11]. # ey 
are the ‘powerhouses of cells’, providing energy via ATP 
generation, which is accomplished through oxidative 
phosphorylation from nutritional sources [12]. Neurons 
have particularly high numbers of mitochondria, and 
they are especially enriched in synapses. Due to their 
limited glycolytic capacity, neurons are highly dependent 
on mitochondrial function for energy production [13]. 
However, when mitochondria fulﬁ l their physiological 
function, it is as if Pandora’s box has been opened, as this 
vital organelle contains potentially harmful proteins and 
biochemical reaction centres: mitochondria are the major 
producers of reactive oxygen species (ROS) and at the 
same time targets of ROS toxicity. # ese include 
Abstract
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mito chondrial DNA, lipids of the mitochondrial 
membrane, and mitochondrial proteins. Dysregulation of 
mito chon drial function because of these insults leads to 
synaptic stress, disruption of synaptic transmission, 
apoptosis and, ultimately, neurodegeneration [14,15]. 
# us, it is important to understand the mechanisms of 
mitochondrial stress related to the pathogenesis of AD 
and to exploit this insight for developing therapeutic 
strategies for AD.
Evidence of mitochondrial dysfunction in 
post-mortem AD brain and peripheral cells
Mitochondrial dysfunction has been proposed as an 
underlying mechanism in the early stages of AD since 
Figure 1. Amyloid-β-related mitochondrial impairment. Mitochondria were found to be the target for amyloid-β (Aβ), which interacts 
with several proteins, leading to mitochondrial dysfunction. Indeed, Aβ was found in the outer mitochondrial membrane (OMM) and inner 
mitochondrial membrane (IMM) as well as in the matrix. The interaction of Aβ with the OMM a+ ects the transport of nuclear-encoded 
mitochondrial proteins, such as subunits of the electron transport chain complex IV, into the organelle via the translocase of the outer membrane 
(TOM) import machinery. Moreover, Aβ disturbs the activity of several enzymes, such as pyruvate dehydrogenase (PDH) and α-ketoglutarate 
dehydrogenase (αKGDH), decreasing NADH reduction, and the electron transport chain enzyme complex IV, reducing the amount of hydrogen that 
is translocated from the matrix to the intermembrane space (IMS), thus impairing the mitochondrial membrane potential (MMP). Taken together, 
these events cause abnormal mitochondrial electron activities, leading to decreased complex V activity and so to a drop in ATP levels, in addition 
to increasing reactive oxygen species (ROS) generation. Moreover, ROS induce peroxidation of several mitochondrial macromolecules, such as 
mitochondrial DNA (mtDNA) and mitochondrial lipids, contributing to mitochondrial impairment in the mitochondrial matrix. The complex of 
Aβ bound to binding alcohol dehydrogenase (ABAD) impairs the binding of NAD+ to ABAD, changes mitochondrial membrane permeability 
and reduces activities of respiratory enzymes, inducing further ROS production and leading to mitochondrial failure. Aβ binding also activates 
Fis1 (# ssion protein) and promotes increased mitochondrial fragmentation; this increased mitochondrial fragmentation produces defective 
mitochondria that ultimately damage neurons. Furthermore, Aβ binding to cyclophilin D (CypD) enhances the protein translocation to the inner 
membrane, favouring the opening of the mitochondrial permeability transition pore, formed by the adenine nucleotide translocator (ANT) and 
voltage-dependent anion channels (VDACs). Cyt C, cytochrome C; DLP1, dynamin-like protein 1; PDH, pyruvate dehydrogenase; ProAp, pro-
apoptotic factors; SOD, superoxide dismutase; TCA, tricarboxylic acid; TIM, translocase of the inner membrane.
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energy deﬁ ciency is a fundamental characteristic of the 
AD brain [16,17] as well as of peripheral cells derived 
from AD patients [18]. # e similar ﬁ ndings in peripheral 
tissue highlight the potential of using surrogate tissue in 
the diagnosis of AD (Figure 2).
Brain imaging studies have demonstrated defects in 
glucose use in living AD patients, an abnormality that 
may occur well before the onset of clinical symptoms 
[17]. Furthermore, several lines of evidence suggest that 
mitochondria intervene in the mechanism by which Aβ, 
which is derived from amyloid precursor protein (APP), 
triggers synaptic failure and neuro degeneration. Crucial 
to this ﬁ nding was the notion that both Aβ and the full 
length protein, APP, accumulate within mitochondria in 
the brains of AD patients [6,19-21].
Furthermore, morphometric analyses revealed that 
mito chondria display structural abnormalities, as illus-
trated by the accumulation of mitochondrial DNA and 
proteins in the cytoplasm and vacuoles; this accelerates 
mitochondrial degradation and thereby leads to a 
signiﬁ cant decrease in mitochondrial numbers in AD 
[22]. # e mitochondrial accumulation of APP and Aβ in 
brain tissues causes both altered activities in key mito-
chon drial enzymes, including cytochrome c oxidase 
(COX, complex IV), pyruvate dehydrogenase (PDH) and 
α-ketoglutarate dehydrogenase complex (αKGDH), and 
import of nuclear-encoded proteins [3,18,21,23]. # e 
activity of αKGDH, but not of PDH, has been found to be 
reduced in cultured skin ﬁ broblasts from sporadic AD 
patients and in a subset of patients with presenilin-1 
mutations. Sorbi and colleagues [24] observed a reduction 
in PHD, ATP-citrate lyase and acetoacetyl-CoA thiolase 
in post-mortem brain tissues from AD-aﬀ ected subjects 
and correlated the decrease of these enzymes to the 
decreased production of acetyl-coenzyme A and 
cholinergic defects that are observed in AD.
# e impairment of mitochondrial oxidative phos phory-
lation in the AD brain was found to be proportional to 
clinical disability [3]. # e most consistent defect in mito-
chondrial electron transport enzymes in AD is a deﬁ ci-
ency in COX, a ﬁ nding reported in AD post-mortem 
brain as well as in platelets and ﬁ broblasts from AD 
patients [25,26]. Dysfunction of COX increases ROS 
produc tion, reduces energy stores, and disturbs energy 
metabolism [27]. Altered levels of antioxidant enzymes, 
such as catalase, copper/zinc superoxide dismutase (Cu/
Zn-SOD) and manganese superoxide dismutase (Mn-
SOD) have been found in AD brain, supporting increased 
oxidative stress as a pathomechanism in AD [28].
Laser-capture microdissection has been applied to 
investigate distinct brain areas as some undergo neuro-
degeneration whereas others do not: the analysis of the 
expression of 80 metabolically relevant nuclear-encoded 
electron transport chain genes from non-NFT-bearing 
AD neurons revealed that 60 to 70% of these were 
signiﬁ cantly lower in metabolically aﬀ ected areas such as 
the posterior cingulate cortex, the middle temporal 
gyrus, and the hippocampal CA1 region [29]. Post-mortem 
tissue also provides strong evidence for increased levels 
of cellular oxidative stress in vulnerable regions of AD 
brains compared to aged controls [30]. Increased protein 
oxidation, protein nitration, and lipid peroxidation were 
Figure 2. Mitochondrial impairment in the brain and peripheral cells of Alzheimer’s disease patients. AD, Alzheimer’s disease; ETC, electron 
transport chain; ROS, reactive oxygen species; TCA, tricarboxylic acid.
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detected in brain areas with overt NFTs and amyloid 
plaques [31].
More recently, abnormal mitochondrial dynamics has 
been identiﬁ ed in ﬁ broblasts from sporadic and familial 
AD cases [32], a distortion probably mediated by altered 
expression of dynamin-like protein 1 (DLP1), a regulator 
of mitochondrial ﬁ ssion and distribution, due to elevated 
oxidative and/or Aβ-induced stress. Moreover, deregu-
lated mitochondrial dynamics might be due to enhanced 
nitrosative stress generated by Aβ, such as S-nitrosylation 
of DLP1 in AD brain [33]. # is modiﬁ cation can disturb 
the balance between ﬁ ssion and fusion of mitochondria 
in favour of mitochondrial ﬁ ssion followed by mito chon-
drial depletion from axons and dendrites and, subse-
quently, synaptic loss.
Altogether, these data indicate that mitochondrial 
dysfunction is a highly relevant event in AD patho-
physiology. Post-mortem studies in AD brain allow the 
identiﬁ cation of long-term synergistic in vivo eﬀ ects of 
tau and Aβ in human because, in the majority of AD 
cases, both pathologies persist in parallel for many years.
Mitochondrial dysfunction in cellular and 
transgenic mouse AD models
Understanding the molecular pathways by which the 
various pathological alterations including Aβ and tau 
compromise neuronal integrity and lead to clinical 
symptoms has been a long-standing goal of AD research. 
# e successful development of cell and mouse models 
that mimic diverse aspects of the disease process have 
facilitated this eﬀ ort and assisted in understanding of the 
interplay of Aβ and tau on bioenergetics processes in vivo 
[10] (Figure 3).
Mitochondria and Aβ
Aβ may exert its toxicity via a plethora of pathways and 
thereby induce synaptic and neuronal degeneration [2].
Using neuronal PC12 cells, we found that expression of 
one known APP gene mutation, the ‘Swedish APP 
(APPSw)’ double mutation (KM670/671NL), leads to an 
enhanced vulnerability of these cells to oxidative stress 
and mitochondrial dysfunction, mediated by diﬀ erent 
caspases and the stress-activated protein kinase pathway 
[34-36] (Figure 3). Of note, we are able to study the 
eﬀ ects of Aβ in a dose- dependent manner as cells 
transfected with APPSw had ﬁ vefold higher Aβ levels than 
wild-type APP (APPwt) transfected cells, similar to the 
increase found in human carriers with the APPSw muta-
tion compared to sporadic AD cases. # e data suggest 
that the mitochondrial dysfunction induced by Aβ is 
probably mediated via enhanced nitric oxide production 
that reduces complex IV activity. # is reduction leads to 
a depletion of intracellular ATP levels, ﬁ nally initiating 
cell death [37]. When intracellular Aβ production is 
prevented by a γ-secretase inhibitor, this restores nitric 
oxide and ATP levels, indicating a direct involvement of 
Aβ in these mechanisms.
Mitochondria were found to be a target for APP 
toxicity as both the full-length protein and Aβ accumulate 
in the mitochondrial import channels, and both lead to 
mitochondrial dysfunction. Recently, APP has been 
demonstrated as a substrate of the mitochondrial γ-
secretase in cultured SH-SY5Y human neuroblastoma 
cells [38]. Pavlov and colleagues [38] proposed that APP 
processing in mitochondria may lead to local Aβ pro-
duction, thereby contributing to mitochondrial dysfunc-
tion. Recently, our group investigated speciﬁ c eﬀ ects of 
Aβ on mitochondrial function under physiological 
conditions by analysing mitochondrial respiratory func-
tion and energy homeostasis in both control and APPwt-
expressing SH-SY5Y cells [8]. One possibility as to how 
chronic exposure to soluble Aβ may result in an impair-
ment of energy homeostasis is through decreased respira-
tory capacity of the mitochondrial respiratory chain, 
mainly of complex IV, which, in turn, may accelerate 
neuronal demise.
Eventually, APP, through Aβ production, causes an 
imbalance of mitochondrial ﬁ ssion/fusion that results in 
mitochondrial fragmentation and abnormal distribution, 
which contributes to mitochondrial and neuronal dys-
func tion [39].
An interesting observation was made when the toxic 
eﬀ ects of Aβ were compared with human amylin (HA), a 
protein aggregating in the pancreas of type 2 diabetic 
patients [40]. Both agents share amyloidogenic properties 
and are toxic to primary neuronal cultures, whereas the 
non-amyloidogenic rat amylin is not [41]. In a next step, 
HA and Aβ toxicity to SH-SY5Y neuroblastoma cells was 
assessed by iTRAQ quantitative proteomics [42]. # is 
revealed the surprising observation that identical proteins 
are deregulated by HA and Aβ, but not rat amylin, and a 
quarter of these were mitochondrial, supporting the 
notion that mitochondrial dysfunction is a common 
target in these two amyloidoses. Functional validation 
revealed that Aβ and HA both exert a shared toxicity, at 
least in part, via deregulation of identical mitochondrial 
proteins and impairment of complex IV activity [42].
AD is believed to be a disease of the synapses, charac-
terized by massive synaptic and, eventually, neuronal 
loss, and these features have been detected in AD 
transgenic mouse models (Figure 3). A decrease of the 
mitochondrially localized chaperone hsp70, which 
stabilizes proteins during their import into mitochondria, 
has been observed in synaptosomal fractions derived 
from the APPSw transgenic strain Tg2576, pointing to a 
mito chondrial stress response [43]. Signiﬁ cant diﬀ er-
ences were revealed in the protein subunit composition 
of respiratory chain complexes I and III. Moreover, 
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endo genous Aβ was found to be associated with brain 
mitochondria in these mice. Cu2+ ions have been shown 
to render Aβ more toxic, possibly in its dimeric con-
formation, as a potent inhibitor of COX, thereby contri-
but ing to neurodegeneration in AD [44]. In APPSw trans-
genic mice, reduced glucose metabolism was observed 
after [14C]-2-deoxyglucose infusion as well as impaired 
Cu/Zn SOD activity, both of which contribute to 
oxidative damage. In another transgenic mouse model, 
APPS/L, which combines the Swedish (K670M/N671L) 
with the London (V717I) mutation in the human APP 
gene, an early energy dysfunction was found as shown by 
a decreased mitochondrial membrane potential as well as 
decreased ATP levels at 3 months of age, when Aβ levels 
are elevated but plaques are not yet present [5,14,37]. A 
stronger reduction in mitochondrial membrane potential 
and in ATP levels was found in double transgenic APP/
PS1 (APPS/L/PS1 M141L) mice, which generate higher 
levels of Aβ compared to their single transgenic litter-
mates (APPS/L), and exhibit Aβ plaques already at an age 
of 3 months [4]. Together, this implies that an Aβ-
dependent mitochondrial dysfunction starts at a very 
young age and accelerates substantially with increasing 
age, as does the Aβ plaque load [4]. Consistent with this 
observation, APP/PS2 (APPSw/PS2 N141I) double trans-
genic mice display age-related cognitive deﬁ cits asso-
ciated with discrete brain Aβ deposition and inﬂ am-
mation [45]. Furthermore, an Aβ insult in APPS/L mice 
caused early deﬁ cits in synaptic mitochondria, as shown 
by increased mitochondrial permeability transition, a 
decline in both respiratory function and activity of COX, 
and increased mitochondrial oxidative stress [46].
Of note, age-dependent impairment of oxygen con-
sump tion, such as a decrease of state 3 and of uncoupled 
respiration, was observed in several APP transgenic 
mouse models compared to aged-matched controls 
[5,14,43,47]. # is indicates that mitochondrial deregula-
tion is a common feature in Aβ-generating mice and 
independent of the mouse model used.
# ere is broad experimental proof that Aβ is indeed 
present in mitochondria. Aβ binds speciﬁ cally to the 
mitochondrial Aβ-binding alcohol dehydrogenase (ABAD) 
[6], a mitochondrial matrix protein that is up-regulated 
in the temporal lobe of AD patients as well as in APP 
Figure 3. Mitochondrial impairment in Alzheimer’s disease cell culture and transgenic mice models. The successful development of 
Alzheimer’s disease (AD) cell culture models as well as single, double and triple transgenic mice models that mimic diverse aspects of the disease 
have been helpful in understanding the pathogenic mechanisms on bioenergetic processes in vivo, particularly the interplay of AD-related 
amyloid-β (Aβ) and tau proteins, leading to the mitochondrial failures underlying AD. APP, amyloid precursor protein; LTP, long-term potentiation; 
MMP, mitochondrial membrane potential; NO, nitric oxide; PDH, pyruvate dehydrogenase; ROS, reactive oxygen species.
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transgenic mice [48]. # e Aβ-ABAD interaction causes 
elevated ROS production, cell death, as well as spatial 
learning and memory deﬁ cits in 5-month-old APP/
ABAD double transgenic mice [49]. # e investigation of 
the crystal structure of ABAD-Aβ demonstrated that the 
formation of the complex prevents the binding of NAD+ 
to ABAD, thereby changing the mitochondrial membrane 
permeability and reducing the activities of respiratory 
enzymes, which then may lead to mitochondrial failure 
[6]. Aβ in mitochondria further interacts with cyclophilin 
D (CypD), an integral part of the mitochondrial permea-
bility transition pore that potentiates free radical produc-
tion, causes synaptic failure, and promotes opening of the 
pore leading to apoptosis [50]. It has been demonstrated 
previously that CypD is capable of forming complexes 
with Aβ within mitochondria of cortical neurons from 
APP mutant mice, increasing the translocation of CypD 
from the matrix to the inner membrane. Furthermore, in 
APP transgenic mice, the abrogation of CypD was 
capable of attenuating Aβ-mediated abnormal mitochon-
drial dysfunction, such as calcium-induced mitochondrial 
swelling, and it lowered mitochondrial calcium uptake 
capacity and impaired mitochondrial respiratory func-
tion. Aβ impaired calcium storage in mitochondria, alter-
ing neuronal function, as it is exported to the cytosol, 
together with other apoptotic factors (ProAp), such as 
cytochrome c (Figure 1). Finally, Anandatheerthavarada 
and Devi [51] showed that APP contains a mitochondrial 
targeting sequence and that an accumulation of APP in 
mitochondrial membranes leads to mitochondrial dys-
func tion in Tg2576 neurons. Taken together, these ﬁ nd-
ings are in line with the recently proposed hypothesis of 
an intracellular Aβ toxicity cascade, which suggests that 
the toxic Aβ species that cause molecular and bio-
chemical abnormalities are in fact intracellular oligo-
meric aggregates rather than the extracellular, insoluble 
plaques [6,20].
Mitochondria and tau protein
How does tau interfere with mitochondrial function? In 
its hyperphosphorylated form, tau, which forms the 
second hallmark lesion in AD, the NFTs, has been shown 
to block mitochondrial transport, which results in energy 
deprivation and oxidative stress at the synapse and, 
hence, neurodegeneration [52-55]. In transgenic pR5 
mice that overexpress human P301L mutant tau [56], the 
biochemical consequences of tau pathology have been 
intensively investigated using proteomics followed by 
functional validation [57,58]. A mass-spectrometric 
analy sis of the brain proteins from these mice revealed 
mainly a deregulation of mitochondrial respiratory chain 
complex components (including complex V), antioxidant 
enzymes, and synaptic proteins (Figure 4). # e functional 
analysis demonstrated a mitochondrial dysfunction in 
the mice, together with reduced NADH-ubiquinone 
oxido reductase (complex I) activity and, with age, 
impaired mitochondrial respiration and ATP synthesis. 
Mitochondrial dysfunction was associated with higher 
levels of ROS in aged transgenic mice. Increased tau 
pathology as in aged homozygous pR5 mice revealed 
modiﬁ ed lipid peroxidation levels and the upregulation of 
antioxidant enzymes in response to oxidative stress [57]. 
# us, this evidence demonstrated for the ﬁ rst time that 
not only Aβ but also tau pathology can lead to metabolic 
impairment and oxidative stress as in AD.
Consistent with observations of a cytosolic accumu la-
tion of the α-chain of ATP synthase observed at early 
stages of neuroﬁ brillary degeneration in AD, one mecha-
nism proposed is that tau accumulation could have direct 
consequences on mitochondrial activity through the 
cytosolic accumulation of the α-chain of ATP synthase. 
Reciprocally, hyperphosphorylation of tau may be 
directly attributable to mitochondrial oxidative stress in a 
mouse model lacking the mitochondrial detoxifying 
enzyme superoxide dismutase 2 (Sod2−/−), consistent with 
a synergistic interaction of APP and mitochondrial 
oxidative stress in contributing to an AD-like neocortical 
pathology [59]. Furthermore, chronic respiratory chain 
dysfunction through inhibition of complex I led, besides 
a concentration-dependent decrease in ATP levels, to a 
redistribution of tau from the axon to the cell body, the 
retrograde transport of mitochondria and, ﬁ nally, cell 
death [60]. Together, these ﬁ ndings support the notion 
that tau pathology involves a mitochondrial and oxidative 
stress disorder possibly distinct from that caused by Aβ.
Pathogenic convergence of Aβ and tau on mitochondria
Although Aβ and tau pathologies are both known hall-
marks in AD, the underlying mechanisms of the interplay 
between plaques and NFTs (or Aβ and tau) have 
remained unresolved. However, a close relationship 
between mitochondrial impairment and Aβ on the one 
hand and tau on the other has been established. How do 
both features in AD relate to each other and might the 
two molecules synergistically aﬀ ect mitochondrial inte-
grity? Several studies suggest that Aβ aggregates and 
hyper phosphorylated tau may block mitochondrial 
carriage to the synapse, leading to energy defects and 
neuro degeneration [61]. Moreover, transport of APP into 
axons and dendrites may be inhibited by enhanced tau 
levels, causing impaired axonal transport, which suggests 
a link between tau and APP [52,55]. Remarkably, Aβ 
injections amplify a pre-existing tau pathology in several 
transgenic mouse models [56,62,63], whereas lack of tau 
abrogates Aβ toxicity [54,64]. Our ﬁ ndings indicate that 
mitochondria in tau transgenic pR5 mice display en-
hanced vulnerability towards Aβ insult in vitro [57,65], 
suggesting a synergistic action of tau and Aβ pathologies 
Eckert et al. Alzheimer’s Research & Therapy 2011, 3:15 
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on this organelle (Figure 3). # e Aβ insult caused a 
greater reduction of mitochondrial membrane potential 
in cerebral cells from pR5 mice [57]. Furthermore, 
incubation of isolated mitochondria from pR5 mice with 
either oligomeric or ﬁ brillar Aβ preparations resulted in 
impairment of the mitochondrial membrane potential 
and of respiration. Interestingly, aging particularly 
increased the sensitivity of mitochondria to oligomeric 
Aβ insult compared to that of ﬁ brillar Aβ. # is suggests 
that while both oligomeric and ﬁ brillar Aβ are toxic, they 
exert diﬀ erent degrees of toxicity [65]. In a related study, 
Crouch and colleagues [66] demonstrated that increasing 
the bioavailability of intracellular copper can restore 
cognitive function by inhibiting the accumulation of 
neurotoxic Aβ trimers and phosphorylated tau in APPSw/
PS1 transgenic mice. In yet another study, it was shown 
that exposure to Aβ induces tau hyperphos phory lation 
by promoting glycogen synthase kinase (GSK)3β activity. 
# is demonstrates an intimate relationship between Aβ 
accumulation and abnormal tau phosphory lation in 
causing the cognitive deﬁ cits that characterize AD, and 
highlights GSK3β activity as an important intermediate 
[67]. In contrast, overexpression of the longest form of 
human wild-type tau (tau441) in mouse neuroblastoma 
(N2A) showed an anti-apoptotic protec tive function of 
tau phosphorylation, which likely inhibited competitively 
phosphorylation of β-catenin by GSK-3β, facilitating the 
function of β-catenin. # us, overexpression of tau seems 
to attenuate Aβ-mediated cell death via suppression of 
the mitochondria-caspase-3 pathway [68,69]. Taken 
together, these studies illustrate a complex interplay 
between the two key proteins in AD.
In a step further, triple transgenic mouse models have 
recently been established that combine Aβ and tau 
pathologies, and the contributions of both AD-related 
proteins to the mitochondrial respiratory machinery and 
energy homeostasis have been investigated in vivo 
(Figure 3). Indeed, our group demonstrated a mitochon-
drial dysfunction in a novel triple transgenic mouse 
model (pR5/APPSw/PS2 N141I) - tripleAD mice - using 
proteomics followed by functional validation [9]. Notably, 
deregulation of complex I was found to be tau-dependent, 
while deregulation of complex IV was Aβ-dependent, at 
both the protein and activity level (Figure  5). Whereas 
down-regulation of several subunits of complex I was 
observed in tripleAD mice compared to both pR5 and 
Figure 4. Di# erential expression of ascertained subunits of the electron transport chain. A quantitative mass-tag labelling proteomic 
technique, iTRAQ, and mass-spectrometric analysis of the brain proteins from single, double and triple transgenic mouse models revealed massive 
deregulation of 24 components mainly related to the mitochondrial respiratory chain complex (including complex V), antioxidant enzymes, and 
synaptic proteins. Functional analysis validated the proteomic approach by con# rming the strongest defects of the respiratory capacity mainly 
at complexes I, IV and V in transgenic mice, at both the protein and activity level. Signi# cantly changed expression of nuclear- encoded (Ndufs2, 
Ndufs8, Ndufb10, IV, Va, Vb, VIIa and D) and mitochondrial-encoded (COX II) complex subunits are highlighted in red. Complex I subunits: Ndufs2, 
NADH dehydrogenase (ubiquinone) Fe-S protein 2; Ndufs8, NADH dehydrogenase (ubiquinone) Fe-S protein 8; Ndufb10, NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex 10. Complex IV subunits: II, Cytochrome c oxidase subunit 2; IV, Cytochorme c oxidase subunit IV isoform 1; Va, 
Cytochrome c oxidase polypeptide Va; Vb, Cytochrome c oxidase polypeptide Va; VIIa, Cytochrome c oxidase polypeptide VIIa- liver/heart. Complex 
V subunits: D, ATP synthase D chain. IMM, inner mitochondrial membrane; IMS, intermembrane space.
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APPSw/PS2 mice, deregulation of several subunits of 
complex V was seen in tripleAD mice compared to pR5 
mice but not compared to APPSw/PS2 mice (Figure 4). 
# e convergent eﬀ ects of Aβ and tau led already at the 
age of 8 months to depolarized mitochondrial membrane 
poten tial in tripleAD mice. Additionally, we found that 
age-related oxidative stress at 12 months of age may 
exaggerate the disturbances in the respiratory system and 
synthesis of ATP and, in turn, take part in the vicious 
cycle that ﬁ nally leads to cell death.
Together, our studies highlight the key role of mito-
chon dria in AD pathogenesis, and the close interrelation-
ship of this organelle and the two main pathological 
hallmarks of this disease. Our data complement those 
obtained in another triple transgenic mouse model, 3xTg-
AD (P301Ltau/APPSw/PS1 M146L) [70]. Mitochondrial 
dysfunction was evidenced by age-related decreased 
activity of regulatory enzymes of the oxidative phos-
phory lation system, and of PDH and COX in 3xTg-AD 
mice aged from 3 to 12 months [71]. # ese mice also 
exhibited increased oxidative stress and lipid peroxida-
tion. Most of the eﬀ ects on mitochondria were seen at 
the age of 9 months, whereas mitochondrial respiration 
was signiﬁ cantly decreased at 12 months of age. Impor-
tantly, mitochondrial bioenergetics deﬁ cits were found to 
precede the development of AD pathology in the 
3xTg-AD mice. More recently, Hyun and colleagues [72] 
demonstrated that the plasma membrane redox system 
(PMRS) is impaired in the 3xTg-AD mice and that the 
activities of PMRS enzymes may protect neurons against 
Aβ toxicity, suggesting enhancement of PMRS function 
as a novel approach for protecting neurons against 
oxidative damage in AD and related disorders. Collec-
tively, these recent data consolidate the idea that a 
synergistic eﬀ ect of tau and Aβ augments the pathological 
deterioration of mitochondria at an early stage of AD.
Conclusion
We discuss here the critical role of mitochondria and the 
close inter-relationship of this organelle with the two 
main pathological features in the pathogenic process 
underlying AD.
Mitochondrial impairment has been recognized as a 
prominent and early event in AD in terms of metabolic 
energy production associated with respiratory chain dys-
function and the regulation of levels of second messen-
gers such as ROS or Ca2+. # is is partially due to either 
accumulated damage to mitochondrial DNA or direct 
harmful eﬀ ects of oxidative stress and/or Aβ on mito-
chondrial components. Also, mitochondrial traﬃ  cking as 
well as mitochondrial fusion/ﬁ ssion are known to be 
altered in AD, compromising normal neurophysiology 
Figure 5. Impairment of the electron transport chain in Alzheimer’s disease. Complexes I (NADH:ubiquinone oxidoreductase) and II (succinate 
dehydrogenase, belongs to the tricarboxylic acid (TCA) cycle) receive electrons from NADH and FADH2, respectively. Electrons are then driven 
from complexes by the mobile carrier molecules coenzyme Q/ubiquinone (UQ) and cytochrome c (Cyt c) to the # nal acceptor, molecular oxygen 
(O
2
). Electron 6 ow is coupled to proton movement across the inner mitochondrial membrane (IMM) in complexes I, III and IV. The resulting proton 
gradient is harvested by complex V to generate ATP. In Alzheimer’s disease, abnormal mitochondrial electron activities have been observed, 
predominantly in complexes I and IV, leading to impaired mitochondrial membrane potential, decreased production of ATP (complex V) and 
enhanced reactive oxygen species (ROS) levels. Interestingly, deregulation of complex I is mainly tau-dependent, while deregulation of complex IV 
is amyloid-β (Aβ)-dependent, at both the protein and activity level. IMS, intermembrane space.
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and a healthy cellular mitochondrial pool, which even-
tually leads to apoptosis. Speciﬁ cally, the mitochondrial 
impairment integrates the close interplay of the two 
common hallmarks of AD, plaques and NFTs, or Aβ and 
tau, which act independently as well as synergistically on 
this vital organelle. With regards to the involvement of 
AD-related proteins in pathogenesis, a vicious cycle as 
well as several vicious circles within the cycle, each 
accelerating the other, can be drawn, emphasizing the 
potency of the synergistic destruction in mitochondria.
Finally, the key role of mitochondrial dysfunction in the 
early pathogenic pathways by which Aβ leads to neuronal 
dysfunction in AD is particularly challenging with 
respect to establishing therapeutic treatments. Besides 
the modulation and/or removal of both Aβ and tau 
pathology, strategies involving eﬀ orts to protect cells at 
the mitochondrial level by stabilizing or restoring mito-
chondrial function or by interfering with energy 
metabolism appear to be promising; these eﬀ orts also 
emphasize the importance of mitochondria in the 
pathogenesis of AD. Cellular models for AD as well as 
transgenic mice, and particularly triple transgenic models 
that combine both pathologies, are valuable tools in 
monitoring therapeutic interventions at the mitochon-
drial level. Eventually, this may lead to therapies that 
prevent the progression of Aβ deposits and tau hyper-
phosphorylation at an early stage of disease.
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Abstract
Significance: Alzheimer’s disease (AD) is an age-related progressive neurodegenerative disorder mainly af-
fecting elderly individuals. The pathology of AD is characterized by amyloid plaques (aggregates of amyloid-b
[Ab]) and neurofibrillary tangles (aggregates of tau), but the mechanisms underlying this dysfunction are still
partially unclear. Recent Advances: A growing body of evidence supports mitochondrial dysfunction as a
prominent and early, chronic oxidative stress-associated event that contributes to synaptic abnormalities and,
ultimately, selective neuronal degeneration in AD. Critical Issues: In this review, we discuss on the one hand
whether mitochondrial decline observed in brain aging is a determinant event in the onset of AD and on the
other hand the close interrelationship of this organelle with Ab and tau in the pathogenic process underlying
AD. Moreover, we summarize evidence from aging and Alzheimer models showing that the harmful trio ‘‘aging,
Ab, and tau protein’’ triggers mitochondrial dysfunction through a number of pathways, such as impairment of
oxidative phosphorylation (OXPHOS), elevation of reactive oxygen species production, and interaction with
mitochondrial proteins, contributing to the development and progression of the disease. Future Directions: The
aging process may weaken the mitochondrial OXPHOS system in a more general way over many years pro-
viding a basis for the specific and destructive effects of Ab and tau. Establishing strategies involving efforts to
protect cells at the mitochondrial level by stabilizing or restoring mitochondrial function and energy homeostasis
appears to be challenging, but very promising route on the horizon. Antioxid. Redox Signal. 00, 000–000.
Introduction
Aging is an inevitable biological process that results in aprogressive structural and functional decline, as well as
biochemical alterations that altogether lead to reduced ability
to adapt to environmental changes. Although aging is almost
universally conserved among all organisms, the molecular
mechanisms underlying this phenomenon still remain un-
clear. There are several theories of aging, in which free radical
(oxidative stress), DNA, or protein modifications are sug-
gested to play the major causative role (54, 72). A growing
body of evidence supports mitochondrial dysfunction as a
prominent and early, chronic oxidative stress-associated
event that contributes to synaptic abnormalities in aging and,
ultimately, increased susceptibility to age-related disorders
including Alzheimer’s disease (AD) (58). AD is the most
common neurodegenerative disorder among elderly indi-
viduals. It accounts for up to 80% of all dementia cases and
ranks as the fourth leading cause of death among those above
65 years of age. With the increasing average life span of hu-
mans, it is highly probable that the number of AD cases will
dangerously raise. The pathology of AD characterized by
abnormal formation of amyloid plaques (aggregates of amy-
loid-b [Ab]) and neurofibrillary tangles (NFT; aggregates
of tau) was shown to be accompanied by mitochondrial
dysfunction. However, the mechanisms underlying this dys-
function are poorly understood. There remain several open
questions: Is age-related oxidative stress accelerating the NFT
andAb pathologies? Are these lesions causing oxidative stress
themselves? Or are there other mechanisms involved? Within
the past years, several mouse models have been developed
that reproduce the aging process and diverse aspects of AD.
These models help in understanding the age-related patho-
genic mechanisms that lead to mitochondrial failure in AD,
and in particular the interplay of AD-related cellular modifi-
cations within this process (17, 18).
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Mitochondrial Aging—the Beginning of the End in AD?
Mitochondria play a pivotal role in cell survival and death
by regulating both energy metabolism and apoptotic path-
ways; they contribute to many cellular functions, including
intracellular calcium homeostasis, the alteration of the cellular
reduction-oxidation (redox) potential, cell cycle regulation,
and synaptic plasticity (47). They are the ‘‘powerhouses of
cells,’’ providing energy from nutritional sources via ATP
generation, which is accomplished through oxidative phos-
phorylation (OXPHOS) (65). However, when mitochondria
fulfill their physiological function, it is as if Pandora’s box has
been opened, as this vital organelle contains potentially
harmful proteins and biochemical reaction centers; mito-
chondria are the major producers of reactive oxygen species
(ROS) at the same time being susceptible targets of ROS tox-
icity. Unstable ROS are capable of damaging many types of
mitochondrial components; this includes oxidative deterio-
ration of mitochondrial DNA (mtDNA), lipids of the mito-
chondrial membrane, and mitochondrial proteins, and it is
thought that this damage that may accumulate over time from
ROS generated from aerobic respiration may play a signifi-
cant role in aging (Fig. 1). Moreover, it was previously dem-
onstrated that nitrosative stress evoked by increased nitric
oxide synthesis also leads to protein oxidation as well as mi-
tochondrial and DNA damage, which are common mecha-
nisms occurred in elderly (13, 34, 70).
Although most mitochondrial proteins are encoded by the
nuclear genome, the mitochondrial genome encodes proteins
required for 13 polypeptide complexes of the respiratory
chain involved in ATP synthesis. Given that mtDNA exists in
the inner matrix and this is in close proximity to the inner
membrane where electrons can form unstable compounds,
mtDNA, unlike nuclear DNA (nDNA), is not protected by
histones (4) making it more vulnerable to oxidative stress and
its mutation rate is about 10-fold higher than that of nDNA,
especially in tissues with a high ATP demand like the brain
(54). These mtDNA mutations occur in genes encoding elec-
tron transport chain (ETC) subunits including NADH dehy-
drogenase, cytochrome c oxidase (COX), and ATP synthase
(83). Eventually, ROS-related mtDNAmutations can result in
the synthesis of mutant ETC proteins that, in turn, can lead to
the leakage of more electrons and increased ROS production.
This so-called ‘‘vicious cycle’’ is hypothesized to play a critical
role in the aging process according to the mitochondrial the-
ory of aging. In addition to age-associated increase in mtDNA
mutations, the amount of mtDNA also declines with age in
various human and rodent tissues (2, 68). Furthermore,
abundance of mtDNA correlates with the rate of mitochon-
drial ATP production (68), suggesting that age-related mito-
chondrial dysfunction in muscle is related to reducedmtDNA
abundance. However, age-associated change in mtDNA
abundance seems to be tissue specific, as several studies have
reported no change in mtDNA abundance with age in other
than muscular tissues in both man and mouse (20, 46).
How does the somatic mtDNA involved in aging pheno-
types contribute to AD development? As only a small fraction
of AD is caused by autosomal dominant mutations, this
comes down to the question of what is causing the prevalent
sporadic cases in the first place. Somatic mutations in mtDNA
could cause energy deficiency, increased oxidative stress, and
accumulation of Ab, which act in a vicious cycle reinforcing
mtDNA damage and oxidative stress (45). Indeed, defects in
mtDNA associated with decreased cytochrome oxidase
activity have been found in AD patients (9). Although a
similarly impaired mitochondrial function and subsequent
compensatory response have been observed in both non-
demented aged andAD subjects, no clear causativemutations
in the mtDNA have been correlated to AD; although some
variations have functional consequences, including changes
in enzymatic activity (40). Perhaps the main differences are
that, in AD brains, defects are more profound due to Ab and
tau accumulation, because of decreased compensatory re-
sponse machinery (Fig. 1).
Many investigators have developed models for studying
mitochondrial-related aging (36). Among them senescence-
acceleratedmice (SAM) strains are especially useful models to
understand the mechanisms of the age-related mitochondrial
decline. Behavioral studies showed that learning andmemory
deficits already started as early as 6 months and worsened
with aging in SAMP8 mice (accelerated senescence-prone 8)
(53, 77). Moreover, Omata and collaborators showed age-
related changes in cerebral energy production in the 2-month-
old SAMP8 followed by a decrease in mitochondrial function
compared with SAMR1 mice (accelerated senescence-resis-
tant 1) (51). Aging is not only connected with increased mi-
tochondrial ROS production due to ETC impairment but also
with a dysbalance of the protective antioxidant machinery
inside mitochondria. For instance, age-related changes in
levels of antioxidant enzymes, such as copper/zinc superox-
ide dismutase (Cu/Zn-SOD) andmanganese SOD (Mn-SOD),
have been found in liver and cortex of SAMP8 mice when
compared with age-matched SAMR1 mice, supporting in-
creased oxidative stress as a key mechanism involved in the
aging process (37). More recently, Yew and collaborators have
shown an impairment of mitochondrial functions including a
decrease of COX activity, mitochondrial ATP content, and
mitochondrial glutathione (GSH) level at a relatively early age
in SAMP8 mice compared with SAMR1 mice (67, 78). Fur-
thermore, the biochemical consequences of aging have been
investigated using proteomic analysis in the brain of SAMP8
and SAMR1 mice at presymptomatic (5-month old) and
symptomatic (15-month old) stages (84), revealing differen-
tially expressed proteins with age in both mouse strains,
such as Cu/Zn-SOD. Besides the progressive mitochondrial
decline and increased oxidative stress, tau hyperpho-
sphorylation was also observed at an early age in the brain of
SAMP8mice (1, 71). In addition, SAMP8mice showed an age-
related increase in mRNA and protein levels of amyloid-b
precursor protein (APP). The cleavage product Ab was sig-
nificantly increased at 9 months in SAMP8 and amyloid pla-
ques started to form at around 16 months of age (48, 73).
Altogether, these data indicate that mitochondrial dysfunc-
tion is a highly relevant event in the aging process, which is
also known as the primary risk factor for AD and other
prevalent neurodegenerative disorders.
Age-Related Ab and Tau Effects on Mitochondria in AD
AD is a progressive, neurodegenerative disorder, charac-
terized by an age-dependent loss of memory and an impair-
ment of multiple cognitive functions. From a genetic point of
view, AD can be classified into two different forms: rare fa-
milial forms (FAD) where the disease onset is at an age below
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60 years (< 1% of the total number of AD case) and the vast
majority of sporadic AD cases where onset occurs at an age
over 60 years. Genetic studies in FAD patients have identified
autosomal dominant mutations in three different genes, en-
coding theAPP (over 20 pathogenic mutations identified) and
the presenilins PS1 and PS2 (more than 130 mutations iden-
tified) (26). These mutations are directly linked to the in-
creased production of Ab from its precursor protein APP,
suggesting a direct and pathological role for Ab accumulation
in the development of AD.
Mitochondrial dysfunction has been proposed as an un-
derlying mechanism in the early stages of AD, since energy
deficiency is a fundamental characteristic feature of AD brains
(44) as well as of peripheral cells derived from AD patients
(22). Understanding the molecular pathways by which the
various pathological alterations including Ab and tau com-
promise neuronal integrity, leading to clinical symptoms, has
been a long-standing goal of AD research. The successful
development of mouse models that mimic diverse aspects of
the AD process has facilitated this effort and assisted in
FIG. 1. Aging, Ab, and tau: toxic consequence on mitochondria. The aging process may weaken the mitochondrial
OXPHOS (oxidative phosphorylation) system in a more general way by the accumulation of ROS-induced damage over
many years thereby sowing the seeds for specific and destructive effects of Ab and tau. ROS induce peroxidation of several
mitochondrial macromolecules, such as mtDNA and mitochondrial lipids, contributing to mitochondrial impairment in the
mitochondrial matrix. In AD, mitochondria were found to be a target of Ab toxicity, which may act directly or indirectly on
several proteins, leading to mitochondrial dysfunction. Indeed, Ab was found in the OMM and IMM as well as in the matrix.
The interaction of Ab with the OMM might affect the transport of nuclear-encoded mitochondrial proteins, such as subunits
of the ETC CIV, into the organelle via the TOM import machinery. Ab seems to be able to enter into the mitochondrial matrix
through TOM and TIM or could be derived from mitochondria-associated APP metabolism. The interaction of Ab with the
IMM would bring it into contact with respiratory chain complexes with the potential for myriad effects on cellular metab-
olism. It may be that Ab by these interactions affects the activity of several enzymes decreasing the ETC enzyme CIV,
reducing the amount of hydrogen that is translocated from the matrix to the intermembrane space, thus impairing the MMP.
The dysfunction of the ETC leads to a decreased CV activity and so to a lower ATP synthesis, in addition to an increased ROS
production. Interestingly, deregulation of CI is mainly tau dependent, while deregulation of CIV is Ab dependent, at both the
protein and activity level. Ab, amyloid-b; AD, Alzheimer’s disease; APP, amyloid precursor protein; CI, complex I; CII,
complex II; CIII, complex III; CIV, complex IV; CV, complex V, Cu/Zn-SOD, copper/zinc superoxide dismutase; cyt c,
cytochrome c; ETC, electron transport chain; IMM, inner mitochondrial membrane; MMP, mitochondrial membrane po-
tential; MnSOD, manganese superoxide dismutase; mtDNA, mitochondrial DNA; OMM, outer mitochondrial membrane;
ROS, reactive oxygen species; TIM, translocase of the inner membrane; TOM, translocase of the outer membrane. (To see this
illustration in color the reader is referred to the Web version of this article at www.liebertonline.com/ars).
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understanding of the age-dependent interplay of Ab and tau
on bioenergetics processes in vivo (Figs. 2 and 3).
Separate modes of Ab and tau toxicity on mitochondria
Mitochondria were found to be a target for APP toxicity as
both the full-length protein and Ab accumulate in the mito-
chondrial import channels, and both lead to mitochondrial
dysfunction (7, 42, 55, 56). Several evidences from cellular and
animal AD models indicate that Ab triggers mitochondrial
dysfunction through a number of pathways such as impair-
ment of OXPHOS, elevation of ROS production, interaction
with mitochondrial proteins, and alteration of mitochondrial
dynamics (52). Indeed, abnormal mitochondrial dynamics
have been identified in sporadic and familial AD cases (43, 76)
as well as in AD mouse model (6); a distortion probably me-
diated by altered expression of dynamin-like protein 1
(DLP1), a regulator of mitochondrial fission and distribution,
due to elevated oxidative and/or Ab-induced stress. This
modification can disturb the balance between fission and fu-
sion of mitochondria in favor of mitochondrial fission fol-
lowed by mitochondrial depletion from axons and dendrites
and, subsequently, synaptic loss.
Success in developing mouse models that mimic diverse
facets of the disease process has greatly facilitated the un-
derstanding of physiopathological mechanisms underlying
AD. Thus, in 1995, Games and collaborators established the
first APP mice model (called PDAPP) bearing the human
‘‘Indiana’’ mutation of the APP gene (V171F). They observed
the accumulation of Ab in the brain and subsequent amyloid
plaque formation as well as astrocytosis and neuritic dystro-
phy (21). Interestingly, in this model cognitive deficits, such as
spatial learning impairment, occur before the formation of Ab
plaques and increase with age (8). This phenomenon was also
observed in Tg2576 transgenic mice bearing the human
Swedishmutation of theAPP gene (K670N,M671L). In fact, in
most of the APP mouse models, the cognitive impairment
begins concomitantlywithAb oligomer formation in the brain
(around 6 months of age), while neuritic amyloid deposits
become visible only between 12 and 23 months and then the
amount of deposits increases (23, 31, 35). Thus, memory def-
icits seem to directly correlate with the accumulation of in-
tracellular Ab oligomers and not with amyloid plaque
formation. Crossing APP transgenicmicewith those bearing a
mutation in presenilin 1 gene enabled an earlier onset of
amyloid plaques compared with APPmice. In one of the most
FIG. 2. Age-dependent appearance of histopathological hallmarks in transgenic AD mouse model.
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aggressive models, double-transgenic APPS/L/PS1
(APPSwedish/London/PS1M141L) mice, Ab accumulation begins
very soon at 1–2 months of age while cognitive deficits and
amyloid plaque formation are already observed at 3 months
(3, 16). A stronger decrease of mitochondrial membrane po-
tential as well as ATP level was also found in these mice.
Mitochondrial dysfunctions also appear to a very early
stage in these transgenic mouse models. For example, in the
APPSw transgenic strain Tg2576, an upregulation of genes
related to mitochondrial energy metabolism and apoptosis
was observed already at 2 months of age. Alterations in
composition of the mitochondrial respiratory chain com-
plexes I and III protein subunit as well as impairment of mi-
tochondrial respirationwere detected around 6months, when
soluble Ab accumulated in the brain without plaque forma-
tion (10, 23, 59). To test the hypothesis that oxidative stress can
underlie the deleterious effects of PS mutations, Schuessel
and collaborators analyzed lipid peroxidation products (4-
hydroxynonenal [HNE] and malondialdehyde) and antioxi-
dant defense mechanisms in brain tissue and ROS levels in
splenic lymphocytes from transgenic mice bearing the human
PS1 M146L mutation (PS1M146L) compared with those from
mice transgenic for wild-type human PS1 (PS1wt) and non-
transgenic littermate control mice (66). In brain tissue,
HNE levels were increased only in aged (19–22 months)
PS1M146L transgenic animals compared with PS1wt mice
and not in young (3–4 months) or middle-aged mice (13–15
months). Similarly, in splenic lymphocytes expressing the
transgenic PS1 proteins, mitochondrial and cytosolic ROS
levels were significantly elevated compared with controls
only in cells from aged PS1M146L animals. Antioxidant
defense mechanisms (activities of antioxidant enzymes in-
cluding Cu/Zn-SOD, GSH peroxidase, and GSH reductase)
as well as susceptibility to oxidative stress in vitro were
unaltered. In summary, these results demonstrate that the
PS1M146L mutation increases mitochondrial ROS formation
and oxidative damage selectively in aged mice. Consistent
with this observation, in Swedish amyloid precursor protein
(APPSw)/PS2 double-transgenic mice, mitochondrial im-
pairment was first detected at 8 months of age, before am-
yloid plaque deposition, but after soluble Ab accumulation
(60, 61). Taken together, these findings are consistent with
the recently proposed hypothesis of the age-related Ab
toxicity cascade that suggests that the most toxic Ab species
that cause majority of molecular and biochemical abnor-
malities are in fact intracellular soluble oligomeric
FIG. 3. Age-dependent mitochondrial dysfunction in senescence-accelerated and transgenic AD mouse models. (Star:
start of the experiments).
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aggregates rather than the extracellular, insoluble plaques
that may comprise the form of cellular defense against tox-
icity of oligomers (19). Interestingly, human amylin that
aggregates in type 2 diabetic pancreas and shares with Ab
its amyloidogenic properties also causes an impaired com-
plex IV activity, whereas nonamyloidogenic rat amylin did
not (39).
How does tau interfere with mitochondrial function? In its
hyperphosphorylated form, tau, which forms the NFTs, the
second hallmark lesion in AD, has been shown to block mi-
tochondrial transport, which results in energy deprivation
and oxidative stress at the synapse and, hence, neurodegen-
eration (27, 33, 57). Till now, no mutations in microtubule-
associated protein tau (MAPT) coding genes have been
detected in relation to familial forms of AD. However, in
familial frontotemporal dementia (FTD) with parkinsonism,
mutations in the MAPT gene were identified on chromosome
17. This was the basis for creating a robust mouse model for
tau pathology in 2001. These P301L tau–expressing pR5 mice
(longest four-repeat 4R2N) show an accumulation of tau as
soon as 3 months of age and develop NFTs around 6 months
of age (24). A mass spectrometric analysis of the brain
proteins from these mice revealed mainly a deregulation of
mitochondrial respiratory chain complex components (in-
cluding complex V), antioxidant enzymes, and synaptic
protein space (11). The reduction in mitochondrial complex V
levels in the P301L tau mice that was revealed using pro-
teomics was also confirmed as decreased in human P301L
FTDP-17 (FTD with parkinsonism linked to chromosome 17)
brains. The functional analysis demonstrated age-related
mitochondrial dysfunction, together with reduced NADH-
ubiquinone oxidoreductase (complex I) activity as well as
age-related impaired mitochondrial respiration and ATP
synthesis in pR5 mice model. Mitochondrial dysfunction was
also associated with higher levels of ROS in aged transgenic
mice. Increased tau pathology resulted in modification of
lipid peroxidation levels and the upregulation of antioxidant
enzymes in response to oxidative stress (11). Thus, this
evidence demonstrated for the first time that not only Ab but
also tau pathology leads to metabolic impairment and
oxidative stress by distinct mechanisms from that caused by
Ab in AD.
Synergistic modes of Ab and tau toxicity
on mitochondria
Although Ab and tau pathologies are both known hall-
marks of AD, the mechanisms underlying the interplay be-
tween plaques and NFTs (or Ab and tau, respectively) have
remained unresolved. However, a close relationship between
mitochondrial impairment and Ab on the one hand and tau
on the other hand has been already established. How do both
AD features relate to each other? Is it possible that these two
molecules synergistically affect mitochondrial integrity?
Several studies suggest that Ab aggregates and hyperpho-
sphorylated tau may block the mitochondrial carriage to the
synapse leading to energy deficiency and neurodegeneration
(28). Moreover, the enhanced tau levels may inhibit the
transport of APP into axons and dendrites, which suggests a
direct link between tau and APP in axonal failure (14, 69).
Remarkably, intracerebral Ab injections amplify a preexisting
tau pathology in several transgenic mouse models (5, 25, 29),
whereas lack of tau abrogates Ab toxicity (32, 33). Our find-
ings indicate that in tau transgenic pR5 mice, mitochondria
display an enhanced vulnerability toward anAb insult in vitro
(12, 15, 16), suggesting a synergistic action of tau and Ab
pathology on this organelle (Figs. 2 and 3). The Ab caused a
significant reduction of mitochondrial membrane potential in
cerebral cells from pR5 mice (11). Furthermore, incubation of
isolated mitochondria from pR5 mice with either oligomeric
or fibrillar Ab species resulted in an impairment of the mito-
chondrial membrane potential and respiration. Interestingly,
aging particularly increased the sensitivity of mitochondria to
oligomeric Ab insult compared with that of fibrillar Ab (15).
This suggests that while both oligomeric and fibrillar Ab
species are toxic, they exert different degrees of toxicity.
Crossing P301L mutant tau transgenic JNPL3 mice (shortest
four-repeat [4R0N] tau together with the P301L mutation)
with APPSw transgenic Tg2576 mice revealed the presence of
NFT pathology in spinal cord and pons already at 3 months of
age (38). Ab plaques were detected at the age of 6 months and
had the samemorphology and distribution than in the 1-year-
old Tg2576 mice. Taken together, these studies illustrate the
existence of a complex interplay between the two key proteins
in AD.
Additionally, in recent years triple-transgenic mouse models
have been established that combineAb and taupathologies (Figs.
2 and 3). In these models the contribution of both AD-related
proteins on themitochondrial respiratorymachinery and energy
homeostasis has been investigated in vivo. Indeed, our group
demonstrated a mitochondrial dysfunction in a novel triple-
transgenic mouse model (pR5/APPSw/PS2 N141I)—tripleAD
mice—using proteomics followed by functional validation
(60). Particularly, deregulation of activity of complex I was
found to be tau dependent, whereas deregulation of complex
IV was Ab dependent, in 10-month-old tripleAD mice. The
convergent effects of Ab and tau led already at the age of
8 months to a depolarization of mitochondrial membrane
potential in tripleAD mice. Additionally, we found that age-
related oxidative stress also plays a significant part in the
deleterious vicious cycle by exaggerating Ab- and tau-
induced disturbances in the respiratory system and ATP
synthesis, finally leading to synaptic failure.
Our data complement those obtained in another triple-
transgenic mouse model 3xTg-AD (P301Ltau/APPSw/PS1
M146L) (50). In these studies, mitochondrial dysfunction was
evidenced by an age-related decrease in the activity of regu-
latory enzymes of OXPHOS such as COX, or of the Krebs cycle
such as pyruvate dehydrogenase, analyzing 3xTg-AD mice
aged from 3 to 12 months (82). Besides, these mice also ex-
hibited increased oxidative stress and lipid peroxidation.
Most of the effects on mitochondria were seen at the age of 9
months, whereas mitochondrial respiration was significantly
decreased at 12 months of age. Importantly, mitochondrial
bioenergetics deficits were found to precede the development
of AD pathology in the 3xTg-AD mice. Figure 4 nicely shows
that AD-specific changes including cognitive impairments,
Ab accumulation, Ab plaques, andmitochondrial dysfunction
seem to occur at an earlier onset from single, double up to
triple AD transgenic mice models. Together, our studies
highlight the key role of mitochondria in AD pathogenesis
and consolidate the notion that a synergistic effect of tau and
Ab enhances the pathological weakening of mitochondria at
an early stage of AD.
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Ab-Binding Alcohol Dehydrogenase: A New Lead
to Decode the Mechanisms of Ab-Induced
Mitochondrial Dysfunction
A few years ago, Yan and collaborators showed that the Ab
peptide can directly bind a mitochondrial enzyme called Ab-
binding alcohol dehydrogenase (ABAD) that is overexpressed
in the brains of Alzheimer’s patients and AD mouse models
(79). The interaction of Ab with this enzyme exacerbates mi-
tochondrial dysfunction induced by Ab (decrease of mito-
chondrial complex IV activity, diminution ofO2 consumption,
and increase of ROS), as shown in double-transgenic mice
overexpressing mutant APP and ABAD (81). Furthermore,
these mice presented an earlier onset of cognitive impairment
and histopathological changes when compared with APP
mice, suggesting that the Ab–ABAD interaction is an impor-
tant mechanism underlying Ab toxicity. The Ab–ABAD
complex could have a direct effect on the ETC because ABAD
was found to be one of three proteins that comprise the fully
functional mammalian mitochondrial RNAse P (63), a func-
tion that may not require dehydrogenase activity and that
links ABAD directly to the production of mitochondrial ETC
proteins and ROS generation.
Recently, it has been shown that inhibition of Ab–ABAD
interaction by a decoy peptide can restore mitochondrial
deficits and improve neuronal and cognitive function (81).
Our findings, using SH-SY5Y neuroblastoma cells treated
with Ab1-42, a cellular model of AD, seem to confirm these
observations (Lim et al., unpublished observations). We em-
ployed a novel small ABAD-specific inhibitor to investigate
the role of this enzyme in Ab toxicity. The inhibitor signifi-
cantly improved metabolic functions impaired by Ab, and
specifically reduced Ab-induced oxidative stress and cell
death. Furthermore, we have shown previously that the
production of estradiol, a well-known neuroprotective neu-
rosteroid and ABAD substrate, is increased after 24 h in the
presence of a ‘‘nontoxic’’ concentration of Ab and is de-
creased when using a toxic concentration of this peptide (64),
suggesting that Ab is able to modulate (directly or indirectly)
neurosteroid levels. Accordingly, new findings from our
group demonstrate that the levels of estradiol in the cytosol
and in mitochondria can differently be influenced by Ab
peptide (500 nM, 5 days of treatment) (Fig. 5A, B). We ob-
served that cytosolic estradiol is reduced in the presence of
Ab, but at the same time mitochondrial estradiol load was
significantly increased. We suggest that this increase is due
to an Ab-induced decrease of ABAD activity, thus limiting
the conversion of estradiol in estrone within mitochondria
(Fig. 5C). Inhibition of ABAD activity by Ab peptide was
already demonstrated by Yan and collaborators (80) using
17b-estradiol as substrate of the enzyme. One mechanism
that could explain this inhibition is the fact that Ab–ABAD
interaction changes the conformation of the enzyme, avoid-
ing the binding of the cofactor NAD + , and this reduces the
metabolic activity of ABAD (41). However, the total amount
of estradiol is about 500-fold higher than in the mitochon-
drial fraction. Even if Ab induced an increase in estradiol
within mitochondria, the reduction of total estradiol level by
other enzymes of the complex steroidogenic pathway may
therefore be more relevant for cellular dysfunction. Besides,
FIG. 4. Age-dependent onset of AD-associated pathological changes in different AD mouse models (age in months). In
both triple Tg mouse models [TripleAD, (60); 3xTgAD, (50–82)] an earlier onset in the appearance of AD-related changes in the
brain can be detected when compared with double transgenic [APPSw/PS2 (60, 61)] and to mice bearing only APP mutations
[APPSw, (24)], suggesting again a synergistic effect of Ab and tau in the pathogenesis of AD. Age of the mice is given in
months. APPSw, APP Swedish transgenic mice; APPSw/PS2, APP Swedish/presenilin 2 transgenic mice; tripleAD, APP
Swedish/presenilin 2/P301L tau transgenic mice; 3xTgAD, APP Swedish/presenilin 1/P301L tau transgenic mice. (To see
this illustration in color the reader is referred to the Web version of this article at www.liebertonline.com/ars).
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it was also speculated that estradiol exhibits a ‘‘prooxidant
effect’’ in the presence of ongoing oxidative stress (49).
Thereby, estradiol is hydroxylated to catecholestrogens that
can enter a redox cycle generating superoxide radicals,
leading to a continuous formation of ROS that amplifies
oxidative stress.
Thus, inhibition of the Ab–ABAD interaction seems to be
an interesting therapeutic target to block or prevent Ab-
inducedmitochondrial toxicity because it could normalize the
imbalance between ROS and estradiol levels in mitochondria
and thereby help in improving mitochondrial and neuronal
function.
Conclusion
We discuss here the recent findings regarding the possible
shared mechanisms involving mitochondrial decline driven
by brain aging and the close interrelationship of this organelle
with the two main pathological features in the pathogenic
process underlying AD.
According to themitochondrial aging theory, ROS-induced
damage and mtDNA mutations accumulate over time in-
ducing ETC impairment and weaken mitochondria function
in a rather unspecific way; thus, laying the ground for the two
common hallmarks of AD, plaques and NFTs, or Ab and tau,
respectively, which destruct independently as well as syner-
gistically this vital organelle via specific mode of actions on
complexes I and IV.
Given the complexities of AD, the key role of mitochondrial
dysfunction in the early pathogenic pathways by which Ab
leads to neuronal dysfunction in AD is particularly chal-
lenging with respect to establishing therapeutic treatments.
Besides the modulation and/or removal of both Ab and tau
pathology, strategies involving efforts to protect cells at the
mitochondrial level by stabilizing or restoring mitochondrial
function or by interfering with energy metabolism appear to
be promising. Transgenic AD mice, and particularly triple-
transgenic models that combine both pathologies in an age-
dependent manner (Fig. 4), are valuable tools in monitoring
therapeutic interventions at the mitochondrial level. Even-
tually, this may lead to therapies that prevent the progression
of the age-related mitochondrial decline thereby reducing the
vulnerability to Ab and/or tau at an early stage of the disease.
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 Chapter 9 
 Advanced Mitochondrial Respiration Assay for Evaluation 
of Mitochondrial Dysfunction in Alzheimer’s Disease 
 Amandine  Grimm ,  Karen  Schmitt , and  Anne  Eckert 
 Abstract 
 Alzheimer’s disease (AD) is characterized by the presence of amyloid plaques (aggregates of amyloid-β 
[Aβ]) and neurofi brillary tangles (aggregates of tau) in the brain, but the underlying mechanisms of the 
disease are still partially unclear. A growing body of evidence supports mitochondrial dysfunction as a 
prominent and early, chronic oxidative stress-associated event that contributes to synaptic abnormalities, 
and, ultimately, selective neuronal degeneration in AD. Using a high-resolution respirometry system, we 
shed new light on the close interrelationship of this organelle with Aβ and tau in the pathogenic process 
underlying AD by showing a synergistic effect of these two hallmark proteins on the oxidative phosphory-
lation capacity of mitochondria isolated from the brain of transgenic AD mice. In the present chapter, we 
fi rst introduce the principle of the Aβ and tau interaction on mitochondrial respiration, and secondly, we 
describe in detail the used respiratory protocol. 
 Key words  Mitochondria ,  Alzheimer’s disease ,  Amyloid-β ,  Tau ,  Oxygraph ,  High-resolution respi-
rometry (HRR) ,  Oxidative phosphorylation 
1  Introduction 
 With the increasing average life span of humans, Alzheimer’s disease 
(AD) is the most common neurodegenerative disorder among 
elderly individuals. It accounts for up to 80 % of all dementia cases 
and ranks as the fourth leading cause of death amongst those above 
65 years of age [ 1 ]. Although the hallmark lesions of the disease 
were already described by Alois Alzheimer in 1906—amyloid-β 
(Aβ) containing plaques and microtubule-associated protein tau- 
containing neurofi brillary tangles (NFTs)—the underlying molec-
ular mechanisms that cause the formation of these end-stage lesions 
are still poorly understood. However, a growing body of evidence 
supports mitochondrial dysfunction as a prominent and early 
chronic oxidative stress-associated event that contributes to synap-
tic abnormalities and, ultimately, selective neuronal degeneration 
in AD [ 2 ,  3 ]. Within the last few years, several cell culture models 
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as well as single, double, and more recently triple transgenic mouse 
models have been developed to reproduce diverse aspects of 
AD. These models help in understanding the pathogenic mecha-
nisms that lead to mitochondrial failure in AD, and in particular 
the interplay of AD-related cellular modifi cations within this pro-
cess [ 4 ]. In this chapter, we highlight the critical key role of mito-
chondria and the close inter-relationship of this organelle with the 
two main pathological features in the pathogenic process underly-
ing AD. Particularly, we will emphasize on the recent insights 
showing independent as well as synergistic effects of Aβ peptide 
and hyperphosphorylated tau on mitochondrial function by using 
a high-resolution respirometry system (Oxygraph-2k). 
 Mitochondria play a pivotal role in cell survival and death by regulat-
ing both energy metabolism and apoptotic pathways. They are the 
“powerhouses of cells” providing energy via ATP generation which 
is accomplished through oxidative phosphorylation (OXPHOS) 
from nutritional sources [ 5 ] (Fig.  1 ). Neurons have particularly high 
numbers of mitochondria which are especially enriched in synapses. 
Due to the limited glycolytic capacity of neurons, those cells are 
1.1  Aβ and Tau 
Induce Mitochondrial 
Toxicity
 Fig. 1  The mitochondrial electron transport chain: impact of Aβ peptide, tau protein, and effects of mitochon-
drial substrates used during the measurement protocol with Oxygraph. Complexes I (NADH: ubiquinone oxido-
reductase) and II (succinate dehydrogenase, belongs to the tricarboxylic acid (TCA) cycle) receive electrons 
from NADH and FADH 2 , respectively. Electrons are then driven from complexes by the mobile carrier molecules 
coenzyme Q/ubiquinone ( UQ ) and cytochrome c ( Cyt c ) to the fi nal acceptor, molecular oxygen ( O  2  ). Electron 
fl ow is coupled to proton movement across the inner mitochondrial membrane ( IMM ) in complexes I, III and 
IV. The resulting proton gradient is harvested by complex V to generate ATP. In Alzheimer’s disease, abnormal 
mitochondrial electron activities have been observed, predominantly in complexes I and IV, leading to impaired 
mitochondrial membrane potential, decreased production of ATP (complex V), and increasing reactive oxygen 
species ( ROS ) levels. Interestingly, deregulation of complex I is mainly tau-dependent, while deregulation of 
complex IV is amyloid-β (Aβ)-dependent, at both the protein and activity levels. The targets of the different 
substrates used during the Oxygraph measurement are marked with an  asterisk and their specifi c actions are 
summarized in Table  1 .  AA antimycin A,  AT ascorbate/TMPD,  IMS intermembrane space 
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highly dependent on mitochondrial function for energy production 
[ 6 ]. Thus, deregulation of mitochondrial function leads to synaptic 
stress, disruption of synaptic transmission, apoptosis and ultimately, 
systemic neurodegeneration [ 7 ,  8 ]. 
 Evidences from cellular and animal AD models indicate that 
Aβ triggers mitochondrial dysfunction through a number of path-
ways such as impairment of OXPHOS, elevation of reactive oxygen 
species (ROS) production, interaction with mitochondrial pro-
teins, and alteration of mitochondrial dynamics [ 9 ,  10 ]. Success in 
developing mouse models that mimic diverse facets of the disease 
process has greatly facilitated the understanding of pathophysio-
logical mechanisms underlying AD. In 1995, Games and collabo-
rators established the fi rst amyloid precursor protein (APP) mouse 
model (called PDAPP) bearing the human “Indiana” mutation of 
the  APP gene (V171F). They observed the accumulation of Aβ in 
the brain and subsequent amyloid plaque formation, as well as 
astrocytosis and neuritic dystrophy [ 4 ]. Interestingly, in most of 
the APP mouse models, the cognitive impairment begins concomi-
tantly with Aβ oligomer formation in the brain (around 6 months 
of age), while neuritic amyloid deposits become visible only 
between 12 and 23 months and the amount of deposits increases 
in parallel [ 11 ]. Thus, memory defi cits seem to correlate directly 
with the accumulation of intracellular Aβ oligomers and not with 
amyloid plaque formation. When those mice were crossed with 
those bearing a mutation in presenilin 1 gene (PS1), coding for a 
gene involved in APP processing, an earlier onset of amyloid 
plaques was observed, alongside a stronger decrease of mitochon-
drial membrane potential as well as ATP level [ 12 ]. 
 Mitochondrial dysfunctions occur at a very early disease stage 
in AD transgenic mouse models. For example, in the APPsw trans-
genic strain Tg2576 (Swedish mutation), an upregulation of genes 
related to mitochondrial energy metabolism and apoptosis was 
observed already at 2 months of age. Alterations in composition of 
the mitochondrial respiratory chain complexes I and III protein 
subunit as well as impairment of mitochondrial respiration were 
detected around 6 months, when soluble Aβ accumulated in the 
brain without plaque formation [ 13 ,  14 ]. 
 Consistent with this observation, in APPsw/presenilin 2 (PS2) 
double-transgenic mice, mitochondrial impairment was fi rst 
detected at 8 months of age, before amyloid plaque deposition, 
but after soluble Aβ accumulation [ 15 ]. Taken together, these 
fi ndings are consistent with the recently proposed hypothesis of an 
age-related Aβ toxicity cascade that suggests that the most toxic Aβ 
species that cause majority of molecular and biochemical abnor-
malities are in fact intracellular soluble oligomeric aggregates rather 
than the extracellular, insoluble plaques [ 16 ]. 
 How does tau, the second hallmark lesion in AD, interfere 
with mitochondrial function? In its abnormally hyperphosphory-
lated form, which forms the neurofi brillary tangles (NFTs), tau has 
Mitochondrial Dysfunction in Alzheimer’s Disease
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been shown to block mitochondrial transport. This results in 
energy deprivation and oxidative stress at the synapse, and, conse-
quently, neurodegeneration [ 17 ,  18 ]. Until now, no mutations in 
microtubule-associated protein tau ( MAPT ) coding genes have 
been detected in relation to familial forms of AD. However, in 
familial frontotemporal dementia (FTD) with parkinsonism, muta-
tions in the microtubule-associated protein tau gene ( MAPT ) were 
identifi ed on chromosome 17. This was the basis for creating 
a robust mouse model for tau pathology in 2001. These P301L 
tau- expressing pR5 mice show an accumulation of tau as soon as 
3 months of age and develop NFTs around 6 months of age [ 19 ]. 
A mass spectrometric analysis of the brain proteins from these mice 
(aged from 8.5 to 10 months) revealed mainly a deregulation of 
mitochondrial respiratory chain complex components (including 
complex V), antioxidant enzymes, and synaptic protein space [ 20 ]. 
The reduction in mitochondrial complex V levels in the P301L tau 
mice was also confi rmed in human P301L FTDP-17 (FTD with 
parkinsonism linked to chromosome 17) brains. The functional 
analysis demonstrated age-related mitochondrial dysfunction, 
together with reduced NADH ubiquinone oxidoreductase (com-
plex I) activity as well as age-related impaired mitochondrial respi-
ration and ATP synthesis in a pR5 mouse model. Mitochondrial 
dysfunction was also associated with higher levels of ROS in aged 
transgenic mice. Increased tau pathology resulted in modifi cation 
of lipid peroxidation levels and the upregulation of antioxidant 
enzymes in response to oxidative stress [ 20 ]. Thus, this evidence 
demonstrated for the fi rst time that not only Aβ but also tau pathol-
ogy weakens gradually mitochondrial function in a rather specifi c 
way leading to metabolic impairment and oxidative stress in AD. 
 Although Aβ and tau pathologies are both known hallmarks of 
AD, the mechanisms underlying the interplay between plaques and 
NFTs (or Aβ and tau, respectively) have remained unclear. 
However, a close relationship between mitochondrial impairment 
and Aβ on the one hand and tau on the other hand has been already 
established. How do both AD features relate to each other? Several 
studies suggest that Aβ aggregates and hyperphosphorylated tau 
may block the mitochondrial transport to the synapse leading to 
energy defi ciency and neurodegeneration [ 21 ]. 
 Remarkably, intracerebral Aβ injections amplify a pre-existing 
tau pathology in several transgenic mouse models [ 22 ,  23 ], whereas 
lack of tau abrogates Aβ toxicity [ 18 ,  24 ]. Our fi ndings indicate 
that in tau transgenic pR5 mice, mitochondria display an enhanced 
vulnerability toward Aβ insult in vitro [ 2 ,  25 ], suggesting a syner-
gistic action of tau and Aβ pathology on this organelle. Thus, these 
studies provide the fi rst evidence for the existence of a complex 
interplay between Aβ and tau in AD whereby these two molecules 
damage mitochondria in multiple ways, but what about their spe-
cifi c effects on mitochondrial respiration? 
1.2  Synergistic Mode 
of Action of Aβ 
and Tau
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 To address this question, we used a high-resolution respiratory 
 system to evaluate the capacity of the entire oxidative phosphoryla-
tion system (OXPHOS) of cerebral mitochondria from mice bear-
ing either an APP/PS2 mutation, P301L mutation (pR5 mice), or 
the triple mutation APP/PS2/P301L ( triple AD mice) compared to 
wild-type mice [ 26 ]. Measurement of oxygen (O 2 ) fl ux and con-
sumption was performed at 37 °C using an Oroboros Oxygraph-2k 
system on freshly isolated mitochondria from cortical brains of age-
matched wild-type, APP/PS2, pR5 and  triple AD mice as follows. 
After detection of endogenous respiration, glutamate and malate 
were added to induce state 4 respiration (Figs.  1 and  2a ), then ADP 
was added to stimulate state 3 respiration. After determining cou-
pled respiration, a mitochondrial uncoupler (FCCP, see below) was 
added and the maximal respiratory capacity measured in the absence 
of a proton gradient. Cytochrome c (cyt c) injection was used to 
demonstrate mitochondrial membrane integrity. To inhibit activi-
ties of complexes I–III, rotenone (rot) and antimycin A (AA) were 
added. Complex IV activity was stimulated by ascorbate/TMPD 
(A/T) before terminating mitochondrial respiration by adding 
sodium azide (azide). Oxygen (O 2 ) consumption was normalized 
to the corresponding citrate synthase activity [ 3 ,  26 ]. 
 We determined fl ux control ratios to obtain information on 
metabolic states of respiration. The respiratory control ratio 
(RCR3/4) is an indicator of the state of coupling of mitochondria. 
State 3 is the rate of phosphorylating respiration in the presence of 
exogenous ADP, and state 4 is associated with proton leakage 
across the inner mitochondrial membrane in the absence of 
ADP. Our fi ndings suggest a pronounced decrease of RCR3/4 in 
mitochondria from APP/PS2 and  triple AD compared with age- 
matched wild-type mice already at 8 months of age. This decrease 
was also found in the oldest mice (12 months of age). When we 
examined the ETS/ROX (electron transport system/residual oxy-
gen consumption) ratio, which yields an index of the maximum 
oxygen consumption capacity relative to the magnitude of residual 
oxygen consumption, we found that it was also decreased in APP/
PS2 and  triple AD compared with age-matched wild-type mice at 8 
and 12 months of age. Interestingly, in a previous study, the 
decreased respiration of mitochondria from pR5 mice compared 
with wild-type controls was not detectable before the age of 
24 months [ 20 ]. In contrast, APP/PS2 mitochondria showed a 
decrease in OXPHOS compared with wild-type already at the age 
of 8 months. At this age, OXPHOS of brain mitochondria from 
 triple AD mice did not differ compared with that of age-matched 
APP/PS2 mitochondria, but it was signifi cantly decreased in  tri-
ple AD mice at the age of 12 months (Fig.  2b ). Taken together, with 
increasing age, the global failure of the mitochondrial respiratory 
capacity deteriorated the strongest in mitochondria from  triple AD 
mice, suggesting a synergistic destructive effect of tau and Aβ on 
mitochondria. 
1.3  High-Resolution 
Respirometry 
in Isolated 
Mitochondria 
to Evaluate OXPHOS 
Capacity
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 In conclusion, our studies highlight the key role of mitochon-
dria in AD pathogenesis and the close interrelationship of this 
organelle and the two main pathological features of the disease. We 
showed that disturbances in the respiratory and energy system of 
 triple AD mice seem to be due to a convergence of Aβ and tau on 
 Fig. 2  Synergistic effects of Aβ and tau on mitochondrial respiration. ( a ) Representative diagrams of O 2 fl ux and 
consumption in mitochondria from 12-month-old wild-type, APP/PS2, and  triple AD transgenic mice in response 
to titrated substrates and inhibitors of mitochondrial complexes. ( b ) Two-way ANOVA revealed a signifi cant 
effect of on the respiratory rates of mitochondria between 12-month-old wild-type and APP/PS2 mice, and this 
impaired respiration was even more pronounced in  triple AD mice. Two-way ANOVA post-hoc Bonferroni. 
* P < 0.05; ** P < 0.01; *** P < 0.001 vs. wild-type;  + P < 0.05;  ++ P < 0.01;  +++ P < 0.001 vs. APP/PS2 ( n = 7–12 
animals/group). Modifi ed from Rhein et al., PNAS (2009) [ 26 ] with permission 
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mitochondria, accelerating defects in respiratory capacity, which 
consolidates the idea that a synergistic effect of tau and Aβ increase 
the pathological deterioration of mitochondria. 
 Now we will describe in detail the protocol which we followed 
previously [ 25 ]. After listing the material needed, we will describe 
the isolation of mitochondria from mouse brains and the steps 
required to measure the mitochondrial respiration. It is important 
to note that this protocol assumes that the Oroboros Oxygraph-2k 
system is routinely used in the laboratory and does not include 
technical details about oxygraph maintenance or calibration, but 
only experimental procedure regarding the assessment of mito-
chondrial respiration. 
2  Materials 
 Prepare all solutions using ultrapure water (prepared by purifying 
deionized water to attain a sensitivity of 18 MΩ cm at 25 °C). 
  1.  Medium 1: 138 mM NaCl, 5.4 mM KCl, 0.17 mM Na 2 HPO 4 , 
0.22 mM KH 2 PO 4 , 5.5 mM glucose·H 2 O, 58.4 mM sucrose, 
pH 7.35. To prepare 1 L of Medium 1, weigh 8 g of NaCl, 
0.4 g of KCl, 0.024 g of Na 2 HPO 4 , 0.03 g of KH 2 PO 4 , 1.1 g 
of glucose·H 2 O, 20 g of sucrose. Add water to a volume of 
900 mL and mix with magnetic stir bar at room temperature 
until all powders are dissolved. Adjust pH and make up to 1 L 
with water. Store at 4 °C. 
  2.  Isolated Mitochondria Buffer: 210 mM mannitol, 70 mM 
sucrose, 10 mM HEPES, 1 mM EDTA (tritriplex III), 0.45 % 
BSA, pH 7.4. To prepare 200 mL of buffer, weigh 7.65 g of 
mannitol, 4.79 g of sucrose, 477 mg of HEPES, 74.4 mg of 
EDTA (tritriplex III) and 0.9 g of BSA. Add water to a vol-
ume of 190 mL and mix with magnetic stir bar at room tem-
perature until all powders are dissolved. Adjust pH and make 
up to 200 mL with water. Prepare aliquots of 10 mL and keep 
at −20 °C ( see  Note 1 ). 
  3.  1 M dithiothreitol (DTT) stock solution in water. 
  1.  Mitochondrial Respiration Buffer: 65 mM sucrose, 10 mM 
KH 2 PO 4 , 10 mM Tris–HCl, 10 mM MgSO 4 ·7H 2 O, 2 mM 
EDTA (tritriplex III)·2H 2 O, pH 7. To prepare 200 mL, weigh 
4.45 g of sucrose, 0.272 g of KH 2 PO 4 , 0.315 g of Tris–HCl, 
0.493 g of MgSO 4 ·7H 2 O, and 0.149 g of EDTA (tritriplex 
III)·2H 2 O. Add water to a volume of ca. 190 mL and mix 
with magnetic stir bar at room temperature until all powders 
are dissolved. Adjust pH and make up to 200 mL with water. 
Prepare aliquots of 20 mL and keep them at −20 °C. 
2.1  Solutions 
for Isolated 
Mitochondria 
Preparation
2.2  Solutions 
for Mitochondrial 
Respiration Assay
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  2.  Mitochondrial Respiration Medium (MiR05): 0.5 mM EGTA, 
3 mM MgCl 2 ·6H 2 O, 60 mM K-lactobionate, 20 mM taurine, 
10 mM KH 2 PO 4 , 20 mM HEPES, 110 mM sucrose, 1 g/L 
BSA, pH 7.1. First, prepare the 0.5 M K-lactobionate stock 
solution dissolving 35.83 g of lactobionic acid in 100 mL of 
H 2 O, adjusting the pH to 7.0 with KOH and bringing the 
volume to 200 mL. To prepare 1 L of MiR05, weigh 0.190 g 
of EGTA, 0.610 g of MgCl 2 ·6H 2 O, 2.502 g of taurine, 
1.361 g of KH 2 PO 4 , 4.77 g of HEPES, 37.65 g of sucrose, 
and 1 g of BSA. Add ca. 750 mL of water and 120 mL of 
0.5 M K- lactobionate stock solution. Mix with magnetic stir 
bar at room temperature, adjust the pH to 7.1 with 5 N KOH 
and make up to 1 L with water. Divide into 20 mL aliquots 
and store them frozen at −20 °C ( see  Note 2 ). 
  3.  Substrates: The substrates (stock solutions) employed and 
details of preparation are summarized in Table  1 ( see  Notes 
3 – 13 ).
 Oroboros Oxygraph-2k system for high resolution respirometry 
(HRR) studies ( http://www.oroboros.at/?Oxygraph ). 
3  Methods 
 Before experiment, perform an instrumental and chemical setup 
with the oxygraph. 
 Prepare isolated mitochondria buffer ( see  Note 1 ) and keep on ice. 
Turn on the centrifuge (4 °C).
  1.  Kill the mice by decapitation and dissect one brain hemisphere 
on ice. Wash in 10 mL of ice-cold medium 1. 
  2.  Put the preparation in the Potter-tube to homogenize in 1 mL 
of isolated mitochondria buffer. Pipette 10–15 times to 
homogenize the preparation ( see  Note 14 ). 
  3.  Wash the Potter’s plug three times with 150 μL of isolated 
mitochondria buffer and put the preparation in a 2 mL tube. 
Wash the Potter’s tube three times with 150 μL of isolated 
mitochondria buffer and put the preparation in the same 2 mL 
tube. Vortex ( see  Note 15 ). 
  4.  Centrifuge at 1,450 ×  g (4 °C) for 7 min and recover the super-
natant in a new 2 mL tube. This step removes nuclei and tissue 
particles. 
  5.  Centrifuge at 1,450 ×  g (4 °C) for 3 min and recover the super-
natant again in a new 2 mL tube. 
  6.  Centrifuge at 10,000 ×  g (4 °C) for 5 min. Throw away the 
supernatant and recover the pellet. 
2.3  Oxygraph 
System
3.1  Isolated 
Mitochondria 
Preparation
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 Table 1 
 Preparation and function of the substrates used to investigate the mitochondrial respiration using the Oroboros Oxygraph-2k system 
 Name/formula  MW (g/mol)  Stock solution  Function  Note # 
 Mitochondrial 
substrates 
 Glutamate  Na-glutamate C 5 H 8 NO 4 Na  169.1  2 M  3.382 g/10 mL H 2 O  Induces state 4 respiration  4 
 Malate  L -Malic acid C 4 H 6 O 5  134.1  0.8 M  1.073 g/10 mL H 2 O  Induces state 4 respiration  5 
 ADP  K-adenosine 5′diphosphate dihydrate 
salt (C 10 H 15 N 5 O 10 P 2 K·2H 2 O) 
 501.32  0.5 M  0.501 g/2 mL H 2 O  Induces state 3 respiration  6 
 cytC  Cytochrome c  12,500  4 mM  50 mg/1 mL H 2 O  Demonstrates mitochondrial 
membrane integrity 
 7 
 Ascorbate  Ascorbate sodium salt C 6 H 7 O 6 Na  198.1  0.8 M  1.584 g/10 mL H 2 O  Stimulates complex IV 
activity 
 8 
 TMPD  N , N , N ′, N ′-Tetramethyl-p - 
phenylenediamine dihydrochloride 
C 10 H 16 N 2 ·2HCl 
 237.2  0.2 M  47.4 mg/1 mL H 2 O  Stimulates complex IV 
activity 
 9 
 Mitochondrial 
inhibitors 
 Rotenone  Rotenone C 23 H 22 O 6  394.4  1 mM  3.94 mg/10 mL Ethanol  Inhibits complex I activity  10 
 AA  Antimycin A  540  5 mM  11 mg/4 mL Ethanol  Inhibits complex III activity  11 
 Azide  Sodium azide NaN 3  65.01  1 M  65 mg/1 mL H 2 O  Inhibits oxygen consumption  12 
 Mitochondrial 
uncouplers 
 FCCP  Carbonyl cyanide 
 p -(trifl uoromethoxy) 
phenylhydrazone C 10 H 5 F 3 N 4 O 
 254.2  0.32 mM  2.54 mg/10 mL ethanol 
results in a 1 mM 
solution. From here, 
dilute 1:3.125 in ethanol 
 Determines uncoupled 
respiration in absence of a 
proton gradient 
 13 
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  7.  Put the pellet (mitochondria) in 1 mL of isolated mitochon-
dria buffer and mix 15 times using the pipette. 
  8.  Repeat  steps 7 and  8 to obtain the mitochondrial fraction and 
put the pellet in 100 μL of isolated mitochondria buffer. Keep 
on ice until the measurement ( see  Note 16 ). 
 Before experiment prepare the substrates (stock solutions) 
(Table  1 ) and the oxygraph ( see  Note 17 ).
  1.  Add 50 μL of isolated mitochondria preparation to each cham-
ber and close the chamber ( see  Note 18 ). Mark it as (01-state 1). 
  2.  Add 10 μL of 2 M glutamate/5 μL of 0.8 M malate (respi-
rometry assay fi nal concentrations will be 10 mM and 2 mM 
respectively). Mark it as (02-GM2). 
  3.  Add 8 μL of 0.5 M ADP/chamber (fi nal assay concentration, 
2 mM). Mark it as (03-GM3). 
  4.  Add 2.5 μL of 0.32 mM FCCP/chamber (assay concentra-
tion, 0.4 μM). Mark it as (04-GP3u). 
  5.  Add 5 μL of 4 mM of Cytochrome c/chamber (assay concen-
tration, 10 μM). Mark it as (05-GM3c). 
  6.  Preparing from stock solution (Table  1 ), add 5 μL of 0.2 mM 
rotenone/chamber (assay concentration, 0.5 μM). Mark it as 
(06-rot). 
  7.  Preparing from stock solution (Table  1 ), add 5 μL of 1 mM 
antimycine A/chamber (assay concentration, 2.5 μM). Mark it 
as (07-AA). 
  8.  Add 5 μL of 0.8 M sodium ascorbate/chamber (assay concen-
tration, 2 mM) and 5 μL of 0.2 M TMPD/chamber (assay 
concentration, 0.5 mM). Mark it as (08-AT). 
  9.  Add 20 μL of 1 M sodium azide/chamber (assay concentra-
tion, 10 mM). Mark it as (09-azide). 
 Mitochondrial oxygen consumption is measured by high- resolution 
respirometry (HRR) at 37 °C using an Oroboros Oxygraph-2k sys-
tem ( http://www.oroboros.at/?Oxygraph ) following the Gnaiger 
method [ 27 ]. 
 After the measurement, extract the raw data from the oxygraph 
software (DatLab) to an Excel fi le. Normalize the data on citrate 
synthase activity, which correlates with mitochondrial content 
( see  Note 19 ). Perform the statistical analysis using GraphPad 
Prim software (or equivalent) and a two-way ANOVA followed 
by Bonferroni post hoc tests to compare the different groups. 
Consider statistically signifi cant only  P values < 0.05. Represent 
data as means ± SEM. 
3.2  Mitochondrial 
Respiration 
Measurement: 
Preparations
3.3  Mitochondrial 
Respiration 
Measurement: 
High-Resolution 
Respirometry
3.4  Analysis
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4  Notes 
  1.  Just before starting the experiment, warm up the isolated 
mitochondria buffer. For two brain hemispheres, add one tab-
let of Complete R Mini (protease inhibitor cocktail tablet) and 
5 μL of 1 M DTT to 10 mL of buffer (fi nal concentration, 
0.5 mM DTT). Prepare fresh, less than 3 h before use. 
  2.  The MiR05 medium is stable for about 2–3 months. The 
K-lactobionate must be prepared fresh. 
  3.  Manipulation of solutions at low temperature (4 °C). After 
rewarming, mix carefully since phase separation may occur and 
compounds may precipitate in cold mixtures. During the 
course of the experiment keep stock solutions on ice. Note: 
Solutions which contain ethanol may have a problem of evap-
oration and subsequent increase of concentration. 
  4.  Glutamate solution ( see Table  1 ). Adjust pH to 7.0 with 37 % 
HCl and divide into 0.5 mL aliquots. Store frozen at −20 °C. 
  5.  Malate solution ( see Table  1 ). Neutralize (adjust to pH 7.0) 
with 10 N KOH and divide into 0.5 mL aliquots. Store frozen 
at −20 °C. 
  6.  ADP solution ( see Table  1 ). Neutralize with 5 N KOH and 
divide into 100 μL aliquots. Store at −80 °C. 
  7.  Cytochrome c solution ( see Table  1 ). Divide into 0.2 mL ali-
quots. Store frozen at −20 °C. Protect from light. 
  8.  Ascorbate solution ( see Table  1 ). To prevent autoxidation, pre-
pare 0.8 M ascorbic acid solution (137.6 mg/mL, pH ca. 2). 
Adjust the pH of the sodium ascorbate solution to ca. 6 with 
ascorbic acid. Divide into 0.2 mL aliquots. Store frozen at 
−20 °C protected from light (light sensitive). 
  9.  TMPD solution ( see Table  1 ). To prevent autoxidation, neu-
tralize with the ascorbate salt solution. Dilute 1:80 to result in 
a solution with 10 mM ascorbate fi nal concentration. Divide 
into 0.2 mL aliquots. Store frozen at −20 °C. 
 10.  Rotenone solution ( see Table  1 ). Diffi cult to dissolve. Divide 
into 0.2 mL aliquots, store at −20 °C protected from light. 
Note: Light sensitive; very toxic. Handle with care. 
 11.  Antimycin A (AA) solution ( see Table  1 ). Divide into 0.2 mL ali-
quots, store frozen at −20 °C. Note: Very toxic. Handle with care. 
 12.  Azide solution ( see Table  1 ). Divide into 0.2 mL aliquots, 
store frozen at −20 °C. Note: Very toxic. Handle with care. 
 13.  FCCP solution ( see Table  1 ). Divide into 0.5 mL aliquots, 
store frozen at −20 °C. 
 14.  Pipette gently up and down to avoid bubble formation and 
strong oxygenation of the sample. 
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  1.  Gibson GE, Huang HM (2002) Oxidative 
processes in the brain and non-neuronal tissues 
as biomarkers of Alzheimer’s disease. Front 
Biosci 7:d1007–d1015 
  2.  Eckert A, Hauptmann S, Scherping I et al 
(2008) Soluble beta-amyloid leads to mito-
chondrial defects in amyloid precursor protein 
and tau transgenic mice. Neurodegener Dis 
5:157–159 
  3.  Rhein V, Baysang G, Rao S et al (2009) 
Amyloid-beta leads to impaired cellular respi-
ration, energy production and mitochondrial 
electron chain complex activities in human 
neuroblastoma cells. Cell Mol Neurobiol 29:
1063–1071 
  4.  Games D, Adams D, Alessandrini R et al (1995) 
Alzheimer-type neuropathology in transgenic 
mice overexpressing V717F beta- amyloid pre-
cursor protein. Nature 373:523–527 
  5.  Scheffl er IE (2001) A century of mitochon-
drial research: achievements and perspectives. 
Mitochondrion 1:3–31 
  6.  Reddy PH (2007) Mitochondrial dysfunction 
in aging and Alzheimer’s disease: strategies to 
protect neurons. Antioxid Redox Signal 9:
1647–1658 
 15.  If you have several mice, stop the process at this step, put the 
preparation on ice and use the next mouse to perform the 
centrifugation steps with all the samples at the same time. 
Since the Oxygraph contains two chambers, it is possible to 
investigate the mitochondrial respiration for only a few ani-
mals per day (6–8 mice/day). 
 16.  A volume of 50 μL of the preparation will be used for the 
Oxygraph measurement. For protein determination, dilute 
3 μL of isolated mitochondria in PBS (dilution 1:5) and per-
form the protein assay (e.g. Biorad DC™ Protein Assay and 
bovine serum albumin (BSA) for the standard curve). 
 17.  The experiment requires an instrumental and chemical back-
ground following the protocol of the company ( http://www.
oroboros.at/?Oxygraph ). Careful calibration will determine 
the “air saturation” (R1) and the “zero saturation” (R0) values. 
 18.  When the oxygraph chambers are closed, check no air bubbles 
are left inside. 
 19.  Citrate synthase activity is frequently used to normalize other 
mitochondrial enzymatic activities and mitochondrial respira-
tion because it correlates to mitochondrial content. Citrate 
synthase activity can be measured following the reduction of 
5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) by citrate syn-
thase at 412 nm (extinction coeffi cient of 13.6 mM −1 cm −1 ) in 
a coupled reaction with coenzyme A (CoA) and oxaloacetate 
[ 3 ,  26 ]. 
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Abstract 
The protein brain derived neurotrophic factor (BDNF) is a member of the 
neurotrophin family of growth factors involved in plasticity of neurons in several brain 
regions. There is numerous evidence that BDNF expression is decreased by 
experiencing psychological stress and that, accordingly, a lack of neurotrophic 
support causes major depression. Furthermore, disruption in sleep homeostatic 
processes results in higher stress vulnerability and is often associated with stress-
related mental disorders. Recently, we reported, for the first time, a relationship 
between BDNF and insomnia and sleep deprivation (SD). Using a biphasic stress 
model as explanation approach, we discuss here the hypothesis that chronic stress 
might induce a deregulation of the hypothalamic- pituitary adrenal system. In the 
long-term it leads to sleep disturbance and depression as well as decreased BDNF 
levels, whereas acute stress like SD can be used as therapeutic intervention in some 
insomniac or depressed patients as compensatory process to normalize BDNF 
levels. Indeed, partial SD (PSD) induced a fast increase in BDNF serum levels within 
hours after PSD which is similar to effects seen after ketamine infusion, another fast-
acting antidepressant intervention, while traditional antidepressants are characterized 
by a major delay until treatment response as well as delayed BDNF level increase. 
 
Keywords 
BDNF, major depression, rapid-acting antidepressants, sleep deprivation, therapy 
response. 
 
Key Messages 
· Brain-derived neurotrophic factor (BDNF) plays a key role in the 
pathophysiology of stress-related mood disorders. 
· The interplay of stress and sleep impacts on BDNF level. 
· Partial sleep deprivation (PSD) shows a fast action on BDNF level increase. 
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Introduction 
In our modern industrialized environment, the brain is a primary mediator and target 
of stress resiliency and vulnerability processes because of its capacity to adapt the 
behavioural and physiological responses to the social and physical stresses (1, 2). 
Yet, depending on the individual genetic background and epigenetic factors, this 
ability is not infinite, which, once a threshold is reached, eventually increases the 
susceptibility to stress-related mental disorders like major depressive disorder 
(MDD). 
Brain-derived neurotrophic factor (BDNF) belongs to the neurotrophin family and is 
produced by astrocytes, in addition to neurons, and the noradrenergic and 
serotonergic systems play a role in controlling BDNF synthesis (3-5). BDNF is 
abundant in various brain regions implicated in mood disorders, including the 
hippocampus, prefrontal cortex, and amygdala, and shows a remarkable activity-
dependent regulation of expression and secretion. Thus, its neurotrophic functions 
are connected to various physiological functions in the brain particularly relevant in 
neuroplasticity, memory and sleep (6-9), suggesting its biological role over the entire 
life span.  
Based on findings in brains from rodents (10, 11) and humans (12), the structure of 
the BDNF gene seems to be highly complex and contains numerous promoters each 
preceding one exon. This complexity leads through alternative splicing to the 
existence of distinct mRNA species that all contain exon IX, which encodes the 
BDNF protein (10). Although the differential regulation of these transcripts is essential 
and may dictate subcellular BDNF mRNA targeting and translational responses 
following neuronal stimulation, their potential implications in neuropsychiatric 
disorders remain mostly unclear. Notably, only one functional mature protein is 
generated, irrespective of the splice variant expressed. BDNF is synthesized as a 
larger precursor protein known as prepro-BDNF that is cleaved into pro-BDNF, which 
can then be further cleaved into mature BDNF (13). It has been suggested that pro-
BDNF and mature BDNF activate different intracellular signaling pathways (reviewed 
in (14)). While pro-BDNF interacts with the low-affinity neurotrophin receptor p75, 
mature BDNF signals through its high-affinity tropomyosin-related kinase B (TrkB) 
receptor, which activates several downstream effectors. Moreover, a functional 
Val66Met polymorphism found in the human pro-BDNF gene induced an impairment 
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of the activity-dependent dendritic trafficking and secretion of mature BDNF protein in 
rat brain. 
Given the complexity of BDNF system in terms of transcriptional, translational and 
post-translational regulatory mechanisms (10), pathological alteration of BDNF may 
lead to defects in neuronal survival and regeneration as well as structural brain 
abnormalities and reduced neuronal plasticity, which in turn may impair the 
individual’s ability to adapt to crisis situation. Because of the role played by BDNF in 
regulating structural, synaptic, and morphological plasticity, BDNF has gained the 
most attention in the understanding of the mechanisms underlying stress-related 
mood disorders (Figure 1). Numerous evidence from preclinical and clinical studies 
demonstrated that the stress-related pathophysiology of MDD is accompanied by a 
down-regulation of BDNF and TrkB expression, which in turn contributes to atrophy 
and cell loss in various brain regions, including the hippocampus (15-17). It is known 
that major depression and inflammation are linked in many ways. Of particular 
interest in this context are findings showing that inflammatory events compromise 
neuroplasticity via reduction of BDNF and may lead in this way to the development of 
depression (reviewed in (18)). Accordingly, several studies demonstrated that 
inflammation induced a significant decrease in the expression of specific BDNF 
variants within the rat brain (19, 20). 
Concomitantly, the “neurotrophin hypothesis of depression” postulates that stress-
related mood disorders result from a stress-induced decrease in BDNF expression 
(7). The BDNF hypothesis predicts that agents that promote BDNF function might be 
clinically effective antidepressants. Over the years, numerous - but not the entirety of 
all - studies showed that antidepressant interventions were able to reverse 
depressive behaviours while concurrently increasing BDNF levels (15, 21). But 
increases in BDNF serum levels during antidepressant treatment appear to be 
confined to certain antidepressants, do not always parallel clinical characteristics like 
depression severity and may depend on therapy response (21, 22). Of note, lack of 
BDNF alone may not be sufficient to explain the pathology of stress-related mental 
disorders (23-25), but it certainly has a prominent role in the pathophysiology of these 
disorders. Given that BDNF plays an important role in the pathophysiology of the 
stress response and in the pathogenesis of stress-associated mood disorders, and 
that its restoration may represent a critical mechanism underlying antidepressant 
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therapeutic effect, many investigators have focused on serum BDNF as a “biomarker” 
predicting the therapy outcome in MDD, since the protein can cross the blood brain-
barrier and circulating BDNF was correspondingly associated with cortical BDNF 
concentrations (16). 
Sleep has a critical role in cognitive functioning including the consolidation of 
synaptic plasticity and long-term memory. Stress itself often disrupts sleep. 
Moreover, sleep disturbances such as insomnia following stressful events may 
further intensify the long-term changes in the brain occurring at the level of synaptic 
plasticity (26). Conversely, stress exposure after partial or total sleep loss impairs the 
hypothalamic- pituitary adrenal (HPA) response to an increase of cortisol (27, 28). 
Hence, sleep disturbances may result in higher stress vulnerability, reduced 
environmental adaptation and cognitive impairment. Interestingly, the introduction of 
SD therapy (SDT) in the 1970-80’s was a major step forward in the sense of its rapid 
and fast (within 24 hours) recovery effect on depressive symptoms (29, 30). 
Particularly, it has been shown that REM- SD in MDD patients leads to a gradual 
improvement (30), suggesting that the antidepressant effects of both selective rapid 
eye movement (REM) SD and total SD are based on the suppression of slow wave 
activity (SWA) (31). Although fast-acting, SDT alone is not sufficient in most of the 
cases since the rate of relapse following the recovery night is rather high. However, 
the evidence for the rapid and robust efficacy of SDT in mood disorders is more 
sustainable for weeks to months when combined with antidepressant medication and/ 
or chronotherapies (32-34). Transcriptomic studies in different species through the 
sleep-wake cycle and after SD revealed that genes encoding proteins involved in 
synaptic plasticity (e.g. BDNF), specifically long-term potentiation (LTP), were up-
regulated during wakefulness and down-regulated during sleep (1, 35-37). 
Particularly, while short-term total SD appears to up-regulate the expression of BDNF 
in various regions of the brain (38-42), selective SD like REM or paradoxical SD in 
rats showed no alterations of BDNF expression (43). However, little is known 
regarding how the interactions between stress and sleep affect sleep-dependent 
plasticity and cognition, especially those explaining the rapid, even though temporary 
antidepressant effect of SD, since a relapse into depression occurs in most patients 
following the recovery night (44). 
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Challenges and progress towards understanding the role of BDNF in stress-
related mental disorders regarding the interplay of stress and the sleep homeostasis 
may lead to new alternative treatment strategies, providing advantages over the 
currently available antidepressants that are characterized by significant limitations 
(i.e.: low response rates, treatment resistance, high incidence of relapse, and a time-
lag of weeks to months for a response), highlighting a major unmet need for more 
efficacious and faster-acting antidepressants (45). 
 
 
BDNF, sleep and insomnia 
Sleep is an essential component of human cognitive performance and health. 
It is generally accepted that our modern society and its resulting stressors impact 
sleep in a negative way by altering both sleep quality and duration (46). Serotonin is 
a major neurotransmitter candidate playing a prominent role in the regulation of both 
sleep-wake circadian cycles as well as in the modulation of mood states in humans 
(47). In addition, it is known that BDNF production is stimulated by serotonin and 
conversely BDNF increases serotonergic signalling (4, 48). BDNF has been shown to 
induce SD and spontaneous wakefulness in animals (49). Moreover, a direct link with 
BDNF as prominent actor has been identified between the synaptic plasticity 
triggered by waking activities and the homeostatic sleep response (50). Particularly, 
the degree of BDNF expression during wakefulness is directly correlated to the extent 
of slow wave activity (SWA), a sensitive marker for sleep pressure and sleep need, in 
the subsequent period (8). Support for a role of BDNF in human sleep regulation 
comes also from a recent study reporting impaired intensity of SWA in non-rapid eye 
movement (NREM) sleep in Val66Met carriers relative to Val/Val homozygotes under 
basal conditions and immediately following a 40 hours period of waking (51). 
Although the exact mechanism by which BDNF induces an increase in sleep SWA 
remains uncertain, it has been proposed that the coupling of waking-associated 
synaptic potentiation among connected cells may directly contribute to SWA increase 
(8). Since the body’s stress system plays a critical role in adapting to a continuously 
changing and challenging environment, it is a major question how stress-related 
disruption of sleep may impair BDNF contents and degrade sleep function. Stress 
has been associated with the activation of the hypothalamic- pituitary- adrenal (HPA) 
axis. The HPA axis is a stress-responsive system that has been implicated in both 
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mood regulation (particularly depression) and cognitive functioning. The system 
consists of forward-stimulating arms as well as feedback loops that together regulate 
the production of stress hormones including cortisol. The fact that the beginning and 
the end of sleep are both involved in the HPA axis activity provides a clue to estimate 
the effects of stress on sleep (52). Chronic stress can lead to a deregulation in this 
biological stress system (53-57), which was suggested to decrease BDNF levels in 
animal studies (58-61) as well as in stress-related mood disorders (16, 62, 63) 
(Figure 1). Sleep problems are common features in many stress-related disorders; 
problems that may lead to impairment of physical and mental health since sleep loss 
is often followed by higher stress vulnerability (64). Insomnia is considered as a state 
of 24-h hyperarousal rather than sleep loss and affects up to one third of the general 
population (65). Epidemiological and clinical studies showed that a higher number of 
insomnia subjects also suffer from a concomitant mood disorder, mainly depression 
or an anxiety disorder (66, 67). Stress-related insomnia is transient and persists for 
only few days. Of note, persistent insomnia increases the risk of relapse into a new 
major depressive disorder episode (68). Although a majority of studies have 
concentrated on specifying the role of BDNF in depression, the mechanism 
underlying the effect of the sleep on the interplay between stress and BDNF was 
unclear until recently. Our group investigated serum BDNF levels of adults with 
current symptoms of insomnia and non-sleep disturbed control subjects (69, 70). We 
demonstrated that subjects suffering from current symptoms of insomnia exhibited 
significantly decreased serum BDNF levels compared with sleep-healthy controls. In 
addition, serum BDNF levels were significantly correlated with severity of insomnia in 
all participants. Moreover, the significance of our data was further emphasized when 
we assessed an external control group that had recovered from occupational 
burnout. Again, serum BDNF levels were significantly lower in those subjects 
reporting symptoms of fatigue compared to sleep healthy subjects. Overall, these 
findings strongly support the hypothesis of increased stress vulnerability due to sleep 
loss, which may lead to decreased BDNF levels. A key follow-up analysis using a 
mediation model further suggests that sleep acts as a mediator in the interplay 
between stress experience and serum BDNF levels (Figure 2, left panel) (69), 
suggesting an important role of this relationship in the pathogenesis of stress-
associated mental disorders. While we found reduced BDNF levels in association 
with insomnia, wakefulness given during SD, which can be considered as an “acute” 
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stressor for the brain, leads to an increase in BDNF content (71, 72). In line with a 
biphasic model of stress, chronic stress leads in the long-term to sleep disturbance 
and decrease of BDNF levels via HPA deregulation, while acute stress increases 
BDNF levels (Figure 1). Of note, the biphasic model of stress on BDNF level is in 
agreement with the biphasic model of stress on the glutamate system (73). The latter 
model argues that the acute stress-induced enhancement of glutamate transmission 
is dependent on activation of corticosterone receptors, while chronic stress induced 
opposite effects.  
 
 
Major depression, sleep deprivation and circadian regulation of BDNF  
Stress-related mood disorders like MDD are complex, multivariate and involve 
numerous neuronal substrates and brain regions. Multiple neurobiological 
mechanisms seem to mediate the therapeutic effects of antidepressant therapy. 
Some of these mechanisms, e.g. BDNF gene transcription inducing long-term 
potentiation, seem to play a role for neuroprotection and neurogenesis. The 
complexity could explain the slow onset of action in antidepressant treatments (74) 
(Figure 2). Furthermore, most currently available classical antidepressants primarily 
target the noradrenergic and serotonergic systems. The glutamate system has 
received much attention in recent years as an avenue for developing novel 
therapeutics since the glutamatergic system is also impaired in stress-related mood 
disorders(75, 76). The use at low doses of the noncompetitive N-methyl-D-aspartate 
(NMDA) receptor antagonist, ketamine, has been shown to have rapid antidepressant 
efficacy (75). In particular, patients with treatment-resistant depression benefit from 
sub-anaesthetic doses of ketamine with quick and persistent antidepressant effects 
(76, 77). It is suggested that the NMDA receptor blockade leads to an upregulation of 
the AMPA receptor expression and subsequent activation of the intracellular 
mammalian target of rapamycin (mTOR) cascade involved in ketamine's 
antidepressant action (78). In vitro studies also show that activation of AMPA 
receptors stimulates BNDF release via activation of L-type voltage-dependent 
calcium channels (VDCC) (79). This, in turn, is followed by an increase of 
synaptogenesis, which might be mirrored by the neuroplasticity marker BDNF (23, 
80). In line, Haile and coworkers could demonstrate a rapid increase of plasma BDNF 
levels already 4 hours after intravenous infusion of ketamine (81). In addition to its 
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role as an NMDA antagonist, ketamine can also alter circadian rhythms by 
attenuating phase-shifting responses to light. Thereby it alters the diurnal rhythms of 
the widespread NMDA and AMPA receptors in the suprachiasmatic nucleus and 
increases the expression of the core clock genes per1 and per2 via its actions on the 
glutamate receptors (reviewed in (82)). 
Some clinical studies have evaluated the changes of plasma or serum BDNF 
levels before and after antidepressant treatments among MDD patients and most 
studies report an increase of BDNF levels after antidepressant treatment (83, 84), 
although very recent data indicate that the normalization of BDNF during 
antidepressant treatment appears to be confined to some but not all antidepressants 
as well as to therapy response and does not correspond with amelioration of clinical 
symptoms (85). Nevertheless, different antidepressant strategies including 
antidepressant drugs and electroconvulsive therapy (ECT) were associated with an 
increase in BDNF levels (71). Besides ketamine, manipulations of the sleep-wake 
cycle such as SD (total or partial) or a phase advance of the sleep period are 
clinically well-documented, robust, and rapid-acting methods for the treatment of 
severely depressed patients (33). Other than SD for the whole night, partial SD 
(PSD) in the second half of the night has also shown comparable antidepressant 
effects in patients with major depression (33).  
Moreover, a growing body of evidence also supports a role for BDNF and its 
tropomyosine-related kinase receptor B (TrkB) in the modulation and mediation of 
circadian rhythms that appear to be disturbed in mood disorders. Alterations in 
rhythmic behaviours such as sleep, mood, concentration, appetite and vigilance are 
typical symptoms linked to depression. With regard to the link between BDNF and the 
HPA axis alteration in MDD, about 60% of depressed patients present a circadian 
deregulation of the cortisol secretion with hypercortisolemia (86-88) or disturbances 
in the temporal pattern of secretion including a flattened circadian curve (89), a 
reduced duration of nocturnal quiescent period (90), and an earlier (91) or elevated 
nadir (92). Of note, the presence of a diurnal BDNF rhythm was also recently 
demonstrated in healthy humans where plasma BDNF displayed the highest 
concentrations in the morning, followed by a significant decrease throughout the day, 
and the lowest values at midnight (93, 94). However, diurnal variation of blood BDNF 
was neglected until now in studies investigating MDD patients. Therefore, our group 
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designed for the first time a study to investigate the potentially fast-acting effects of 
PSD on BDNF profiles in MDD patients and if a diurnal variation of serum BDNF 
plays a role for the therapy outcome (72). Thus, post-PSD BDNF levels were 
investigated within hours after PSD: up to 18 h by using a 6 h interval post-PSD, 
specifically at 8 am, 2pm, and 8 pm. This is in contrast to all other published studies 
where treatment-related BDNF changes were collected and analyzed no earlier than 
one to six weeks after antidepressive therapy with classic antidepressants.  
We could confirm a similar pattern of diurnal variation of serum BDNF in 
patients identified as responders as it was previously reported in healthy subjects. 
After six hours post-PSD, we observed an increase in BDNF level, a fast effect 
comparable to that of ketamine on BNDF elevation in plasma, which was detectable 
already after 4 hours post-infusion and associated with therapeutic response. 
Importantly, early and rapid changes of BDNF levels after PSD and post-infusion of 
ketamine (81) imply a rapid adaptation mechanism at the synapses, e.g. remodelling 
of synapses following an increase and secretion of BDNF (reviewed in (6)). It can be 
speculated on the one hand that BDNF is secreted with a pulsatory circadian rhythm 
that is characterized by a progressive reduction in the amplitude of pulses throughout 
the day. On the other hand, it has been shown that brain BDNF is able to cross the 
blood brain barrier via a rapidly saturable transport system (95). While BDNF peaks 
around midnight in rat brains and thus may exert its modulating effect on 
neuroplasticity and long-term potentiation (96, 97), peripheral BDNF in the blood, 
namely both, of plasma and serum, peaks in the morning at 8 am and exhibits its 
lowest expression level at midnight, indicating that BDNF cycles in opposite phases 
in brain and blood. Thus, it seems legitimate to speculate that rapid changes to 
remodel neuronal networks involve the release of BDNF as a critical backbone, a 
phenomenon that might also occur in the periphery, since serum BDNF levels 
increase within hours (Figure 2). 
Furthermore and unexpectedly, not only post-PSD BDNF but also pre-PSD 
serum BDNF levels exhibited a diurnal pattern that was only prominent in subjects 
who were identified as responders. For non-responders, serum BDNF remained flat 
throughout the day. Accordingly, Wolkowitz and colleagues (98) found that high 
baseline serum BDNF levels (at 10 am) before the treatment with a selective 
serotonin reuptake inhibitor, predicted therapy response in depressed patients. 
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Moreover, response after treatment with duloxetine – a serotonin-norepinephrine 
reuptake inhibitor - in patients with MDD was also associated with a higher baseline 
serum BDNF concentration (99). Recognition that circadian rhythm disruption might 
also play a key role in mood disorders has led to the development of the new 
antidepressant agomelatine. Recent data from various groups showed that 
agomelatine led to an increase in BDNF expression in treated animals, and that this 
effect follows a specific temporal profile (100). Overall, diurnal BDNF variation seems 
to precede, rather than follow a favorable treatment outcome in depressed patients, 
suggesting that diurnal BDNF change is a prerequisite for successful therapy 
response independent from the specific treatment strategy, e.g. antidepressant drugs 
or SD. 
 
 
BDNF, acute and chronic stress 
In summary, our findings are in line with the hypothesis of an increased stress 
vulnerability due to sleep loss which may lead to a decrease in BDNF. Such a 
decrease might be associated with a decrease in BDNF mRNA expression in 
peripheral blood mononuclear cells and/or might correspond to a BDNF decline in the 
brain. To what extent peripheral BDNF corresponds to brain BDNF level is still not 
known. Nevertheless, the use of serum BDNF as potential indicator of brain alteration 
was justified by substantial evidence, but a time delay to monitor brain tissue 
alterations in the periphery should be taken into account (101). While we report a 
reduction of BDNF levels linked to sleep disturbance reflecting chronic stress on the 
one side, we and others consistently showed that prolonged wakefulness caused by 
SD (partial or total), which can be considered as an acute stressor for the brain, leads 
to a rapid increase of BDNF (1, 36). However, little is known about the differential 
effects of chronic and acute stress on the molecular level. Nevertheless, previous 
studies provide valuable leads of a biphasic modulation of hippocampal plasticity by 
stress, demonstrating that the same chronic stress that elicited hippocampal dendritic 
atrophy also reduced levels of BDNF in the rodent hippocampus while acute stress 
triggered opposite effects on BDNF levels (Figure 1) (25, 59, 102). This suggests 
that BDNF could be a final point of convergence for the stress-induced effects in the 
hippocampus. BDNF-mediated signalling is involved in stress response, but the 
direction and nature of signalling seems to be region- specific (e.g. hippocampus 
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versus amygdala), stress- specific and influenced by epigenetic modifications along 
with post-translational modifications (102). 
Using the biphasic model of stress on BDNF (Figure 1), we hypothesise that 
chronic stress might induce a deregulation of the HPA system leading in the long-
term to sleep disturbance and decreased BDNF levels. In this scenario, sleep is a 
key mediator at the connection between stress and BDNF (Figure 2, left panel) and 
inadequate sleep, such as insomnia, can amplify the depletion in BDNF levels. In 
contrast, an acute stressor like SD, e.g. one night of SD, can be used as a fast-acting 
therapeutic intervention in some insomniac or depressed patients as a compensatory 
process to normalize BDNF levels. 
Conclusion 
We discuss here recent new insights regarding the association of sleep with 
BDNF, the stress-induced BDNF modifications that may be mediated by sleep and, 
the effect of PSD as fast-acting but transient antidepressant on serum BDNF levels 
(Figures 1 and 2). 
Besides the biological link between BDNF and sleep, stress experience and 
subjective sleep perception interact with each other and directly affect BDNF levels, 
which eventually amplify the susceptibility to stress-associated mood disorders. 
Similar to ketamine, SD and PSD are able to induce a fast increase in serum BDNF 
levels within few hours. This is in contrast to the rather “delayed” effects of classical 
antidepressants (up to 6 weeks). Given the complexities of the pathogenesis of 
stress-related mood disorder, further studies including the monitoring of insomnia and 
sleep should be conducted. Especially the molecular mechanisms underlying the 
rapid response of ketamine and PSD on BDNF deserve further investigation as well 
as the downstream signalling pathways of BDNF and the relationship between BDNF 
and cortisol with regard to their role in the HPA axis deregulation. 
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Figure 1: Conceptual representation of changes in BDNF level induced by stress: a biphasic 
process. Point 1 illustrates the increase of BDNF during acute stress while point 2 corresponds to a 
maximal benefit of short-term stress on BDNF level. Points 1 and 2 might be linked to an induced 
increase of synaptic transmission and plasticity. Point 3 illustrates the deleterious effects of chronic 
stress on BDNF content. 
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Figure 2: Left panel: Scheme representing the mediation model where sleep acts as key mediator in 
the association between stress and BDNF. Chronic stress and insomnia lead to a decrease in BDNF 
and synaptic activity. Right panel: Fast-acting effect of ketamine and sleep deprivation versus 
delayed long-term effects of classical antidepressants on BDNF levels. 
 
 
